{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# PROTAC-DB Article Scraping\n",
    "\n",
    "This notebook is used to scrape the article data from the PROTAC-DB website. The data is then saved in a CSV file for further analysis.\n",
    "\n",
    "This code has been developed to double check that the reported information in the PROTAC-DB website is the same as the one reported in their CSV downloadeable file."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from IPython.display import display_html\n",
    "\n",
    "import logging\n",
    "import warnings\n",
    "import re\n",
    "import os\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import pickle\n",
    "import pickle\n",
    "import requests\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "from rdkit import Chem\n",
    "from rdkit.Chem import AllChem\n",
    "from typing import Literal, Union, List, Dict, Any, Callable\n",
    "from collections import defaultdict\n",
    "from tqdm.auto import tqdm\n",
    "from rdkit import RDLogger\n",
    "\n",
    "RDLogger.DisableLog('rdApp.*')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Filter out some warnings..."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "def set_global_logging_level(level=logging.ERROR, prefices=[\"\"]):\n",
    "    \"\"\"\n",
    "    Override logging levels of different modules based on their name as a prefix.\n",
    "    It needs to be invoked after the modules have been loaded so that their loggers have been initialized.\n",
    "\n",
    "    Args:\n",
    "        - level: desired level. e.g. logging.INFO. Optional. Default is logging.ERROR\n",
    "        - prefices: list of one or more str prefices to match (e.g. [\"transformers\", \"torch\"]). Optional.\n",
    "          Default is `[\"\"]` to match all active loggers.\n",
    "          The match is a case-sensitive `module_name.startswith(prefix)`\n",
    "    \"\"\"\n",
    "    prefix_re = re.compile(fr'^(?:{ \"|\".join(prefices) })')\n",
    "    for name in logging.root.manager.loggerDict:\n",
    "        if re.match(prefix_re, name):\n",
    "            logging.getLogger(name).setLevel(level)\n",
    "\n",
    "\n",
    "# Filter out annoying Pytorch Lightning printouts\n",
    "warnings.filterwarnings('ignore')\n",
    "warnings.filterwarnings(\n",
    "    'ignore', '.*Covariance of the parameters could not be estimated.*')\n",
    "warnings.filterwarnings(\n",
    "    'ignore', '.*You seem to be using the pipelines sequentially on GPU.*')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Setup working directories:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_dir = os.path.join(os.getcwd(), '..', 'data')\n",
    "src_dir = os.path.join(os.getcwd(), '..', 'src')\n",
    "fig_dir = os.path.join(data_dir, 'figures')\n",
    "checkpoint_dir = os.path.join(os.getcwd(), '..', 'checkpoints')\n",
    "dirs_to_make = [\n",
    "    data_dir,\n",
    "    # os.path.join(data_dir, 'raw'),\n",
    "    # os.path.join(data_dir, 'processed'),\n",
    "    fig_dir,\n",
    "    # os.path.join(data_dir, 'train'),\n",
    "    # os.path.join(data_dir, 'val'),\n",
    "    # os.path.join(data_dir, 'test'),\n",
    "    # src_dir,\n",
    "    # checkpoint_dir,\n",
    "]\n",
    "for d in dirs_to_make:\n",
    "    if not os.path.exists(d):\n",
    "        os.makedirs(d)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Download or load the raw PROTAC-DB dataset:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loaded protac.csv\n"
     ]
    }
   ],
   "source": [
    "protacdb_file = os.path.join(data_dir, 'PROTAC-DB.csv')\n",
    "protacdb_url = 'http://cadd.zju.edu.cn/protacdb/statics/binaryDownload/csv/protac/protac.csv'\n",
    "if os.path.exists(protacdb_file):\n",
    "    protac_df = pd.read_csv(protacdb_file).reset_index(drop=True)\n",
    "    print(f'Loaded protac.csv')\n",
    "else:\n",
    "    print(f'Downloading {protacdb_url}')\n",
    "    !wget {protacdb_url} {protacdb_file}\n",
    "    protac_df = pd.read_csv(protacdb_file).reset_index(drop=True)\n",
    "    print(f'PROTAC-DB loaded')\n",
    "\n",
    "old2new = {\n",
    "    'E3 ligase': 'E3 Ligase',\n",
    "}\n",
    "protac_df = protac_df.rename(columns=old2new)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Compound ID</th>\n",
       "      <th>Target</th>\n",
       "      <th>Percent degradation (%)</th>\n",
       "      <th>Article DOI</th>\n",
       "      <th>DC50 (nM)</th>\n",
       "      <th>Dmax (%)</th>\n",
       "      <th>Assay (DC50/Dmax)</th>\n",
       "      <th>Assay (Percent degradation)</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>BRD7</td>\n",
       "      <td>20/12 (WB)</td>\n",
       "      <td>10.1021/acs.jmedchem.8b01413</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD7 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>BRD9</td>\n",
       "      <td>19/30 (WB)</td>\n",
       "      <td>10.1021/acs.jmedchem.8b01413</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD9 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>BRD7</td>\n",
       "      <td>19/27 (WB)</td>\n",
       "      <td>10.1021/acs.jmedchem.8b01413</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD7 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>BRD9</td>\n",
       "      <td>5/21 (WB)</td>\n",
       "      <td>10.1021/acs.jmedchem.8b01413</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD9 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>3</td>\n",
       "      <td>BRD9</td>\n",
       "      <td>94/93 (WB)</td>\n",
       "      <td>10.1021/acs.jmedchem.8b01413</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD9 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Compound ID Target Percent degradation (%)                   Article DOI  \\\n",
       "0            1   BRD7              20/12 (WB)  10.1021/acs.jmedchem.8b01413   \n",
       "1            1   BRD9              19/30 (WB)  10.1021/acs.jmedchem.8b01413   \n",
       "2            2   BRD7              19/27 (WB)  10.1021/acs.jmedchem.8b01413   \n",
       "3            2   BRD9               5/21 (WB)  10.1021/acs.jmedchem.8b01413   \n",
       "4            3   BRD9              94/93 (WB)  10.1021/acs.jmedchem.8b01413   \n",
       "\n",
       "  DC50 (nM) Dmax (%) Assay (DC50/Dmax)  \\\n",
       "0       NaN      NaN               NaN   \n",
       "1       NaN      NaN               NaN   \n",
       "2       NaN      NaN               NaN   \n",
       "3       NaN      NaN               NaN   \n",
       "4       NaN      NaN               NaN   \n",
       "\n",
       "                         Assay (Percent degradation)  \n",
       "0  % BRD7 degradation in HeLa cells after 4/16 h ...  \n",
       "1  % BRD9 degradation in HeLa cells after 4/16 h ...  \n",
       "2  % BRD7 degradation in HeLa cells after 4/16 h ...  \n",
       "3  % BRD9 degradation in HeLa cells after 4/16 h ...  \n",
       "4  % BRD9 degradation in HeLa cells after 4/16 h ...  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PROTAC-DB scraped len: 6000\n",
      "Number of non-NaN DC50 values: 959\n",
      "Number of non-NaN Dmax values: 783\n",
      "Number of non-NaN DC50 and Dmax values: 374\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Compound ID</th>\n",
       "      <th>Target</th>\n",
       "      <th>Percent degradation (%)</th>\n",
       "      <th>Article DOI</th>\n",
       "      <th>DC50 (nM)</th>\n",
       "      <th>Dmax (%)</th>\n",
       "      <th>Assay (DC50/Dmax)</th>\n",
       "      <th>Assay (Percent degradation)</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>11</td>\n",
       "      <td>BRD9</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.1021/acs.jmedchem.8b01413</td>\n",
       "      <td>560</td>\n",
       "      <td>80</td>\n",
       "      <td>Degradation of BRD9 in HeLa cells after 4 h tr...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>22</td>\n",
       "      <td>BRD9</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.1021/acs.jmedchem.8b01413</td>\n",
       "      <td>1.76</td>\n",
       "      <td>95</td>\n",
       "      <td>Degradation of BRD9 in RI-1 cells after 8 h tr...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>22</td>\n",
       "      <td>BRD7</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.1021/acs.jmedchem.8b01413</td>\n",
       "      <td>4.5</td>\n",
       "      <td>95</td>\n",
       "      <td>Degradation of BRD7 in RI-1 cells after 8 h tr...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>104</th>\n",
       "      <td>118</td>\n",
       "      <td>AR</td>\n",
       "      <td>76/&gt;95/&gt;99</td>\n",
       "      <td>10.1021/acs.jmedchem.9b01393</td>\n",
       "      <td>7.2/1</td>\n",
       "      <td>&gt;95/&gt;95</td>\n",
       "      <td>Degradation of AR in LNCaP/VCaP AR+ cells afte...</td>\n",
       "      <td>% AR degradation in LNCaP cells after 6 h trea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>106</th>\n",
       "      <td>120</td>\n",
       "      <td>AR</td>\n",
       "      <td>89/99/100</td>\n",
       "      <td>10.1021/acs.jmedchem.8b01631</td>\n",
       "      <td>0.86/0.76/10.4</td>\n",
       "      <td>&gt;95/&gt;95/&gt;95</td>\n",
       "      <td>Degradation of AR in LNCaP/VCaP/22Rv1 cells af...</td>\n",
       "      <td>% AR degradation in LNCaP cells after 6 h trea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5901</th>\n",
       "      <td>3218</td>\n",
       "      <td>BCL-xL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.1038/s41467-021-27210-x</td>\n",
       "      <td>12.1</td>\n",
       "      <td>81</td>\n",
       "      <td>Degradation of BCL-xL in 293T cells after 16 h...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5902</th>\n",
       "      <td>3218</td>\n",
       "      <td>BCL2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.1038/s41467-021-27210-x</td>\n",
       "      <td>354.8</td>\n",
       "      <td>69</td>\n",
       "      <td>Degradation of BCL2 in 293T cells after 16 h t...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5950</th>\n",
       "      <td>3217</td>\n",
       "      <td>BCL-xL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.1038/s41467-021-27210-x</td>\n",
       "      <td>12.8</td>\n",
       "      <td>96</td>\n",
       "      <td>Degradation of BCL-xL in 293T cells after 16 h...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5951</th>\n",
       "      <td>3218</td>\n",
       "      <td>BCL-xL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.1038/s41467-021-27210-x</td>\n",
       "      <td>12.1</td>\n",
       "      <td>81</td>\n",
       "      <td>Degradation of BCL-xL in 293T cells after 16 h...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5952</th>\n",
       "      <td>3218</td>\n",
       "      <td>BCL2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10.1038/s41467-021-27210-x</td>\n",
       "      <td>354.8</td>\n",
       "      <td>69</td>\n",
       "      <td>Degradation of BCL2 in 293T cells after 16 h t...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>374 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Compound ID  Target Percent degradation (%)  \\\n",
       "19             11    BRD9                     NaN   \n",
       "40             22    BRD9                     NaN   \n",
       "42             22    BRD7                     NaN   \n",
       "104           118      AR              76/>95/>99   \n",
       "106           120      AR               89/99/100   \n",
       "...           ...     ...                     ...   \n",
       "5901         3218  BCL-xL                     NaN   \n",
       "5902         3218    BCL2                     NaN   \n",
       "5950         3217  BCL-xL                     NaN   \n",
       "5951         3218  BCL-xL                     NaN   \n",
       "5952         3218    BCL2                     NaN   \n",
       "\n",
       "                       Article DOI       DC50 (nM)     Dmax (%)  \\\n",
       "19    10.1021/acs.jmedchem.8b01413             560           80   \n",
       "40    10.1021/acs.jmedchem.8b01413            1.76           95   \n",
       "42    10.1021/acs.jmedchem.8b01413             4.5           95   \n",
       "104   10.1021/acs.jmedchem.9b01393           7.2/1      >95/>95   \n",
       "106   10.1021/acs.jmedchem.8b01631  0.86/0.76/10.4  >95/>95/>95   \n",
       "...                            ...             ...          ...   \n",
       "5901    10.1038/s41467-021-27210-x            12.1           81   \n",
       "5902    10.1038/s41467-021-27210-x           354.8           69   \n",
       "5950    10.1038/s41467-021-27210-x            12.8           96   \n",
       "5951    10.1038/s41467-021-27210-x            12.1           81   \n",
       "5952    10.1038/s41467-021-27210-x           354.8           69   \n",
       "\n",
       "                                      Assay (DC50/Dmax)  \\\n",
       "19    Degradation of BRD9 in HeLa cells after 4 h tr...   \n",
       "40    Degradation of BRD9 in RI-1 cells after 8 h tr...   \n",
       "42    Degradation of BRD7 in RI-1 cells after 8 h tr...   \n",
       "104   Degradation of AR in LNCaP/VCaP AR+ cells afte...   \n",
       "106   Degradation of AR in LNCaP/VCaP/22Rv1 cells af...   \n",
       "...                                                 ...   \n",
       "5901  Degradation of BCL-xL in 293T cells after 16 h...   \n",
       "5902  Degradation of BCL2 in 293T cells after 16 h t...   \n",
       "5950  Degradation of BCL-xL in 293T cells after 16 h...   \n",
       "5951  Degradation of BCL-xL in 293T cells after 16 h...   \n",
       "5952  Degradation of BCL2 in 293T cells after 16 h t...   \n",
       "\n",
       "                            Assay (Percent degradation)  \n",
       "19                                                  NaN  \n",
       "40                                                  NaN  \n",
       "42                                                  NaN  \n",
       "104   % AR degradation in LNCaP cells after 6 h trea...  \n",
       "106   % AR degradation in LNCaP cells after 6 h trea...  \n",
       "...                                                 ...  \n",
       "5901                                                NaN  \n",
       "5902                                                NaN  \n",
       "5950                                                NaN  \n",
       "5951                                                NaN  \n",
       "5952                                                NaN  \n",
       "\n",
       "[374 rows x 8 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "scraped_protac_df = pd.read_csv(os.path.join(\n",
    "    data_dir, 'PROTAC-DB-Scraped.csv'))\n",
    "# Rename columns\n",
    "old2new = {\n",
    "    \"Assay (Percent degradation)\": \"Percent degradation (%)\",\n",
    "    \"PROTAC to Target\": \"Assay (Percent degradation)\",\n",
    "    \"DOI\": \"Article DOI\",\n",
    "    \"DC50\": \"DC50 (nM)\",\n",
    "    \"Dmax\": \"Dmax (%)\",\n",
    "}\n",
    "scraped_protac_df = scraped_protac_df.rename(columns=old2new)\n",
    "\n",
    "display(scraped_protac_df.head())\n",
    "print(f'PROTAC-DB scraped len: {len(scraped_protac_df)}')\n",
    "print(f'Number of non-NaN DC50 values: {scraped_protac_df[\"DC50 (nM)\"].notna().sum()}')\n",
    "print(f'Number of non-NaN Dmax values: {scraped_protac_df[\"Dmax (%)\"].notna().sum()}')\n",
    "print(f'Number of non-NaN DC50 and Dmax values: {len(scraped_protac_df[scraped_protac_df[\"DC50 (nM)\"].notna() & scraped_protac_df[\"Dmax (%)\"].notna()])}')\n",
    "scraped_protac_df[scraped_protac_df[\"DC50 (nM)\"].notna() & scraped_protac_df[\"Dmax (%)\"].notna()]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Merged df len: 5343\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Compound ID</th>\n",
       "      <th>Uniprot</th>\n",
       "      <th>Target</th>\n",
       "      <th>E3 Ligase</th>\n",
       "      <th>PDB</th>\n",
       "      <th>Name</th>\n",
       "      <th>Smiles</th>\n",
       "      <th>IC50 (nM, Protac to Target)</th>\n",
       "      <th>Assay (Protac to Target, IC50)</th>\n",
       "      <th>EC50 (nM, Protac to Target)</th>\n",
       "      <th>...</th>\n",
       "      <th>Rotatable Bond Count</th>\n",
       "      <th>Topological Polar Surface Area</th>\n",
       "      <th>Molecular Formula</th>\n",
       "      <th>InChI</th>\n",
       "      <th>InChI Key</th>\n",
       "      <th>Percent degradation (%)</th>\n",
       "      <th>DC50 (nM)</th>\n",
       "      <th>Dmax (%)</th>\n",
       "      <th>Assay (DC50/Dmax)</th>\n",
       "      <th>Assay (Percent degradation)</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Q9NPI1</td>\n",
       "      <td>BRD7</td>\n",
       "      <td>VHL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>19</td>\n",
       "      <td>189.92</td>\n",
       "      <td>C50H64N8O9S</td>\n",
       "      <td>InChI=1S/C50H64N8O9S/c1-32-45(68-31-53-32)34-1...</td>\n",
       "      <td>RPMQBLMPGMFXLD-PDUNVWSESA-N</td>\n",
       "      <td>20/12 (WB)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD7 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Q9H8M2</td>\n",
       "      <td>BRD9</td>\n",
       "      <td>VHL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>19</td>\n",
       "      <td>189.92</td>\n",
       "      <td>C50H64N8O9S</td>\n",
       "      <td>InChI=1S/C50H64N8O9S/c1-32-45(68-31-53-32)34-1...</td>\n",
       "      <td>RPMQBLMPGMFXLD-PDUNVWSESA-N</td>\n",
       "      <td>19/30 (WB)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD9 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Q9NPI1</td>\n",
       "      <td>BRD7</td>\n",
       "      <td>VHL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>25</td>\n",
       "      <td>208.38</td>\n",
       "      <td>C54H72N8O11S</td>\n",
       "      <td>InChI=1S/C54H72N8O11S/c1-36-49(74-35-57-36)38-...</td>\n",
       "      <td>NGWWVKZONFCNQP-SHPBXJAASA-N</td>\n",
       "      <td>19/27 (WB)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD7 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>Q9H8M2</td>\n",
       "      <td>BRD9</td>\n",
       "      <td>VHL</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>25</td>\n",
       "      <td>208.38</td>\n",
       "      <td>C54H72N8O11S</td>\n",
       "      <td>InChI=1S/C54H72N8O11S/c1-36-49(74-35-57-36)38-...</td>\n",
       "      <td>NGWWVKZONFCNQP-SHPBXJAASA-N</td>\n",
       "      <td>5/21 (WB)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD9 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>3</td>\n",
       "      <td>Q9H8M2</td>\n",
       "      <td>BRD9</td>\n",
       "      <td>CRBN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>18</td>\n",
       "      <td>202.97</td>\n",
       "      <td>C43H50N8O10</td>\n",
       "      <td>InChI=1S/C43H50N8O10/c1-48-24-31(28-9-10-44-23...</td>\n",
       "      <td>RMBNUDOJPQLHMV-UHFFFAOYSA-N</td>\n",
       "      <td>94/93 (WB)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>% BRD9 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 89 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Compound ID Uniprot Target E3 Ligase  PDB Name  \\\n",
       "0            1  Q9NPI1   BRD7       VHL  NaN  NaN   \n",
       "1            1  Q9H8M2   BRD9       VHL  NaN  NaN   \n",
       "2            2  Q9NPI1   BRD7       VHL  NaN  NaN   \n",
       "3            2  Q9H8M2   BRD9       VHL  NaN  NaN   \n",
       "4            3  Q9H8M2   BRD9      CRBN  NaN  NaN   \n",
       "\n",
       "                                              Smiles  \\\n",
       "0  COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...   \n",
       "1  COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...   \n",
       "2  COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...   \n",
       "3  COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...   \n",
       "4  COC1=CC(C2=CN(C)C(=O)C3=CN=CC=C23)=CC(OC)=C1CN...   \n",
       "\n",
       "  IC50 (nM, Protac to Target) Assay (Protac to Target, IC50)  \\\n",
       "0                         NaN                            NaN   \n",
       "1                         NaN                            NaN   \n",
       "2                         NaN                            NaN   \n",
       "3                         NaN                            NaN   \n",
       "4                         NaN                            NaN   \n",
       "\n",
       "  EC50 (nM, Protac to Target)  ... Rotatable Bond Count  \\\n",
       "0                         NaN  ...                   19   \n",
       "1                         NaN  ...                   19   \n",
       "2                         NaN  ...                   25   \n",
       "3                         NaN  ...                   25   \n",
       "4                         NaN  ...                   18   \n",
       "\n",
       "  Topological Polar Surface Area Molecular Formula  \\\n",
       "0                         189.92       C50H64N8O9S   \n",
       "1                         189.92       C50H64N8O9S   \n",
       "2                         208.38      C54H72N8O11S   \n",
       "3                         208.38      C54H72N8O11S   \n",
       "4                         202.97       C43H50N8O10   \n",
       "\n",
       "                                               InChI  \\\n",
       "0  InChI=1S/C50H64N8O9S/c1-32-45(68-31-53-32)34-1...   \n",
       "1  InChI=1S/C50H64N8O9S/c1-32-45(68-31-53-32)34-1...   \n",
       "2  InChI=1S/C54H72N8O11S/c1-36-49(74-35-57-36)38-...   \n",
       "3  InChI=1S/C54H72N8O11S/c1-36-49(74-35-57-36)38-...   \n",
       "4  InChI=1S/C43H50N8O10/c1-48-24-31(28-9-10-44-23...   \n",
       "\n",
       "                     InChI Key Percent degradation (%) DC50 (nM) Dmax (%)  \\\n",
       "0  RPMQBLMPGMFXLD-PDUNVWSESA-N              20/12 (WB)       NaN      NaN   \n",
       "1  RPMQBLMPGMFXLD-PDUNVWSESA-N              19/30 (WB)       NaN      NaN   \n",
       "2  NGWWVKZONFCNQP-SHPBXJAASA-N              19/27 (WB)       NaN      NaN   \n",
       "3  NGWWVKZONFCNQP-SHPBXJAASA-N               5/21 (WB)       NaN      NaN   \n",
       "4  RMBNUDOJPQLHMV-UHFFFAOYSA-N              94/93 (WB)       NaN      NaN   \n",
       "\n",
       "  Assay (DC50/Dmax)                        Assay (Percent degradation)  \n",
       "0               NaN  % BRD7 degradation in HeLa cells after 4/16 h ...  \n",
       "1               NaN  % BRD9 degradation in HeLa cells after 4/16 h ...  \n",
       "2               NaN  % BRD7 degradation in HeLa cells after 4/16 h ...  \n",
       "3               NaN  % BRD9 degradation in HeLa cells after 4/16 h ...  \n",
       "4               NaN  % BRD9 degradation in HeLa cells after 4/16 h ...  \n",
       "\n",
       "[5 rows x 89 columns]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Merge scraped data with PROTAC-DB on Compound ID and get non-assay columns\n",
    "param_cols = [\n",
    "    \"Percent degradation (%)\",\n",
    "    \"Dmax (%)\",\n",
    "    \"DC50 (nM)\",\n",
    "    \"Assay (Percent degradation)\",\n",
    "    \"Assay (DC50/Dmax)\",\n",
    "]\n",
    "cols = [c for c in protac_df.columns if c not in param_cols]\n",
    "on_cols = [c for c in scraped_protac_df.columns if c not in param_cols]\n",
    "scraped_protac_df = protac_df[cols].merge(\n",
    "    scraped_protac_df,\n",
    "    on=on_cols,\n",
    ").drop_duplicates()\n",
    "print(f'Merged df len: {len(scraped_protac_df)}')\n",
    "scraped_protac_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "362\n",
      "737\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Percent degradation (%)</th>\n",
       "      <th>Assay (Percent degradation)</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>20/12 (WB)</td>\n",
       "      <td>% BRD7 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>19/30 (WB)</td>\n",
       "      <td>% BRD9 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>19/27 (WB)</td>\n",
       "      <td>% BRD7 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>5/21 (WB)</td>\n",
       "      <td>% BRD9 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>94/93 (WB)</td>\n",
       "      <td>% BRD9 degradation in HeLa cells after 4/16 h ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4861</th>\n",
       "      <td>54 (WB)</td>\n",
       "      <td>% JAK3 degradation in MHH-CALL-4 cells at 100 nM</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4863</th>\n",
       "      <td>42 (WB)</td>\n",
       "      <td>% JAK3 degradation in MHH-CALL-4 cells at 100 nM</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4864</th>\n",
       "      <td>1/32/69/19 (WB)</td>\n",
       "      <td>% JAK2 degradation in MHH-CALL-4 cells at 1/10...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4881</th>\n",
       "      <td>0/30/30/53/29 (WB)</td>\n",
       "      <td>% EGFR del19 degradation in HCC827 cells at 5/...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4882</th>\n",
       "      <td>10/7/7/27/34 (WB)</td>\n",
       "      <td>% EGFR EGFR L858R/T790M degradation in H1975 c...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>334 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Percent degradation (%)  \\\n",
       "0                 20/12 (WB)   \n",
       "1                 19/30 (WB)   \n",
       "2                 19/27 (WB)   \n",
       "3                  5/21 (WB)   \n",
       "4                 94/93 (WB)   \n",
       "...                      ...   \n",
       "4861                 54 (WB)   \n",
       "4863                 42 (WB)   \n",
       "4864         1/32/69/19 (WB)   \n",
       "4881      0/30/30/53/29 (WB)   \n",
       "4882       10/7/7/27/34 (WB)   \n",
       "\n",
       "                            Assay (Percent degradation)  \n",
       "0     % BRD7 degradation in HeLa cells after 4/16 h ...  \n",
       "1     % BRD9 degradation in HeLa cells after 4/16 h ...  \n",
       "2     % BRD7 degradation in HeLa cells after 4/16 h ...  \n",
       "3     % BRD9 degradation in HeLa cells after 4/16 h ...  \n",
       "4     % BRD9 degradation in HeLa cells after 4/16 h ...  \n",
       "...                                                 ...  \n",
       "4861   % JAK3 degradation in MHH-CALL-4 cells at 100 nM  \n",
       "4863   % JAK3 degradation in MHH-CALL-4 cells at 100 nM  \n",
       "4864  % JAK2 degradation in MHH-CALL-4 cells at 1/10...  \n",
       "4881  % EGFR del19 degradation in HCC827 cells at 5/...  \n",
       "4882  % EGFR EGFR L858R/T790M degradation in H1975 c...  \n",
       "\n",
       "[334 rows x 2 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "print(len(scraped_protac_df.dropna(\n",
    "    subset=['DC50 (nM)', 'Dmax (%)']).dropna(how='all')))\n",
    "print(len(scraped_protac_df.dropna(\n",
    "    subset=['Percent degradation (%)']).dropna(how='all')))\n",
    "\n",
    "tmp = scraped_protac_df.dropna(subset=['Percent degradation (%)'])\n",
    "\n",
    "tmp[tmp['Percent degradation (%)'].str.contains(\n",
    "    'WB')][['Percent degradation (%)', 'Assay (Percent degradation)']].drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "protac_pedia_df len: 1203\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PROTACDB ID</th>\n",
       "      <th>PROTAC SMILES</th>\n",
       "      <th>Active/Inactive</th>\n",
       "      <th>Best PROTAC</th>\n",
       "      <th>Cells</th>\n",
       "      <th>cLogP</th>\n",
       "      <th>Comments</th>\n",
       "      <th>Curator</th>\n",
       "      <th>Dc50</th>\n",
       "      <th>Dmax</th>\n",
       "      <th>...</th>\n",
       "      <th>Proteomics Data Available</th>\n",
       "      <th>Secondary Pubmed</th>\n",
       "      <th>Status</th>\n",
       "      <th>Target</th>\n",
       "      <th>Tested A Non Binding E3 Control</th>\n",
       "      <th>Tested Competition With Ligand</th>\n",
       "      <th>Tested Engagement In Cells</th>\n",
       "      <th>Tested Proteaseome Inhibitor</th>\n",
       "      <th>Time</th>\n",
       "      <th>TPSA</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...</td>\n",
       "      <td>Inactive</td>\n",
       "      <td>No</td>\n",
       "      <td>MOLT-4</td>\n",
       "      <td>10.83732</td>\n",
       "      <td>IC50's are for cell viability assays</td>\n",
       "      <td>Ronen Gabizon</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Reviewed</td>\n",
       "      <td>Q07817</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>48</td>\n",
       "      <td>251.07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...</td>\n",
       "      <td>Inactive</td>\n",
       "      <td>No</td>\n",
       "      <td>MOLT-4</td>\n",
       "      <td>11.22742</td>\n",
       "      <td>IC50's are for cell viability assays</td>\n",
       "      <td>Ronen Gabizon</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Reviewed</td>\n",
       "      <td>Q07817</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>48</td>\n",
       "      <td>251.07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...</td>\n",
       "      <td>Inactive</td>\n",
       "      <td>No</td>\n",
       "      <td>MOLT-4</td>\n",
       "      <td>11.61752</td>\n",
       "      <td>IC50's are for cell viability assays</td>\n",
       "      <td>Ronen Gabizon</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Reviewed</td>\n",
       "      <td>Q07817</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>48</td>\n",
       "      <td>251.07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...</td>\n",
       "      <td>Active</td>\n",
       "      <td>No</td>\n",
       "      <td>MOLT-4</td>\n",
       "      <td>12.00762</td>\n",
       "      <td>IC50's are for cell viability assays</td>\n",
       "      <td>Ronen Gabizon</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Reviewed</td>\n",
       "      <td>Q07817</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>48</td>\n",
       "      <td>251.07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...</td>\n",
       "      <td>Active</td>\n",
       "      <td>No</td>\n",
       "      <td>MOLT-4</td>\n",
       "      <td>12.39772</td>\n",
       "      <td>IC50's are for cell viability assays</td>\n",
       "      <td>Ronen Gabizon</td>\n",
       "      <td>53 nM</td>\n",
       "      <td>~ 100 %</td>\n",
       "      <td>...</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Reviewed</td>\n",
       "      <td>Q07817</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>48</td>\n",
       "      <td>251.07</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 43 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   PROTACDB ID                                      PROTAC SMILES  \\\n",
       "0            1  Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...   \n",
       "1            2  Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...   \n",
       "2            3  Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...   \n",
       "3            4  Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...   \n",
       "4            5  Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)...   \n",
       "\n",
       "  Active/Inactive Best PROTAC   Cells     cLogP  \\\n",
       "0        Inactive          No  MOLT-4  10.83732   \n",
       "1        Inactive          No  MOLT-4  11.22742   \n",
       "2        Inactive          No  MOLT-4  11.61752   \n",
       "3          Active          No  MOLT-4  12.00762   \n",
       "4          Active          No  MOLT-4  12.39772   \n",
       "\n",
       "                               Comments        Curator   Dc50     Dmax  ...  \\\n",
       "0  IC50's are for cell viability assays  Ronen Gabizon    NaN      NaN  ...   \n",
       "1  IC50's are for cell viability assays  Ronen Gabizon    NaN      NaN  ...   \n",
       "2  IC50's are for cell viability assays  Ronen Gabizon    NaN      NaN  ...   \n",
       "3  IC50's are for cell viability assays  Ronen Gabizon    NaN      NaN  ...   \n",
       "4  IC50's are for cell viability assays  Ronen Gabizon  53 nM  ~ 100 %  ...   \n",
       "\n",
       "  Proteomics Data Available Secondary Pubmed    Status  Target  \\\n",
       "0                        No              NaN  Reviewed  Q07817   \n",
       "1                        No              NaN  Reviewed  Q07817   \n",
       "2                        No              NaN  Reviewed  Q07817   \n",
       "3                        No              NaN  Reviewed  Q07817   \n",
       "4                        No              NaN  Reviewed  Q07817   \n",
       "\n",
       "  Tested A Non Binding E3 Control  Tested Competition With Ligand  \\\n",
       "0                              No                              No   \n",
       "1                              No                              No   \n",
       "2                              No                              No   \n",
       "3                              No                              No   \n",
       "4                              No                              No   \n",
       "\n",
       "   Tested Engagement In Cells Tested Proteaseome Inhibitor Time    TPSA  \n",
       "0                          No                           No   48  251.07  \n",
       "1                          No                           No   48  251.07  \n",
       "2                          No                           No   48  251.07  \n",
       "3                          No                           No   48  251.07  \n",
       "4                         Yes                           No   48  251.07  \n",
       "\n",
       "[5 rows x 43 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_file = os.path.join(data_dir, 'PROTAC-Pedia.csv')\n",
    "protac_pedia_df = pd.read_csv(df_file)\n",
    "print(f'protac_pedia_df len: {len(protac_pedia_df)}')\n",
    "protac_pedia_df.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Get Article Data from PubMed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "unique_dois len: 233\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Article DOI</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1021/acs.jmedchem.8b01413</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>10.1021/acs.jmedchem.9b00455</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>10.1021/acs.jmedchem.8b00909</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>10.1021/acs.jmedchem.8b01572</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>164</th>\n",
       "      <td>10.1021/acs.jmedchem.6b01816</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Article DOI\n",
       "0    10.1021/acs.jmedchem.8b01413\n",
       "71   10.1021/acs.jmedchem.9b00455\n",
       "72   10.1021/acs.jmedchem.8b00909\n",
       "92   10.1021/acs.jmedchem.8b01572\n",
       "164  10.1021/acs.jmedchem.6b01816"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Get unique article DOIs from PROTAC-DB for which the Assay (DC50/Dmax) is NaN\n",
    "unique_dois = protac_df[protac_df['Assay (DC50/Dmax)'].isna() & protac_df['Assay (Percent degradation)'].isna()][['Article DOI']].drop_duplicates()\n",
    "print(f'unique_dois len: {len(unique_dois)}')\n",
    "unique_dois.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Convert article DOIs to PubMed IDs:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PMC ID for DOI 10.1021/acs.jmedchem.8b01413 is PMC6348446.\n",
      "PMC ID for DOI 10.1021/acs.jmedchem.9b00455 is PMC10688117.\n",
      "PMC ID for DOI 10.1021/acs.jmedchem.8b00909 is PMC6545112.\n",
      "PMC ID for DOI 10.1021/acs.jmedchem.8b01572 is PMC10788944.\n",
      "PMC ID for DOI 10.1021/acs.jmedchem.6b01816 is PMC5788414.\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "\n",
    "def doi_to_pmcid(dois):\n",
    "    base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/\"\n",
    "    pmc_ids = []\n",
    "\n",
    "    for doi in dois:\n",
    "        # Step 1: Use esearch to find the PMID for the DOI\n",
    "        search_url = f\"{base_url}esearch.fcgi?db=pubmed&term={doi}&retmode=json\"\n",
    "        search_response = requests.get(search_url)\n",
    "        search_data = search_response.json()\n",
    "        pmid = search_data['esearchresult']['idlist'][0] if search_data['esearchresult']['idlist'] else None\n",
    "\n",
    "        if not pmid:\n",
    "            print(f\"No PMID found for DOI {doi}.\")\n",
    "            pmc_ids.append(None)\n",
    "            continue\n",
    "\n",
    "        # Step 2: Use elink to find the PMC ID for the PMID\n",
    "        link_url = f\"{base_url}elink.fcgi?dbfrom=pubmed&db=pmc&id={pmid}&retmode=json\"\n",
    "        link_response = requests.get(link_url)\n",
    "        link_data = link_response.json()\n",
    "        pmc_id = None\n",
    "        for linksetdb in link_data[\"linksets\"][0].get(\"linksetdbs\", []):\n",
    "            if linksetdb[\"dbto\"] == \"pmc\":\n",
    "                pmc_id = linksetdb[\"links\"][0]\n",
    "                break\n",
    "\n",
    "        if pmc_id:\n",
    "            print(f\"PMC ID for DOI {doi} is PMC{pmc_id}.\")\n",
    "        else:\n",
    "            print(f\"No PMC ID found for DOI {doi}.\")\n",
    "        \n",
    "        pmc_ids.append(pmc_id if pmc_id else None)\n",
    "\n",
    "    return pmc_ids\n",
    "\n",
    "# Example usage\n",
    "dois = [\n",
    "    '10.1021/acs.jmedchem.8b01413',\n",
    "    '10.1021/acs.jmedchem.9b00455',\n",
    "    '10.1021/acs.jmedchem.8b00909',\n",
    "    '10.1021/acs.jmedchem.8b01572',\n",
    "    '10.1021/acs.jmedchem.6b01816',\n",
    "]\n",
    "\n",
    "pmc_ids = doi_to_pmcid(dois)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Fetch article XML data from PubMed:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "b'<?xml version=\"1.0\" ?>\\n<!DOCTYPE pmc-articleset PUBLIC \"-//NLM//DTD ARTICLE SET 2.0//EN\" \"https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd\">\\n<pmc-articleset><article xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" article-type=\"research-article\" xml:lang=\"EN\">\\n  <?properties open_access?>\\n  <front>\\n    <journal-meta>\\n      <journal-id journal-id-type=\"nlm-ta\">J Med Chem</journal-id>\\n      <journal-id journal-id-type=\"iso-abbrev\">J. Med. Chem</journal-id>\\n      <journal-id journal-id-type=\"publisher-id\">jm</journal-id>\\n      <journal-id journal-id-type=\"coden\">jmcmar</journal-id>\\n      <journal-title-group>\\n        <journal-title>Journal of Medicinal Chemistry</journal-title>\\n      </journal-title-group>\\n      <issn pub-type=\"ppub\">0022-2623</issn>\\n      <issn pub-type=\"epub\">1520-4804</issn>\\n      <publisher>\\n        <publisher-name>American Chemical\\nSociety</publisher-name>\\n      </publisher>\\n    </journal-meta>\\n    <article-meta>\\n      <article-id pub-id-type=\"pmid\">30540463</article-id>\\n      <article-id pub-id-type=\"pmc\">6348446</article-id>\\n      <article-id pub-id-type=\"doi\">10.1021/acs.jmedchem.8b01413</article-id>\\n      <article-categories>\\n        <subj-group>\\n          <subject>Article</subject>\\n        </subj-group>\\n      </article-categories>\\n      <title-group>\\n        <article-title>Iterative Design and Optimization of Initially Inactive\\nProteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent,\\nFast, and Selective von Hippel&#x2013;Lindau (VHL) Based Dual Degrader\\nProbe of BRD9 and BRD7</article-title>\\n      </title-group>\\n      <contrib-group>\\n        <contrib contrib-type=\"author\" id=\"ath1\">\\n          <name>\\n            <surname>Zoppi</surname>\\n            <given-names>Vittoria</given-names>\\n          </name>\\n          <xref rid=\"aff1\" ref-type=\"aff\">&#x2020;</xref>\\n          <xref rid=\"aff2\" ref-type=\"aff\">&#x2021;</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" id=\"ath2\">\\n          <name>\\n            <surname>Hughes</surname>\\n            <given-names>Scott J.</given-names>\\n          </name>\\n          <xref rid=\"aff1\" ref-type=\"aff\">&#x2020;</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" id=\"ath3\">\\n          <name>\\n            <surname>Maniaci</surname>\\n            <given-names>Chiara</given-names>\\n          </name>\\n          <xref rid=\"aff1\" ref-type=\"aff\">&#x2020;</xref>\\n          <xref rid=\"aff3\" ref-type=\"aff\">&#xA7;</xref>\\n          <xref rid=\"notes2\" ref-type=\"notes\">#</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" id=\"ath4\">\\n          <name>\\n            <surname>Testa</surname>\\n            <given-names>Andrea</given-names>\\n          </name>\\n          <xref rid=\"aff1\" ref-type=\"aff\">&#x2020;</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" id=\"ath5\">\\n          <name>\\n            <surname>Gmaschitz</surname>\\n            <given-names>Teresa</given-names>\\n          </name>\\n          <xref rid=\"aff4\" ref-type=\"aff\">&#x2225;</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" id=\"ath6\">\\n          <name>\\n            <surname>Wieshofer</surname>\\n            <given-names>Corinna</given-names>\\n          </name>\\n          <xref rid=\"aff4\" ref-type=\"aff\">&#x2225;</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" id=\"ath7\">\\n          <name>\\n            <surname>Koegl</surname>\\n            <given-names>Manfred</given-names>\\n          </name>\\n          <xref rid=\"aff4\" ref-type=\"aff\">&#x2225;</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" id=\"ath8\">\\n          <name>\\n            <surname>Riching</surname>\\n            <given-names>Kristin M.</given-names>\\n          </name>\\n          <xref rid=\"aff5\" ref-type=\"aff\">&#x22A5;</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" id=\"ath9\">\\n          <name>\\n            <surname>Daniels</surname>\\n            <given-names>Danette L.</given-names>\\n          </name>\\n          <xref rid=\"aff5\" ref-type=\"aff\">&#x22A5;</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" id=\"ath10\">\\n          <name>\\n            <surname>Spallarossa</surname>\\n            <given-names>Andrea</given-names>\\n          </name>\\n          <xref rid=\"aff2\" ref-type=\"aff\">&#x2021;</xref>\\n        </contrib>\\n        <contrib contrib-type=\"author\" corresp=\"yes\" id=\"ath11\">\\n          <name>\\n            <surname>Ciulli</surname>\\n            <given-names>Alessio</given-names>\\n          </name>\\n          <xref rid=\"cor1\" ref-type=\"other\">*</xref>\\n          <xref rid=\"aff1\" ref-type=\"aff\">&#x2020;</xref>\\n        </contrib>\\n        <aff id=\"aff1\"><label>&#x2020;</label>Division\\nof Biological Chemistry and Drug Discovery, School of Life Sciences,\\nJames Black Centre, <institution>University of Dundee</institution>, Dow Street, DD1 5EH, Dundee, Scotland, <country>United Kingdom</country></aff>\\n        <aff id=\"aff2\"><label>&#x2021;</label>Dipartimento\\ndi Farmacia, Sezione di Chimica del Farmaco e del Prodotto Cosmetico, <institution>Universit&#xE0; degli Studi di Genova</institution>, Viale Benedetto XV 3, 16132 Genova, <country>Italy</country></aff>\\n        <aff id=\"aff3\"><label>&#xA7;</label>Medical\\nResearch Council Protein Phosphorylation and Ubiquitylation Unit,\\nSchool of Life Sciences, James Black Centre, <institution>University of Dundee</institution>, Dow Street, DD1 5EH, Dundee, Scotland, <country>United Kingdom</country></aff>\\n        <aff id=\"aff4\"><label>&#x2225;</label><institution>Boehringer\\nIngelheim RCV GmbH &amp; Co. KG</institution>, 1221 Vienna, <country>Austria</country></aff>\\n        <aff id=\"aff5\"><label>&#x22A5;</label><institution>Promega\\nCorporation</institution>, 2800 Woods Hollow Road, Madison, Wisconsin 53711, <country>United States</country></aff>\\n      </contrib-group>\\n      <author-notes>\\n        <corresp id=\"cor1\"><label>*</label>E-mail: <email>a.ciulli@dundee.ac.uk</email>.</corresp>\\n      </author-notes>\\n      <pub-date pub-type=\"epub\">\\n        <day>12</day>\\n        <month>12</month>\\n        <year>2018</year>\\n      </pub-date>\\n      <pub-date pub-type=\"ppub\">\\n        <day>24</day>\\n        <month>01</month>\\n        <year>2019</year>\\n      </pub-date>\\n      <volume>62</volume>\\n      <issue>2</issue>\\n      <fpage>699</fpage>\\n      <lpage>726</lpage>\\n      <history>\\n        <date date-type=\"received\">\\n          <day>11</day>\\n          <month>09</month>\\n          <year>2018</year>\\n        </date>\\n      </history>\\n      <permissions>\\n        <copyright-statement>Copyright &#xA9; 2018 American Chemical Society</copyright-statement>\\n        <copyright-year>2018</copyright-year>\\n        <copyright-holder>American Chemical Society</copyright-holder>\\n        <license>\\n          <license-p>This is an open access article published under a Creative Commons Attribution (CC-BY) <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html\">License</ext-link>, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.</license-p>\\n        </license>\\n      </permissions>\\n      <abstract>\\n        <p content-type=\"toc-graphic\">\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0022\" id=\"ab-tgr1\"/>\\n        </p>\\n        <p>Developing\\nPROTACs to redirect the ubiquitination activity of E3\\nligases and potently degrade a target protein within cells can be\\na lengthy and unpredictable process, and it remains unclear whether\\nany combination of E3 and target might be productive for degradation.\\nWe describe a probe-quality degrader for a ligase&#x2013;target pair\\ndeemed unsuitable: the von Hippel&#x2013;Lindau (VHL) and BRD9, a\\nbromodomain-containing subunit of the SWI/SNF chromatin remodeling\\ncomplex BAF. VHL-based degraders could be optimized from suboptimal\\ncompounds in two rounds by systematically varying conjugation patterns\\nand linkers and monitoring cellular degradation activities, kinetic\\nprofiles, and ubiquitination, as well as ternary complex formation\\nthermodynamics. The emerged structure&#x2013;activity relationships\\nguided the discovery of VZ185, a potent, fast, and selective degrader\\nof BRD9 and of its close homolog BRD7. Our findings qualify a new\\nchemical tool for BRD7/9 knockdown and provide a roadmap for PROTAC\\ndevelopment against seemingly incompatible target&#x2013;ligase combinations.</p>\\n      </abstract>\\n      <custom-meta-group>\\n        <custom-meta>\\n          <meta-name>document-id-old-9</meta-name>\\n          <meta-value>jm8b01413</meta-value>\\n        </custom-meta>\\n        <custom-meta>\\n          <meta-name>document-id-new-14</meta-name>\\n          <meta-value>jm-2018-01413x</meta-value>\\n        </custom-meta>\\n        <custom-meta>\\n          <meta-name>ccc-price</meta-name>\\n          <meta-value/>\\n        </custom-meta>\\n      </custom-meta-group>\\n    </article-meta>\\n  </front>\\n  <body>\\n    <sec id=\"sec1\">\\n      <title>Introduction</title>\\n      <p>Targeted\\nprotein degradation is an emerging strategy to use small\\nmolecules to knock down a protein by hijacking the ubiquitin&#x2013;proteasome\\nsystem.<sup><xref ref-type=\"bibr\" rid=\"ref1\">1</xref>,<xref ref-type=\"bibr\" rid=\"ref2\">2</xref></sup> PROTACs (proteolysis targeting chimeras)\\nare bifunctional degrader molecules composed of a ligand for the target\\nprotein and a ligand for E3 ligase recruitment, connected by a linker.<sup><xref ref-type=\"bibr\" rid=\"ref3\">3</xref>,<xref ref-type=\"bibr\" rid=\"ref4\">4</xref></sup> Upon formation of a ternary complex target:degrader:E3,<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref>&#x2212;<xref ref-type=\"bibr\" rid=\"ref7\">7</xref></sup> the protein of interest is ubiquitinated and degraded by the proteasome.\\nCompared to target blockade, post-translational protein degradation\\nmore closely phenocopies genetic approaches to target validation and\\ncan lead to a more sustained cellular effect with more extended duration\\nof action. An attractive feature of PROTACs is their catalytic mode\\nof action, as any one molecule may perform multiple rounds of target\\nubiquitination and degradation.<sup><xref ref-type=\"bibr\" rid=\"ref8\">8</xref></sup> A consequence\\nof this feature is that degraders can function at substoichiometric\\nreceptor occupancies, meaning they exhibit degradation activities\\nat concentrations that can be orders of magnitude lower than their\\nbinary dissociation constants (<italic>K</italic><sub>d</sub>) from\\nthe target, alleviating the requirement for full target engagement.<sup><xref ref-type=\"bibr\" rid=\"ref9\">9</xref></sup> Moreover, PROTAC molecules can add a layer of\\ntarget selectivity beyond that expected from the constitutive binding\\nligands, thus providing highly selective degraders with reduced off-target\\neffect.<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref>,<xref ref-type=\"bibr\" rid=\"ref10\">10</xref>&#x2212;<xref ref-type=\"bibr\" rid=\"ref12\">12</xref></sup> The mounting interest\\nin PROTAC drug discovery is also motivated by the promise to target\\nproteins considered &#x201C;undruggable&#x201D; via conventional medicinal\\nchemistry approaches.<sup><xref ref-type=\"bibr\" rid=\"ref13\">13</xref></sup> To date, different\\ntarget classes have been successfully degraded, including epigenetic\\ntargets such as bromodomain-containing proteins BRD2, BRD3, and BRD4,<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref>,<xref ref-type=\"bibr\" rid=\"ref10\">10</xref>,<xref ref-type=\"bibr\" rid=\"ref11\">11</xref>,<xref ref-type=\"bibr\" rid=\"ref14\">14</xref>&#x2212;<xref ref-type=\"bibr\" rid=\"ref17\">17</xref></sup> BRD9,<sup><xref ref-type=\"bibr\" rid=\"ref18\">18</xref></sup> TRIM24,<sup><xref ref-type=\"bibr\" rid=\"ref19\">19</xref></sup> SIRT2,<sup><xref ref-type=\"bibr\" rid=\"ref20\">20</xref></sup> PCAF/GNC5,<sup><xref ref-type=\"bibr\" rid=\"ref21\">21</xref></sup> protein kinases,<sup><xref ref-type=\"bibr\" rid=\"ref8\">8</xref>,<xref ref-type=\"bibr\" rid=\"ref12\">12</xref>,<xref ref-type=\"bibr\" rid=\"ref22\">22</xref>&#x2212;<xref ref-type=\"bibr\" rid=\"ref26\">26</xref></sup> nuclear receptors,<sup><xref ref-type=\"bibr\" rid=\"ref27\">27</xref>,<xref ref-type=\"bibr\" rid=\"ref28\">28</xref></sup> and E3 ubiquitin ligases to self-degrade.<sup><xref ref-type=\"bibr\" rid=\"ref29\">29</xref>,<xref ref-type=\"bibr\" rid=\"ref30\">30</xref></sup></p>\\n      <p>To fulfill the potential of targeted protein degradation,\\na general\\nmethodology for an efficient PROTAC design would be desirable. However,\\nthe development of active PROTAC degraders is often a laborious and\\nunguided process. The choice of E3 ligase and the selection of target\\nligands and their conjugation are all potential optimization variables\\nthat expand the chemical space to be exploited by medicinal chemists.\\nProperties of the linker, such as length, composition, and site of\\nattachment, are known to be important but often their impact on activity\\nvary in a target- and context-dependent fashion.<sup><xref ref-type=\"bibr\" rid=\"ref11\">11</xref>,<xref ref-type=\"bibr\" rid=\"ref24\">24</xref>,<xref ref-type=\"bibr\" rid=\"ref29\">29</xref>,<xref ref-type=\"bibr\" rid=\"ref31\">31</xref>,<xref ref-type=\"bibr\" rid=\"ref32\">32</xref></sup> Moreover, small-molecule binders for both the protein\\nof interest and the E3 ligase are required. Despite the large number\\nof human E3 ubiquitin ligases postulated to function in cells, only\\na few have good-quality ligands<sup><xref ref-type=\"bibr\" rid=\"ref33\">33</xref></sup> that\\nhave been successfully used for PROTACs.<sup><xref ref-type=\"bibr\" rid=\"ref34\">34</xref></sup> The most common ligases recruited are the von Hippel&#x2013;Lindau\\n(VHL) protein complex CRL2<sup>VHL</sup> and the cereblon (CRBN) complex\\nCRL4<sup>CRBN</sup>. Studies have shown that PROTACs made of the same\\ntarget ligand but either VHL or CRBN ligands can exhibit different\\ndegradation selectivity and efficacy.<sup><xref ref-type=\"bibr\" rid=\"ref11\">11</xref>,<xref ref-type=\"bibr\" rid=\"ref14\">14</xref>,<xref ref-type=\"bibr\" rid=\"ref18\">18</xref>,<xref ref-type=\"bibr\" rid=\"ref22\">22</xref></sup> In some systems, CRBN-based\\ndegraders show a more active profile than VHL-based molecules. Potential\\ngreater flexibility of the Cullin4 based CRL4<sup>CRBN</sup> compared\\nto CRL2<sup>VHL</sup> has been invoked to suggest more productive\\nubiquitination of the accessible lysine residues on the target protein.<sup><xref ref-type=\"bibr\" rid=\"ref1\">1</xref>,<xref ref-type=\"bibr\" rid=\"ref32\">32</xref>,<xref ref-type=\"bibr\" rid=\"ref35\">35</xref></sup> These observations would suggest\\nthat the development of VHL-based degraders might require more exploration\\nin the PROTAC design than those based on CRBN. Even if degradation\\nof a given target protein can be readily obtained by recruiting one\\nE3 ligase, emerging evidence suggests that it could be beneficial\\nto develop a parallel chemical series hijacking other E3 ligases.\\nFor example, chemical liabilities on a particular ligase ligand could\\nbe readily circumvented by switching to a different compound. The\\nhijacked E3 ligase expression and intrinsic activity may be context-dependent,\\nand vary widely among different cells and tissue types.<sup><xref ref-type=\"bibr\" rid=\"ref36\">36</xref></sup> Furthermore, resistance mechanisms could potentially\\narise from the loss of the hijacked E3 ligase, as demonstrated by\\nthe correlation between level of CRBN and response to CRBN-recruiting\\ndrugs in multiple myeloma.<sup><xref ref-type=\"bibr\" rid=\"ref37\">37</xref></sup> Switching\\nthe hijacked ligase can thus aid targeted protein degradation. It\\nhowever remains unclear whether optimal target&#x2013;E3 pairs exist\\nor indeed whether any combination of E3 ligase and target protein\\nmight be tractable.</p>\\n      <p>Here, we demonstrate the development of\\nprobe-quality PROTACs for\\na ligase&#x2013;target pair previously considered incompatible: VHL\\nand the protein BRD9.<sup><xref ref-type=\"bibr\" rid=\"ref18\">18</xref></sup> BRD9 and its close\\nhomolog BRD7 (85% sequence identity<sup><xref ref-type=\"bibr\" rid=\"ref38\">38</xref></sup>)\\nare bromodomain-containing subunits of the BAF (BRG-/BRM-associated\\nfactor) and PBAF (polybromo-associated BAF) complexes, respectively.<sup><xref ref-type=\"bibr\" rid=\"ref39\">39</xref>,<xref ref-type=\"bibr\" rid=\"ref40\">40</xref></sup> BAF and PBAF represent two variants of the SWI/SNF complex, one\\nof the four mammalian ATP-dependent chromatin remodeling complexes.\\nThe SWI/SNF complexes control gene expression, DNA replication, and\\nDNA repair by modulating access to promoters and coding regions of\\nDNA through modification of the degree of compactness of chromatin.<sup><xref ref-type=\"bibr\" rid=\"ref41\">41</xref>&#x2212;<xref ref-type=\"bibr\" rid=\"ref43\">43</xref></sup> Mounting evidence from genetics and sequencing of cancer-associated\\nmutations have spurred efforts to unravel yet largely elusive physiological\\nroles of BAF/PBAF subunits and to develop targeted therapeutics in\\ncancer and other human diseases.<sup><xref ref-type=\"bibr\" rid=\"ref39\">39</xref></sup> In particular,\\nBRD9 is overexpressed in several malignancies, such as cervical cancer\\nand in non-small-cell lung cancer (NSCLC).<sup><xref ref-type=\"bibr\" rid=\"ref44\">44</xref>,<xref ref-type=\"bibr\" rid=\"ref45\">45</xref></sup> In contrast, BRD7 gene has been proposed as candidate tumor suppressor\\ngene,<sup><xref ref-type=\"bibr\" rid=\"ref46\">46</xref>&#x2212;<xref ref-type=\"bibr\" rid=\"ref49\">49</xref></sup> as it regulates breast cancer cell metabolism<sup><xref ref-type=\"bibr\" rid=\"ref50\">50</xref></sup> and acts as negative regulator of aerobic glycolysis essential\\nfor tumor progression.<sup><xref ref-type=\"bibr\" rid=\"ref51\">51</xref></sup> BRD7 also promotes\\nX-box binding protein 1 (XBP1) nuclear translocation, which prevents\\nthe development of insulin-resistance disorders.<sup><xref ref-type=\"bibr\" rid=\"ref52\">52</xref></sup> In contrast to these roles, it has been recently shown\\nthat inactivation of the BRD7 gene sensitizes tumor cells to T cell-mediated\\nkilling, suggesting that knockdown of BRD7 could be an attractive\\ntarget for cancer immunotherapy.<sup><xref ref-type=\"bibr\" rid=\"ref53\">53</xref></sup> Potent\\nand selective inhibitors that bind to the BRD7/9 bromodomains have\\nrecently emerged from structure-guided medicinal chemistry campaigns,\\nincluding compounds I-BRD9,<sup><xref ref-type=\"bibr\" rid=\"ref38\">38</xref></sup> LP99,<sup><xref ref-type=\"bibr\" rid=\"ref54\">54</xref></sup> ketone &#x201C;compound <bold>28</bold>&#x201D;,<sup><xref ref-type=\"bibr\" rid=\"ref55\">55</xref></sup> BI-7273 and BI-9564<sup><xref ref-type=\"bibr\" rid=\"ref56\">56</xref></sup> (<bold>1a</bold>,<bold>b</bold>, <xref rid=\"fig1\" ref-type=\"fig\">Figure <xref rid=\"fig1\" ref-type=\"fig\">1</xref></xref>), and GNE-375.<sup><xref ref-type=\"bibr\" rid=\"ref57\">57</xref></sup> These BRD7/9 inhibitors have been used in cells to help clarify\\nthe roles of the BRD7/9 bromodomains in oncogenesis and other disease\\nstates. For example, pharmacological studies of inhibitors <bold>1a</bold> and <bold>1b</bold> in combination with domain-swap protein engineering\\nrevealed that an active bromodomain of BRD9 is required to sustain\\nMYC transcription and proliferation of leukemic cells.<sup><xref ref-type=\"bibr\" rid=\"ref56\">56</xref>,<xref ref-type=\"bibr\" rid=\"ref58\">58</xref></sup> These findings and availability of bromodomain ligands prompted\\nus to initiate a PROTAC medicinal chemistry campaign to target BRD7\\nand BRD9 proteins for degradation.</p>\\n      <fig id=\"fig1\" position=\"float\">\\n        <label>Figure 1</label>\\n        <caption>\\n          <p>Chemical structures of parent (<bold>1a</bold>, <bold>1b</bold>, <bold>2</bold>&#x2013;<bold>4</bold>) and modified\\n(<bold>1c</bold>, <bold>2a</bold>&#x2013;<bold>4a</bold>) BRD7/9 and\\nE3 ligase ligands.\\nFunctional groups selected for conjugation are shown in blue on parent\\nligands and in red on modified ligands.</p>\\n        </caption>\\n        <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0001\" id=\"gr1\" position=\"float\"/>\\n      </fig>\\n    </sec>\\n    <sec id=\"sec2\">\\n      <title>Results and Discussion</title>\\n      <sec id=\"sec2.1\">\\n        <title>First Generation of BRD7 and BRD9 Degraders</title>\\n        <p>We began\\nour investigation by designing a small set of PROTACs aimed to induce\\nBRD7/9 degradation by recruiting three different E3 ubiquitin ligases:\\nVHL, CRBN, and DCAF15.<sup><xref ref-type=\"bibr\" rid=\"ref59\">59</xref>,<xref ref-type=\"bibr\" rid=\"ref60\">60</xref></sup> We aimed to leverage available\\nE3 ligase ligands and to maximize the opportunity for complementary\\nsurfaces between the bromodomain and the ligase within the ternary\\ncomplex. As BRD7/9 bromodomain ligands, we selected compounds <bold>1a</bold>,<bold>b</bold> (<xref rid=\"fig1\" ref-type=\"fig\">Figure <xref rid=\"fig1\" ref-type=\"fig\">1</xref></xref>),<sup><xref ref-type=\"bibr\" rid=\"ref56\">56</xref></sup> on the basis of their\\nhigh binding affinity<sup><xref ref-type=\"bibr\" rid=\"ref56\">56</xref></sup> and of their superiority\\nas BRD9 chemical probes over other ligands.<sup><xref ref-type=\"bibr\" rid=\"ref58\">58</xref></sup> To design the first generation of degraders, we inspected the crystal\\nstructure of <bold>1a</bold> bound to BRD9 (PDB code 5EU1)<sup><xref ref-type=\"bibr\" rid=\"ref56\">56</xref></sup> to identify suitable attachment points and vectors for\\nlinker conjugation, important considerations for PROTAC design as\\nknown to greatly influence degradation activities.<sup><xref ref-type=\"bibr\" rid=\"ref11\">11</xref>,<xref ref-type=\"bibr\" rid=\"ref29\">29</xref></sup> The dimethylamine group of the molecule was identified as a solvent-exposed\\ngroup not involved in interactions with the protein. For synthetic\\nreasons, the dimethylamine group of compound <bold>1a</bold> was replaced\\nby a piperazine group (BrdL1 (<bold>1c</bold>), <xref rid=\"fig1\" ref-type=\"fig\">Figure <xref rid=\"fig1\" ref-type=\"fig\">1</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S1</ext-link>), providing a convenient isosteric handle. As E3\\nligase recruiting moieties, VH032 (<bold>2</bold>, VHL ligand, <xref rid=\"fig1\" ref-type=\"fig\">Figure <xref rid=\"fig1\" ref-type=\"fig\">1</xref></xref>)<sup><xref ref-type=\"bibr\" rid=\"ref61\">61</xref>&#x2212;<xref ref-type=\"bibr\" rid=\"ref63\">63</xref></sup> and pomalidomide\\n(<bold>3</bold>, CRBN ligand, <xref rid=\"fig1\" ref-type=\"fig\">Figure <xref rid=\"fig1\" ref-type=\"fig\">1</xref></xref>)<sup><xref ref-type=\"bibr\" rid=\"ref64\">64</xref></sup> were selected and modified\\nto afford compounds VHL1 (<bold>2a</bold>) and <bold>3a</bold> (<xref rid=\"fig1\" ref-type=\"fig\">Figure <xref rid=\"fig1\" ref-type=\"fig\">1</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S1</ext-link>). The amino\\nterminal groups of <bold>2a</bold> and <bold>3a</bold> were conjugated\\nvia amide bond to the linker without perturbing the interaction with\\nthe E3 ligases, as previously demonstrated.<sup><xref ref-type=\"bibr\" rid=\"ref8\">8</xref>,<xref ref-type=\"bibr\" rid=\"ref10\">10</xref>,<xref ref-type=\"bibr\" rid=\"ref15\">15</xref>,<xref ref-type=\"bibr\" rid=\"ref22\">22</xref></sup> To expand\\nthe arsenal of E3 ligase ligands being explored, we designed conjugates\\ncontaining indisulam (<bold>4</bold>, <xref rid=\"fig1\" ref-type=\"fig\">Figure <xref rid=\"fig1\" ref-type=\"fig\">1</xref></xref>), a small molecule recently reported to\\nbind to the E3 ligase DCAF15 and to redirect the activity of the CRL4<sup>DCAF15</sup> complex toward the neosubstrate CAPER&#x3B1; (also known\\nas RBM39).<sup><xref ref-type=\"bibr\" rid=\"ref59\">59</xref>,<xref ref-type=\"bibr\" rid=\"ref60\">60</xref></sup> As the binding mode of <bold>4</bold> is not known, we leveraged information on the activity of\\na biotinylated photoactive analogue probe to guide our conjugation\\nstrategy.<sup><xref ref-type=\"bibr\" rid=\"ref60\">60</xref></sup> Accordingly, a <italic>para</italic>-benzylamine analogue of <bold>4</bold> (derivative <bold>4a</bold>, <xref rid=\"fig1\" ref-type=\"fig\">Figure <xref rid=\"fig1\" ref-type=\"fig\">1</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S1</ext-link>) was designed\\nas conjugatable ligase ligand. To generate a first set of compounds,\\nwe decided to use PEG linkers composed of two or four PEG units to\\nconnect the two warheads (compounds <bold>5</bold>&#x2013;<bold>10</bold>, <xref rid=\"sch2\" ref-type=\"scheme\">Scheme <xref rid=\"sch2\" ref-type=\"scheme\">2</xref></xref>).</p>\\n        <p>Compounds <bold>5</bold>&#x2013;<bold>10</bold> were obtained as\\nreported in <xref rid=\"sch1\" ref-type=\"scheme\">Schemes <xref rid=\"sch1\" ref-type=\"scheme\">1</xref></xref> and <xref rid=\"sch2\" ref-type=\"scheme\">2</xref>. Briefly,\\nreductive amination between the commercially available 4-bromo-2,6-dimethoxybenzaldehyde\\n(<bold>11</bold>) and boc-piperazine led to the formation of compound <bold>12</bold> which was then cross-coupled with <bold>14</bold> (obtained\\nby methylation of <bold>13</bold>) under the Myaura&#x2013;Suzuki\\ncondition (one-pot two steps); the cleavage of <italic>tert</italic>-butyloxycarbonyl protecting group in acidic conditions afforded <bold>1c</bold> in quantitative yield (<xref rid=\"sch1\" ref-type=\"scheme\">Scheme <xref rid=\"sch1\" ref-type=\"scheme\">1</xref></xref>). The primary alcohol functionality of the\\nlinkers (<bold>15</bold> and <bold>16</bold>) was oxidized to aldehyde\\ngroup using a Swern reaction and condensed with the terminal secondary\\namine of <bold>1c</bold> to afford the <italic>tert</italic>-butyl\\nester intermediates <bold>17</bold> and <bold>18</bold> that were\\nconverted into the corresponding acids by trifluoroacetic acid (TFA)\\ntreatment (<xref rid=\"sch2\" ref-type=\"scheme\">Scheme <xref rid=\"sch2\" ref-type=\"scheme\">2</xref></xref>). Compounds <bold>19</bold> and <bold>20</bold> were then conjugated\\nwith the conjugatable E3 ligands (<bold>2a</bold> and <bold>3a</bold> prepared as previously described,<sup><xref ref-type=\"bibr\" rid=\"ref61\">61</xref>,<xref ref-type=\"bibr\" rid=\"ref65\">65</xref></sup> and <bold>4a</bold> synthesis in <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Synthetic Procedures</ext-link>) using HATU as coupling reagent yielding\\nfinal compounds <bold>5</bold>&#x2013;<bold>10</bold>.</p>\\n        <fig id=\"sch1\" position=\"float\">\\n          <label>Scheme 1</label>\\n          <caption>\\n            <title>Synthesis\\nof the BRD7/9 Ligand <bold>1c</bold></title>\\n            <p id=\"s1fn1\">Reagents\\nand conditions: (a)\\n1-Boc-piperazine, NaBH(OAc)<sub>3</sub>, THF, rt, overnight, yield\\n97%; (b) NaH, CH<sub>3</sub>I, DMF, 0 &#xB0;C, 5 h, yield 95%. (c)\\nStep 1: <bold>12</bold>, B<sub>2</sub>pin<sub>2</sub>, KOAc, Pd(dppf)Cl<sub>2</sub>, 1,4 dioxane, microwave, 140 &#xB0;C, 40 min. Step 2: <bold>14</bold> and K<sub>2</sub>CO<sub>3</sub> (aq) are added to step\\n1; microwave, 120 &#xB0;C, 30 min, yield 55%. (d) HCl 4 M in dioxane,\\nDCM, rt, 1 h, quantitative yield.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0013\" id=\"gr13\" position=\"float\"/>\\n        </fig>\\n        <fig id=\"sch2\" position=\"float\">\\n          <label>Scheme 2</label>\\n          <caption>\\n            <title>Synthesis of the\\nFirst Generation of Degraders</title>\\n            <p id=\"s2fn1\">Reagents and conditions:\\n(a)\\noxalyl chloride, DMSO, DCM, then TEA, &#x2212;78 &#xB0;C to rt, 2\\nh; (b) <bold>1c</bold>, NaBH(OAc)<sub>3</sub>, TEA, DMF, rt, overnight;\\n(c) TFA, DCM, rt, 2 h; (d) E3 ligand (<bold>2a</bold>, <bold>3a</bold>, or <bold>4a</bold>), HATU, HOAt, DIPEA, DMF, rt, 2 h.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0014\" id=\"gr14\" position=\"float\"/>\\n        </fig>\\n        <p>To assess the degradation activity of the first generation\\nof PROTACs,\\nHeLa cells were treated with compounds <bold>5</bold>&#x2013;<bold>10</bold> at fixed concentration of 1 &#x3BC;M, for 4 and 16 h before\\nharvesting (<xref rid=\"fig2\" ref-type=\"fig\">Figure <xref rid=\"fig2\" ref-type=\"fig\">2</xref></xref>A). CRBN-based PROTACs <bold>7</bold> and <bold>8</bold> demonstrated\\nstrong degradation of BRD9 already after 4 h of treatment, whereas\\nno BRD7 degradation was observed (<xref rid=\"fig2\" ref-type=\"fig\">Figure <xref rid=\"fig2\" ref-type=\"fig\">2</xref></xref>A). In contrast, VHL-based degraders <bold>5</bold> and <bold>6</bold> showed weak activity against both BRD7\\nand BRD9, inducing at most 20% degradation after 4 h and 30% after\\n16 h, and even weaker activity was observed with the indisulam-based\\nPROTACs <bold>9</bold> and <bold>10</bold> (<xref rid=\"fig2\" ref-type=\"fig\">Figure <xref rid=\"fig2\" ref-type=\"fig\">2</xref></xref>A). siRNA knockdown experiments (<xref rid=\"fig2\" ref-type=\"fig\">Figure <xref rid=\"fig2\" ref-type=\"fig\">2</xref></xref>B) validated the\\nspecificity of the bands observed by Western blot.</p>\\n        <fig id=\"fig2\" position=\"float\">\\n          <label>Figure 2</label>\\n          <caption>\\n            <p>Screening of first generation\\nof degraders. (A) Western blot analysis\\nof BRD9 and BRD7 levels after treatment of HeLa cells with 1 &#x3BC;M\\ncompounds for 4 and 16 h before harvesting. Degradation activity is\\nreported below each lane as % of protein abundance relative to 0.1%\\nDMSO vehicle. (B) Western blot analysis of BRD9 and BRD7 levels after\\n48 h transfection with 1.25 nM siRNA targeting respectively BRD7,\\nBRD9, or negative control (N.C.) siRNA. Intensity values are quantified\\nas described in the <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0002\" id=\"gr2\" position=\"float\"/>\\n        </fig>\\n        <p>While this research was underway,\\nRemillard et al.<sup><xref ref-type=\"bibr\" rid=\"ref18\">18</xref></sup> disclosed the BRD9 degrader\\ndBRD9 (<bold>21</bold>, <xref rid=\"fig3\" ref-type=\"fig\">Figure <xref rid=\"fig3\" ref-type=\"fig\">3</xref></xref>) confirming the\\nstrong degradation activity of our CRBN-recruiting PROTACs. Compounds <bold>7</bold> and <bold>21</bold> share the same target and E3 ligands,\\nwhich, however, were differently modified to attach two distinct linkers\\n(<xref rid=\"fig3\" ref-type=\"fig\">Figure <xref rid=\"fig3\" ref-type=\"fig\">3</xref></xref>). CRBN-based\\nPROTACs, however, can exhibit off-target degradation of non-PROTAC-targets\\nsuch as IKZF1/3 and GSPT1 due to the neomorphic activity of the CRBN\\nligand alone.<sup><xref ref-type=\"bibr\" rid=\"ref18\">18</xref>,<xref ref-type=\"bibr\" rid=\"ref66\">66</xref></sup></p>\\n        <fig id=\"fig3\" position=\"float\">\\n          <label>Figure 3</label>\\n          <caption>\\n            <p>Structures of compounds <bold>7</bold> and <bold>21</bold>.<sup><xref ref-type=\"bibr\" rid=\"ref18\">18</xref></sup></p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0003\" id=\"gr3\" position=\"float\"/>\\n        </fig>\\n        <p>We therefore turned our attention to VHL-based\\nPROTACs. Encouraged\\nby the degradation, albeit partial, of both BRD7 and BRD9 induced\\nby our initial VHL-based PROTACs, we decided to characterize the binding\\nof <bold>5</bold> biophysically and structurally. To determine the\\nbinding mode of the conjugated bromodomain ligand, compound <bold>5</bold> was cocrystallized with the BRD9 bromodomain (BRD9-BD).\\nIn the BRD9-BD:<bold>5</bold> complex, the bromodomain ligand was\\nclearly observed within its binding pocket, and its binding mode closely\\nrecapitulates that of <bold>1a</bold> (rmsd = 0.569 &#xC5;) (<xref rid=\"fig4\" ref-type=\"fig\">Figure <xref rid=\"fig4\" ref-type=\"fig\">4</xref></xref>A,B). The alkylated\\npiperazine is favorably accommodated within the binding site, with\\nthe linker directed toward solvent, as desired (<xref rid=\"fig4\" ref-type=\"fig\">Figure <xref rid=\"fig4\" ref-type=\"fig\">4</xref></xref>A,B).</p>\\n        <fig id=\"fig4\" position=\"float\">\\n          <label>Figure 4</label>\\n          <caption>\\n            <p>Ternary complex formation and analysis\\nof binding mode for compound <bold>5</bold>. (A) Cocrystal structure\\nof BRD9-BD and compound <bold>5</bold>. The warhead component of the\\ndegrader (purple and cyan; one from\\neach protomer in the ASU) recapitulates the binding of inhibitor <bold>1a</bold> (magenta, PDB code 5EUI),<sup><xref ref-type=\"bibr\" rid=\"ref56\">56</xref></sup> whereas\\nthe alkylated piperazine used to attach the linker is solvent-exposed\\nand does not form any unfavorable interactions with the protein. (B) <italic>F</italic><sub>o</sub> &#x2013; <italic>F</italic><sub>c</sub> omit\\nmap of compound <bold>5</bold> (contoured at 2.5&#x3C3;) showing electron\\ndensity for the alkylated piperazine ring. (C) BRD9-BD titrated into <bold>5</bold> alone. (D) VCB titrated into <bold>5</bold> alone. (E) VCB\\ntitrated into BRD9-BD:<bold>5</bold> binary complex. VCB binds more\\nweakly to the binary complex BRD9-BD:<bold>5</bold> (<italic>K</italic><sub>d</sub> = 73 nM) compared to compound <bold>5</bold> alone (<italic>K</italic><sub>d</sub> = 33 nM), indicating negative cooperativity.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0004\" id=\"gr4\" position=\"float\"/>\\n        </fig>\\n        <p>To characterize biophysically\\nthe interplay between VCB (VHL-ElonginC-ElonginB\\ncomplex), compound <bold>5</bold>, and the BRD9 bromodomain, we applied\\nour previously developed ITC assay<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref>,<xref ref-type=\"bibr\" rid=\"ref11\">11</xref></sup> that measures\\nthe thermodynamics and cooperativities of ternary complex formation.\\nPrevious work has demonstrated that VHL is capable of forming highly\\nstable and cooperative ternary complexes, as seen with MZ1-Brd4BD2\\n(ref (<xref ref-type=\"bibr\" rid=\"ref5\">5</xref>)) and with\\nthe homo-PROTAC dimerizer CM11 (ref (<xref ref-type=\"bibr\" rid=\"ref29\">29</xref>)). Titrations of protein into PROTAC alone revealed\\na binary binding affinity for VCB (<italic>K</italic><sub>d</sub> =\\n33 &#xB1; 2 nM, <xref rid=\"fig4\" ref-type=\"fig\">Figure <xref rid=\"fig4\" ref-type=\"fig\">4</xref></xref>D and <xref rid=\"tbl1\" ref-type=\"other\">Table <xref rid=\"tbl1\" ref-type=\"other\">1</xref></xref>) within\\n2-fold of that measured on previously characterized VHL-based BET\\ndegrader MZ1 (<italic>K</italic><sub>d</sub> = 70 nM, refs (<xref ref-type=\"bibr\" rid=\"ref5\">5</xref>) and (<xref ref-type=\"bibr\" rid=\"ref11\">11</xref>)). Similarly, the binary\\naffinity (<italic>K</italic><sub>d</sub> = 15 &#xB1; 3 nM) and binding\\nenthalpy (&#x394;<italic>H</italic> = &#x2212;12 kcal/mol) for BRD9-BD\\n(<xref rid=\"fig4\" ref-type=\"fig\">Figure <xref rid=\"fig4\" ref-type=\"fig\">4</xref></xref>C and <xref rid=\"tbl1\" ref-type=\"other\">Table <xref rid=\"tbl1\" ref-type=\"other\">1</xref></xref>) were comparable\\nto that of inhibitor <bold>1a</bold>,<sup><xref ref-type=\"bibr\" rid=\"ref56\">56</xref></sup> consistent with the conserved binding modes of <bold>5</bold> and\\ninhibitor <bold>1a</bold> observed crystallographically (<xref rid=\"fig4\" ref-type=\"fig\">Figure <xref rid=\"fig4\" ref-type=\"fig\">4</xref></xref>A). The titrations\\nof VCB into BRD9-BD:<bold>5</bold> complex (<xref rid=\"fig4\" ref-type=\"fig\">Figure <xref rid=\"fig4\" ref-type=\"fig\">4</xref></xref>E) showed that VCB binds more weakly to the\\nbinary complex BRD9-BD:<bold>5</bold> (<italic>K</italic><sub>d</sub> = 73 nM) than to compound <bold>5</bold> alone (<italic>K</italic><sub>d</sub> = 33 nM), indicating negative cooperativity (&#x3B1;\\n&lt; 1, <xref rid=\"tbl1\" ref-type=\"other\">Table <xref rid=\"tbl1\" ref-type=\"other\">1</xref></xref>). Negative\\ncooperativity has previously been observed with tetrahydroquinoline-based\\nBET PROTACs, where it was demonstrated that linker length and exit\\nvector can significantly influence ternary complex formation.<sup><xref ref-type=\"bibr\" rid=\"ref11\">11</xref></sup> On the basis of these considerations, we reasoned\\nto explore variations on the linker as well as the point of derivatization.</p>\\n        <table-wrap id=\"tbl1\" position=\"float\">\\n          <label>Table 1</label>\\n          <caption>\\n            <title>Thermodynamic Parameters of Formation\\nof Binary and Ternary Complexes between VCB, BRD9 Bromodomain, and\\nCompound <bold>5</bold> Measured by Isothermal Titration Calorimetry\\n(ITC)<xref rid=\"t1fn1\" ref-type=\"table-fn\">a</xref></title>\\n          </caption>\\n          <table frame=\"hsides\" rules=\"groups\" border=\"0\">\\n            <colgroup>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n            </colgroup>\\n            <thead>\\n              <tr>\\n                <th style=\"border:none;\" align=\"center\">syringe</th>\\n                <th style=\"border:none;\" align=\"center\">cell</th>\\n                <th style=\"border:none;\" align=\"center\"><italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">&#x394;<italic>H</italic> (kcal/mol)</th>\\n                <th style=\"border:none;\" align=\"center\">&#x394;<italic>G</italic> (kcal/mol)</th>\\n                <th style=\"border:none;\" align=\"center\">&#x2013;<italic>T</italic>&#x394;<italic>S</italic> (kcal/mol)</th>\\n                <th style=\"border:none;\" align=\"center\">\\n                  <italic>N</italic>\\n                </th>\\n                <th style=\"border:none;\" align=\"center\">&#x3B1;</th>\\n              </tr>\\n            </thead>\\n            <tbody>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">BRD9-BD</td>\\n                <td style=\"border:none;\" align=\"left\">\\n                  <bold>5</bold>\\n                </td>\\n                <td style=\"border:none;\" align=\"left\">15&#xA0;&#xB1;&#xA0;3</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;12.5&#xA0;&#xB1;&#xA0;0.4</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;10.7&#xA0;&#xB1;&#xA0;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">1.8&#xA0;&#xB1;&#xA0;0.5</td>\\n                <td style=\"border:none;\" align=\"left\">0.753&#xA0;&#xB1;&#xA0;0.004</td>\\n                <td style=\"border:none;\" align=\"left\">&#xA0;</td>\\n              </tr>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">VCB</td>\\n                <td style=\"border:none;\" align=\"left\">\\n                  <bold>5</bold>\\n                </td>\\n                <td style=\"border:none;\" align=\"left\">33&#xA0;&#xB1;&#xA0;2</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;15.2&#xA0;&#xB1;&#xA0;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;10.2&#xA0;&#xB1;&#xA0;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">4.9&#xA0;&#xB1;&#xA0;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">0.60&#xA0;&#xB1;&#xA0;0.01</td>\\n                <td style=\"border:none;\" align=\"left\">&#xA0;</td>\\n              </tr>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">&#xA0;</td>\\n                <td style=\"border:none;\" align=\"left\">BRD9-BD:<bold>5</bold></td>\\n                <td style=\"border:none;\" align=\"left\">73&#xA0;&#xB1;&#xA0;2</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;6.4&#xA0;&#xB1;&#xA0;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;9.7&#xA0;&#xB1;&#xA0;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;3.3&#xA0;&#xB1;&#xA0;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">0.75&#xA0;&#xB1;&#xA0;0.05</td>\\n                <td style=\"border:none;\" align=\"left\">0.45</td>\\n              </tr>\\n            </tbody>\\n          </table>\\n          <table-wrap-foot>\\n            <fn id=\"t1fn1\">\\n              <label>a</label>\\n              <p>All ITC titrations were performed\\nat 25 &#xB0;C. Values reported are the mean &#xB1; SEM from at least\\nthree independent measurements (<italic>n</italic> &#x2265; 3).</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n      </sec>\\n      <sec id=\"sec2.2\">\\n        <title>Second Generation of BRD7 and BRD9 Degraders</title>\\n        <p>To improve\\nternary complex formation and degradation activity of PROTACs <bold>5</bold> and <bold>6</bold>, we explored the impact of varying their\\nderivatization point, linker length, and composition (compounds <bold>22</bold>&#x2013;<bold>31</bold>, <xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref>). First, to expand the conjugation pattern\\nbetween VHL1 and BrdL1 (<xref rid=\"fig1\" ref-type=\"fig\">Figure <xref rid=\"fig1\" ref-type=\"fig\">1</xref></xref>), the number of PEG units was modified (3 units for <bold>24</bold>; 5 units for <bold>22</bold>), a more lipophilic 11-atoms\\nchain was inserted (compound <bold>23</bold>), and a different attachment\\nto BrdL1 moiety via amide conjugation was explored (compound <bold>25</bold>) (<xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref>). Furthermore, we explored a conjugation vector via a phenolic position\\n(VHL2 (<bold>2b</bold>), compounds <bold>28</bold> and <bold>31</bold>, <xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S1</ext-link>), as previously\\ndescribed.<sup><xref ref-type=\"bibr\" rid=\"ref29\">29</xref>,<xref ref-type=\"bibr\" rid=\"ref67\">67</xref></sup> To improve binary binding affinities\\nto VHL and potentially fine-tune intermolecular interactions in the\\nternary complex,<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref></sup> we replaced the VHL2\\nacetyl group with either a cyanocyclopropyl group (VHL3 (<bold>2c</bold>), derivatives <bold>27</bold> and <bold>30</bold>, <xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S1</ext-link>)<sup><xref ref-type=\"bibr\" rid=\"ref29\">29</xref>,<xref ref-type=\"bibr\" rid=\"ref62\">62</xref></sup> or a fluorocyclopropyl\\ngroup (VHL4 (<bold>2d</bold>), derivatives <bold>26</bold> and <bold>29</bold>, <xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S1</ext-link>).<sup><xref ref-type=\"bibr\" rid=\"ref63\">63</xref></sup> As assessed by crystallographic studies (for <bold>2c</bold>, PDB code 5LLI; for <bold>2d</bold>, PDB code 5NVX), these modifications accommodate snugly\\non the VHL protein surface and enhance binding affinity.<sup><xref ref-type=\"bibr\" rid=\"ref62\">62</xref>,<xref ref-type=\"bibr\" rid=\"ref63\">63</xref></sup> To allow direct comparison with the compounds from the first series,\\ncompounds <bold>26</bold>&#x2013;<bold>28</bold> and <bold>29</bold>&#x2013;<bold>31</bold> were designed to contain PEG2 and PEG4 linkers,\\nrespectively.</p>\\n        <table-wrap id=\"tbl2\" position=\"float\">\\n          <label>Table 2</label>\\n          <caption>\\n            <title>SAR of Second Generation of PROTACs<xref rid=\"t2fn1\" ref-type=\"table-fn\">a</xref></title>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0018\" id=\"GRAPHIC-d7e1465-autogenerated\" position=\"float\"/>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0019\" id=\"gr18\" position=\"float\"/>\\n          <table-wrap-foot>\\n            <fn id=\"t2fn1\">\\n              <label>a</label>\\n              <p>Footnote: *Degradation\\nactivity\\nreported as % of total protein remaining after 1 &#x3BC;M compound\\ntreatment relative to 0.1% DMSO vehicle as quantified by Western blotting\\nof HeLa cell lysates.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        <p>Compounds <bold>22</bold> and <bold>24</bold> were obtained via\\nthe same synthetic route used for the first generation (synthesis\\nof compounds <bold>22</bold>, <bold>24</bold>, and <bold>25</bold> detailed in the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>). The synthesis of <bold>23</bold> (<xref rid=\"sch3\" ref-type=\"scheme\">Scheme <xref rid=\"sch3\" ref-type=\"scheme\">3</xref></xref>) involved nucleophilic attack of diethylene\\nglycol (PEG2) to 6-bromo-1-hexene to afford derivative <bold>33</bold> that was oxidized to carboxylic acid <bold>34</bold> by treatment\\nwith TEMPO and bis-acetoxyiodobenzene (BAIB). After coupling\\nwith <bold>2a</bold>, Lemieux&#x2013;Johnson oxidation of the double\\nbond yielded the aldehyde intermediate that was reacted with amine <bold>1c</bold> to yield compound <bold>23</bold> in 54% yield. A similar\\nsynthetic strategy was applied for the synthesis of degraders <bold>26</bold>&#x2013;<bold>31</bold> (<xref rid=\"sch4\" ref-type=\"scheme\">Scheme <xref rid=\"sch4\" ref-type=\"scheme\">4</xref></xref>). Briefly, after nucleophilic substitution\\nof polyethylene glycol (PEG2 and PEG4) with allyl bromide, the alcoholic\\ngroup of <bold>38</bold> and <bold>39</bold> was activated as mesylate\\nand reacted with the phenolic group present in the VHL ligand scaffold\\naffording derivatives <bold>40</bold>&#x2013;<bold>45</bold>. The\\nalkene moiety was then oxidized, and the resulting aldehyde derivative\\nwas directly used for the final reductive amination step with <bold>1c</bold> to afford the final products <bold>26</bold>&#x2013;<bold>31</bold>.</p>\\n        <fig id=\"sch3\" position=\"float\">\\n          <label>Scheme 3</label>\\n          <caption>\\n            <title>Synthesis of Compound <bold>23</bold></title>\\n            <p id=\"s3fn1\">Reagents and conditions: (a)\\nNaH, 6-bromo-1-hexene, DMF/THF, rt, overnight; (b) BAIB, TEMPO, ACN/H<sub>2</sub>O, rt, overnight; (c) <bold>2a</bold>, HATU, HOAt, DIPEA,\\nDMF, rt, 2 h; (d) OsO<sub>4</sub> 4 wt % in H<sub>2</sub>O, NaIO<sub>4</sub>, pyridine, dioxane/H<sub>2</sub>O, rt; (e) <bold>1c</bold>, NaBH(OAc)<sub>3</sub>, TEA, DMF, rt, overnight.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0015\" id=\"gr15\" position=\"float\"/>\\n        </fig>\\n        <fig id=\"sch4\" position=\"float\">\\n          <label>Scheme 4</label>\\n          <caption>\\n            <title>Synthesis of Compounds <bold>26</bold>&#x2013;<bold>31</bold></title>\\n            <p id=\"s4fn1\">Reagents and conditions: (a)\\nNaOH, allyl bromide, dioxane, rt, overnight; (b) MsCl, TEA, DCM, rt,\\n3 h; (c) VHL ligands <bold>2b</bold>&#x2013;<bold>d</bold>, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 &#xB0;C, overnight; (d) OsO<sub>4</sub>, NaIO<sub>4</sub>, pyridine, dioxane/H<sub>2</sub>O, rt; (e) <bold>1c</bold>, NaBH(OAc)<sub>3</sub>, TEA, DMF, rt, overnight.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0016\" id=\"gr16\" position=\"float\"/>\\n        </fig>\\n        <p>All second-generation compounds were profiled for\\nBRD9 and BRD7\\ndegradation after treatment for 4 and 16 h (<xref rid=\"fig5\" ref-type=\"fig\">Figure <xref rid=\"fig5\" ref-type=\"fig\">5</xref></xref>A and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figures S2 and S3</ext-link>). The two VHL-based PROTACs <bold>5</bold> and <bold>6</bold> were included as reference compounds. Derivative <bold>26</bold> (<xref rid=\"fig5\" ref-type=\"fig\">Figure <xref rid=\"fig5\" ref-type=\"fig\">5</xref></xref>B) demonstrated marked and selective (around 90%) depletion of BRD9\\nover BRD7 already after 4 h treatment in HeLa cells (<xref rid=\"fig5\" ref-type=\"fig\">Figure <xref rid=\"fig5\" ref-type=\"fig\">5</xref></xref>A, <xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref>). By comparing and contrasting the degradation\\nprofiles of related compounds, structure&#x2013;activity relationships\\nbegan to emerge (<xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref>). As expected, the length of linkers influenced degradation profiles,\\nwith more pronounced BRD9 degradation observed with shorter linkers\\nfor given matched pairs (compare <bold>26</bold> and <bold>29</bold>; <bold>27</bold> and <bold>30</bold>; <bold>5</bold> with <bold>24</bold>, <bold>6</bold>, and <bold>22</bold>). We also observed\\nthat for a given linker length, replacement of an oxygen atom with\\na methylene group was beneficial to degradation activity (compare <bold>23</bold> vs <bold>24</bold>). Among conjugates derivatized at the\\nphenolic position of the VHL ligand, the nature of the terminal capping\\ngroup also influenced degradation potency. Within each series of conjugates\\nof fixed linker, compounds bearing the fluorocyclopropyl moiety (VHL4)\\nwere more potent degraders than those containing cyanocyclopropyl\\n(VHL3) and even more so than acetyl group (VHL2) (<bold>26</bold> vs <bold>27</bold> and <bold>28</bold>; and <bold>29</bold> vs <bold>30</bold> and <bold>31</bold>, respectively) (<xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref>). These trends are consistent with the binary\\nbinding affinity values measured for the corresponding VHL ligands.<sup><xref ref-type=\"bibr\" rid=\"ref63\">63</xref></sup> To account for potential different protein expression\\nlevels, compounds <bold>22</bold>&#x2013;<bold>31</bold> were tested\\nacross a panel of different cancer cell lines (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figures S2 and S3</ext-link>). From these degradation\\nscreens, <bold>26</bold> was confirmed as the most active compound,\\nconsistently across all assays and cell lines.</p>\\n        <fig id=\"fig5\" position=\"float\">\\n          <label>Figure 5</label>\\n          <caption>\\n            <p>Compound <bold>26</bold> induces rapid and profound depletion of\\nBRD9 in cells. (A) Western blot analysis of BRD9, BRD7, and &#x3B2;-actin\\nafter treatment of HeLa cells with 1 &#x3BC;M compounds for 4 h before\\nharvesting (data reported in <xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref>). (B) Chemical structure of <bold>26</bold>. (C) Quantification\\nof BRD9 protein levels after treatment of HeLa with six different\\nconcentrations of <bold>26</bold> at 30 min and 4 h before harvesting.\\n(D) Quantification of BRD9 protein levels after treatment with 1 &#x3BC;M <bold>26</bold> in HeLa at the desired time points. Intensity values, DC<sub>50</sub>, and half-lives were quantified as described in the <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0005\" id=\"gr5\" position=\"float\"/>\\n        </fig>\\n        <p>Compound <bold>26</bold> was further characterized by profiling\\nits concentration-dependent activity at early time points (30 min\\nand 4 h before harvesting; <xref rid=\"fig5\" ref-type=\"fig\">Figure <xref rid=\"fig5\" ref-type=\"fig\">5</xref></xref>C and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S4</ext-link>). PROTAC <bold>26</bold> induced preferential degradation\\nof BRD9 over BRD7, resulting in a half-degrading concentration (DC<sub>50</sub>) of 560 nM against BRD9 (<xref rid=\"fig5\" ref-type=\"fig\">Figure <xref rid=\"fig5\" ref-type=\"fig\">5</xref></xref>C and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S4</ext-link>). More than 60% of degradation of BRD9 was observed\\nat 1 &#x3BC;M after 4 h, while maximal degradation (<italic>D</italic><sub>max</sub> around 80%) was reached at 10 &#x3BC;M. At higher\\ndoses, the characteristic &#x201C;hook effect&#x201D; was observed,\\nconsistent with <bold>26</bold> acting preferentially as inhibitor\\nover degrader at high concentrations. Rapid and selective target degradation\\nwas confirmed by profiling cellular activities over time (<xref rid=\"fig5\" ref-type=\"fig\">Figure <xref rid=\"fig5\" ref-type=\"fig\">5</xref></xref>D and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S4</ext-link>). Treatments\\nof HeLa cells at fixed concentration (1 &#x3BC;M) of <bold>26</bold> at varying time points revealed rapid degradation of BRD9 with an\\napparent half-life of 3.5 h, resulting in more than 50% degradation\\nalready after 4 h treatment and achieving the highest level of depletion\\nafter 8 h (<xref rid=\"fig5\" ref-type=\"fig\">Figure <xref rid=\"fig5\" ref-type=\"fig\">5</xref></xref>D).</p>\\n        <p>To determine to what extent a correlation could be seen\\nbetween\\nternary complex formation and the improved degradation properties\\nof <bold>26</bold>, we turned to measurements of thermodynamic parameters\\nand cooperativity by ITC (<xref rid=\"fig6\" ref-type=\"fig\">Figure <xref rid=\"fig6\" ref-type=\"fig\">6</xref></xref>A and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S5</ext-link>). Titrating VCB into <bold>26</bold> alone or BRD9-BD:<bold>26</bold> complex indicated a cooperativity &#x3B1; = 1, an over\\n2-fold improvement over <bold>5</bold>. At the binary level compared\\nto <bold>5</bold>, we observed negligible difference between <bold>26</bold> and <bold>5</bold> in binding affinity for BRD9-BD, but\\na slight loss in affinity for VCB (<italic>K</italic><sub>d</sub> =\\n87 &#xB1; 5 nM for <bold>26</bold> compared to 33 &#xB1; 2 nM for <bold>5</bold>) (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Table S1</ext-link>).</p>\\n        <fig id=\"fig6\" position=\"float\">\\n          <label>Figure 6</label>\\n          <caption>\\n            <p>Improved ternary complex formation by series-2 degraders. (A) Overlay\\nof compound <bold>26</bold> titrations shows no difference between\\nbinary (VCB into <bold>26</bold> alone; black) and ternary (VCB into\\nBRD9-BD:<bold>26</bold> binary complex; green) titrations. (B) Fluorescence\\npolarization measurements for compound <bold>5</bold> in the presence\\n(red) and absence (black) of BRD9-BD. The rightward shift in the presence\\nof BRD9-BD indicates negative cooperativity. Each point is the mean\\n&#xB1; SEM of at least two individual experiments performed in triplicate.\\n(C) Fluorescence polarization measurements for compound <bold>26</bold> in the presence (green) and absence (black) of BRD9-BD. Each point\\nis the mean &#xB1; SEM of at least two individual experiments performed\\nin triplicate. (D) AlphaLISA assay showing increased ternary complex\\nformation for <bold>26</bold> (green) compared to <bold>5</bold> (red).\\nEach point is the mean &#xB1; SEM of at least one experiment performed\\nin quadruplicate.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0006\" id=\"gr6\" position=\"float\"/>\\n        </fig>\\n        <p>To confirm these findings,\\nwe repurposed an existing fluorescence\\npolarization (FP) assay that involves the competitive displacement\\nof a FAM-labeled HIF-1&#x3B1; peptide.<sup><xref ref-type=\"bibr\" rid=\"ref68\">68</xref></sup> By comparing PROTAC-induced peptide displacement in the presence\\nand absence of BRD9-BD, it is possible to determine the cooperativity\\n(<xref rid=\"fig6\" ref-type=\"fig\">Figure <xref rid=\"fig6\" ref-type=\"fig\">6</xref></xref>B,C). FP measurements\\nfor compound <bold>5</bold> showed a rightward shift in the IC<sub>50</sub> curve in the presence of BRD9-BD, indicating negative cooperativity,\\nwhereas compound <bold>26</bold> showed no shift. Back-calculation\\nof <italic>K</italic><sub>d</sub> values<sup><xref ref-type=\"bibr\" rid=\"ref63\">63</xref></sup> produced affinity values that were comparable to those obtained\\nby ITC (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Table S1 and Figure S5</ext-link>).</p>\\n        <p>Previous studies with VCB and BET bromodomains have\\ndemonstrated\\nthat the amount of ternary complex formed is well correlated to the\\ncooperativity of the system.<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref></sup> Therefore,\\nwe employed an AlphaLISA proximity assay to determine the effect of\\nincreasing cooperativity on ternary complex formation (<xref rid=\"fig6\" ref-type=\"fig\">Figure <xref rid=\"fig6\" ref-type=\"fig\">6</xref></xref>D). Indeed, there was a 50%\\nincrease in the maximum &#x3B1; intensity measured for VCB:<bold>26</bold>:BRD9-BD compared to VCB:<bold>5</bold>:BRD9-BD, suggesting that\\nthe increased cooperativity of <bold>26</bold> compared to <bold>5</bold> resulted in increased population of ternary complex.</p>\\n      </sec>\\n      <sec id=\"sec2.3\">\\n        <title>Third Generation\\nof BRD7 and BRD9 Degraders</title>\\n        <p>The pronounced\\ndegradation of BRD9 observed with <bold>26</bold> motivated us to\\ndesign a third generation of PROTACs with the goal to further optimize\\nour degrader. On the basis of the SAR previously acquired, the design\\nstrategy was to keep VHL4 moiety fixed and to focus on systematically\\nvarying the linker length and composition, as well as the substitution\\nand conjugation chemistry at the BRD7/9 warhead. The focus on the\\nlinker concentrated on exploring varying ratios between hydrophilic\\nand lipophilic portions within the context of three different lengths:\\n5, 8, and 11 atoms (<xref rid=\"tbl3\" ref-type=\"other\">Table <xref rid=\"tbl3\" ref-type=\"other\">3</xref></xref>). We reasoned that varying the balance between hydrophilicity\\nand lipophilicity might influence the conformational equilibria and\\nintrinsic folding propensity of the linker, with direct impact on\\nthe process of ternary complex formation as well as potentially cell\\npermeability. Linkers were connected to four different analogues of\\nBRD7/9 ligands. Guided by the structure&#x2013;activity relationships\\nof BRD7/9 bromodomain inhibitors developed by Martin et al.,<sup><xref ref-type=\"bibr\" rid=\"ref56\">56</xref></sup> we introduced two structural variations, single\\nor in combination. First, we arranged the methoxy groups on the phenyl\\nring in either meta (BrdL1, <bold>1c</bold>) or para (BrdL2, <bold>1d</bold>) (<xref rid=\"tbl3\" ref-type=\"other\">Table <xref rid=\"tbl3\" ref-type=\"other\">3</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S1</ext-link>)\\nrelative to each other. Second, we replaced the piperazine moiety\\nwith an azetidine group (BrdL3, <bold>1e</bold> and BrdL4, <bold>1f</bold>, <xref rid=\"tbl3\" ref-type=\"other\">Table <xref rid=\"tbl3\" ref-type=\"other\">3</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S1</ext-link>). For conjugation\\nbetween the bromodomain ligand and the linker, either tertiary amines\\n(via reductive amination reactions) or amide bonds were contemplated.\\nThis design yielded a set of 19 new PROTACs (<xref rid=\"tbl3\" ref-type=\"other\">Table <xref rid=\"tbl3\" ref-type=\"other\">3</xref></xref>).</p>\\n        <table-wrap id=\"tbl3\" position=\"float\">\\n          <label>Table 3</label>\\n          <caption>\\n            <title>SAR of Third Generation\\nof PROTACs<xref rid=\"t3fn1\" ref-type=\"table-fn\">a</xref></title>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0020\" id=\"GRAPHIC-d7e1999-autogenerated\" position=\"float\"/>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0021\" id=\"gr19\" position=\"float\"/>\\n          <table-wrap-foot>\\n            <fn id=\"t3fn1\">\\n              <label>a</label>\\n              <p>Footnote: *Degradation activity\\nreported as % of total protein remaining after 1 &#x3BC;M compound\\ntreatment relative to 0.1% DMSO vehicle as quantified by Western blotting\\nof HeLa and RI-1 cell lysates.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        <p>To circumvent the need to use the hazardous reagent osmium tetroxide\\npreviously applied in the Lemieux&#x2013;Johnson reaction, some key\\nmodifications and optimization to the synthesis were made (<xref rid=\"sch5\" ref-type=\"scheme\">Scheme <xref rid=\"sch5\" ref-type=\"scheme\">5</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Synthetic Procedures</ext-link>).\\nMesylation of the free hydroxy group of the linkers allowed nucleophilic\\nattack by the phenolic group of <bold>2d</bold> (<xref rid=\"sch5\" ref-type=\"scheme\">Scheme <xref rid=\"sch5\" ref-type=\"scheme\">5</xref></xref>). The lipophilic compound <bold>66</bold>, instead, was conjugated to <bold>2d</bold> via alkylation\\n(<xref rid=\"sch5\" ref-type=\"scheme\">Scheme <xref rid=\"sch5\" ref-type=\"scheme\">5</xref></xref>). Then, the\\ndiacetal functional group on the linker was hydrolyzed to aldehyde\\nunder acidic conditions to allow reductive amination with <bold>1c</bold>,<bold>d</bold> (synthesis of <bold>1d</bold> is described in the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>) warheads, leading to\\nthe formation of compounds <bold>46</bold>&#x2013;<bold>54</bold>.\\nTo conjugate the linker to <bold>1e</bold>,<bold>f</bold> via amide\\nbond, VHL-linker aldehyde intermediates were oxidized to acid through\\na Pinnick reaction. Then, HATU-mediated coupling with <bold>1e</bold>,<bold>f</bold> (synthesis described in the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>) was applied to obtain the final compounds <bold>55</bold>&#x2013;<bold>64</bold> (<xref rid=\"sch5\" ref-type=\"scheme\">Scheme <xref rid=\"sch5\" ref-type=\"scheme\">5</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Synthetic Procedures</ext-link>).</p>\\n        <fig id=\"sch5\" position=\"float\">\\n          <label>Scheme 5</label>\\n          <caption>\\n            <title>General Synthetic Routes for Third-Generation\\nCompounds</title>\\n            <p id=\"s5fn1\">Reagents and conditions: (a)\\nMsCl, TEA, DCM, rt, 3 h; (b) <bold>2d</bold>, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 &#xB0;C, overnight; (c) K<sub>2</sub>CO<sub>3</sub>, DMF, 70 &#xB0;C, overnight; (d) HCl 1 N, THF (1:1), 50 &#xB0;C,\\n2 h; (e) <bold>1c</bold>,<bold>d</bold>, NaBH(OAc)<sub>3</sub>, TEA,\\nDMF, rt, overnight; (f) Na<sub>2</sub>HPO<sub>4</sub>, NaClO<sub>2</sub>, 2-methyl-2-butene, <italic>t</italic>-BuOH, H<sub>2</sub>O, rt,\\n4 h ; (g) <bold>1e</bold>,<bold>f</bold>, HATU, HOAt, DIPEA, DMF,\\nrt, 2 h.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0017\" id=\"gr17\" position=\"float\"/>\\n        </fig>\\n        <p>Degraders <bold>46</bold>&#x2013;<bold>64</bold> were screened\\nat 1 &#x3BC;M in HeLa cells following 4 and 16 h of treatment (<xref rid=\"tbl3\" ref-type=\"other\">Table <xref rid=\"tbl3\" ref-type=\"other\">3</xref></xref>, <xref rid=\"fig7\" ref-type=\"fig\">Figure <xref rid=\"fig7\" ref-type=\"fig\">7</xref></xref>A and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S6</ext-link>). A large proportion of compounds induced\\nefficient degradation of both BRD7 and BRD9 in HeLa cells, with less\\nthan 10% total protein remaining after 4 h treatment (<xref rid=\"tbl3\" ref-type=\"other\">Table <xref rid=\"tbl3\" ref-type=\"other\">3</xref></xref>, <xref rid=\"fig7\" ref-type=\"fig\">Figure <xref rid=\"fig7\" ref-type=\"fig\">7</xref></xref>A). Overall, within matched pairs, greater\\ndegradation activity was observed for compounds containing <italic>meta</italic> (BrdL1 and BrdL3) over <italic>para</italic> (BrdL2\\nand BrdL4) dimethoxy substituents (as representative examples: <bold>46</bold> vs <bold>47</bold>, <bold>26</bold> vs <bold>48</bold>, <bold>51</bold> vs <bold>52</bold>, <xref rid=\"fig7\" ref-type=\"fig\">Figure <xref rid=\"fig7\" ref-type=\"fig\">7</xref></xref>A). To assess consistency of cellular activity, compound\\nscreening was repeated in RI-1 (DLBCL) cells after 2 h of treatment\\n(<xref rid=\"tbl3\" ref-type=\"other\">Table <xref rid=\"tbl3\" ref-type=\"other\">3</xref></xref>, <xref rid=\"fig7\" ref-type=\"fig\">Figure <xref rid=\"fig7\" ref-type=\"fig\">7</xref></xref>B). This cell line\\nwas chosen because it is sensitive to BRD9 inhibition,<sup><xref ref-type=\"bibr\" rid=\"ref58\">58</xref></sup> it is of clinical relevance, and it also expresses\\nboth VHL and CRBN ligases (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S7</ext-link>). The compounds that induced greatest protein degradation\\nactivity after 2 h were <bold>46</bold> and <bold>52</bold> (on BRD9),\\nand <bold>51</bold> (on BRD7) (<xref rid=\"fig7\" ref-type=\"fig\">Figure <xref rid=\"fig7\" ref-type=\"fig\">7</xref></xref>B). Compounds <bold>46</bold> and <bold>51</bold> differ\\nonly by one atom in the center of the linker, which is oxygen or carbon,\\nrespectively (<xref rid=\"tbl3\" ref-type=\"other\">Table <xref rid=\"tbl3\" ref-type=\"other\">3</xref></xref>). Compound <bold>52</bold> is the analogue of <bold>51</bold> but\\nwith BrdL2 instead of BrdL1 (<xref rid=\"tbl3\" ref-type=\"other\">Table <xref rid=\"tbl3\" ref-type=\"other\">3</xref></xref>). <bold>46</bold> and <bold>51</bold> showed enhanced\\ndegradation of BRD9 compared to <bold>26</bold>, and similar levels\\nof degradation compared to CRBN-based degrader <bold>7</bold> in RI-1\\ncells after 8 h treatment. In addition, <bold>46</bold> and <bold>51</bold> achieved PROTAC-induced degradation of BRD7 in addition\\nto BRD9 (<xref rid=\"fig7\" ref-type=\"fig\">Figure <xref rid=\"fig7\" ref-type=\"fig\">7</xref></xref>C).</p>\\n        <fig id=\"fig7\" position=\"float\">\\n          <label>Figure 7</label>\\n          <caption>\\n            <p>Screening\\nof third generation of degraders. (A) Western-blot analysis\\nof BRD9 and BRD7 levels after treatment of HeLa cells with 1 &#x3BC;M\\ncompounds for 4 h before harvesting. (B) Western blot analysis of\\nBRD9 and BRD7 levels after treatment of RI-1 cells with 1 &#x3BC;M\\ncompounds for 2 h before harvesting. (C) Western blot analysis of\\nBRD9 and BRD7 levels after treatment of RI-1 cells with 1 &#x3BC;M <bold>7</bold>, <bold>26</bold>, <bold>46</bold>, and <bold>51</bold> for\\n2 and 8 h before harvesting. Intensity values were quantified as described\\nin the <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0007\" id=\"gr7\" position=\"float\"/>\\n        </fig>\\n        <p>We next decided to assess the concentration-dependent\\nactivity\\nof <bold>46</bold> and <bold>51</bold> in RI-1 cells at two time points\\n(2 and 8 h) after treatments at different concentrations (<xref rid=\"fig8\" ref-type=\"fig\">Figure <xref rid=\"fig8\" ref-type=\"fig\">8</xref></xref>A,C). This experiment\\nrevealed <bold>51</bold> to be the most potent of the two, achieving\\nmaximal protein degradation of BRD9 in the 10&#x2013;100 nM window,\\nand of BRD7 between 0.1&#x2013;1 &#x3BC;M, with the hook effect observed\\nat higher concentrations with both proteins (<xref rid=\"fig8\" ref-type=\"fig\">Figure <xref rid=\"fig8\" ref-type=\"fig\">8</xref></xref>A). In contrast, <bold>46</bold> required\\nconcentrations of about 10-fold higher than <bold>51</bold> to achieve\\nits <italic>D</italic><sub>max</sub>, and consequently longer treatment\\ntimes to achieve similar degradation levels of both BRD9 and BRD7\\n(<xref rid=\"fig8\" ref-type=\"fig\">Figure <xref rid=\"fig8\" ref-type=\"fig\">8</xref></xref>A). Dose-dependent\\ndegradation profiles of <bold>51</bold> at the 8 h time-point gave\\nhalf-degrading concentrations (DC<sub>50</sub>) of 1.76 nM and 4.5\\nnM against BRD9 and BRD7, respectively (<xref rid=\"fig8\" ref-type=\"fig\">Figure <xref rid=\"fig8\" ref-type=\"fig\">8</xref></xref>C). The pronounced hook effect observed on\\nBRD9 protein levels upon treatment with 1 &#x3BC;M of <bold>51</bold> (<xref rid=\"fig8\" ref-type=\"fig\">Figure <xref rid=\"fig8\" ref-type=\"fig\">8</xref></xref>A,C) explains\\nits apparent weaker degradation activity in the initial screening\\n(<xref rid=\"fig7\" ref-type=\"fig\">Figure <xref rid=\"fig7\" ref-type=\"fig\">7</xref></xref>B). The potent\\nand rapid protein degradation induced by <bold>51</bold> was confirmed\\nby assessing its activity in RI-1 cells treated with 10 nM or 100\\nnM of compound at varying time points (<xref rid=\"fig8\" ref-type=\"fig\">Figure <xref rid=\"fig8\" ref-type=\"fig\">8</xref></xref>D). Levels of both BRD7 and BRD9 decreased\\nby more than 50% already after 30 min of treatment at 100 nM, reaching\\nmore than 90% of degradation after 4 h. No protein recovery was observed\\nthrough 48 h of treatment. At the lower concentration used (10 nM) <bold>51</bold> was seen to degrade preferentially BRD9 over BRD7, consistent\\nwith the lower DC<sub>50</sub> value for BRD9 versus BRD7. Together,\\nthe results of the stepwise design and optimization of VHL-based degraders\\nallowed us to identify <bold>51</bold> as our most potent degrader,\\nwith DC<sub>50</sub> in the single-digit nanomolar range and profound <italic>D</italic><sub>max</sub> greater than 90% (<xref rid=\"fig8\" ref-type=\"fig\">Figure <xref rid=\"fig8\" ref-type=\"fig\">8</xref></xref>). These data qualified PROTAC <bold>51</bold> as a potent dual BRD9 and BRD7 degrader, hence afterward referred\\nto as VZ185.</p>\\n        <fig id=\"fig8\" position=\"float\">\\n          <label>Figure 8</label>\\n          <caption>\\n            <p>VZ185 induces strong and rapid degradation in a time-\\nand dose-dependent\\nmanner. (A) Western blot analysis of BRD9, BRD7, and &#x3B2;-actin\\nafter treatment of RI-1 cells with six different concentrations of\\ncompounds <bold>46</bold> and <bold>51</bold> for 2 and 8 h before\\nharvesting. (B) Chemical structures of <bold>51</bold> (VZ185) and <bold>46</bold>. (C) Quantification of protein levels relative to DMSO\\ncontrol after treatment with different concentration of VZ185 and\\nDC<sub>50</sub> values. (D) Time-dependent experiment in RI-1 cells\\nafter treatment with 10 nM and 100 nM <bold>51</bold> at the desired\\ntime points. Intensity values and DC<sub>50</sub> were quantified\\nas described in the <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0008\" id=\"gr8\" position=\"float\"/>\\n        </fig>\\n        <p>To confirm the potent and rapid\\ndegradation activity of VZ185 and\\nits superiority over close analogues, we employed orthogonal kinetic\\ndegradation studies using live cell luminescent monitoring of BRD7\\nand BRD9 endogenously tagged with HiBiT in HEK293 cells using CRISPR/Cas9.<sup><xref ref-type=\"bibr\" rid=\"ref69\">69</xref></sup> Degradation profile experiments carried out\\nover 24 h confirmed the superior degradation activity of VZ185 over\\ncompounds <bold>26</bold> and <bold>46</bold> at a fixed concentration\\nof 1 &#x3BC;M (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S8</ext-link>). Treatment across a range of concentrations of VZ185 of both HiBiT-BRD7\\nand HiBiT-BRD9 revealed differential degradation profiles (<xref rid=\"fig9\" ref-type=\"fig\">Figure <xref rid=\"fig9\" ref-type=\"fig\">9</xref></xref>A) and allowed the\\ncalculation of <italic>D</italic><sub>max</sub>, DC<sub>50</sub> values,\\nand initial rates of degradation (<xref rid=\"fig9\" ref-type=\"fig\">Figure <xref rid=\"fig9\" ref-type=\"fig\">9</xref></xref>B,C). Indeed, rapid degradation was observed\\nwithin a few hours by VZ185 showing preference for BRD9 as compared\\nto BRD7 (BRD9-DC<sub>50</sub> = 4 nM; BRD7-DC<sub>50</sub> = 34 nM)\\n(<xref rid=\"fig9\" ref-type=\"fig\">Figure <xref rid=\"fig9\" ref-type=\"fig\">9</xref></xref>B). Degradation\\nrate was directly proportional to the concentration of VZ185 except\\nat high concentration for BRD9 where the curve reaches a plateau (<xref rid=\"fig9\" ref-type=\"fig\">Figure <xref rid=\"fig9\" ref-type=\"fig\">9</xref></xref>C). This trend was\\nin line with the strong &#x201C;hook effect&#x201D; previously observed\\nwith VZ185. Degradation activity was also confirmed within matched-pairs <bold>26</bold>&#x2013;<bold>48</bold> and VZ185-<bold>52</bold> with CRISPR/Cas9-mediated\\nHiBiT endogenous tagging of BRD9 and BRD7 in HEK293 cells (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S8</ext-link>). In addition,\\ndegradation analysis in a panel of other human cancer cell lines (EOL-1,\\nA-204) confirmed the potency of VZ185, showing a DC<sub>50</sub> between\\n2 and 8 nM for BRD9 (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S9</ext-link>).</p>\\n        <fig id=\"fig9\" position=\"float\">\\n          <label>Figure 9</label>\\n          <caption>\\n            <p>Quantitative live-cell kinetics of VZ185 induced degradation of\\nBRD7 and BRD9. Degradation profile (A), calculation of DC<sub>50</sub> values (B), and initial degradation rate (C) across concentration\\nseries indicated of VZ185 using continual luminescent reading of CRISPR/Cas9\\nendogenously tagged HiBiT-BRD7 or HiBiT-BRD9 in HEK293 cells. Error\\nbars are expressed as SEM taken from <italic>n</italic> = 3 experiments.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0009\" id=\"gr9\" position=\"float\"/>\\n        </fig>\\n        <p>Following its identification as\\nthe best degrader, we subjected\\nVZ185 to a thorough biophysical characterization in order to dissect\\nthe molecular basis underpinning its potent degradation activity.\\nBoth the ITC and FP data indicated that the PROTAC was not more cooperative\\nthan <bold>26</bold> (<xref rid=\"tbl4\" ref-type=\"other\">Table <xref rid=\"tbl4\" ref-type=\"other\">4</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figures S5 and S10</ext-link>). Consistent with this, the amount of ternary complex\\nestimated by AlphaLISA was also not significantly different from that\\nmeasured for <bold>26</bold> (<xref rid=\"tbl4\" ref-type=\"other\">Table <xref rid=\"tbl4\" ref-type=\"other\">4</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S10</ext-link>). However, the binary affinity for both VCB (<italic>K</italic><sub>d</sub> = 26 &#xB1; 9 nM) and the BRD9 bromodomain (<italic>K</italic><sub>d</sub> = 5.1 &#xB1; 0.6 nM) was significantly greater\\nthan <bold>26</bold>. The pronounced binary affinity for each respective\\nprotein provides some basis for the strong &#x201C;hook effect&#x201D;\\nobserved in the degradation assays, consistent with previous reports\\nthat a high binary affinity can direct PROTACs to function preferentially\\nas inhibitors at higher concentrations and exhibit strong hook effects.<sup><xref ref-type=\"bibr\" rid=\"ref11\">11</xref></sup> Despite the absence of a significant boost in\\ncooperativity over <bold>26</bold>, the total &#x394;<italic>G</italic>&#xB0; for ternary complex formation increased to &#x2212;21.7 kcal/mol,\\nwhich is greater compared to those of <bold>26</bold> (&#x2212;20.7\\nkcal/mol) and <bold>5</bold> (&#x2212;20.4 kcal/mol) (<xref rid=\"tbl4\" ref-type=\"other\">Table <xref rid=\"tbl4\" ref-type=\"other\">4</xref></xref>) and in line with that of our\\npotent Brd4 degrader MZ1 (&#x2212;22.2 kcal/mol).<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref></sup> VZ185 and its analogues <bold>26</bold> and <bold>46</bold> all showed low cell permeability in PAMPA assay, suggesting that\\npermeability is unlikely to be the main driver of the enhanced degradation\\nactivity of VZ185 (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Table S3</ext-link>). The data\\ntogether suggest that the thermodynamically more stable ternary complex\\nformed by VZ185 helps to drive its more potent and rapid degradation\\nactivity, in spite of its low cell permeability.</p>\\n        <table-wrap id=\"tbl4\" position=\"float\">\\n          <label>Table 4</label>\\n          <caption>\\n            <title>Biophysical Comparison between BRD9\\nDegraders from Three Generations</title>\\n          </caption>\\n          <table frame=\"hsides\" rules=\"groups\" border=\"0\">\\n            <colgroup>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n            </colgroup>\\n            <thead>\\n              <tr>\\n                <th style=\"border:none;\" align=\"center\">&#xA0;</th>\\n                <th colspan=\"4\" align=\"center\">ITC<xref rid=\"t4fn1\" ref-type=\"table-fn\">a</xref><hr/></th>\\n                <th colspan=\"3\" align=\"center\">FP<xref rid=\"t4fn2\" ref-type=\"table-fn\">b</xref><hr/></th>\\n                <th style=\"border:none;\" align=\"center\">AlphaLISA</th>\\n              </tr>\\n              <tr>\\n                <th style=\"border:none;\" align=\"center\">compd</th>\\n                <th style=\"border:none;\" align=\"center\">binary <italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">ternary <italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">&#x3B1;</th>\\n                <th style=\"border:none;\" align=\"center\">total &#x394;<italic>G</italic> (kcal/mol)</th>\\n                <th style=\"border:none;\" align=\"center\">binary <italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">ternary <italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">&#x3B1;</th>\\n                <th style=\"border:none;\" align=\"center\">max intensity</th>\\n              </tr>\\n            </thead>\\n            <tbody>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">\\n                  <bold>5</bold>\\n                </td>\\n                <td style=\"border:none;\" align=\"left\">33&#xA0;&#xB1;&#xA0;2</td>\\n                <td style=\"border:none;\" align=\"left\">73&#xA0;&#xB1;&#xA0;2</td>\\n                <td style=\"border:none;\" align=\"left\">0.45</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;20.4</td>\\n                <td style=\"border:none;\" align=\"left\">24&#xA0;&#xB1;&#xA0;6</td>\\n                <td style=\"border:none;\" align=\"left\">98&#xA0;&#xB1;&#xA0;2</td>\\n                <td style=\"border:none;\" align=\"left\">0.24</td>\\n                <td style=\"border:none;\" align=\"left\">1.0&#xA0;&#xD7;&#xA0;10<sup>6</sup></td>\\n              </tr>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">\\n                  <bold>26</bold>\\n                </td>\\n                <td style=\"border:none;\" align=\"left\">87&#xA0;&#xB1;&#xA0;5</td>\\n                <td style=\"border:none;\" align=\"left\">83&#xA0;&#xB1;&#xA0;2</td>\\n                <td style=\"border:none;\" align=\"left\">1.05</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;20.7</td>\\n                <td style=\"border:none;\" align=\"left\">70&#xA0;&#xB1;&#xA0;14</td>\\n                <td style=\"border:none;\" align=\"left\">60&#xA0;&#xB1;&#xA0;5</td>\\n                <td style=\"border:none;\" align=\"left\">1.17</td>\\n                <td style=\"border:none;\" align=\"left\">1.56&#xA0;&#xD7;&#xA0;10<sup>6</sup></td>\\n              </tr>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">VZ185</td>\\n                <td style=\"border:none;\" align=\"left\">26&#xA0;&#xB1;&#xA0;9</td>\\n                <td style=\"border:none;\" align=\"left\">27&#xA0;&#xB1;&#xA0;3</td>\\n                <td style=\"border:none;\" align=\"left\">0.96</td>\\n                <td style=\"border:none;\" align=\"left\">&#x2013;21.7</td>\\n                <td style=\"border:none;\" align=\"left\">35&#xA0;&#xB1;&#xA0;5</td>\\n                <td style=\"border:none;\" align=\"left\">35&#xA0;&#xB1;&#xA0;6</td>\\n                <td style=\"border:none;\" align=\"left\">1.00</td>\\n                <td style=\"border:none;\" align=\"left\">1.47&#xA0;&#xD7;&#xA0;10<sup>6</sup></td>\\n              </tr>\\n            </tbody>\\n          </table>\\n          <table-wrap-foot>\\n            <fn id=\"t4fn1\">\\n              <label>a</label>\\n              <p>All ITC titrations\\nwere performed\\nat 25 &#xB0;C. Values reported are the mean &#xB1; SEM from at least\\ntwo independent measurements (<italic>n</italic> &#x2265; 2).</p>\\n            </fn>\\n            <fn id=\"t4fn2\">\\n              <label>b</label>\\n              <p><italic>K</italic><sub>d</sub> values\\nare reported as the mean &#xB1; SEM of at least two individual experiments\\nperformed in triplicate.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        <p>We next studied the functional mechanism of VZ185 by confirming\\nproteasome and CRL2<sup>VHL</sup> involvement and ubiquitination of\\nBRD7 and BRD9 (<xref rid=\"fig10\" ref-type=\"fig\">Figure <xref rid=\"fig10\" ref-type=\"fig\">10</xref></xref>). Combined treatment of the active degrader with the proteasome\\ninhibitor MG132 and the neddylation inhibitor MLN4924, which blocks\\nthe activity of CRL2<sup>VHL</sup>,<sup><xref ref-type=\"bibr\" rid=\"ref70\">70</xref></sup> suppressed\\nthe degradation of BRD7 and BRD9, clearly indicating that the degradation\\nis proteasome- and CRL2<sup>VHL</sup>-dependent (<xref rid=\"fig10\" ref-type=\"fig\">Figure <xref rid=\"fig10\" ref-type=\"fig\">10</xref></xref>A). Moreover, to investigate\\nlevels of target ubiquitination, NanoBRET experiments were performed\\nusing the endogenously tagged HiBiT-BRD7 and BRD9 as energy donors\\nand a polyclonal-Ub primary in conjunction with a fluorescently labeled\\nsecondary antibody as an energy acceptor (<xref rid=\"fig10\" ref-type=\"fig\">Figure <xref rid=\"fig10\" ref-type=\"fig\">10</xref></xref>B). Increases in BRET can be observed over\\ntime after treatment with VZ185 for both proteins, indicating PROTAC-induced\\ntarget ubiquitination. The observed signal was stronger for BRD9 as\\ncompared to BRD7, consistent with the trends observed for VZ185 inducing\\npreferential degradation of BRD9 compared to BRD7 (<xref rid=\"fig10\" ref-type=\"fig\">Figure <xref rid=\"fig10\" ref-type=\"fig\">10</xref></xref>B). Additionally, to confirm\\nthe involvement of VHL in the mechanism of action of VZ185, a competition\\nassay with VHL inhibitor VH298 (ref (<xref ref-type=\"bibr\" rid=\"ref62\">62</xref>)) was carried out. RI-1 cells were treated with\\n100 &#x3BC;M VH298 30 min before adding VZ185 (100 nM), and the cells\\nwere incubated for 4 h before cell lysis (<xref rid=\"fig10\" ref-type=\"fig\">Figure <xref rid=\"fig10\" ref-type=\"fig\">10</xref></xref>A). As anticipated, pretreatment with VHL\\ninhibitor blocked the degradation activity of VZ185. Moreover, since\\nthe <italic>trans</italic> stereochemistry of the hydroxyl group of\\nthe hydroxyproline moiety on VHL is essential for the binding to VHL,<sup><xref ref-type=\"bibr\" rid=\"ref62\">62</xref>,<xref ref-type=\"bibr\" rid=\"ref71\">71</xref></sup> RI-1 cells were treated with <italic>cis</italic>VZ185 (100 nM)\\nas inactive negative control (synthesis detailed in the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>) for 4 h before harvesting.\\nAs expected, no degradation of BRD7 or BDR9 was observed with <italic>cis</italic>VZ185 (<xref rid=\"fig10\" ref-type=\"fig\">Figure <xref rid=\"fig10\" ref-type=\"fig\">10</xref></xref>A).</p>\\n        <fig id=\"fig10\" position=\"float\">\\n          <label>Figure 10</label>\\n          <caption>\\n            <p>Mechanistic characterization of VZ185 mode of action.\\n(A) VZ185\\nactivity is proteasome and CRL2<sup>VHL</sup>-dependent. RI-1 cells\\nwere treated in two replicates with MG132, MLN4924, VH298, and <italic>cis</italic>VZ185 in the presence of absence of VZ185 (100 nM) at\\ndesired time points before harvesting. (B) NanoBRET experiments in\\nHEK293 cells to monitor ubiquitination of HiBiT endogenously tagged\\nBRD9 (purple) or BRD7 (green) using monoclonal-Ub primary and Alexa594\\nsecondary antibodies at times indicated after treatment with 1 &#x3BC;M\\nVZ185. Error bars expressed as SEM of <italic>n</italic> = 3 experiments.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0010\" id=\"gr10\" position=\"float\"/>\\n        </fig>\\n        <p>We next assessed the impact of\\ncompound-induced BRD7/9 degradation\\non the viability of cancer cell lines. EOL-1 (acute myeloid eosinophilic\\nleukemia) and A-204 (malignant rhabdoid tumor) cell lines were chosen\\nbecause they are sensitive to BRD9 inhibition/degradation<sup><xref ref-type=\"bibr\" rid=\"ref18\">18</xref>,<xref ref-type=\"bibr\" rid=\"ref56\">56</xref></sup> and dependent on an active BAF complex,<sup><xref ref-type=\"bibr\" rid=\"ref72\">72</xref></sup> respectively. Cellular ATP presence was quantified as signal of\\nmetabolically active cells (<xref rid=\"fig11\" ref-type=\"fig\">Figure <xref rid=\"fig11\" ref-type=\"fig\">11</xref></xref>). VZ185 was cytotoxic in both cell lines, with EC<sub>50</sub> of 3 nM (EOL-1) and 40 nM (A-402), and proved to be equipotent\\nto CRBN-based degrader <bold>21</bold> (dBRD9, EC<sub>50</sub> of\\n5 and 90 nM, respectively) (<xref rid=\"fig11\" ref-type=\"fig\">Figure <xref rid=\"fig11\" ref-type=\"fig\">11</xref></xref>). Differential cytotoxicity of BRD7/9 degradation\\nby VZ185 over and above BRD7/9 bromodomain inhibition was clearly\\nobserved (EC<sub>50</sub> of 90&#x2013;340 nM and 370&#x2013;3550\\nnM for compounds <bold>1a</bold> and <bold>1b</bold>, respectively).\\nThe activity in A-204 cells is of particular relevance as malignant\\nrhabdoid tumors are rare, chemoresistant cancers with poor survival\\nrate (&lt;25%) that are distinctly characterized by biallelic inactivation\\nof SMARCB1, a core subunit of the BAF complex, suggesting specific\\nvulnerabilities.<sup><xref ref-type=\"bibr\" rid=\"ref86\">86</xref></sup></p>\\n        <fig id=\"fig11\" position=\"float\">\\n          <label>Figure 11</label>\\n          <caption>\\n            <p>Effect of BRD7/9 degradation\\non viability of BRD9-sensitive cancer\\ncell lines. Cell proliferation activity assessed in EOL-1 (A) and\\nA-204 (B) cell lines after treatment with <bold>1a</bold>, <bold>1b</bold>, VZ185, <bold>7</bold>, <bold>21</bold> (dBRD9), and doxorubicin\\nfor 7 days.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0011\" id=\"gr11\" position=\"float\"/>\\n        </fig>\\n        <p>Finally, to assess the\\ncellular selectivity of VZ185 for BRD7/9\\ndegradation and identify potential degradation off-targets, multiplexed\\nisobaric tagging mass spectrometry proteomic experiments were performed\\nto monitor protein levels in a quantitative and unbiased manner. RI-1\\ncells were treated in triplicate with DMSO, 100 nM VZ185, or 100 nM <italic>cis</italic>VZ185 for 4 h. Among 6273 proteins quantified in this\\nanalysis, of those that met the criteria for a statistically significant\\nchange in abundance (<italic>p</italic>-value <italic>y</italic> &lt;\\n0.001; fold change {<italic>x</italic> &lt; &#x2212;20% <italic>U</italic>, <italic>x</italic> &gt; 20%}, <xref rid=\"fig12\" ref-type=\"fig\">Figure <xref rid=\"fig12\" ref-type=\"fig\">12</xref></xref> and <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figures S11 and S12</ext-link>), markedly selective degradation of BRD7 and BRD9\\nwas observed. As expected, BRD7/9 proteins were not depleted by treatment\\nwith negative control <italic>cis</italic>VZ185 (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figures S11 and S12</ext-link>). Protein levels\\nof other bromodomain-containing proteins or other BAF/PBAF subunits\\nremained unaffected. To confirm selectivity over key potential off-target\\nproteins within the bromodomain protein family, live cell kinetic\\nanalyses of endogenously tagged BRD2/3/4 and SMARCA4 proteins expressing\\nLgBiT were performed (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Figure S13</ext-link>). These results together with the proteomic data confirmed\\nVZ185 as an effective and highly selective degrader of BRD7/9 proteins\\nin cells. In vitro PK data further showed high stabilities of VZ185\\nin both plasma and microsomes from both human and mouse species, as\\nwell as high aqueous kinetic solubility (up to &#x223C;100 &#x3BC;M, <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Table S3</ext-link>). Together, the data qualify VZ185 as\\na novel high-quality degrader probe for cellular and potentially in\\nvivo investigations.</p>\\n        <fig id=\"fig12\" position=\"float\">\\n          <label>Figure 12</label>\\n          <caption>\\n            <p>Impact of VZ185 on the cellular proteome after treatment\\nof RI-1\\ncells with 100 nM compound for 4 h before harvesting. Data are plotted\\nas fold change (%) versus &#x2212;log<sub>10</sub> of <italic>p</italic>-value (<italic>t</italic> test) for a total of 6273 proteins, expressed\\nas the mean of the replicates. For quantification, see <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0012\" id=\"gr12\" position=\"float\"/>\\n        </fig>\\n      </sec>\\n    </sec>\\n    <sec id=\"sec3\">\\n      <title>Conclusion</title>\\n      <p>We describe the development of a new series\\nof PROTACs against\\nBRD9, a target thought as not degradable through recruitment of the\\nE3 ligase VHL. In spite of starting from unimpressive degradation\\nprofiles of initial compounds, VHL-based degraders could be optimized\\nby systematically varying the conjugation patterns and monitoring\\ncellular degradation activities and formation of ternary complexes.\\nThroughout the campaign, we revealed important structure&#x2013;activity\\nrelationships that proved invaluable to guide the optimization search\\nspace and led to significant improvements in degradation activities.\\nWe thoroughly characterize VZ185 as a highly selective, potent, and\\nrapid dual degrader with a slight preference for BRD9 over BRD7. Our\\nfindings thus qualify VZ185 as a new high-quality chemical probe that\\nwill be valuable to explore the biology and therapeutic potential\\nof degrading these two proteins.</p>\\n      <p>Biophysical and mechanistic\\nstudies suggest that increased ternary\\ncomplex stability correlates with improved degradation profiles. The\\nabsence of positive cooperativity in VZ185 allows much scope for optimizing\\nthe thermodynamics of ternary complex formation, which in turn should\\nwarrant enhanced degradation activities of future compounds.<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref>,<xref ref-type=\"bibr\" rid=\"ref11\">11</xref>,<xref ref-type=\"bibr\" rid=\"ref32\">32</xref></sup> Further investigation of the\\ncontributing factors of single-target selectivity would be important\\nand could also allow rational design of single-target selective degraders,\\nfor example, for BRD7 over BRD9. More generally, this successful campaign\\nexemplifies a broadly applicable approach to arrive at degraders that\\nare effective for any target&#x2013;ligase pairs, even those that\\nmight have been considered unproductive based on negative studies\\nwith initial compounds. It is thus tempting to speculate that there\\nmay not exist a preferred E3 ligase for &#x201C;PROTACing&#x201D;\\na given target protein. Any E3 ligase might, in principle, be hijacked\\nfor productive target ubiquitination and degradation, provided the\\ncombinatorial chemical space is adequately explored.</p>\\n    </sec>\\n    <sec id=\"sec4\">\\n      <title>Experimental Section</title>\\n      <sec id=\"sec4.1.1\">\\n        <title>Chemistry. Synthesis</title>\\n        <p>Chemicals,\\ncommercially available,\\nwere purchased from Apollo Scientific, Sigma-Aldrich, Fluorochem,\\nor Manchester Organics and used without any further purification.\\nAll reactions were carried out using anhydrous solvents. Analytical\\nthin-layer chromatography (TLC) was performed on precoated TLC plates\\n(layer 0.20 mm silica gel 60 with fluorescent indicator (UV 254: Merck)).\\nThe TLC plates were air-dried and revealed under UV lamp (254/365\\nnm). Flash column chromatography was performed using prepacked silica\\ngel cartridges (230&#x2013;400 mesh, 40&#x2013;63 mm; SiliCycle) using\\na Teledyne ISCO Combiflash Companion or Combiflash Retrieve using\\nthe solvent mixtures stated for each synthesis as mobile phase. Liquid\\nchromatography&#x2013;mass spectrometry (LC&#x2013;MS) analyses were\\nperformed with either an Agilent HPLC 1100 series connected to a Bruker\\nDaltonics MicroTOF or an Agilent Technologies 1200 series HPLC connected\\nto an Agilent Technologies 6130 quadrupole spectrometer or a Waters\\n2795 connected to a Waters ZQ Micromass spectrometer; all instruments\\nwere connected to a diode array detector. All of the final compounds\\nused in all of the experiments were evaluated after preparative LC&#x2013;MS\\nseparations with a Waters X-bridge C18 column (50 mm &#xD7; 2.1 mm\\n&#xD7; 3.5 mm particle size); flow rate, 0.5 mL/min with a mobile\\nphase of water/MeCN + 0.1% NH<sub>4</sub>OH or water/MeCN + 0.1% CHOOH;\\n95/5 water/MeCN was initially held for 0.5 min followed by a linear\\ngradient from 95/5 to 5/95 water/MeCN over 3.5 min which was then\\nheld for 2 min. The purity of all the compounds was evaluated using\\nthe analytical LC&#x2013;MS system described before, and purity was\\n&gt;95%. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded\\non a Bruker Avance II 500 spectrometer (<sup>1</sup>H at 500.1 MHz, <sup>13</sup>C at 125.8 MHz) or on a Bruker DPX-400 spectrometer (<sup>1</sup>H at 400.1 MHz, <sup>13</sup>C at 101 MHz). Chemical shifts\\n(&#x3B4;) are expressed in ppm reported using residual solvent as\\nthe internal reference in all cases. Signal splitting patterns are\\ndescribed as singlet (s), doublet (d), triplet (t), multiplet (m),\\nor a combination thereof. Coupling constants (<italic>J</italic>)\\nare quoted to the nearest 0.1 Hz.</p>\\n      </sec>\\n      <sec id=\"sec4.1.1.1\">\\n        <title>General Method A</title>\\n        <p>To a mixture of aryl bromide (1 equiv)\\nin dioxane (0.2 M), Pd(dppf)Cl<sub>2</sub> (0.1 equiv), bis(pinacolato)diboron\\n(1.2 equiv), and KOAc (3 equiv) were added. The mixture was heated\\nunder microwave conditions at 140 &#xB0;C for 40 min. Then aryl iodide <bold>14</bold> (1 equiv) and a degassed solution of K<sub>2</sub>CO<sub>3</sub> 2 M (2 equiv) were added. The reaction mixture was heated\\nin microwave at 120 &#xB0;C for 30 min. The resulting mixture was\\nfiltered through Celite and washed several times with DCM. The organic\\nphase was washed with H<sub>2</sub>O and brine, dried over MgSO<sub>4</sub>, filtered, and evaporated in vacuum. The crude was purified\\nby flash column chromatography using a gradient from 0% to 20% of\\nMeOH in DCM to obtain the desired compound. Then the intermediate\\nwas taken up in a mixture 1:1 HCl 4 N in dioxane/DCM and stirred at\\nrt for 3 h. The solvents were evaporated to dryness to obtain the\\ndesired compound as hydrochloride salt.</p>\\n      </sec>\\n      <sec id=\"sec4.1.1.2\">\\n        <title>General Method B</title>\\n        <p>To a solution of acid (1 equiv) in\\nDMF (0.2 M), HATU (1 equiv), HOAt (1 equiv), amine (1 equiv), and\\nDIPEA (5 equiv) were added. The reaction mixture was stirred at rt\\nfor 2 h. The solvent was evaporated under reduced pressure to give\\nthe corresponding crude, which was chromatographically purified to\\nyield the final compound.</p>\\n      </sec>\\n      <sec id=\"sec4.1.1.3\">\\n        <title>General Method C</title>\\n        <p>A mixture of aldehyde (1 equiv), amine\\n(HCl salt, 1.1 equiv), and TEA (1.1 equiv) in DMF (0.2 M) was stirred\\nat rt. After 15 min, NaBH(OAc)<sub>3</sub> (1.5 equiv) was added,\\nand the reaction was stirred overnight at rt under nitrogen. The solvent\\nwas evaporated under reduced pressure to give the corresponding crude,\\nwhich was purified accordingly to yield the desired compound.</p>\\n      </sec>\\n      <sec id=\"sec4.1.1.4\">\\n        <title>General\\nMethod D</title>\\n        <p>To a stirred solution of oxalyl chloride\\n(1.5 equiv) in DCM (0.3 M), DMSO (2 equiv) was added dropwise at &#x2212;78\\n&#xB0;C. After 10 min at &#x2212;78 &#xB0;C, the alcohol starting\\nmaterial (1 equiv) in DCM (0.3 M) was added. The reaction was stirred\\nat &#x2212;78 &#xB0;C for 1 h, TEA (10 equiv) was added dropwise,\\nand temperature was increased to rt. After 1 h, the reaction mixture\\nwas diluted with DCM, washed with a saturated solution of ammonium\\nchloride. The organic phases were combined, washed with brine, dried\\nover MgSO<sub>4</sub>, filtered, and evaporated to dryness. Then the\\ncrude was dissolved in DMF (0.05 M); <bold>1c</bold> (1 equiv) and\\nTEA (1.1 equiv) were added. After 15 min, NaBH(OAc)<sub>3</sub> was\\nadded and the reaction mixture was stirred overnight at rt under nitrogen.\\nThe solvent was evaporated under reduced pressure to give the corresponding\\ncrude, which was purified by preparative HPLC to yield the desired\\ncompound.</p>\\n      </sec>\\n      <sec id=\"sec4.1.1.5\">\\n        <title>General Method E</title>\\n        <p>To a solution of\\nthe alcohol starting\\nmaterial (1 equiv) and trimethylamine (1.5 equiv) in DCM (0.2 M),\\nmethansulfonyl chloride (1.2 equiv) was added at 0 &#xB0;C. The reaction\\nmixture was stirred at 0 &#xB0;C for 3 h. The reaction was quenched\\nwith a saturated solution of ammonium chloride and extracted with\\nDCM. The organic phases were combined, dried over MgSO<sub>4</sub>, filtered, and evaporated to dryness. The crude (1.5 equiv) was\\nsuspended in DMF (0.2 M), and <bold>2b</bold>&#x2013;<bold>d</bold> inhibitor derivative (1 equiv) and K<sub>2</sub>CO<sub>3</sub> (3\\nequiv) were added. The mixture was heated overnight at 70 &#xB0;C.\\nThe reaction mixture was diluted with water and extracted with DCM.\\nThe organic phases were combined, dried over MgSO<sub>4</sub>, filtered,\\nand evaporated to dryness. The crude was purified by flash column\\nchromatography using a gradient from 0% to 20% of MeOH in DCM to yield\\nthe desired compound.</p>\\n      </sec>\\n      <sec id=\"sec4.1.1.6\">\\n        <title>General Method F</title>\\n        <p>A 1 M aqueous solution\\nof HCl (1 mL)\\nwas added to the VHL-acetal linker (0.06 mmol) in THF (1 mL). The\\nreaction mixture was heated at 50 &#xB0;C for 2 h. The solvent was\\nevaporated under reduced pressure, and the product was extracted with\\nDCM/MeOH (9:1). The organic phases were combined, dried over MgSO<sub>4</sub>, filtered, and evaporated to dryness. The crude was used\\ndirectly without any further purification.</p>\\n      </sec>\\n      <sec id=\"sec4.1.1.7\">\\n        <title>General method G</title>\\n        <p>Aldehyde (1 equiv) was taken up in <italic>t</italic>-BuOH and water\\n(4:1) (0.3 M). Then 2-methyl-2-butene 2\\nM in THF (4 equiv) was added, followed by sodium phosphate dibasic\\n(1 equiv) and sodium chlorite (2 equiv). The reaction mixture was\\nstirred at rt for 4 h. A 1 M aqueous solution of HCl was added. The\\nproduct was extracted with DCM. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThe crude was used directly without any further purification.</p>\\n      </sec>\\n      <sec id=\"sec4.1.2\">\\n        <title>4-(3,5-Dimethoxy-4-(piperazin-1-ylmethyl)phenyl)-2-methyl-2,7-naphthyridin-1(2<italic>H</italic>)-one (<bold>1c</bold>)</title>\\n        <p>Following general method\\nA, compound <bold>1c</bold> was obtained from compound <bold>12</bold> and <bold>14</bold> as brown powder. Yield: 50 mg, 55%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;: 9.67 (s, 1H), 8.76 (d, <italic>J</italic> = 6.9 Hz, 1H), 8.27 (s, 1H), 8.21 (d, <italic>J</italic> = 6.9 Hz,\\n1H), 6.95 (s, 2H), 4.62 (s, 2H), 4.03 (s, 6H), 3.81 (s, 3H), 3.73\\n(s, 8H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x3B4;: 161.5,\\n161.4, 148.6, 146.3, 145.5, 141.9, 139.7, 122.9, 117.9, 107.1, 105.8,\\n57.2, 50.8, 49.7, 41.9, 37.9. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub> 394.2, found 395.3 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.3\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-1-((S)-2-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-<italic>N</italic>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\\n(<bold>5</bold>)</title>\\n        <p>Following general method B, compound <bold>5</bold> was obtained from <bold>19</bold> and <bold>2a</bold> (synthesized\\naccordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref61\">61</xref></sup>). The crude\\nwas purified by HPLC using a gradient of 5% to 95% v/v acetonitrile\\nin 0.1% aqueous solution of formic acid to obtain <bold>5</bold> as\\nwhite powder. Yield: 6.3 mg, 44%. <sup>1</sup>H NMR (400 MHz, MeOD)\\n&#x3B4;: 9.44 (s, 1H), 8.80 (s, 1H), 8.59 (d, <italic>J</italic> =\\n5.5 Hz, 1H), 7.66 (s, 1H), 7.54 (d, <italic>J</italic> = 5.9 Hz, 1H),\\n7.37 (q, <italic>J</italic> = 7.8 Hz, 4H), 6.73 (s, 2H), 4.66 (s,\\n1H), 4.52&#x2013;4.26 (m, 4H), 4.05&#x2013;3.95 (m, 4H), 3.86&#x2013;3.72\\n(m, 8H), 3.69&#x2013;3.59 (m, 9H), 2.96&#x2013;2.73 (m, 10H), 2.40\\n(s, 3H), 2.21&#x2013;2.14 (m, 1H), 2.06&#x2013;1.97 (m, 1H), 0.99\\n(s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;: 174.3, 172.0,\\n171.7, 163.0, 161.0, 152.8, 151.7, 151.2, 149.1, 143.5, 140.3, 139.0,\\n133.3, 131.6, 130.5, 130.4, 129.5, 129.0, 121.7, 119.2, 119.0, 106.6,\\n72.2, 71.3, 71.1, 71.0, 69.1, 60.9, 58.2, 58.1, 57.9, 56.6, 52.8,\\n52.4, 43.7, 39.0, 37.4, 37.2, 27.0, 15.8. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>50</sub>H<sub>64</sub>N<sub>8</sub>O<sub>9</sub>S 952.45, found 953.4728 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.4\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>S</italic>)-2-(<italic>tert</italic>-Butyl)-17-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-<italic>N</italic>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\\n(<bold>6</bold>)</title>\\n        <p>Following general method B, compound <bold>6</bold> was obtained from <bold>20</bold> and <bold>2a</bold> (synthesized\\naccordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref61\">61</xref></sup>). The crude\\nwas purified by HPLC using a gradient of 5% to 95% v/v acetonitrile\\nin 0.1% aqueous solution of formic acid to obtain <bold>6</bold> as\\nwhite powder. Yield: 4.9 mg, 30%. <sup>1</sup>H NMR (400 MHz, MeOD)\\n&#x3B4;: 9.44 (s, 1H), 8.81 (s, 1H), 8.60 (d, <italic>J</italic> =\\n5.6 Hz, 1H), 7.67 (s, 1H), 7.54 (d, <italic>J</italic> = 5.6 Hz, 1H),\\n7.37 (q, <italic>J</italic> = 9.0 Hz, 4H), 6.73 (s, 2H), 4.63 (s,\\n1H), 4.53&#x2013;4.26 (m, 4H), 4.02&#x2013;3.94 (m, 4H), 3.84&#x2013;3.72\\n(m, 8H), 3.66&#x2013;3.50 (m, 17H), 2.89&#x2013;2.67 (m, 10H), 2.41\\n(s, 3H), 2.20&#x2013;2.14 (m, 1H), 2.06&#x2013;1.97 (m, 1H), 0.98\\n(s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;: 174.4, 172.0,\\n171.7, 163.0, 161.0, 152.9, 151.7, 151.2, 149.1, 143.5, 140.3, 139.0,\\n138.6, 133.4, 131.5, 130.5, 130.4, 129.5, 129.0, 121.7, 119.2, 119.1,\\n106.6, 72.3, 71.7, 71.6, 71.5, 71.4, 71.1, 71.0, 68.9, 60.9, 58.2,\\n58.0, 56.6, 52.8, 43.7, 39.0, 37.4, 37.1, 27.0, 15.9. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>54</sub>H<sub>72</sub>N<sub>8</sub>O<sub>11</sub>S 1040.50, found 1041.5287 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.5\">\\n        <title>2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-<italic>N</italic>-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)acetamide\\n(<bold>7</bold>)</title>\\n        <p>Following general method B, compound <bold>7</bold> was obtained from compound <bold>19</bold> and <bold>3a</bold> (synthesized accordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref73\">73</xref></sup>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid to obtain compound <bold>7</bold> as yellow powder. Yield: 5.6 mg, 33%. <sup>1</sup>H NMR\\n(400 MHz, MeOD) &#x3B4;: 9.54 (d, <italic>J</italic> = 0.8 Hz, 1H),\\n8.70 (d, <italic>J</italic> = 6.0 Hz, 1H), 8.11 (s, 1NH), 7.84 (s,\\n1H), 7.73 (dd, <italic>J</italic> = 0.6, 6.0 Hz, 1H), 7.55&#x2013;7.49\\n(m, 1H), 7.10&#x2013;7.03 (m, 2H), 6.87 (s, 2H), 5.08 (dd, <italic>J</italic> = 5.5, 12.7 Hz, 1H), 4.38 (s, 2H), 4.05 (s, 2H), 3.96\\n(s, 6H), 3.77&#x2013;3.67 (m, 9H), 3.51&#x2013;3.46 (m, 4H), 3.39\\n(s, 4H), 3.20 (s, 4H), 3.01 (t, <italic>J</italic> = 4.8 Hz, 2H),\\n2.94&#x2013;2.67 (m, 4H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;:\\n174.6, 173.4, 171.6, 170.6, 169.1, 162.7, 161.1, 150.9, 149.8, 147.9,\\n144.0, 140.1, 137.2, 133.9, 121.8, 119.6, 118.5, 117.9, 112.2, 111.4,\\n106.7, 71.7, 71.3, 71.0, 67.7, 57.5, 56.8, 51.8, 51.1, 50.2, 50.0,\\n42.6, 39.4, 37.5, 32.2, 23.8. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>43</sub>H<sub>50</sub>N<sub>8</sub>O<sub>10</sub> 838.36, found 839.3796 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.6\">\\n        <title>14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-<italic>N</italic>-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-3,6,9,12-tetraoxatetradecanamide\\n(<bold>8</bold>)</title>\\n        <p>Following general method B, compound <bold>8</bold> was obtained from compound <bold>20</bold> and <bold>3a</bold> (synthesized accordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref73\">73</xref></sup>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid to obtain compound <bold>8</bold> as yellow powder. Yield: 10 mg, 54%. <sup>1</sup>H NMR (400\\nMHz, MeOD) &#x3B4;: 9.53 (s, 1H), 8.70 (d, <italic>J</italic> = 5.7\\nHz, 1H), 8.15 (s, 1NH), 7.77 (s, 1H), 7.64 (d, <italic>J</italic> =\\n5.7 Hz, 1H), 7.59&#x2013;7.53 (m, 1H), 7.17&#x2013;7.13 (m, 1H), 7.08&#x2013;7.04\\n(m, 1H), 6.86 (s, 2H), 5.07 (dd, <italic>J</italic> = 5.5, 12.5 Hz,\\n1H), 4.29 (s, 2H), 4.01 (s, 2H), 3.96 (s, 6H), 3.72&#x2013;3.63 (m,\\n17H), 3.54 (s, 4H), 3.25 (s, 4H), 3.02 (s, 4H), 2.94&#x2013;2.67 (m,\\n6H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;: 174.6, 173.5, 171.5,\\n170.6, 169.2, 163.0, 161.0, 151.7, 151.2, 148.0, 143.4, 139.8, 139.2,\\n137.3, 133.9, 121.7, 119.1, 118.7, 118.1, 112.1, 111.4, 108.1, 106.7,\\n72.0, 71.4, 71.1, 68.5, 57.6, 56.8, 52.4, 51.6, 50.2, 49.9, 42.5,\\n39.4, 37.5, 32.2, 23.8. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>47</sub>H<sub>58</sub>N<sub>8</sub>O<sub>12</sub> 926.42, found 927.4396 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.7\">\\n        <title><italic>N</italic>-(4-(<italic>N</italic>-(3-Chloro-1<italic>H</italic>-indol-7-yl)sulfamoyl)benzyl)-2-(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetamide\\n(<bold>9</bold>)</title>\\n        <p>Following general method B, compound <bold>9</bold> was obtained from compound <bold>19</bold> and <bold>4a</bold> (synthesis detailed in the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid to obtain compound <bold>9</bold> as white powder. Yield: 10.8 mg, 34%. <sup>1</sup>H NMR\\n(400 MHz, MeOD) &#x3B4;: 9.54 (s, 1H), 8.69 (d, <italic>J</italic> = 5.8 Hz, 1H), 8.27 (s, 1NH), 7.75 (s, 1H), 7.68&#x2013;7.62 (m,\\n3H), 7.39 (d, <italic>J</italic> = 8.3 Hz, 2H), 7.33 (dd, <italic>J</italic> = 0.9, 8.1 Hz, 1H), 7.26 (s, 1H), 6.91 (t, <italic>J</italic> = 7.8 Hz, 1H), 6.85 (s, 2H), 6.70 (d, <italic>J</italic> = 7.7 Hz,\\n1H), 4.49 (s, 2H), 4.28 (s, 2H), 4.11 (s, 2H), 3.94 (s, 6H), 3.76&#x2013;3.66\\n(m, 7H), 3.63 (t, <italic>J</italic> = 5.3 Hz, 2H), 3.22 (s, 4H),\\n2.88 (s, 4H), 2.73 (t, <italic>J</italic> = 5.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;: 173.0, 166.4, 163.0, 161.0, 151.7,\\n151.2, 145.5, 143.3, 140.0, 139.4, 139.1, 132.0, 128.8, 128.7, 128.2,\\n123.4, 122.7, 121.6, 120.9, 119.4, 119.1, 118.8, 117.0, 107.5, 106.7,\\n106.2, 71.9, 71.4, 71.3, 68.7, 57.6, 56.8, 52.5, 51.3, 49.9, 43.0,\\n37.5. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>43</sub>H<sub>48</sub>ClN<sub>7</sub>O<sub>8</sub>S 857.30, found 858.3111\\n[M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.8\">\\n        <title><italic>N</italic>-(4-(<italic>N</italic>-(3-Chloro-1<italic>H</italic>-indol-7-yl)sulfamoyl)benzyl)-14-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecanamide\\n(<bold>10</bold>)</title>\\n        <p>Following general method B, compound <bold>10</bold> was obtained from compound <bold>20</bold> and <bold>4a</bold> (synthesis detailed in the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid to obtain compound <bold>10</bold> as white powder. Yield: 11.1 mg, 37%. <sup>1</sup>H NMR\\n(400 MHz, MeOD) &#x3B4;: 9.54 (d, <italic>J</italic> = 0.6 Hz, 1H),\\n8.69 (d, <italic>J</italic> = 5.7 Hz, 1H), 8.30 (s, 1NH), 7.75 (s,\\n1H), 7.68&#x2013;7.62 (m, 3H), 7.41 (d, <italic>J</italic> = 8.2 Hz,\\n2H), 7.34 (dd, <italic>J</italic> = 0.8, 8.1 Hz, 1H), 7.27 (s, 1H),\\n6.92 (t, <italic>J</italic> = 7.8 Hz, 1H), 6.84 (s, 2H), 6.72 (dd, <italic>J</italic> = 0.9, 7.5 Hz, 1H), 4.50 (s, 2H), 4.26 (s, 2H), 4.09 (s,\\n2H), 3.94 (s, 6H), 3.73&#x2013;3.67 (m, 7H), 3.65&#x2013;3.59 (m,\\n4H), 3.58&#x2013;3.53 (m, 6H), 3.22 (s, 4H), 2.96 (s, 4H), 2.82 (t, <italic>J</italic> = 5.3 Hz, 2H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;:\\n173.1, 166.7, 163.1, 161.0, 151.7, 151.2, 145.5, 143.4, 139.7, 139.2,\\n139.0, 131.9, 128.9, 128.6, 128.2, 123.4, 122.7, 121.6, 121.0, 119.3,\\n119.2, 118.9, 117.0, 108.0, 106.7, 106.2, 72.0, 71.3, 71.3, 71.2,\\n68.3, 57.5, 56.8, 52.3, 51.5, 49.9, 42.9, 37.6. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>47</sub>H<sub>56</sub>ClN<sub>7</sub>O<sub>10</sub>S 945.35, found 946.3676 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.9\">\\n        <title><italic>tert</italic>-Butyl 4-(4-Bromo-2,6-dimethoxybenzyl)piperazine-1-carboxylate\\n(<bold>12</bold>)</title>\\n        <p>Following general method C, compound <bold>12</bold> was obtained from 4-bromo-2,6-dimethoxybenzaldehyde\\n(<bold>11</bold>) and boc-piperazine (both commercially available).\\nThe reaction was quenched with saturated solution of NaHCO<sub>3</sub>, extracted with DCM, washed with water and brine. The organic phases\\nwere combined, dried over MgSO<sub>4</sub>, filtered, and evaporated\\nto dryness to give the desired compound without any further purification\\nas sticky oil. Yield: 495 mg, 97%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x3B4;: 6.69 (s, 2H), 3.78 (s, 6H), 3.62 (s, 2H), 3.38\\n(t, <italic>J</italic> = 5.0 Hz, 4H), 2.41 (t, <italic>J</italic> =\\n4.4 Hz, 4H), 1.43 (s, 9H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) &#x3B4;: 159.9, 154.7, 122.8, 107.7, 79.8, 56.1, 51.8, 48.5, 31.0,\\n28.5. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>18</sub>H<sub>27</sub>BrN<sub>2</sub>O<sub>4</sub> 414.12, found 415.2 [M\\n+ H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.10\">\\n        <title>4-Iodo-2-methyl-2,7-naphthyridin-1(2<italic>H</italic>)-one\\n(<bold>14</bold>)</title>\\n        <p>A mixture of 4-iodo-2,7-naphthyridin-1(2<italic>H</italic>)-one <bold>13</bold> (synthesized accordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref74\">74</xref></sup>) (1 equiv) and NaH (2 equiv) was stirred 30\\nmin at 0 &#xB0;C in DMF (0.2 M). Then CH<sub>3</sub>I (1.6 equiv)\\nwas added and the reaction mixture was stirred at 0 &#xB0;C for 5\\nh. Water was added, and the precipitate formed was filtered and dried\\nin vacuum. Yield: 300 mg, 95%. <sup>1</sup>H NMR (400 MHz, DMSO) &#x3B4;:\\n9.27 (s, 1H), 8.82 (d, <italic>J</italic> = 5.6 Hz, 1H), 8.26 (s,\\n1H), 7.47 (d, <italic>J</italic> = 5.5 Hz, 1H), 3.52 (s,3H). <sup>13</sup>C NMR (101 MHz, DMSO) &#x3B4;: 160.3, 152.0, 150.3, 144.8,\\n143.0, 122.4, 120.7, 67.9, 36.2. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>9</sub>H<sub>7</sub>IN<sub>2</sub>O 285.96, found\\n287.1 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.11\">\\n        <title><italic>tert</italic>-Butyl\\n2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetate\\n(<bold>17</bold>)</title>\\n        <p>Following general method D, compound <bold>17</bold> was obtained from <italic>tert</italic>-butyl 2-(2-(2-hydroxyethoxy)ethoxy)acetate <bold>15</bold> and <bold>1c</bold> after purification by HPLC using a\\ngradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of\\nammonia as white powder. Yield: 8.8 mg, 32%. <sup>1</sup>H NMR (500\\nMHz, CDCl<sub>3</sub>) &#x3B4;: 9.69 (d, <italic>J</italic> = 0.8\\nHz, 1H), 8.70 (d, <italic>J</italic> = 5.7 Hz, 1H), 7.43 (dd, <italic>J</italic> = 0.8, 5.6 Hz, 1H), 7.26 (s, 1H), 6.52 (s, 2H), 4.00 (s,\\n2H), 3.81 (s, 6H), 3.70&#x2013;3.60 (m, 11H), 2.65&#x2013;2.56 (m,\\n10H), 1.46 (s, 9H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)\\n&#x3B4;: 170.0, 161.8, 160.0, 152.0, 151.3, 142.1, 136.1, 135.5, 120.8,\\n118.4, 117.8, 113.9, 105.7, 81.9, 71.0, 70.7, 69.3, 58.1, 56.2, 53.7,\\n52.6, 48.9, 37.4, 28.4. MS <italic>m</italic>/<italic>z</italic> calcd\\nfor C<sub>32</sub>H<sub>44</sub>N<sub>4</sub>O<sub>7</sub> 596.32,\\nfound 597.34 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.12\">\\n        <title><italic>tert</italic>-Butyl\\n14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecanoate\\n(<bold>18</bold>)</title>\\n        <p>Following general method D, compound <bold>18</bold> was obtained from <italic>tert</italic>-butyl 14-hydroxy-3,6,9,12-tetraoxatetradecanoate <bold>16</bold> and <bold>1c</bold> after purification by HPLC using a\\ngradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of\\nammonia as white powder. Yield: 10.7 mg, 34%. <sup>1</sup>H NMR (500\\nMHz, CDCl<sub>3</sub>) &#x3B4;: 9.69 (d, <italic>J</italic> = 0.8\\nHz, 1H), 8.70 (d, <italic>J</italic> = 5.6 Hz, 1H), 7.43 (d, <italic>J</italic> = 5.6 Hz, 1H), 7.26 (s, 1H), 6.52 (s, 2H), 4.00 (s, 2H),\\n3.81 (s, 6H), 3.73&#x2013;3.57 (m, 19H), 2.67&#x2013;2.55 (m, 10H),\\n1.46 (s, 9H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) &#x3B4;:\\n170.0, 161.8, 160.0, 152.0, 151.3, 142.1, 136.2, 120.8, 118.4, 117.8,\\n105.7, 81.9, 71.1, 70.9, 70.7, 69.4, 69.2, 58.0, 56.3, 53.8, 52.4,\\n48.9, 37.5, 28.5. MS <italic>m</italic>/<italic>z</italic> calcd for\\nC<sub>36</sub>H<sub>52</sub>N<sub>4</sub>O<sub>9</sub> 684.37, found\\n685.39 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.13\">\\n        <title>2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetic\\nAcid (<bold>19</bold>)</title>\\n        <p>A mixture of compound <bold>17</bold> (0.015 mmol), TFA (0.5 mL), and DCM (0.5 mL) was stirred at rt for\\n3 h. Then the solvent was evaporated; the crude was dried under high\\npressure overnight and used directly in the next step without any\\nfurther purification. Quantitative yield. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>28</sub>H<sub>36</sub>N<sub>4</sub>O<sub>7</sub> 540.26, found 541.4 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.14\">\\n        <title>17-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecanoic\\nAcid (<bold>20</bold>)</title>\\n        <p>A mixture of compound <bold>18</bold> (0.034 mmol), TFA (0.5 mL), and DCM (0.5 mL) was stirred at rt for\\n3 h. Then the solvent was evaporated; the crude was dried under high\\npressure overnight and used directly without any further purification.\\nQuantitative yield. MS <italic>m</italic>/<italic>z</italic> calcd\\nfor C<sub>34</sub>H<sub>48</sub>N<sub>4</sub>O<sub>10</sub> 672.34,\\nfound 673.36 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.15\">\\n        <title>(2<italic>R</italic>,4<italic>S</italic>)-1-((<italic>R</italic>)-2-(2-(2-((5-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-<italic>N</italic>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\\n(<bold>23</bold>)</title>\\n        <p>A mixture of <bold>35</bold> (1 equiv),\\nosmium tetroxide 4% in H<sub>2</sub>O (0.2 equiv), sodium periodate\\n(4 equiv), pyridine (2 equiv) in dioxane/H<sub>2</sub>O (3:1) was\\nstirred at rt for 48 h. Then H<sub>2</sub>O was added to the reaction\\nand the product was extracted with DCM. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThe crude was dissolved in DCE, and a mixture of <bold>1c</bold> (1\\nequiv) and TEA (1.1 equiv) in DCE (0.02 M) was added. After 15 min,\\nNaBH(OAc)<sub>3</sub> was added and the reaction mixture was stirred\\nat rt for 4 h under nitrogen. The solvent was evaporated under reduced\\npressure to give the corresponding crude, which was purified by HPLC\\nusing a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution\\nof ammonia. Compound <bold>23</bold> was obtained as a white powder.\\nYield: 6.9 mg, 54%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)\\n&#x3B4;: 9.68 (s, 1H), 8.69 (d, <italic>J</italic> = 5.6 Hz, 1H),\\n8.66 (s, 1H), 7.41 (dd, <italic>J</italic> = 0.6, 5.6 Hz, 1H), 7.37&#x2013;7.32\\n(m, 4H), 7.27 (s, 1H), 6.53 (s, 2H), 4.72 (t, <italic>J</italic> =\\n8.0 Hz, 1H), 4.59&#x2013;4.49 (m, 3H), 4.35&#x2013;4.29 (m, 1H), 4.07&#x2013;3.95\\n(m, 3H), 3.85&#x2013;3.80 (m, 8H), 3.67&#x2013;3.55 (m, 8H), 3.43\\n(t, <italic>J</italic> = 6.4 Hz, 2H), 2.74&#x2013;2.37 (m, 14H), 2.15&#x2013;2.09\\n(m, 1H), 1.60&#x2013;1.47 (m, 4H), 1.36&#x2013;1.27 (m, 2H), 0.94\\n(s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x3B4;: 171.5,\\n170.9, 170.5, 168.6, 161.6, 159.8, 151.8, 151.1, 150.4, 148.6, 141.9,\\n138.3, 136.0, 131.7, 131.1, 129.6, 128.3, 120.6, 118.1, 117.6, 105.5,\\n71.4, 71.3, 70.6, 70.1, 58.6, 58.2, 57.2, 56.9, 56.1, 52.5, 51.7,\\n48.6, 43.4, 37.3, 36.1, 35.2, 29.4, 26.6, 26.0, 24.2, 16.2. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>53</sub>H<sub>70</sub>N<sub>8</sub>O<sub>9</sub>S 994.50, found 995.5178 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.16\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>26</bold>)</title>\\n        <p>A mixture of <bold>40</bold> (1 equiv),\\nosmium tetroxide 4% in H<sub>2</sub>O (0.2 equiv), sodium periodate\\n(4 equiv), pyridine (2 equiv) in dioxane/H<sub>2</sub>O (3:1) was\\nstirred at rt for 48 h. Then H<sub>2</sub>O was added to the reaction\\nand the product was extracted with DCM. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThen, following general method A, compound <bold>26</bold> was synthesized\\nfrom the aldehyde derivative and <bold>1c</bold>. The solvent was\\nremoved in vacuum to give the corresponding crude, which was purified\\nby HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous\\nsolution of formic acid to yield compound <bold>26</bold> as white\\npowder. Yield: 7 mg, 45%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;:\\n9.54 (s, 1H), 8.90 (s, 1H), 8.70 (d, <italic>J</italic> = 5.8 Hz,\\n1H), 8.58 (s, 1NH), 7.75 (s, 1H), 7.63 (dd, <italic>J</italic> = 0.6,\\n5.7 Hz, 1H), 7.51 (d, <italic>J</italic> = 7.8 Hz, 1H), 7.10&#x2013;7.04\\n(m, 2H), 6.79 (s, 2H), 4.78 (s, 1H), 4.66 (t, <italic>J</italic> =\\n8.4 Hz, 1H), 4.55&#x2013;4.42 (m, 3H), 4.32&#x2013;4.23 (m, 2H), 3.97&#x2013;3.77\\n(m, 14H), 3.73&#x2013;3.66 (m, 7H), 2.85&#x2013;2.68 (m, 10H), 2.52\\n(s, 3H), 2.30&#x2013;2.24 (m, 1H), 2.16&#x2013;2.09 (m, 1H), 1.46&#x2013;1.27\\n(m, 4H), 1.07 (s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;:\\n174.2, 171.7, 171.5, 171.3, 170.2, 163.0, 161.0, 158.0, 152.8, 151.7,\\n151.2, 149.1, 143.6, 138.9, 138.1, 133.5, 132.9, 130.0, 128.4, 122.9,\\n121.7, 119.2, 113.8, 106.5, 80.3, 78.0, 71.8, 71.4, 71.0, 70.8, 69.4,\\n69.3, 60.8, 58.7, 58.3, 58.2, 56.5, 53.3, 53.0, 39.5, 39.0, 37.4,\\n37.3, 26.9, 16.0, 14.1, 14.0, 13.9. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>54</sub>H<sub>69</sub>FN<sub>8</sub>O<sub>10</sub>S 1040.48, found 1041.4430 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.17\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>S</italic>)-2-(1-Cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-<italic>N</italic>-(2-(2-(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>27</bold>)</title>\\n        <p>A mixture of <bold>42</bold> (1 equiv),\\nosmium tetroxide 4% in H<sub>2</sub>O (0.2 equiv), sodium periodate\\n(4 equiv), pyridine (2 equiv) in dioxane/H<sub>2</sub>O (3:1) was\\nstirred at rt for 48 h. Then H<sub>2</sub>O was added to the reaction\\nand the product was extracted with DCM. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThen, following general method A, from the aldehyde derivative and <bold>1c</bold> compound <bold>27</bold> was obtained after purification\\nby HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous\\nsolution of formic acid as white powder. Yield: 11 mg, 44%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;: 9.55 (s, 1H), 8.90 (s, 1H), 8.69 (d, <italic>J</italic> = 5.8 Hz, 1H), 8.58 (s, 1NH), 7.75 (s, 1H), 7.63 (d, <italic>J</italic> = 5.6 Hz, 1H), 7.50 (d, <italic>J</italic> = 7.7 Hz, 1H),\\n7.10&#x2013;7.03 (m, 2H), 6.79 (s, 2H), 4.71&#x2013;4.63 (m, 2H),\\n4.56&#x2013;4.42 (m, 3H), 4.33&#x2013;4.23 (m, 2H), 3.98&#x2013;3.66\\n(m, 21H), 2.86&#x2013;2.69 (m, 10H), 2.52 (s, 3H), 2.30&#x2013;2.23\\n(m, 1H), 2.16&#x2013;2.08 (m, 1H), 1.70&#x2013;1.55 (m, 4H), 1.06\\n(s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;: 174.1, 171.5,\\n170.1, 167.1, 163.0, 161.0, 158.1, 152.8, 151.7, 151.2, 149.1, 143.5,\\n138.9, 138.1, 133.4, 132.9, 130.1, 128.4, 122.8, 121.7, 120.8, 119.2,\\n119.2, 113.8, 106.5, 71.8, 71.4, 71.0, 70.8, 69.4, 69.2, 60.8, 59.5,\\n58.3, 58.1, 56.5, 53.2, 53.0, 39.5, 38.9, 37.7, 37.4, 26.8, 18.1,\\n18.0, 16.0, 14.8. HRMS <italic>m</italic>/<italic>z</italic> calcd\\nfor C<sub>55</sub>H<sub>69</sub>N<sub>9</sub>O<sub>10</sub>S 1047.49,\\nfound 1048.4493 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.18\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-1-((S)-2-Acetamido-3,3-dimethylbutanoyl)-<italic>N</italic>-(2-(2-(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>28</bold>)</title>\\n        <p>A mixture of <bold>44</bold> (1 equiv),\\nosmium tetroxide 4% in H<sub>2</sub>O (0.2 equiv), sodium periodate\\n(4 equiv), pyridine (2 equiv) in dioxane/H<sub>2</sub>O (3:1) was\\nstirred at rt for 48 h. Then H<sub>2</sub>O was added to the reaction\\nand the product was extracted with DCM. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThen, following general method A, from the aldehyde derivative and <bold>1c</bold> compound <bold>28</bold> was obtained after purification\\nby HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous\\nsolution of formic acid as white powder. Yield: 3.3 mg, 17%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;: 9.55 (d, <italic>J</italic> = 0.7 Hz, 1H), 8.90 (s, 1H), 8.70 (d, <italic>J</italic> = 5.9 Hz,\\n1H), 7.76 (s, 1H), 7.64 (dd, <italic>J</italic> = 0.7, 5.9 Hz, 1H),\\n7.52 (d, <italic>J</italic> = 7.7 Hz, 1H), 7.09 (d, <italic>J</italic> = 1.5 Hz, 1H), 7.03 (dd, <italic>J</italic> = 1.7, 7.7 Hz, 1H),\\n6.79 (s, 2H), 4.65&#x2013;4.60 (m, 2H), 4.54&#x2013;4.42 (m, 3H),\\n4.28&#x2013;4.25 (m, 2H), 3.96&#x2013;3.65 (m, 21H), 2.86&#x2013;2.67\\n(m, 10H), 2.52 (s, 3H), 2.27&#x2013;2.21 (m, 1H), 2.15&#x2013;2.08\\n(m, 1H), 2.04 (s, 3H), 1.05 (s, 9H). <sup>13</sup>C NMR (101 MHz,\\nMeOD) &#x3B4;: 174.4, 173.1, 172.3, 163.1, 161.0, 158.0, 152.8, 151.7,\\n151.2, 149.1, 143.6, 138.9, 133.5, 132.9, 130.0, 128.4, 122.8, 121.7,\\n119.2, 113.7, 106.5, 71.8, 71.4, 71.1, 70.8, 69.4, 69.2, 60.7, 59.2,\\n58.2, 58.0, 56.5, 53.2, 53.0, 49.8, 39.4, 38.9, 37.4, 36.5, 27.0,\\n22.3, 16.0. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>52</sub>H<sub>68</sub>N<sub>8</sub>O<sub>10</sub>S 996.48, found\\n997.5008 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.19\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-((14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>29</bold>)</title>\\n        <p>A mixture of <bold>41</bold> (1 equiv),\\nosmium tetroxide 4% in H<sub>2</sub>O (0.2 equiv), sodium periodate\\n(4 equiv), pyridine (2 equiv) in dioxane/H<sub>2</sub>O (3:1) was\\nstirred at rt for 48 h. Then H<sub>2</sub>O was added to the reaction\\nand the product was extracted with DCM. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThen, following general method A, from the aldehyde derivative and <bold>1c</bold> compound <bold>29</bold> was obtained after purification\\nby HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous\\nsolution of ammonia as white powder. Yield: 9.5 mg, 46%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;: 9.54 (s, 1H), 8.90 (s, 1H), 8.70 (d, <italic>J</italic> = 5.8 Hz, 1H), 7.75 (s, 1H), 7.64 (dd, <italic>J</italic> = 0.6, 5.9 Hz, 1H), 7.51 (d, <italic>J</italic> = 7.6 Hz, 1H), 7.10&#x2013;7.03\\n(m, 2H), 6.77 (s, 2H), 4.78 (s, 1H), 4.69&#x2013;4.63 (m, 1H), 4.55&#x2013;4.42\\n(m, 3H), 4.31&#x2013;4.23 (m, 2H), 3.97&#x2013;3.57 (m, 29H), 2.71&#x2013;2.60\\n(m, 10H), 2.52 (s, 3H), 2.30&#x2013;2.24 (m, 1H), 2.17&#x2013;2.08\\n(m, 1H), 1.43&#x2013;1.29 (m, 4H), 1.07 (s, 9H). <sup>13</sup>C NMR\\n(101 MHz, MeOD) &#x3B4;: 174.2, 171.6, 171.3, 163.0, 161.0, 158.0,\\n152.8, 151.7, 151.2, 149.1, 143.6, 138.8, 137.3, 133.5, 132.9, 130.0,\\n128.4, 122.8, 121.7, 119.4, 119.3, 113.8, 113.2, 106.5, 80.3, 78.0,\\n73.7, 71.8, 71.6, 71.5, 71.4, 71.0, 70.8, 69.6, 69.4, 62.2, 60.8,\\n58.7, 58.6, 58.2, 56.3, 54.0, 53.3, 39.5, 38.9, 37.4, 37.3, 26.9,\\n16.0, 14.1, 14.0, 13.9. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>58</sub>H<sub>77</sub>FN<sub>8</sub>O<sub>12</sub>S 1128.54, found 1129.5445 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.20\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>S</italic>)-2-(1-Cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-<italic>N</italic>-(2-((14-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>30</bold>)</title>\\n        <p>A mixture of <bold>43</bold> (1 equiv),\\nosmium tetroxide 4% in H<sub>2</sub>O (0.2 equiv), sodium periodate\\n(4 equiv), pyridine (2 equiv) in dioxane/H<sub>2</sub>O (3:1) was\\nstirred at rt for 48 h. Then H<sub>2</sub>O was added to the reaction\\nand the product was extracted with DCM. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThen, following general method A, from the aldehyde derivative and <bold>1c</bold> compound <bold>30</bold> was obtained after purification\\nby HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous\\nsolution of ammonia as white powder. Yield: 9 mg, 39%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;: 9.55 (d, <italic>J</italic> = 0.7\\nHz, 1H), 8.89 (s, 1H), 8.70 (d, <italic>J</italic> = 5.9 Hz, 1H),\\n7.74 (s, 1H), 7.64 (dd, <italic>J</italic> = 0.7, 5.8 Hz, 1H), 7.49\\n(d, <italic>J</italic> = 7.7 Hz, 1H), 7.09&#x2013;7.02 (m, 2H), 6.76\\n(s, 2H), 4.69&#x2013;4.63 (m, 2H), 4.55&#x2013;4.42 (m, 3H), 4.34&#x2013;4.23\\n(m, 2H), 3.95 (t, <italic>J</italic> = 4.5 Hz, 2H), 3.89 (s, 6H),\\n3.84&#x2013;3.75 (m, 6H), 3.73&#x2013;3.70 (m, 5H), 3.69&#x2013;3.58\\n(m, 9H), 2.68&#x2013;2.56 (m, 10H), 2.52 (s, 3H), 2.32&#x2013;2.22\\n(m, 1H), 2.17&#x2013;2.09 (m, 1H), 1.71&#x2013;1.55 (m, 4H), 1.06\\n(s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;: 174.1, 171.5,\\n167.2, 163.1, 161.0, 158.1, 152.8, 151.7, 151.2, 149.2, 143.7, 138.8,\\n137.2, 133.5, 133.0, 130.2, 128.4, 122.8, 121.7, 120.7, 119.5, 119.3,\\n113.9, 113.7, 106.5, 71.8, 71.6, 71.6, 71.4, 71.1, 70.9, 69.7, 69.4,\\n60.8, 59.5, 58.7, 58.1, 56.3, 54.2, 53.4, 39.6, 38.9, 37.4, 37.3,\\n26.8, 18.1, 18.0, 16.0, 14.9. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>59</sub>H<sub>77</sub>N<sub>9</sub>O<sub>12</sub>S 1035.54, found 1036.5169 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.21\">\\n        <title>14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-<italic>N</italic>-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-3,6,9,12-tetraoxatetradecanamide\\n(<bold>31</bold>)</title>\\n        <p>A mixture of <bold>45</bold> (1 equiv),\\nosmium tetroxide 4% in H<sub>2</sub>O (0.2 equiv), sodium periodate\\n(4 equiv), pyridine (2 equiv) in dioxane/H<sub>2</sub>O (3:1) was\\nstirred at rt for 48 h. Then H<sub>2</sub>O was added to the reaction\\nand the product was extracted with DCM. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThen, following general method A, from the aldehyde derivative and <bold>1c</bold> compound <bold>31</bold> was obtained after purification\\nby HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous\\nsolution of formic acid as white powder. Yield: 3.7 mg, 17%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;: 9.55 (d, <italic>J</italic> = 0.7 Hz, 1H), 8.90 (s, 1H), 8.70 (d, <italic>J</italic> = 5.8 Hz,\\n1H), 7.76 (s, 1H), 7.64 (dd, <italic>J</italic> = 0.6, 5.8 Hz, 1H),\\n7.52 (d, <italic>J</italic> = 7.7 Hz, 1H), 7.08&#x2013;7.01 (m, 2H),\\n6.81 (s, 2H), 4.65&#x2013;4.60 (m, 2H), 4.53&#x2013;4.41 (m, 3H),\\n4.27&#x2013;4.25 (m, 2H), 4.02&#x2013;3.61 (m, 29H), 2.96&#x2013;2.76\\n(m, 10H), 2.51 (s, 3H), 2.27&#x2013;2.21 (m, 1H), 2.15&#x2013;2.08\\n(m, 1H), 2.04 (s, 3H), 1.06 (s, 9H). <sup>13</sup>C NMR (101 MHz,\\nMeOD) &#x3B4;: 174.4, 173.1, 172.3, 163.0, 161.0, 158.0, 152.8, 151.8,\\n151.3, 151.2, 149.1, 143.5, 139.0, 133.5, 132.8, 130.0, 128.4, 122.8,\\n121.7, 119.2, 119.1, 113.7, 106.6, 71.9, 71.6, 71.5, 71.4, 71.1, 70.9,\\n69.4, 60.7, 59.2, 58.1, 58.0, 56.6, 52.8, 49.8, 39.4, 38.9, 37.4,\\n36.5, 27.0, 22.3, 16.0. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>56</sub>H<sub>76</sub>N<sub>8</sub>O<sub>12</sub>S 1084.53, found 1085.5658 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.22\">\\n        <title>2-(2-(Hex-5-en-1-yloxy)ethoxy)ethan-1-ol\\n(<bold>33</bold>)</title>\\n        <p>To a suspension of NaH (2.5 equiv) in DMF\\n(1 M) and THF (1 M),\\ndiethylene glycol (5 equiv) was added at 0 &#xB0;C under nitrogen.\\nAfter 45 min 6-bromo-1-hexene (1 equiv) was added dropwise at 0 &#xB0;C.\\nThen the ice bath was removed, and the reaction mixture was stirred\\novernight at rt under nitrogen. Distillate water was added, and the\\nreaction mixture was acidified with HCl 1 M up to pH 2. The product\\nwas extracted with CHCl<sub>3</sub>. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThe resulting oil was purified by flash column chromatography using\\na gradient from 50% to 100% of ethyl acetate in heptane to obtain\\nthe desired compound <bold>33</bold> as an oil. Yield: 552 mg, 49%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3B4;: 5.85&#x2013;5.74\\n(m, 1H), 5.03&#x2013;4.96 (m, 1H), 4.96&#x2013;4.91 (m, 1H), 3.75&#x2013;3.56\\n(m, 8H), 3.46 (t, <italic>J</italic> = 6.7 Hz, 2H), 2.09&#x2013;2.03\\n(m, 2H), 1.65&#x2013;1.56 (m, 2H), 1.48&#x2013;1.39 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x3B4;: 138.8, 114.7,\\n72.6, 71.5, 70.6, 70.3, 62.0, 33.6, 29.2, 25.5.</p>\\n      </sec>\\n      <sec id=\"sec4.1.23\">\\n        <title>2-(2-(Hex-5-en-1-yloxy)ethoxy)acetic\\nAcid (<bold>34</bold>)</title>\\n        <p>A mixture of 30 (1 equiv), BAIB (2.2\\nequiv), TEMPO (0.22 equiv)\\nin ACN/H<sub>2</sub>O (1:1) (0.5 M) was stirred overnight at rt. The\\nday after the solvent was evaporated, the crude was resuspended in\\nDCM and washed with H<sub>2</sub>O. The organic phases were combined,\\ndried over MgSO<sub>4</sub>, filtered, and evaporated to dryness.\\nThe resulting product was purified by flash column chromatography\\nusing a gradient from 0% to 20% of MeOH in DCM to obtain compound <bold>34</bold> as an oil. Yield: 472 mg, 81%. <sup>1</sup>H NMR (400 MHz,\\nCDCl<sub>3</sub>) &#x3B4;: 5.84&#x2013;5.73 (m, 1H), 5.03&#x2013;4.97\\n(m, 1H), 4.96&#x2013;4.92 (m, 1H), 4.15 (s, 2H), 3.76&#x2013;3.73\\n(m, 2H), 3.63&#x2013;3.59 (m, 2H), 3.52 (t, <italic>J</italic> = 6.6\\nHz, 2H), 2.10&#x2013;2.03 (m, 2H), 1.65&#x2013;1.57 (m, 2H), 1.49&#x2013;1.40\\n(m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x3B4;: 173.2,\\n138.7, 114.8, 71.7, 71.6, 69.7, 69.1, 33.6, 28.9, 25.4.</p>\\n      </sec>\\n      <sec id=\"sec4.1.24\">\\n        <title>(2<italic>R</italic>,4<italic>S</italic>)-1-((<italic>R</italic>)-2-(2-(2-(Hex-5-en-1-yloxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-<italic>N</italic>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\\n(<bold>35</bold>)</title>\\n        <p>Following general method B, compound <bold>35</bold> was obtained from compounds <bold>34</bold> and <bold>2a</bold> (synthesized accordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref61\">61</xref></sup>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid to obtain <bold>35</bold> as white powder. Yield: 14.7 mg, 30%. <sup>1</sup>H NMR\\n(400 MHz, CDCl<sub>3</sub>) &#x3B4;: 8.64 (s, 1H), 7.28&#x2013;7.23\\n(m, 4H), 5.74&#x2013;5.63 (m, 1H), 4.93&#x2013;4.82 (m, 2H), 4.65\\n(t, <italic>J</italic> = 7.9 Hz, 1H), 4.49&#x2013;4.21 (m, 4H), 4.03&#x2013;3.85\\n(m, 3H), 3.59&#x2013;3.47 (m, 5H), 3.40&#x2013;3.34 (m, 2H), 2.47&#x2013;2.39\\n(m, 4H), 2.06&#x2013;1.91 (m, 3H), 1.54&#x2013;1.45 (m, 2H), 1.37&#x2013;1.29\\n(m, 2H), 0.87 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x3B4;: 171.6, 170.8, 150.7, 148.1, 138.7, 138.4, 132.0, 130.7,\\n129.6, 128.3, 114.8, 71.5, 71.4, 70.4, 70.3, 69.8, 58.6, 57.5, 56.7,\\n43.3, 36.0, 34.9, 33.6, 29.1, 26.5, 25.4, 16.0. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>32</sub>H<sub>46</sub>N<sub>4</sub>O<sub>6</sub>S 614.31, found 615.4 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.25\">\\n        <title>2-(2-(Allyloxy)ethoxy)ethan-1-ol\\n(<bold>38</bold>)</title>\\n        <p>To a mixture of NaOH (1 equiv) in dioxane\\n(0.3 M), diethylene glycol\\n(2 equiv) and allyl bromide (1 equiv) were added dropwise. The mixture\\nwas heated overnight at 55 &#xB0;C. Then the reaction mixture was\\ndried over MgSO<sub>4</sub>, filtered, and evaporated in vacuum. The\\ncrude was purified by flash column chromatography using a gradient\\nfrom 50% to 100% of ethyl acetate in heptane to obtain compound <bold>38</bold> as an oil. Yield: 329 mg, 54%. <sup>1</sup>H NMR (400 MHz,\\nCDCl<sub>3</sub>) &#x3B4;: 5.90&#x2013;5.80 (m, 1H), 5.21 (qd, <italic>J</italic> = 1.6, 17.2 Hz, 1H), 5.14&#x2013;5.10 (m, 1H), 3.96 (td, <italic>J</italic> = 1.4, 5.7 Hz, 2H), 3.68&#x2013;3.59 (m, 4H), 3.56&#x2013;3.52\\n(m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) &#x3B4;: 134.5,\\n117.3, 72.6, 72.2, 70.4, 69.4, 61.7.</p>\\n      </sec>\\n      <sec id=\"sec4.1.26\">\\n        <title>3,6,9,12-Tetraoxapentadec-14-en-1-ol\\n(<bold>39</bold>)</title>\\n        <p>Following the same procedure applied for\\ncompound <bold>38</bold>, from tetraethylene glycol and allyl bromide\\ncompound <bold>39</bold> was obtained as oil. Yield: 3.29 g, 68%.\\nAnalytical data matched\\nthose previously reported.<sup><xref ref-type=\"bibr\" rid=\"ref75\">75</xref></sup></p>\\n      </sec>\\n      <sec id=\"sec4.1.27\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-(2-(2-(Allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>40</bold>)</title>\\n        <p>Following general method E, compound <bold>40</bold> was obtained from compounds <bold>38</bold> and <bold>2d</bold> (synthesis detailed in the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid. Yield: 21.7\\nmg, 42%. <sup>1</sup>H NMR (500 MHz, MeOD) &#x3B4;: 8.91 (s, 1H),\\n8.52 (t, <italic>J</italic> = 5.9 Hz, 1H), 7.55 (dd, <italic>J</italic> = 3.4, 9.4 Hz, 1H), 7.51 (d, <italic>J</italic> = 7.8 Hz, 1H), 7.10\\n(d, <italic>J</italic> = 1.6 Hz, 1H), 7.06 (dd, <italic>J</italic> = 1.6, 7.8 Hz, 1H), 5.98&#x2013;5.90 (m, 1H), 5.30 (ddt, <italic>J</italic> = 1.7, 6.9, 8.6 Hz, 1H), 5.18 (ddt, <italic>J</italic> = 1.4, 4.5, 5.2 Hz, 1H), 4.79 (d, <italic>J</italic> = 9.6 Hz, 1H),\\n4.66 (t, <italic>J</italic> = 8.3 Hz, 1H), 4.54&#x2013;4.43 (m, 3H),\\n4.31&#x2013;4.26 (m, 2H), 4.07&#x2013;4.04 (m, 2H), 3.97&#x2013;3.94\\n(m, 2H), 3.90&#x2013;3.82 (m, 2H), 3.80&#x2013;3.76 (m, 2H), 3.69&#x2013;3.66\\n(m, 2H), 2.53 (s, 3H), 2.29&#x2013;2.24 (m, 1H), 2.17&#x2013;2.10\\n(m, 1H), 1.42&#x2013;1.30 (m, 4H), 1.07 (s, 10H). MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>33</sub>H<sub>45</sub>FN<sub>4</sub>O<sub>7</sub>S 660.30, found 661.3 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.28\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>41</bold>)</title>\\n        <p>Following general method E, compound <bold>41</bold> was obtained from compounds <bold>39</bold> and <bold>2d</bold> (synthesis detailed in the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid. Yield: 26.9\\nmg, 46%. <sup>1</sup>H NMR (500 MHz, MeOD) &#x3B4;: 8.91 (s, 1H),\\n8.51 (t, <italic>J</italic> = 6.1 Hz, 1H), 7.56 (dd, <italic>J</italic> = 3.2, 9.6 Hz, 1H), 7.51 (d, <italic>J</italic> = 7.8 Hz, 1H), 7.10\\n(d, <italic>J</italic> = 1.6 Hz, 1H), 7.06 (dd, <italic>J</italic> = 1.7, 7.7 Hz, 1H), 5.97&#x2013;5.89 (m, 1H), 5.30 (ddt, <italic>J</italic> = 1.7, 6.9, 8.7 Hz, 1H), 5.19&#x2013;5.16 (m, 1H), 4.79\\n(d, <italic>J</italic> = 9.1 Hz, 1H), 4.66 (t, <italic>J</italic> =\\n8.2 Hz, 1H), 4.56&#x2013;4.43 (m, 3H), 4.30&#x2013;4.26 (m, 2H), 4.04&#x2013;4.02\\n(m, 2H), 3.97&#x2013;3.94 (m, 2H), 3.90&#x2013;3.82 (m, 2H), 3.80&#x2013;3.77\\n(m, 2H), 3.73&#x2013;3.70 (m, 2H), 3.69&#x2013;3.64 (m, 7H), 3.62&#x2013;3.59\\n(m, 2H), 2.54 (s, 3H), 2.30&#x2013;2.25 (m, 1H), 2.16&#x2013;2.11\\n(m, 1H), 1.42&#x2013;1.31 (m, 4H), 1.07 (s, 9H). MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>37</sub>H<sub>53</sub>FN<sub>4</sub>O<sub>9</sub>S 748.35, found 749.4 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.29\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-(2-(2-(Allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>42</bold>)</title>\\n        <p>Following general method E, compound <bold>42</bold> was obtained from compounds <bold>38</bold> and <bold>2c</bold> (synthesized as previously reported<sup><xref ref-type=\"bibr\" rid=\"ref29\">29</xref></sup>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid. Yield: 15.8\\nmg, 61%. <sup>1</sup>H NMR (500 MHz, MeOD) &#x3B4;: 8.91 (s, 1H),\\n8.50 (t, <italic>J</italic> = 5.9 Hz, 1H), 7.50 (d, <italic>J</italic> = 7.9 Hz, 1H), 7.10 (d, <italic>J</italic> = 1.8 Hz, 1H), 7.06 (dd, <italic>J</italic> = 1.7, 8.0 Hz, 1H), 5.98&#x2013;5.90 (m, 1H), 5.30 (ddt, <italic>J</italic> = 1.8, 6.9, 8.6 Hz, 1H), 5.20&#x2013;5.16 (m, 1H), 4.71&#x2013;4.64\\n(m, 2H), 4.54&#x2013;4.44 (m, 4H), 4.31&#x2013;4.27 (m, 2H), 4.06\\n(td, <italic>J</italic> = 1.4, 5.6 Hz, 2H), 3.97&#x2013;3.95 (m, 2H),\\n3.87&#x2013;3.78 (m, 5H), 3.69&#x2013;3.66 (m, 3H), 2.53 (s, 4H),\\n2.28&#x2013;2.23 (m, 1H), 2.16&#x2013;2.10 (m, 1H), 1.71&#x2013;1.56\\n(m, 4H), 1.06 (s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;:\\n174.3, 171.6, 167.3, 158.2, 152.9, 149.2, 136.2, 133.6, 133.0, 130.2,\\n128.5, 122.9, 120.8, 117.4, 113.9, 73.2, 71.9, 71.1, 71.0, 70.7, 69.5,\\n60.9, 59.7, 59.6, 39.8, 39.0, 37.4, 26.9, 18.2, 18.1, 16.0, 15.0,\\n14.9. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>34</sub>H<sub>45</sub>N<sub>5</sub>O<sub>7</sub>S 667.30, found 668.4 [M\\n+ H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.30\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>43</bold>)</title>\\n        <p>Following general method E, compound <bold>43</bold> was obtained from compounds <bold>39</bold> and <bold>2c</bold> (synthesized as previously reported<sup><xref ref-type=\"bibr\" rid=\"ref29\">29</xref></sup>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid. Yield: 15.3\\nmg, 52%. <sup>1</sup>H NMR (500 MHz, MeOD) &#x3B4;: 8.91 (s, 1H),\\n8.49 (t, <italic>J</italic> = 6.1 Hz, 1H), 7.51 (d, <italic>J</italic> = 7.7 Hz, 1H), 7.10 (d, <italic>J</italic> = 1.6 Hz, 1H), 7.06 (dd, <italic>J</italic> = 1.6, 7.7 Hz, 1H), 5.97&#x2013;5.89 (m, 1H), 5.30 (ddt, <italic>J</italic> = 1.6, 6.9, 8.6 Hz, 1H), 5.19&#x2013;5.16 (m, 1H), 4.71&#x2013;4.64\\n(m, 2H), 4.55&#x2013;4.43 (m, 3H), 4.31&#x2013;4.26 (m, 2H), 4.03\\n(td, <italic>J</italic> = 1.4, 5.6 Hz, 2H), 3.97&#x2013;3.94 (m, 2H),\\n3.87&#x2013;3.77 (m, 4H), 3.73&#x2013;3.71 (m, 2H), 3.69&#x2013;3.64\\n(m, 7H), 3.62&#x2013;3.59 (m, 2H), 2.54 (s, 3H), 2.30&#x2013;2.25\\n(m, 1H), 2.16&#x2013;2.10 (m, 1H), 1.71&#x2013;1.56 (m, 4H), 1.06\\n(s, 9H). MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>38</sub>H<sub>53</sub>N<sub>5</sub>O<sub>9</sub>S 755.36, found 756.5\\n[M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.31\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>S</italic>)-2-Acetamido-3,3-dimethylbutanoyl)-<italic>N</italic>-(2-(2-(2-(allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>44</bold>)</title>\\n        <p>Following general method E, compound <bold>44</bold> was obtained from compounds <bold>38</bold> and <bold>2b</bold> (synthesized accordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref29\">29</xref></sup>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid. Yield: 12.7\\nmg, 53%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;: 8.91 (s, 1H),\\n7.52 (d, <italic>J</italic> = 7.8 Hz, 1H), 7.08 (s, 1H), 7.04 (dd, <italic>J</italic> = 1.4, 7.8 Hz, 1H), 5.99&#x2013;5.88 (m, 1H), 5.30 (dq, <italic>J</italic> = 1.7, 6.9 Hz, 1H), 5.18 (dq, <italic>J</italic> = 1.3,\\n4.5 Hz, 1H), 4.67&#x2013;4.60 (m, 2H), 4.55&#x2013;4.42 (m, 3H), 4.30&#x2013;4.25\\n(m, 2H), 4.05 (dt, <italic>J</italic> = 1.4, 5.6 Hz, 2H), 3.97&#x2013;3.90\\n(m, 3H), 3.85&#x2013;3.77 (m, 3H), 3.68&#x2013;3.65 (m, 2H), 2.53\\n(s, 3H), 2.28&#x2013;2.20 (m, 1H), 2.16&#x2013;2.07 (m, 1H), 2.03\\n(s, 3H), 1.06 (s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;:\\n174.4, 173.1, 172.3, 158.0, 152.8, 149.1, 136.1, 133.5, 132.8, 130.0,\\n128.4, 122.8, 117.3, 114.0, 113.8, 73.1, 71.8, 70.9, 70.6, 69.4, 60.7,\\n59.1, 57.9, 39.4, 38.9, 36.5, 27.0, 22.3, 15.9. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>31</sub>H<sub>44</sub>N<sub>4</sub>O<sub>7</sub>S 616.29, found 617.4 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.32\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-acetamido-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>45</bold>)</title>\\n        <p>Following general method E, compound <bold>45</bold> was obtained from compounds <bold>39</bold> and <bold>2b</bold> (synthesized accordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref29\">29</xref></sup>). The crude was purified by HPLC using a gradient of 5% to 95% v/v\\nacetonitrile in 0.1% aqueous solution of formic acid. Yield: 13.8\\nmg, 53%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;: 8.92 (s, 1H),\\n7.52 (d, <italic>J</italic> = 7.9 Hz, 1H), 7.08 (s, 1H), 7.04 (dd, <italic>J</italic> = 1.5, 7.8 Hz, 1H), 6.01&#x2013;5.88 (m, 1H), 5.29 (dq, <italic>J</italic> = 1.7, 6.9 Hz, 1H), 5.17 (dq, <italic>J</italic> = 1.3,\\n4.5 Hz, 1H), 4.67&#x2013;4.60 (m, 2H), 4.56&#x2013;4.39 (m, 2H), 4.29&#x2013;4.25\\n(m, 2H), 4.03 (dt, <italic>J</italic> = 1.4, 5.7 Hz, 2H), 3.97&#x2013;3.90\\n(m, 3H), 3.85&#x2013;3.76 (m, 3H), 3.73&#x2013;3.63 (m, 9H), 3.62&#x2013;3.58\\n(m, 2H), 2.53 (s, 3H), 2.28&#x2013;2.21 (m, 1H), 2.16&#x2013;2.08\\n(m, 1H), 2.04 (s, 3H), 1.06 (s, 9H). <sup>13</sup>C NMR (101 MHz,\\nMeOD) &#x3B4;: 174.4, 173.1, 172.2, 158.0, 152.8, 149.1, 136.1, 133.5,\\n132.8, 130.0, 128.4, 122.8, 117.2, 113.7, 73.1, 71.8, 71.6, 71.5,\\n71.1, 70.8, 70.6, 69.4, 60.7, 59.1, 58.0, 39.4, 38.9, 36.5, 27.0,\\n22.3, 15.9. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>35</sub>H<sub>52</sub>N<sub>4</sub>O<sub>9</sub>S 704.35, found 705.4\\n[M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.33\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>46</bold>)</title>\\n        <p>Following general method C, from <bold>69</bold> (0.033 mmol) and <bold>1c</bold> (0.033 mmol) compound <bold>46</bold> was obtained after purification by HPLC using a gradient\\nof 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\\nas white powder. Yield: 5.3 mg, 16%. <sup>1</sup>H NMR (400 MHz, MeOD)\\n&#x3B4;: 9.61 (s, 1H), 8.95 (s, 1H), 8.71 (d, <italic>J</italic> =\\n6.2 Hz, 1H), 7.97 (s, 1H), 7.85 (d, <italic>J</italic> = 6.0 Hz, 1H),\\n7.53 (d, <italic>J</italic> = 8.2 Hz, 1H), 7.10&#x2013;7.07 (m, 2H),\\n6.90 (s, 2H), 4.78 (s, 1H), 4.66 (t, <italic>J</italic> = 8.5 Hz,\\n1H), 4.54&#x2013;4.44 (m, 3H), 4.32&#x2013;4.29 (m, 2H), 4.00&#x2013;3.81\\n(m, 14H), 3.76 (s, 3H), 3.55 (s, 4H), 3.45 (s, 4H), 3.30&#x2013;3.27\\n(m, 2H), 2.53 (s, 3H), 2.32&#x2013;2.26 (m, 1H), 2.18&#x2013;2.10\\n(m, 1H), 1.44&#x2013;1.30 (m, 4H), 1.08 (s, 9H). <sup>13</sup>C NMR\\n(101 MHz, MeOD) &#x3B4;: 174.2, 171.8, 164.4, 162.2, 161.2, 157.8,\\n153.0, 149.0, 146.4, 142.3, 140.0, 133.5, 132.9, 129.9, 128.2, 122.9,\\n122.3, 120.8, 118.2, 113.5, 106.8, 80.3, 78.0, 71.0, 70.9, 69.1, 67.2,\\n60.9, 58.8, 58.7, 58.2, 57.5, 56.9, 50.7, 50.1, 39.4, 39.0, 37.6,\\n37.3, 26.9, 15.8, 14.1, 14.0, 14.0, 13.9. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>52</sub>H<sub>65</sub>FN<sub>8</sub>O<sub>9</sub>S 996.46, found 997.4810 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.34\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-(2-(2-(4-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>47</bold>)</title>\\n        <p>Following general method C, from <bold>69</bold> (0.033 mmol) and <bold>1d</bold> (synthesis detailed in\\nthe <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>) (0.033 mmol)\\ncompound <bold>47</bold> was obtained after purification by HPLC using\\na gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution\\nof formic acid as white powder. Yield: 5.3 mg, 5%. <sup>1</sup>H NMR\\n(400 MHz, MeOD) &#x3B4;: 9.52 (s, 1H), 8.91 (s, 1H), 8.62 (d, <italic>J</italic> = 5.7 Hz, 1H), 7.65 (s, 1H), 7.51 (d, <italic>J</italic> = 7.9 Hz, 1H), 7.23&#x2013;7.19 (m, 2H), 7.10 (d, <italic>J</italic> = 1.2 Hz, 1H), 7.06 (dd, <italic>J</italic> = 1.6, 7.7 Hz, 1H),\\n6.98 (s, 1H), 4.78 (s, 1H), 4.66 (t, <italic>J</italic> = 8.5 Hz,\\n1H), 4.55&#x2013;4.45 (m, 3H), 4.32&#x2013;4.28 (m, 2H), 3.95&#x2013;3.89\\n(m, 2H), 3.88&#x2013;3.80 (m, 7H), 3.76&#x2013;3.71 (m, 8H), 2.78&#x2013;2.71\\n(m, 10H), 2.53 (s, 3H), 2.30&#x2013;2.24 (m, 1H), 2.17&#x2013;2.11\\n(m, 1H), 1.42&#x2013;1.31 (m, 4H), 1.07 (s, 9H). <sup>13</sup>C NMR\\n(101 MHz, MeOD) &#x3B4;: 174.1, 171.7, 163.3, 158.0, 153.7, 152.8,\\n151.4, 150.6, 144.2, 139.2, 133.5, 133.0, 128.4, 124.1, 122.8, 121.5,\\n120.3, 115.8, 113.9, 80.3, 71.0, 70.8, 69.8, 69.3, 60.8, 58.7, 58.2,\\n56.7, 56.5, 54.3, 53.5, 39.4, 38.9, 37.4, 37.3, 26.9, 15.9, 14.1,\\n14.0, 13.9. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>52</sub>H<sub>65</sub>FN<sub>8</sub>O<sub>9</sub>S 996.46, found\\n997.4712 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.35\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-((5-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>51</bold>, VZ185)</title>\\n        <p>Following general method C, from <bold>70</bold> (0.02 mmol) and <bold>1c</bold> (0.02 mmol) compound <bold>51</bold> was obtained after purification by HPLC using a gradient\\nof 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\\nas white powder. Yield: 4.8 mg, 24%. <sup>1</sup>H NMR (400 MHz, MeOD)\\n&#x3B4;: 9.56 (d, <italic>J</italic> = 0.8 Hz, 1H), 8.92 (s, 1H),\\n8.71 (d, <italic>J</italic> = 5.8 Hz, 1H), 7.78 (s, 1H), 7.65 (dd, <italic>J</italic> = 0.7, 5.8 Hz, 1H), 7.52 (d, <italic>J</italic> = 7.7\\nHz, 1H), 7.07&#x2013;7.03 (m, 2H), 6.86 (s, 2H), 4.79 (s, 1H), 4.67\\n(t, <italic>J</italic> = 12.4 Hz, 1H), 4.55&#x2013;4.47 (m, 3H), 4.18\\n(s, 2H), 4.14 (t, <italic>J</italic> = 6.0 Hz, 2H), 3.96&#x2013;3.82\\n(m, 8H), 3.74 (s, 3H), 3.18&#x2013;2.78 (m, 10H), 2.53 (s, 3H), 2.32&#x2013;2.25\\n(m, 1H), 2.19&#x2013;2.12 (m, 1H), 1.98&#x2013;1.91 (m, 2H), 1.79&#x2013;1.71\\n(m, 2H), 1.68&#x2013;1.61 (m, 2H), 1.42&#x2013;1.29 (m, 4H), 1.08\\n(s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;: 174.2, 171.8,\\n171.4, 163.1, 161.0, 158.0, 152.8, 151.7, 151.2, 149.1, 143.6, 138.8,\\n133.6, 132.8, 129.7, 128.0, 122.5, 121.7, 119.2, 113.1, 106.6, 80.3,\\n78.0, 71.0, 69.2, 60.8, 59.2, 58.7, 58.1, 56.4, 53.1, 49.8, 39.3,\\n38.9, 37.4, 37.3, 30.1, 26.9, 25.1, 15.9, 14.1, 14.0, 13.8. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>53</sub>H<sub>67</sub>FN<sub>8</sub>O<sub>8</sub>S 994.48, found 995.5024 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.36\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-((5-(4-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>52</bold>)</title>\\n        <p>Following general method C, from <bold>70</bold> (0.02 mmol) and <bold>1d</bold> (0.02 mmol) compound <bold>52</bold> was obtained after purification by HPLC using a gradient\\nof 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\\nas white powder. Yield: 4 mg, 20%. <sup>1</sup>H NMR (400 MHz, MeOD)\\n&#x3B4;: 9.53 (s, 1H), 8.92 (s, 1H), 8.62 (d, <italic>J</italic> =\\n5.7 Hz, 1H), 7.65 (s, 1H), 7.53 (d, <italic>J</italic> = 7.4 Hz, 1H),\\n7.23&#x2013;7.19 (m, 2H), 7.05 (s, 2H), 7.02 (s, 1H), 4.79 (s, 1H),\\n4.68 (t, <italic>J</italic> = 8.4 Hz, 1H), 4.55&#x2013;4.47 (m, 3H),\\n4.15 (t, <italic>J</italic> = 5.9 Hz, 2H), 3.92&#x2013;3.82 (m, 7H),\\n3.75 (s, 3H), 3.72 (s, 3H), 3.18&#x2013;2.91 (m, 10H), 2.53 (s, 3H),\\n2.32&#x2013;2.26 (m, 1H), 2.19&#x2013;2.12 (m, 1H), 2.00&#x2013;1.93\\n(m, 2H), 1.87&#x2013;1.78 (m, 2H), 1.70&#x2013;1.62 (m, 2H), 1.43&#x2013;1.30\\n(m, 4H), 1.08 (s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;:174.2,\\n171.8, 163.3, 157.9, 153.7, 152.8, 151.4, 150.5, 149.2, 144.1, 139.3,\\n133.6, 132.9, 129.6, 127.9, 122.6, 121.5, 120.1, 116.0, 115.6, 113.1,\\n80.4, 78.1, 71.0, 69.0, 60.9, 58.7, 58.4, 58.2, 56.8, 56.5, 56.2,\\n53.1, 51.8, 39.3, 38.9, 37.4, 37.3, 29.8, 26.9, 24.7, 15.9, 14.1,\\n14.0, 13.9. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>53</sub>H<sub>67</sub>FN<sub>8</sub>O<sub>8</sub>S 994.48, found\\n995.4771 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.37\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-(2-(2-((1-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-2-oxoethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>55</bold>)</title>\\n        <p>Following general method B, from the <bold>71</bold> (0.02 mmol) and <bold>1e</bold> (0.02 mmol) compound <bold>55</bold> was obtained after purification by HPLC using a gradient\\nof 5% to 95% v/v acetonitrile in 0.1% aqueous solution of ammonia\\nas white powder. Yield: 2.4 mg, 12%. <sup>1</sup>H NMR (400 MHz, MeOD)\\n&#x3B4;: 9.56 (d, <italic>J</italic> = 0.6 Hz, 1H), 8.93 (s, 1H),\\n8.71 (d, <italic>J</italic> = 6.0 Hz, 1H), 7.80 (s, 1H), 7.63 (dd, <italic>J</italic> = 0.6, 5.8 Hz, 1H), 7.55 (d, <italic>J</italic> = 8.1\\nHz, 1H), 7.12&#x2013;7.08 (m, 2H), 6.89 (s, 2H), 4.80&#x2013;4.64\\n(m, 3H), 4.60&#x2013;4.31 (m, 11H), 4.23 (s, 2H), 4.06 (t, <italic>J</italic> = 4.0 Hz, 2H), 3.98 (s, 6H), 3.91&#x2013;3.80 (m, 2H),\\n3.74 (s, 3H), 2.53 (s, 3H), 2.31&#x2013;2.25 (m, 1H), 2.18&#x2013;2.10\\n(m, 1H), 1.42&#x2013;1.30 (m, 4H), 1.07 (s, 9H). <sup>13</sup>C NMR\\n(101 MHz, MeOD) &#x3B4;: 174.3, 171.8, 166.7, 160.7, 157.8, 152.9,\\n151.8, 151.3, 149.2, 143.3, 140.4, 139.2, 133.4, 133.0, 130.0, 128.2,\\n123.0, 121.7, 119.1, 118.6, 113.4, 106.8, 71.5, 71.5, 71.0, 69.2,\\n60.9, 60.9, 58.7, 58.2, 56.9, 49.5, 39.4, 38.9, 37.5, 37.3, 29.5,\\n26.9, 15.9, 13.9. HRMS <italic>m</italic>/<italic>z</italic> calcd\\nfor C<sub>51</sub>H<sub>61</sub>FN<sub>8</sub>O<sub>10</sub>S 996.42,\\nfound 997.4452 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.38\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-(2-(2-((1-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-2-oxoethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>56</bold>)</title>\\n        <p>Following general method B, from <bold>71</bold> (0.02 mmol) and <bold>1f</bold> (synthesis detailed in\\nthe <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information</ext-link>) (0.02 mmol)\\ncompound <bold>56</bold> was obtained after purification by HPLC using\\na gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution\\nof ammonia as white powder. Yield: 3.3 mg, 17%. <sup>1</sup>H NMR\\n(400 MHz, MeOD) &#x3B4;: 9.39 (s, 1H), 8.80 (s, 1H), 8.49 (d, <italic>J</italic> = 5.7 Hz, 1H), 7.54 (s, 1H), 7.42 (d, <italic>J</italic> = 8.2 Hz, 1H), 7.10 (s, 1H), 7.04 (d, <italic>J</italic> = 5.6 Hz,\\n1H), 6.99 (s, 1H), 6.98&#x2013;6.94 (m, 2H), 4.66 (s, 1H), 4.60&#x2013;4.51\\n(m, 2H), 4.45&#x2013;4.32 (m, 5H), 4.27&#x2013;4.15 (m, 6H), 4.10\\n(s, 2H), 3.93 (t, <italic>J</italic> = 4.1 Hz, 2H), 3.81 (s, 3H),\\n3.78&#x2013;3.67 (m, 2H), 3.63 (s, 3H), 3.58 (s, 3H), 2.40 (s, 3H),\\n2.19&#x2013;2.10 (m, 1H), 2.05&#x2013;1.98 (m, 1H), 1.30&#x2013;1.16\\n(m, 4H), 0.94 (s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;:\\n174.2, 173.2, 171.8, 167.1, 166.6, 163.2, 157.8, 153.4, 153.0, 152.9,\\n151.4, 150.6, 149.2, 143.8, 139.5, 133.4, 133.0, 130.0, 128.2, 127.1,\\n123.0, 121.5, 120.9, 120.0, 116.1, 115.6, 113.4, 80.3, 78.0, 71.5,\\n71.5, 71.0, 69.2, 69.1, 60.9, 58.7, 58.2, 56.8, 56.6, 55.9, 49.5,\\n49.5, 40.7, 39.4, 38.9, 37.4, 37.3, 26.9, 15.9, 14.0. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>51</sub>H<sub>61</sub>FN<sub>8</sub>O<sub>10</sub>S 996.42, found 997.4435 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.39\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-((5-((1-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-5-oxopentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>61</bold>)</title>\\n        <p>Following general method B, from <bold>72</bold> (0.025 mmol) and <bold>1e</bold> (0.025 mmol) compound <bold>61</bold> was obtained after purification by HPLC using a gradient\\nof 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\\nas white powder. Yield: 4.5 mg, 18%. <sup>1</sup>H NMR (400 MHz, MeOD)\\n&#x3B4;: 9.45 (d, <italic>J</italic> = 0.5 Hz, 1H), 8.81 (s, 1H),\\n8.61 (d, <italic>J</italic> = 5.7 Hz, 1H), 7.68 (s, 1H), 7.54 (d, <italic>J</italic> = 5.5 Hz, 1H), 7.41 (d, <italic>J</italic> = 7.6 Hz, 1H),\\n6.96&#x2013;6.91 (m, 2H), 6.74 (s, 2H), 4.69 (s, 1H), 4.58 (t, <italic>J</italic> = 8.5 Hz, 1H), 4.54&#x2013;4.32 (m, 5H), 4.24 (s, 2H),\\n4.11&#x2013;4.01 (m, 4H), 3.85 (s, 6H), 3.81&#x2013;3.70 (m, 3H),\\n3.63 (s, 3H), 2.42 (s, 3H), 2.28 (t, <italic>J</italic> = 6.5 Hz,\\n2H), 2.21&#x2013;2.15 (m, 1H), 2.08&#x2013;2.01 (m, 1H), 1.85&#x2013;1.78\\n(m, 4H), 1.32&#x2013;1.20 (m, 4H), 0.96 (s, 9H). <sup>13</sup>C NMR\\n(101 MHz, MeOD) &#x3B4;: 176.1, 174.3, 171.7, 163.0, 160.7, 157.9,\\n152.8, 151.7, 151.3, 149.1, 148.6, 143.4, 139.4, 139.1, 133.6, 132.8,\\n129.7, 128.2, 128.0, 122.5, 121.7, 120.9, 119.2, 118.9, 113.0, 106.7,\\n80.3, 78.0, 71.0, 68.8, 61.1, 60.8, 58.7, 58.2, 56.7, 56.1, 40.9,\\n39.3, 38.9, 37.4, 37.3, 36.4, 29.8, 29.5, 26.9, 23.4, 15.9, 14.1,\\n14.0, 13.9. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>52</sub>H<sub>63</sub>FN<sub>8</sub>O<sub>9</sub>S 994.44, found\\n995.4634 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.40\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-((5-((1-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-5-oxopentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>62</bold>)</title>\\n        <p>Following general method B, from <bold>72</bold> (0.025 mmol) and <bold>1f</bold> (0.025 mmol) compound <bold>62</bold> was obtained after purification by HPLC using a gradient\\nof 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\\nas white powder. Yield: 5.8 mg, 23%. <sup>1</sup>H NMR (400 MHz, MeOD)\\n&#x3B4;: 9.51 (d, <italic>J</italic> = 0.7 Hz, 1H), 8.91 (s, 1H),\\n8.62 (d, <italic>J</italic> = 6.0 Hz, 1H), 7.64 (s, 1H), 7.52 (d, <italic>J</italic> = 7.5 Hz, 1H), 7.19 (dd, <italic>J</italic> = 0.8, 5.8\\nHz, 1H), 7.14 (s, 1H), 7.06&#x2013;7.02 (m, 2H), 7.01 (s, 1H), 4.79\\n(s, 1H), 4.69 (t, <italic>J</italic> = 8.5 Hz, 1H), 4.58&#x2013;4.43\\n(m, 4H), 4.13 (s, 2H), 4.01&#x2013;3.81 (m, 10H), 3.74 (s, 3H), 3.71\\n(s, 3H), 3.47 (s, 1H), 2.52 (s, 3H), 2.36 (t, <italic>J</italic> =\\n6.5 Hz, 2H), 2.31&#x2013;2.24 (m, 1H), 2.20&#x2013;2.11 (m, 1H), 1.92\\n(t, <italic>J</italic> = 2.6 Hz, 4H), 1.46&#x2013;1.29 (m, 4H), 1.08\\n(s, 9H). <sup>13</sup>C NMR (101 MHz, MeOD) &#x3B4;: 175.8, 174.3,\\n171.7, 171.6, 171.4, 163.2, 157.9, 153.2, 152.8, 152.8, 151.3, 150.5,\\n149.1, 144.1, 139.3, 133.6, 132.8, 129.7, 128.0, 124.7, 122.5, 121.5,\\n120.2, 116.1, 115.6, 115.0, 113.0, 80.3, 78.0, 71.1, 68.8, 61.8, 60.8,\\n58.7, 58.2, 57.2, 56.6, 56.5, 41.4, 39.3, 38.9, 37.4, 37.3, 36.4,\\n29.8, 26.9, 23.5, 15.9, 14.1, 14.0, 13.9. HRMS <italic>m</italic>/<italic>z</italic> calcd for C<sub>52</sub>H<sub>63</sub>FN<sub>8</sub>O<sub>9</sub>S 994.44, found 995.4664 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.41\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-(2-(2,2-Diethoxyethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>67</bold>)</title>\\n        <p>Following general method E, compound <bold>67</bold> was obtained after reaction between 2-(2,2-diethoxyethoxy)ethan-1-ol\\n(synthesized accordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref76\">76</xref></sup>) and <bold>2d</bold> as white powder. Yield: 92 mg, 87%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#x3B4;: 8.66 (s, 1H), 7.31 (d, <italic>J</italic> = 7.7 Hz, 1H), 6.95 (dd, <italic>J</italic> = 1.2, 7.7\\nHz, 1H), 6.88 (s, 1H), 4.66 (t, <italic>J</italic> = 7.6 Hz, 2H),\\n4.55&#x2013;4.40 (m, 4H), 4.23&#x2013;4.13 (m, 2H), 3.97&#x2013;3.87\\n(m, 3H), 3.71&#x2013;3.49 (m, 7H), 2.50 (s, 3H), 2.44&#x2013;2.34\\n(m, 1H), 2.13&#x2013;2.05 (m, 1H), 1.35&#x2013;1.26 (m, 4H), 1.18\\n(t, <italic>J</italic> = 7.1 Hz, 6H), 0.93 (s, 9H). <sup>13</sup>C\\nNMR (101 MHz, CDCl<sub>3</sub>) &#x3B4;: 170.8, 170.3, 170.1, 156.9,\\n150.4, 148.6, 132.4, 131.8, 129.8, 126.9, 122.1, 112.9, 101.0, 79.5,\\n72.0, 70.3, 70.1, 68.0, 62.5, 62.3, 58.7, 57.5, 56.7, 39.1, 36.5,\\n35.6, 26.4, 16.2, 15.4, 13.9, 13.8, 13.7. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>34</sub>H<sub>49</sub>FN<sub>4</sub>O<sub>8</sub>S 692.33, found 693.3 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.42\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-<italic>N</italic>-(2-((5,5-Dimethoxypentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((<italic>S</italic>)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\\n(<bold>68</bold>)</title>\\n        <p>A mixture of <bold>2d</bold> (0.075 mmol,\\n1 equiv), 5-bromo-1,1-dimethoxypentane <bold>66</bold> (synthesized\\naccordingly to literature<sup><xref ref-type=\"bibr\" rid=\"ref77\">77</xref></sup>) (0.112 mmol,\\n1.8 equiv), and K<sub>2</sub>CO<sub>3</sub> (0.225 mmol, 3 equiv)\\nin DMF (0.5 mL) was stirred at 70 &#xB0;C overnight. The reaction\\nmixture was diluted with water and extracted with DCM, dried over\\nMgSO<sub>4</sub>, filtered and evaporated to dryness. The crude was\\npurified by flash column chromatography using a gradient from 0% to\\n20% of methanol in DCM to obtain the desired compound as white powder.\\nYield: 23 mg, 55%. <sup>1</sup>H NMR (400 MHz, MeOD) &#x3B4;: 8.91\\n(s, 1H), 7.51 (d, <italic>J</italic> = 8.0 Hz, 1H), 7.05 (d, <italic>J</italic> = 1.5 Hz, 1H), 7.03 (s, 1H), 4.80 (d, <italic>J</italic> = 8.6 Hz, 1H), 4.68 (t, <italic>J</italic> = 8.3 Hz, 1H), 4.57&#x2013;4.42\\n(m, 4H), 4.11 (t, <italic>J</italic> = 6.2 Hz, 2H), 3.81&#x2013;3.62\\n(m, 2H), 3.36 (s, 6H), 2.53 (s, 3H), 2.31&#x2013;2.25 (m, 1H), 2.21&#x2013;2.14\\n(m, 1H), 1.95&#x2013;1.88 (m, 2H), 1.76&#x2013;1.68 (m, 2H), 1.67&#x2013;1.58\\n(m, 2H), 1.38&#x2013;1.29 (m, 4H), 1.08 (s, 9H). <sup>13</sup>C NMR\\n(101 MHz, MeOD) &#x3B4;: 174.2, 171.7, 171.4, 158.0, 152.8, 149.1,\\n133.6, 132.8, 129.6, 127.9, 122.4, 113.0, 106.2, 80.3, 71.1, 69.2,\\n60.8, 58.1, 55.8, 53.5, 43.8, 39.3, 38.9, 37.3, 33.4, 30.1, 26.9,\\n22.3, 15.9, 14.1, 14.0, 13.9, 13.2. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>33</sub>H<sub>47</sub>FN<sub>4</sub>O<sub>7</sub>S 662.31, found 663.5 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.43\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>S</italic>)-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-<italic>N</italic>-(4-(4-methylthiazol-5-yl)-2-(2-(2-oxoethoxy)ethoxy)benzyl)pyrrolidine-2-carboxamide\\n(<bold>69</bold>)</title>\\n        <p>Following general method F, compound <bold>69</bold> was obtained from <bold>67</bold> (0.066 mmol) and directly\\nused in the next step without any further purification. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>30</sub>H<sub>39</sub>FN<sub>4</sub>O<sub>7</sub>S 618.15, found 619.3 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.44\">\\n        <title>(2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>S</italic>)-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-<italic>N</italic>-(4-(4-methylthiazol-5-yl)-2-((5-oxopentyl)oxy)benzyl)pyrrolidine-2-carboxamide\\n(<bold>70</bold>)</title>\\n        <p>Following general method F, compound <bold>70</bold> was obtained from <bold>68</bold> (0.04 mmol) and directly\\nused in the next step without any further purification. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>31</sub>H<sub>41</sub>FN<sub>4</sub>O<sub>6</sub>S 616.27, found 617.3 [M + H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.45\">\\n        <title>2-(2-(2-(((2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>S</italic>)-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethoxy)acetic\\nAcid (<bold>71</bold>)</title>\\n        <p>Following general method G, compound <bold>71</bold> was obtained from compound <bold>69</bold> (0.04 mmol)\\nand was used in the next step without any further purification. Quantitative\\nyield. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>30</sub>H<sub>39</sub>FN<sub>4</sub>O<sub>8</sub>S 634.25, found 635.3 [M\\n+ H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.1.46\">\\n        <title>5-(2-(((2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>S</italic>)-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)pentanoic\\nAcid (<bold>72</bold>)</title>\\n        <p>Following general method G, compound <bold>72</bold> was obtained from compound <bold>70</bold> (0.05 mmol)\\nand was used in the next step without any further purification. Quantitative\\nyield. MS <italic>m</italic>/<italic>z</italic> calcd for C<sub>31</sub>H<sub>41</sub>FN<sub>4</sub>O<sub>7</sub>S 632.27, found 633.3 [M\\n+ H<sup>+</sup>].</p>\\n      </sec>\\n      <sec id=\"sec4.2.1\">\\n        <title>Biology. Cell Culture</title>\\n        <p>Human cell\\nlines HeLa and Hek293\\nwere purchased from ATCC and propagated in DMEM medium (Gibco), supplemented\\nwith 10% fetal bovine serum (FBS) (Gibco), <sc>l</sc>-glutamine (Gibco),\\n100 &#x3BC;g mL<sup>&#x2013;1</sup> of penicillin/streptomycin. RI-1\\ncells, purchased from DSMZ, were propagated in RPMI medium (Gibco),\\nsupplemented with 10% fetal bovine serum (FBS) (Gibco), <sc>l</sc>-glutamine, 100 &#x3BC;g mL<sup>&#x2013;1</sup> of penicillin/streptomycin.\\nCells were kept at 37 &#xB0;C and 5% of CO<sub>2</sub>. EOL-1 and\\nA-204 cell lines were purchased from ATCC and DSMZ. EOL-1 cells were\\ngrown in RPMI supplemented with 10% fetal calf serum. A-204 cells\\nwere grown in McCoy&#x2019;s medium supplemented with 10% fetal calf\\nserum. All cell lines were routinely tested for mycoplasma contamination\\nusing MycoAlert kit from Lonza.</p>\\n      </sec>\\n      <sec id=\"sec4.2.2\">\\n        <title>Testing Compounds in Cells</title>\\n        <p>HeLa and Hek293 cells were\\nseeded at either 0.3 &#xD7; 10<sup>6</sup> or 0.5 &#xD7; 10<sup>6</sup> cells per well in 6-well plate in 2 mL of medium. At 80% confluency,\\ncells were treated with compounds at the desired concentration, with\\nfinal DMSO concentration of 0.1% v/v. Cells were incubated at 37 &#xB0;C\\nand 5% of CO<sub>2</sub> for the desired time before harvesting. For\\nprotein extraction from adherent cells, cells were washed twice with\\nDPBS (Gibco) and lysed with RIPA buffer (Sigma-Aldrich), supplemented\\nwith cOmplete Mini EDTA-free protease inhibitor cocktail (Roche).\\nInsoluble material was removed by centrifugation at 14&#x202F;000\\nrpm for 15 min at 4 &#xB0;C. Supernatant was collected and protein\\nconcentration was quantified by Bradford assay (Thermo Scientific\\nno. 23200, mean of two replicates). For RI-1 cells, (1&#x2013;1.5)\\n&#xD7; 10<sup>6</sup> cells/mL were seeded in 6-well plate in 2 mL\\nof medium. The day after, cells were treated with compounds at the\\ndesired concentration, with final DMSO concentration of 0.1% v/v.\\nBefore harvesting, cells were incubated at 37 &#xB0;C and 5% CO<sub>2</sub> for the desired time. Cells were washed twice with DPBS (Gibco)\\nand lysed with RIPA buffer (Sigma-Aldrich), supplemented with cOmplete\\nMini EDTA-free protease inhibitor cocktail (Roche). Lysates were sonicated\\n(10 s) and centrifuged at 14&#x202F;000 rpm for 20 min at 4 &#xB0;C.\\nSupernatant was collected, and protein concentration was quantified\\nby Bradford assay (mean of two replicates). For EOL-1 and A-204 cell\\nline, 20&#x202F;000 cells were seeded in 300 &#x3BC;L per well in\\na 24-well plate and incubated at 37 &#xB0;C overnight. Compounds were\\nadded from DMSO stock solution using a digital dispenser D300 (Tecan),\\nnormalizing for added DMSO, and cells were incubated at 37 &#xB0;C\\nfor 18 h. Medium was removed, and cells were washed with PBS and lysed\\nin 80 &#x3BC;L of lysis buffer (1% Triton, 350 mM KCl, 10 mM Tris,\\npH 7,4, phosphatase-protease inhibitor cocktail (Thermo Scientific\\nno. 1861281), 10 mM DTT, Benzonase 0.5 &#x3BC;L/ml (Novagen no. 70746\\n10KU, 25 U/&#x3BC;L)) for 30 min on ice before insoluble debris was\\npelleted by centrifugation.</p>\\n      </sec>\\n      <sec id=\"sec4.2.3\">\\n        <title>Small Interfering RNA</title>\\n        <p>HeLa cells were seeded at 0.3\\n&#xD7; 10<sup>6</sup> cells per well in 6-well plates in 2 mL of medium,\\nwith a goal to achieve 70% of confluence on the day of transfection.\\nBRD7, BRD9, and CRBN targeting siRNA (L-020297-00-0005 ON-TARGETplus\\nhuman BRD7, L-014250-02-0005 ON-TARGETplus human BRD9, and L-021086-00-0005\\nON-TARGETplus human CRBN SMARTpool, 5 nmol, Dharmacon) were prepared\\nas a 20 &#x3BC;M solution in RNase-free 1&#xD7; siRNA buffer (Dharmacon).\\nNontargeting siRNA (On-TARGETplus control pool, nontargeting pool\\nD-001810-10-05, 5 nmol, Dharmacon) was used as negative control. Medium\\nwas replaced on the day of transfection. siRNA solution (5 &#x3BC;L)\\nof BRD7, BRD9, or CRBN targeting siRNA, negative control, and vehicle\\ncontrol (1&#xD7; siRNA buffer) were added to 250 &#x3BC;L of Opti-mem\\n(Gibco), prepared in duplicate. Lipofectamine RNAiMax (5 &#x3BC;L,\\nThermo Fisher Scientific) was added to 250 &#x3BC;L of Opti-mem in\\nanother tube, also in duplicate. The two solutions were combined,\\nincubated for 20 min at rt, and added to the wells. Plates were incubated\\nat 37 &#xB0;C and 5% CO<sub>2</sub> for 48 h before harvesting as\\ndescribed above.</p>\\n      </sec>\\n      <sec id=\"sec4.2.4\">\\n        <title>Mechanistic Evaluation</title>\\n        <p>Cells were\\nseeded in 6-well\\nplates with 5 &#xD7; 10<sup>5</sup> cells per well in 2 mL of complete\\nmedium to aim for 80% confluence on the day of treatment. At time\\nzero, ML4924 was added at final concentration of 3 &#x3BC;M with 0.1%\\nv/v of DMSO. DMSO was added to the remaining wells in order to match\\nconcentration of vehicle in all wells. After 3 h, MG132 (50 &#x3BC;M)\\nor VH298 (100 &#x3BC;M) was added to the designated wells at a final\\nconcentration of 0.1% v/v of DMSO. Again, DMSO was added to the remaining\\nwells to match vehicle concentration. At <italic>t</italic> = 3.5\\nh, VZ185 or <italic>cis</italic>VZ185 was added at 100 nM and 0.1%\\nv/v of DMSO, matching the DMSO concentration in the remaining wells\\n(final concentration 0.3% v/v). Plates were incubated for an additional\\n4 h at 37 &#xB0;C and 5% CO<sub>2</sub> before harvesting as described\\nbefore. The experiment was performed in duplicate.</p>\\n      </sec>\\n      <sec id=\"sec4.2.5\">\\n        <title>Immunoblotting</title>\\n        <p>Proteins were resolved by SDS&#x2013;PAGE\\non NuPage 4&#x2013;12% Bis-Tris Midi Gel (Invitrogen) and transferred\\nto Amersham Protran 0.45 NC nitrocellulose membrane (GE Healthcare)\\nusing wet transfer. The membrane was blocked with 5% w/v milk in Tris-buffered\\nsaline (TBS) with 0.1% w/v Tween-20. The following primary antibodies\\nat the given concentration were used: anti &#x3B2;-actin (Cell Signaling\\nTechnology, 4970S, 13E5) 1:2000, anti-Brd9 (Bethyl A303-781A) 1:1000,\\nanti-Brd7 (Bethyl A302-304A) 1:1000, VHL rabbit Ab (Cell Signaling\\nTechnology, no. 68547S) 1:1000, anti-CRBN (Novus Bio, NBP 1-9-1810)\\n1:1000, anti-actin hFAB rhodamine antibody, Bio-Rad, no. 12004164.\\nFollowing incubation with horseradish peroxidase-conjugated secondary\\nantibody (Cell Signaling Technology) or IRDye secondary antibody (Licor),\\nbands were developed using Amersham ECL Prime Western blotting detection\\nkit on Amersham Hyperfilm ECL film (Amersham) or ChemiDoc imaging\\nsystem (Bio-Rad). ImageJ software was used for band quantification,\\nand the last was reported as relative amount as ratio of each protein\\nband relative to the lane&#x2019;s loading control. Then the values\\nobtained were normalized to 0.1% DMSO vehicle control. Alternatively,\\nprotein levels were determined on a WES capillary electrophoresis\\ninstrument (Proteinsimple) using a BRD9 antibody (Bethyl A303-781A)\\nand a GAPDH antibody (Abcam no. ab9485) for normalization. DC<sub>50</sub> and half-lives were determined by assuming a linear model\\nbetween the two data points across 50% protein level mark.</p>\\n      </sec>\\n      <sec id=\"sec4.2.6\">\\n        <title>Proliferation\\nAssays</title>\\n        <p>A-204 cells (1 &#xD7; 10<sup>3</sup>) were seeded\\nper well of 384-well plates. After overnight incubation,\\ncompounds were added to the cells at logarithmic dose series using\\nthe HP digital dispenser D300 (Tecan), normalizing for added DMSO.\\n1 day and 8 days after seeding cellular ATP content was measured using\\nCellTiterGlo (Promega). Measurements after 8 days were divided by\\nthe measurement after 1 day (i.e., the <italic>T</italic><sub>0</sub> plate) to derive fold proliferation. Data were analyzed with GraphPad\\nPrism software to obtain EC<sub>50</sub> values.</p>\\n      </sec>\\n      <sec id=\"sec4.2.7\">\\n        <title>MS Proteomics</title>\\n        <sec id=\"sec4.2.7.1\">\\n          <title>Sample\\nPreparation</title>\\n          <p>RI-1 cells were seeded at 2 &#xD7;\\n10<sup>6</sup> cells/mL in a 10 cm plate 12 h before treatment. Cells\\nwere treated with 0.1% DMSO as vehicle control and with 100 nM VZ185\\nand 100 nM <italic>cis</italic>VZ185 as negative control. Cells were\\nincubated at 37 &#xB0;C and 5% CO<sub>2</sub> for 4 h before harvesting.\\nCells were washed twice with DPBS (Gibco) and lysed with 0.5 mL of\\n100 mM Tris, pH 8.0, 4% (w/v) SDS, supplemented with cOmplete Mini\\nEDTA-free protease inhibitor cocktail (Roche). Lysates were sonicated\\n(2 &#xD7; 10 s) and centrifuged at 14&#x202F;000 rpm for 20 min at\\n4 &#xB0;C. The supernatant fraction of the cell extract was collected,\\nand protein concentration was quantified by BCA assay (Thermo Fisher\\nScientific). Further sample processing, digestion, desalting, TMT\\n10-plex isobaric labeling were performed as previously described.<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref></sup> After labeling, the peptides from the 9 samples\\nwere pooled together in equal proportion. The pooled sample was fractionated\\ninto 20 discrete fractions using high pH reverse-phase chromatography\\non an XBridge peptide BEH column (130 &#xC5;, 3.5 &#x3BC;m, 2.1 mm\\n&#xD7; 150 mm, Waters) on an Ultimate 3000 HPLC system (Thermo Scientific/Dionex).\\nA mixture of buffer A (10 mM ammonium formate in water, pH 9) and\\nB (10 mM ammonium formate in 90% CH<sub>3</sub>CN, pH 9) was used\\nover a linear gradient of 5% to 60% buffer B over 60 min at a flow\\nrate of 200 &#x3BC;L/min. The peptides eluted from the column were\\ncollected in 80 fractions before concatenation into 20 fractions based\\non the UV signal of each fraction. All the fractions were dried in\\na Genevac EZ-2 concentrator and resuspended in 1% formic acid for\\nMS analysis.</p>\\n        </sec>\\n        <sec id=\"sec4.2.7.2\">\\n          <title>nLC&#x2013;MS/MS Analysis</title>\\n          <p>The fractions\\nwere analyzed\\nsequentially on a Q Exactive HF hybrid quadrupole-Orbitrap mass spectrometer\\n(Thermo Scientific) coupled to an UltiMate 3000 RSLCnano UHPLC system\\n(Thermo Scientific) and EasySpray column (75 &#x3BC;m &#xD7; 50 cm,\\nPepMap RSLC C18 column, 2 &#x3BC;m, 100 &#xC5;, Thermo Scientific).\\nA mix of buffer A (0.1% formic acid in H<sub>2</sub>O) and B (0.08%\\nformic acid in 80% CH<sub>3</sub>CN) was used over a linear gradient\\nfrom 5% to 35% buffer B over 125 min using a flow rate of 300 nL/min.\\nColumn temperature was set at 50 &#xB0;C. The Q Exactive HF hybrid\\nquadrupole-Orbitrap mass spectrometer was operated in data dependent\\nmode with a single MS survey scan from 335 to 1600 <italic>m</italic>/<italic>z</italic> followed by 15 sequential <italic>m</italic>/<italic>z</italic> dependent MS2 scans. The 15 most intense precursor ions\\nwere sequentially fragmented by higher energy collision dissociation\\n(HCD). The MS1 isolation window was set to 0.7 Da and the resolution\\nset at 120&#x202F;000. MS2 resolution was set at 60&#x202F;000. The\\nAGC targets for MS1 and MS2 were set at 3e6 ions and 1e5 ions, respectively.\\nThe normalized collision energy was set at 32%. The maximum ion injection\\ntimes for MS1 and MS2 were set at 50 and 200 ms, respectively.</p>\\n        </sec>\\n        <sec id=\"sec4.2.7.3\">\\n          <title>Peptide\\nand Protein Identification and Quantification</title>\\n          <p>The raw MS\\ndata files for all 20 fractions were merged and searched\\nagainst the Uniprot-sprot-Human-Canonical database by Maxquant software\\n1.6.0.16 for protein identification and TMT reporter ion quantitation.\\nThe identifications were based on the following criteria: enzyme used\\ntrypsin/P; maximum number of missed cleavages equal to 2; precursor\\nmass tolerance equal to 10&#x2009;ppm; fragment mass tolerance equal\\nto 20&#x2009;ppm. Variable modifications: oxidation (M), acetyl (N-term),\\ndeamidation (NQ), Gln &#x2192; pyro-Glu (Q N-term). Fixed modifications:\\ncarbamidomethyl (C). The data were filtered by applying a 1% false\\ndiscovery rate followed by exclusion of proteins with less than two\\nunique peptides. Quantified proteins were filtered if the absolute\\nfold-change difference between the three DMSO replicates was&#x2009;\\n&#x2265;1.5.</p>\\n        </sec>\\n      </sec>\\n      <sec id=\"sec4.2.8\">\\n        <title>Protein Expression and Purification</title>\\n        <p>Human proteins\\nVHL (UniProt accession number P40337), ElonginC (Q15369), and ElonginB\\n(Q15370) and the bromodomain (residues 134&#x2013;239) for BRD9 (Q9H8M2)\\nwere used for all protein expression. His<sub>6</sub>-tagged constructs\\nwere transformed into <italic>Escherichia coli</italic> BL21(DE3),\\nand expression was induced by the addition of isopropyl &#x3B2;-<sc>d</sc>-1-thiogalactopyranoside (IPTG). <italic>E. coli</italic> cells\\nwere lysed using a pressure cell homogenizer (Stansted Fluid Power);\\nlysates were clarified by centrifuge and loaded onto a HisTrap FF\\naffinity column (GE Healthcare). Following elution, His-tags were\\nremoved with TEV protease and samples were loaded onto a second Ni\\naffinity column to obtain tag-free protein. Following dialysis in\\na low-salt buffer, BRD9 bromodomain and VCB complex proteins were\\nfurther purified using cation exchange (Resource S; GE Healthcare)\\nor anion exchange (Resource Q; GE Healthcare) chromatography, respectively.\\nThis was followed by a final polish by size-exclusion chromatography\\nusing a Superdex-75 16/600 column (GE Healthcare) equilibrated with\\n20&#x2009;mM HEPES, pH 7.5, 100&#x2009;mM sodium chloride, and 1&#x2009;mM\\nTCEP.</p>\\n      </sec>\\n      <sec id=\"sec4.2.9\">\\n        <title>Crystallization and Structure Solution of BRD9 Bromodomain Binary\\nComplex</title>\\n        <p>The binary complex of Brd9-BD:<bold>5</bold> was\\ngenerated by incubating 500 &#x3BC;M Brd9 bromodomain with 750 &#x3BC;M\\ncompound <bold>5</bold> (from a 100 mM stock in DMSO). Crystals were\\ngrown using the hanging-drop vapor diffusion method by mixing equal\\nvolumes of binary complex solution and a crystallization solution\\ncontaining 24% PEG 3350 and 0.2 M NH<sub>4</sub>F. Small needle crystals\\nappeared within 48 h but took approximately 2 weeks to reach a suitable\\nsize for harvesting. Crystals were flash-frozen in liquid nitrogen\\nusing 20% ethylene glycol in liquor solution as a cryoprotectant.\\nDiffraction data were collected at Diamond Light Source beamline I24\\nusing a Pilatus 6M-F detector at a wavelength of 0.98962 &#xC5;. Data\\nwere indexed and integrated using XDS,<sup><xref ref-type=\"bibr\" rid=\"ref78\">78</xref></sup> and scaling and merging were performed with AIMLESS<sup><xref ref-type=\"bibr\" rid=\"ref79\">79</xref></sup> in CCP4i.<sup><xref ref-type=\"bibr\" rid=\"ref80\">80</xref></sup> The structure was\\nsolved by molecular replacement using MOLREP<sup><xref ref-type=\"bibr\" rid=\"ref81\">81</xref></sup> and a search model derived from a BRD9 bromodomain structure (PDB\\nentry 5I40).\\nThe initial model underwent iterative rounds of model building and\\nrefinement with COOT<sup><xref ref-type=\"bibr\" rid=\"ref82\">82</xref></sup> and REFMAC5,<sup><xref ref-type=\"bibr\" rid=\"ref83\">83</xref></sup> respectively. Compound <bold>5</bold> geometry\\nrestraints for refinement were prepared with the PRODRG<sup><xref ref-type=\"bibr\" rid=\"ref84\">84</xref></sup> server. Model geometry and steric clashes were\\nvalidated using the MOLPROBITY server;<sup><xref ref-type=\"bibr\" rid=\"ref85\">85</xref></sup> Ramachandran plots indicate that 97.7% of backbone torsion angles\\nare in the favored region and there are no outliers. The structure\\nhas been deposited in the Protein Data Bank (PDB) with accession code 6HM0; data collection\\nand refinement statistics are presented in <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">Supporting Information Table S1</ext-link>.</p>\\n      </sec>\\n      <sec id=\"sec4.2.10\">\\n        <title>AlphaLISA Proximity Assay</title>\\n        <p>All assays were performed\\nat room temperature in 384-well plates with a final assay volume of\\n25&#x2009;&#x3BC;L per well, as described previously.<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref></sup> All reagents were prepared as 5&#xD7; stocks diluted in\\n50&#x2009;mM HEPES, pH 7.5, 100&#x2009;mM NaCl, 0.1% (w/v) bovine\\nserum albumin, and 0.02% (w/v) 3-[(cholamidopropyl)dimethylammonio]-1-propanesulfonate\\n(CHAPS). Plates were sealed by transparent film and briefly centrifuged\\nat 100<italic>g</italic> between additions of reagents. Biotinylated\\nVCB (100&#x2009;nM final) and His<sub>6</sub>-BRD9-bromodomain (100&#x2009;nM\\nfinal) were incubated with a range of PROTAC concentrations (0.5&#x2013;2000&#x2009;nM;\\ntwo-in-one serial dilution) for 1&#x2009;h. Streptavidin-coated donor\\nbeads and nickel chelate acceptor beads (PerkinElmer) were added to\\na final concentration of 10&#x2009;&#x3BC;g&#x2009;mL<sup>&#x2013;1</sup>, and plates were incubated for another hour. Plates were read on\\na PHERAstar FS (BMG Labtech) using an optic module with an excitation\\nwavelength of 680&#x2009;nm and emission wavelength of 615&#x2009;nm.\\nIntensity values were plotted against PROTAC concentration on a log<sub>10</sub> scale using GraphPad Prism, version 7. To obtain biotinylated-VCB,\\nprotein was mixed with EZ-link NHS-PEG<sub>4</sub>-biotin (Thermo\\nScientific) in a 1:1 molar ratio and incubated at room temperature\\nfor 1&#x2009;h. The reaction was quenched using 1 M Tris-HCl, pH 7.5,\\nand unreacted NHS-biotin was removed with a PD-10 MiniTrap desalting\\ncolumn (GE Healthcare) equilibrated with 20&#x2009;mM HEPES, pH 7.5,\\n150&#x2009;mM NaCl, and 1&#x2009;mM DTT.</p>\\n      </sec>\\n      <sec id=\"sec4.2.11\">\\n        <title>Fluorescence Polarization</title>\\n        <p>All measurements were taken\\nusing a PHERAstar FS (BMG LABTECH) with fluorescence excitation and\\nemission wavelengths (&#x3BB;) of 485 and 520 nm, respectively. FP\\ncompetitive binding assays were run in triplicate in 384-well plates\\n(Corning 3575) using a total well volume of 15 &#x3BC;L (ref (<xref ref-type=\"bibr\" rid=\"ref63\">63</xref>)). Each well solution contained\\n15 nM VCB protein, 10 nM FAM-labeled HIF-1&#x3B1; peptide (FAM-DEALAHypYIPMDDDFQLRSF, <italic>K</italic><sub>d</sub> = 3 nM as measured by a direct FP titration),\\nand decreasing concentrations of PROTAC (14-point serial 2-fold dilutions\\nstarting from 50 &#x3BC;M PROTAC) or PROTAC:bromodomain (14-point\\nserial 2-fold dilutions starting from 50 &#x3BC;M PROTAC:100 &#x3BC;M\\nbromodomain into wells containing an additional 1 &#x3BC;M bromodomain)\\nin 100 mM Bis-Tris propane, 100 mM NaCl, 1 mM TCEP, pH 7, with a final\\nDMSO concentration of 1%. Control wells containing VCB and peptide\\nwith no compound (zero displacement), or peptide in the absence of\\nprotein (maximum displacement), were also included. Control values\\nwere used to obtain the percentage of displacement which was graphed\\nagainst log[PROTAC]. Average IC<sub>50</sub> values and the standard\\nerror of the mean (SEM) were determined for each titration using Prism\\n7. Dissociation constants <italic>K</italic><sub>d</sub> were back-calculated\\nfrom the measured IC<sub>50</sub> values using a displacement binding\\nmodel, as described previously.<sup><xref ref-type=\"bibr\" rid=\"ref68\">68</xref></sup></p>\\n      </sec>\\n      <sec id=\"sec4.2.12\">\\n        <title>Isothermal\\nTitration Calorimetry</title>\\n        <p>ITC experiments were\\nperformed in an ITC200 microcalorimeter (GE Healthcare) as described\\npreviously.<sup><xref ref-type=\"bibr\" rid=\"ref5\">5</xref></sup> Titrations were carried out\\nat 25 &#xB0;C while stirring at 750 rpm and were performed as reverse\\nmode (protein in the syringe and the ligand in the cell). Compounds\\nwere diluted in ITC buffer (20 mM Bis-Tris propane, 100 mM NaCl, 1\\nmM tris(2-carboxyethyl)phosphine (TCEP), pH 7.5) from 10 mM\\nDMSO stock solutions to a final concentration of 20 &#x3BC;M (0.2%\\nDMSO). Each run consisted of 19 injections of 2 &#x3BC;L of protein\\nsolution (ITC buffer with 0.2% DMSO) at a rate of 0.5 &#x3BC;L/s at\\n120 s time intervals. An initial injection of 0.4 &#x3BC;L was made\\nand discarded during data analysis. BRD9 bromodomain (200 &#x3BC;M,\\nin the syringe) was first titrated into the PROTAC (20 &#x3BC;M, in\\nthe cell); at the end of the titration, the excess of solution was\\nremoved from the cell and the syringe was washed and dried. VCB complex\\n(168 &#x3BC;M, in the same buffer) was loaded in the syringe and titrated\\ninto the complex PROTAC-bromodomain. The concentration of the complex\\nin the cell (<italic>C</italic>) after the first titration (16.8 &#x3BC;M),\\nwas calculated as follows:<disp-formula id=\"ueq1\"><graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_m001\" position=\"anchor\"/></disp-formula>where <italic>C</italic><sub>0</sub> is the\\ninitial concentration of the PROTAC in the cell (20 &#x3BC;M), <italic>V</italic><sub>cell</sub> is the volume of the sample cell (200.12\\n&#x3BC;L), and <italic>V</italic><sub>inj</sub> is the volume of titrant\\ninjected during the first titration (38.4 &#x3BC;L). Titrations for\\nthe binary complex PROTAC-VCB were performed by first adding buffer\\n(38.4 &#x3BC;L) to the solution of PROTAC (20 &#x3BC;M, in the cell)\\nby a single ITC injection. After removal of the excess solution from\\nthe cell, VCB complex (168 &#x3BC;M, in the same buffer) was loaded\\ninto the (washed and dried) syringe and titrated into the diluted\\nPROTAC solution. The data were fitted to a single binding-site model\\nusing the MicroCal PEAQ-ITC analysis software provided by the manufacturer\\nto obtain the stoichiometry <italic>n</italic>, the dissociation constant <italic>K</italic><sub>d</sub>, and the enthalpy of binding &#x394;<italic>H</italic>.</p>\\n      </sec>\\n      <sec id=\"sec4.2.13\">\\n        <title>Live Cell Kinetic Analysis of BRD7 and BRD9\\nDegradation</title>\\n        <p>HEK293 cells stably expressing LgBiT protein\\ncultured in DMEM (Gibco)\\nsupplemented with 10% fetal bovine serum (Seradigm) and maintained\\nat 37 &#xB0;C and 5% CO<sub>2</sub> were genome-edited using CRISPR/Cas9\\nto generate endogenous HiBiT-BRD7 or HiBiT-BRD9 fusions. Clonal populations\\nwere isolated, and cells were plated in 96-well tissue culture plates\\nat a density of 2 &#xD7; 10<sup>4</sup> cells per well in 100 &#x3BC;L\\nof growth medium. Following overnight incubation at 37 &#xB0;C and\\n5% CO<sub>2</sub> medium was replaced with CO<sub>2</sub>-independent\\nmedium (Gibco) containing 20 &#x3BC;M Endurazine, an extended time-released\\nsubstrate (Promega), and plates were incubated at 37 &#xB0;C, 5% CO<sub>2</sub>, for 2.5 h before addition of a 3-fold serial dilution of\\n1 &#x3BC;M final concentration VZ185 compound. Plates retaining the\\nplate lids were then read every 5 min for a period of 24 h on a GloMax\\nDiscover (Promega) set to 37 &#xB0;C. Degradation traces for each\\nconcentration were plotted in GraphPad Prism, and the degradation\\nportion of each curve was fitted to a one-component exponential decay\\nmodel to obtain degradation parameters, rate, and <italic>D</italic><sub>max</sub>, as previously described.<sup><xref ref-type=\"bibr\" rid=\"ref69\">69</xref></sup></p>\\n      </sec>\\n      <sec id=\"sec4.2.14\">\\n        <title>NanoBRET Ubiquitination of BRD7 and BRD9</title>\\n        <p>Clonal populations\\nof edited HEK293 cells expressing HiBiT-BRD7 or HiBiT-BRD9 were plated\\nin tissue 96-well tissue culture plates at a density of 2 &#xD7; 10<sup>4</sup> cells per well in 100 &#x3BC;L of growth medium and incubated\\novernight at 37 &#xB0;C, 5% CO<sub>2</sub>. Following treatment with\\n1 &#x3BC;M VZ185 for the indicated time frames, medium was replaced\\nwith Opti-MEM (Gibco) containing 200 &#x3BC;g/mL digitonin, 1:200\\ndilution of primary anti-Ub antibody (Enzo Life Sciences, BML-PW8810),\\n1:500 dilution of secondary anti-mouse Alexa 594 antibody (Cell Signaling\\nTechnologies, 8890), and 20 &#x3BC;M NanoGlo (Promega) substrate.\\nAdditional control wells received no antibodies (control for background\\nNanoBRET) or no primary antibody (control for specificity). Plates\\nwere placed on an orbital shaker for 10 min, and NanoBRET measurements\\nwere collected on a CLARIOstar (BMG Labtech). Background subtracted\\nNanoBRET ratios were generated by calculating the ratios of acceptor\\nsignal to donor signal in both the presence and absence of the Alexa594\\nantibody and computing the difference. Background subtracted BRET\\nratios were expressed in milliBRET units by multiplying by 1000.</p>\\n      </sec>\\n    </sec>\\n  </body>\\n  <back>\\n    <notes id=\"notes1\" notes-type=\"si\">\\n      <title>Supporting Information Available</title>\\n      <p>The Supporting Information is\\navailable free of charge on the <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org\">ACS Publications website</ext-link> at DOI: <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b01413\">10.1021/acs.jmedchem.8b01413</ext-link>.<list id=\"silist\" list-type=\"simple\"><list-item><p>Additional Western\\nBlots and quantification of protein\\nlevels in HeLa, Hek293 and RI-1 cells; ITC titration curves and results;\\nprotein level profile of HiBiT-BRD2/3/4/7/9 and HiBiT-SMARCA4 after\\ntreatment with desired compounds; concentration-dependency evaluation\\nof VZ185 and dBRD9 activity in EOL-1 and A-204 cells; AlphaLISA ternary\\ncomplex formation for <bold>5</bold>, <bold>26</bold>, and VZ185 and\\ncooperativity with VZ185 with FP; proteomic supplementary blots and\\ngraph for <italic>cis</italic>VZ185; physicochemical properties and\\nin vitro PK data on compounds <bold>26</bold>, <bold>46</bold>, VZ185,\\nand <italic>cis</italic>VZ185; original blot images; NMR spectra;\\nHPLC traces of VZ185 and <italic>cis</italic>VZ185 (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_001.pdf\">PDF</ext-link>)</p></list-item><list-item><p>Molecular formula strings\\n(<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_002.csv\">CSV</ext-link>)</p></list-item><list-item><p>Proteomics\\nraw data (<ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01413/suppl_file/jm8b01413_si_003.xls\">XLS</ext-link>)</p></list-item></list></p>\\n    </notes>\\n    <sec sec-type=\"supplementary-material\">\\n      <title>Supplementary Material</title>\\n      <supplementary-material content-type=\"local-data\" id=\"sifile1\">\\n        <media xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm8b01413_si_001.pdf\">\\n          <caption>\\n            <p>jm8b01413_si_001.pdf</p>\\n          </caption>\\n        </media>\\n      </supplementary-material>\\n      <supplementary-material content-type=\"local-data\" id=\"sifile2\">\\n        <media xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm8b01413_si_002.csv\">\\n          <caption>\\n            <p>jm8b01413_si_002.csv</p>\\n          </caption>\\n        </media>\\n      </supplementary-material>\\n      <supplementary-material content-type=\"local-data\" id=\"sifile3\">\\n        <media xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm8b01413_si_003.xls\">\\n          <caption>\\n            <p>jm8b01413_si_003.xls</p>\\n          </caption>\\n        </media>\\n      </supplementary-material>\\n    </sec>\\n    <notes notes-type=\"accession-codes\" id=\"notes4\">\\n      <title>Accession Codes</title>\\n      <p>Atomic coordinates\\nand structure factors for BRD9-BD:<bold>5</bold> have been deposited\\nto the Protein Data Bank (PDB) under accession number 6HM0. Authors will release\\nthe atomic coordinates and experimental data upon article publication.</p>\\n    </notes>\\n    <notes notes-type=\"\" id=\"notes2\">\\n      <title>Author Present Address</title>\\n      <p><sup>#</sup> C.M.: Chemistry Research Laboratory, Department of Chemistry,\\nUniversity\\nof Oxford, 12 Mansfield Road, Oxford OX1 3TA, United Kingdom.</p>\\n    </notes>\\n    <notes notes-type=\"\" id=\"notes3\">\\n      <title>Author Contributions</title>\\n      <p>The\\nmanuscript\\nwas written through contributions of all authors. All authors have\\ngiven approval to the final version of the manuscript.</p>\\n    </notes>\\n    <notes notes-type=\"COI-statement\" id=\"notes6\">\\n      <p>The\\nauthors\\ndeclare the following competing financial interest(s): The Ciulli\\nlaboratory receives sponsored research support from Boehringer Ingelheim\\nand Nurix Inc. A.C. is a scientific founder, director, and shareholder\\nof Amphista Therapeutics, a company that is developing targeted protein\\ndegradation therapeutic platforms.</p>\\n    </notes>\\n    <ack>\\n      <title>Acknowledgments</title>\\n      <p>We thank J. Wright and\\nthe staff of the MRC tissue\\nculture facility for assistance with tissue culture; A. Atrih and\\nD. Lamont for support with proteomics experiments; N. Trainor for\\nassistance with proteomics data analysis; P. Fyfe for support with\\nin-house X-ray facilities, and the Diamond Light Source for beamtime\\n(BAG Proposal 14980) and beamline support at beamline I24; and Kevin\\nRead and his team at the Dundee Drug Discovery Unit for in vitro DMPK\\ndata. This project has received funding from the European Research\\nCouncil (ERC) under the European Union&#x2019;s Seventh Framework\\nProgramme (FP7/2007&#x2013;2013) as a Starting Grant to A.C. (Grant\\nAgreement ERC-2012-StG-311460 DrugE3CRLs). Biophysics and drug discovery\\nactivities are supported by Wellcome Trust strategic awards to Dundee\\n(Grants 100476/Z/12/Z and 094090/Z/10/Z, respectively). V.Z. was supported\\nby the &#x201C;Scuola di Dottorato in Scienze e Tecnologie della Chimica\\ne dei Materiali&#x201D; of the University of Genova, Italy.</p>\\n    </ack>\\n    <glossary id=\"dl1\">\\n      <def-list>\\n        <title>Abbreviations Used</title>\\n        <def-item>\\n          <term>BET</term>\\n          <def>\\n            <p>bromodomain\\nand extra-terminal</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>BRD2/3/4/7/9</term>\\n          <def>\\n            <p>bromodomain-containing\\nprotein 2/3/4/7/9</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>CRBN</term>\\n          <def>\\n            <p>cereblon</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>DLBCL</term>\\n          <def>\\n            <p>diffuse large B cell lymphoma</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>DIPEA</term>\\n          <def>\\n            <p><italic>N</italic>,<italic>N</italic>-diisopropylethylamine</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>HATU</term>\\n          <def>\\n            <p>1-[bis(dimethylamino)methylene]-1<italic>H</italic>-1,2,3-triazolo[4,5-<italic>b</italic>]pyridinium\\n3-oxide hexafluorophosphate</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>HOAt</term>\\n          <def>\\n            <p>1-hydroxy-7-azabenzotriazole solution</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>MsCl</term>\\n          <def>\\n            <p>methanesulfonyl chloride</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>PROTAC</term>\\n          <def>\\n            <p>proteolysis-targeting\\nchimera</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>NaHMDS</term>\\n          <def>\\n            <p>sodium\\nbis(trimethylsilyl)amide</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>NaH</term>\\n          <def>\\n            <p>sodium hydride</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>TEMPO</term>\\n          <def>\\n            <p>2,2,6,6-tetramethyl-1-piperidinyloxy</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>VCB</term>\\n          <def>\\n            <p>VHL-ElonginC-ElonginB\\ncomplex</p>\\n          </def>\\n        </def-item>\\n        <def-item>\\n          <term>VHL</term>\\n          <def>\\n            <p>von\\nHippel&#x2013;Lindau</p>\\n          </def>\\n        </def-item>\\n      </def-list>\\n    </glossary>\\n    <ref-list>\\n      <title>References</title>\\n      <ref id=\"ref1\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit1\"><name><surname>Lai</surname><given-names>A. C.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>\\n<article-title>Induced\\nProtein Degradation: An Emerging Drug Discovery\\nParadigm</article-title>. <source>Nat. Rev. Drug Discovery</source>\\n<year>2017</year>, <volume>16</volume> (<issue>2</issue>), <fpage>101</fpage>&#x2013;<lpage>114</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nrd.2016.211</pub-id>.<pub-id pub-id-type=\"pmid\">27885283</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref2\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit2\"><name><surname>Collins</surname><given-names>I.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Caldwell</surname><given-names>J. J.</given-names></name>; <name><surname>Chopra</surname><given-names>R.</given-names></name>\\n<article-title>Chemical Approaches\\nto Targeted Protein Degradation Through Modulation of the Ubiquitin&#x2013;Proteasome\\nPathway</article-title>. <source>Biochem. J.</source>\\n<year>2017</year>, <volume>474</volume> (<issue>7</issue>), <fpage>1127</fpage>&#x2013;<lpage>1147</lpage>. <pub-id pub-id-type=\"doi\">10.1042/BCJ20160762</pub-id>.<pub-id pub-id-type=\"pmid\">28298557</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref3\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit3\"><name><surname>Sakamoto</surname><given-names>K. M.</given-names></name>; <name><surname>Kim</surname><given-names>K. B.</given-names></name>; <name><surname>Kumagai</surname><given-names>A.</given-names></name>; <name><surname>Mercurio</surname><given-names>F.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>; <name><surname>Deshaies</surname><given-names>R. J.</given-names></name>\\n<article-title>Protacs: Chimeric\\nMolecules That Target Proteins to\\nthe Skp1-Cullin-F Box Complex for Ubiquitination and Degradation</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>\\n<year>2001</year>, <volume>98</volume> (<issue>15</issue>), <fpage>8554</fpage>&#x2013;<lpage>8559</lpage>. <pub-id pub-id-type=\"doi\">10.1073/pnas.141230798</pub-id>.<pub-id pub-id-type=\"pmid\">11438690</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref4\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit4\"><name><surname>Ottis</surname><given-names>P.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>\\n<article-title>Proteolysis-Targeting\\nChimeras: Induced Protein Degradation\\nas a Therapeutic Strategy</article-title>. <source>ACS Chem. Biol.</source>\\n<year>2017</year>, <volume>12</volume> (<issue>4</issue>), <fpage>892</fpage>&#x2013;<lpage>898</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acschembio.6b01068</pub-id>.<pub-id pub-id-type=\"pmid\">28263557</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref5\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit5\"><name><surname>Gadd</surname><given-names>M. S.</given-names></name>; <name><surname>Testa</surname><given-names>A.</given-names></name>; <name><surname>Lucas</surname><given-names>X.</given-names></name>; <name><surname>Chan</surname><given-names>K.-H.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name>; <name><surname>Lamont</surname><given-names>D. J.</given-names></name>; <name><surname>Zengerle</surname><given-names>M.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Structural Basis of\\nPROTAC Cooperative Recognition for Selective Protein Degradation</article-title>. <source>Nat. Chem. Biol.</source>\\n<year>2017</year>, <volume>13</volume> (<issue>5</issue>), <fpage>514</fpage>&#x2013;<lpage>521</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nchembio.2329</pub-id>.<pub-id pub-id-type=\"pmid\">28288108</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref6\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit6\"><name><surname>Nowak</surname><given-names>R. P.</given-names></name>; <name><surname>DeAngelo</surname><given-names>S. L.</given-names></name>; <name><surname>Buckley</surname><given-names>D.</given-names></name>; <name><surname>He</surname><given-names>Z.</given-names></name>; <name><surname>Donovan</surname><given-names>K. A.</given-names></name>; <name><surname>An</surname><given-names>J.</given-names></name>; <name><surname>Safaee</surname><given-names>N.</given-names></name>; <name><surname>Jedrychowski</surname><given-names>M. P.</given-names></name>; <name><surname>Ponthier</surname><given-names>C. M.</given-names></name>; <name><surname>Ishoey</surname><given-names>M.</given-names></name>; <name><surname>Zhang</surname><given-names>T.</given-names></name>; <name><surname>Mancias</surname><given-names>J. D.</given-names></name>; <name><surname>Gray</surname><given-names>N. S.</given-names></name>; <name><surname>Bradner</surname><given-names>J. E.</given-names></name>; <name><surname>Fischer</surname><given-names>E. S.</given-names></name>\\n<article-title>Plasticity in Binding\\nConfers Selectivity in Ligand-Induced\\nProtein Degradation</article-title>. <source>Nat. Chem. Biol.</source>\\n<year>2018</year>, <volume>14</volume> (<issue>7</issue>), <fpage>706</fpage>&#x2013;<lpage>714</lpage>. <pub-id pub-id-type=\"doi\">10.1038/s41589-018-0055-y</pub-id>.<pub-id pub-id-type=\"pmid\">29892083</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref7\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit7\"><name><surname>Hughes</surname><given-names>S. J.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Molecular Recognition of Ternary Complexes: A New Dimension\\nin the Structure-Guided Design of Chemical Degraders</article-title>. <source>Essays Biochem.</source>\\n<year>2017</year>, <volume>61</volume> (<issue>5</issue>), <fpage>505</fpage>&#x2013;<lpage>516</lpage>. <pub-id pub-id-type=\"doi\">10.1042/EBC20170041</pub-id>.<pub-id pub-id-type=\"pmid\">29118097</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref8\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit8\"><name><surname>Bondeson</surname><given-names>D. P.</given-names></name>; <name><surname>Mares</surname><given-names>A.</given-names></name>; <name><surname>Smith</surname><given-names>I. E. D.</given-names></name>; <name><surname>Ko</surname><given-names>E.</given-names></name>; <name><surname>Campos</surname><given-names>S.</given-names></name>; <name><surname>Miah</surname><given-names>A. H.</given-names></name>; <name><surname>Mulholland</surname><given-names>K. E.</given-names></name>; <name><surname>Routly</surname><given-names>N.</given-names></name>; <name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>Gustafson</surname><given-names>J. L.</given-names></name>; <name><surname>Zinn</surname><given-names>N.</given-names></name>; <name><surname>Grandi</surname><given-names>P.</given-names></name>; <name><surname>Shimamura</surname><given-names>S.</given-names></name>; <name><surname>Bergamini</surname><given-names>G.</given-names></name>; <name><surname>Faelth-Savitski</surname><given-names>M.</given-names></name>; <name><surname>Bantscheff</surname><given-names>M.</given-names></name>; <name><surname>Cox</surname><given-names>C.</given-names></name>; <name><surname>Gordon</surname><given-names>D. A.</given-names></name>; <name><surname>Willard</surname><given-names>R. R.</given-names></name>; <name><surname>Flanagan</surname><given-names>J. J.</given-names></name>; <name><surname>Casillas</surname><given-names>L. N.</given-names></name>; <name><surname>Votta</surname><given-names>B. J.</given-names></name>; <name><surname>den Besten</surname><given-names>W.</given-names></name>; <name><surname>Famm</surname><given-names>K.</given-names></name>; <name><surname>Kruidenier</surname><given-names>L.</given-names></name>; <name><surname>Carter</surname><given-names>P. S.</given-names></name>; <name><surname>Harling</surname><given-names>J. D.</given-names></name>; <name><surname>Churcher</surname><given-names>I.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>\\n<article-title>Catalytic\\nin Vivo Protein Knockdown by Small-Molecule PROTACs</article-title>. <source>Nat. Chem. Biol.</source>\\n<year>2015</year>, <volume>11</volume> (<issue>8</issue>), <fpage>611</fpage>&#x2013;<lpage>617</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nchembio.1858</pub-id>.<pub-id pub-id-type=\"pmid\">26075522</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref9\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit9\"><name><surname>Durham</surname><given-names>T. B.</given-names></name>; <name><surname>Blanco</surname><given-names>M.-J.</given-names></name>\\n<article-title>Target Engagement\\nin Lead Generation</article-title>. <source>Bioorg. Med. Chem. Lett.</source>\\n<year>2015</year>, <volume>25</volume> (<issue>5</issue>), <fpage>998</fpage>&#x2013;<lpage>1008</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.bmcl.2014.12.076</pub-id>.<pub-id pub-id-type=\"pmid\">25630223</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref10\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit10\"><name><surname>Zengerle</surname><given-names>M.</given-names></name>; <name><surname>Chan</surname><given-names>K.-H.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Selective Small Molecule Induced\\nDegradation of the BET Bromodomain Protein BRD4</article-title>. <source>ACS Chem. Biol.</source>\\n<year>2015</year>, <volume>10</volume> (<issue>8</issue>), <fpage>1770</fpage>&#x2013;<lpage>1777</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acschembio.5b00216</pub-id>.<pub-id pub-id-type=\"pmid\">26035625</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref11\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit11\"><name><surname>Chan</surname><given-names>K.-H.</given-names></name>; <name><surname>Zengerle</surname><given-names>M.</given-names></name>; <name><surname>Testa</surname><given-names>A.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Impact of Target Warhead\\nand Linkage Vector on Inducing Protein Degradation: Comparison of\\nBromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine\\n(JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds</article-title>. <source>J. Med. Chem.</source>\\n<year>2018</year>, <volume>61</volume> (<issue>2</issue>), <fpage>504</fpage>&#x2013;<lpage>513</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.jmedchem.6b01912</pub-id>.<pub-id pub-id-type=\"pmid\">28595007</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref12\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit12\"><name><surname>Bondeson</surname><given-names>D. P.</given-names></name>; <name><surname>Smith</surname><given-names>B. E.</given-names></name>; <name><surname>Burslem</surname><given-names>G. M.</given-names></name>; <name><surname>Buhimschi</surname><given-names>A. D.</given-names></name>; <name><surname>Hines</surname><given-names>J.</given-names></name>; <name><surname>Jaime-Figueroa</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Hamman</surname><given-names>B. D.</given-names></name>; <name><surname>Ishchenko</surname><given-names>A.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>\\n<article-title>Lessons in PROTAC Design from Selective\\nDegradation with a Promiscuous Warhead</article-title>. <source>Cell\\nChem. Biol.</source>\\n<year>2018</year>, <volume>25</volume> (<issue>1</issue>), <fpage>78</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.chembiol.2017.09.010</pub-id>.<pub-id pub-id-type=\"pmid\">29129718</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref13\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit13\"><name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Dixit</surname><given-names>V. M.</given-names></name>\\n<article-title>Drugging the Undruggables:\\nExploring the Ubiquitin\\nSystem for Drug Development</article-title>. <source>Cell Res.</source>\\n<year>2016</year>, <volume>26</volume> (<issue>4</issue>), <fpage>484</fpage>&#x2013;<lpage>498</lpage>. <pub-id pub-id-type=\"doi\">10.1038/cr.2016.31</pub-id>.<pub-id pub-id-type=\"pmid\">27002218</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref14\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit14\"><name><surname>Winter</surname><given-names>G.\\nE.</given-names></name>; <name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>Paulk</surname><given-names>J.</given-names></name>; <name><surname>Roberts</surname><given-names>J. M.</given-names></name>; <name><surname>Souza</surname><given-names>A.</given-names></name>; <name><surname>Dhe-Paganon</surname><given-names>S.</given-names></name>; <name><surname>Bradner</surname><given-names>J. E.</given-names></name>\\n<article-title>Phthalimide Conjugation as a Strategy\\nfor in Vivo Target Protein Degradation</article-title>. <source>Science</source>\\n<year>2015</year>, <volume>348</volume> (<issue>6241</issue>), <fpage>1376</fpage>&#x2013;<lpage>1381</lpage>. <pub-id pub-id-type=\"doi\">10.1126/science.aab1433</pub-id>.<pub-id pub-id-type=\"pmid\">25999370</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref15\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit15\"><name><surname>Lu</surname><given-names>J.</given-names></name>; <name><surname>Qian</surname><given-names>Y.</given-names></name>; <name><surname>Altieri</surname><given-names>M.</given-names></name>; <name><surname>Dong</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Raina</surname><given-names>K.</given-names></name>; <name><surname>Hines</surname><given-names>J.</given-names></name>; <name><surname>Winkler</surname><given-names>J. D.</given-names></name>; <name><surname>Crew</surname><given-names>A. P.</given-names></name>; <name><surname>Coleman</surname><given-names>K.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>\\n<article-title>Hijacking the E3 Ubiquitin Ligase\\nCereblon to Efficiently Target BRD4</article-title>. <source>Chem. Biol.</source>\\n<year>2015</year>, <volume>22</volume> (<issue>6</issue>), <fpage>755</fpage>&#x2013;<lpage>763</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.chembiol.2015.05.009</pub-id>.<pub-id pub-id-type=\"pmid\">26051217</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref16\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit16\"><name><surname>Qin</surname><given-names>C.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>B.</given-names></name>; <name><surname>Fernandez-Salas</surname><given-names>E.</given-names></name>; <name><surname>Yang</surname><given-names>C.-Y.</given-names></name>; <name><surname>Liu</surname><given-names>L.</given-names></name>; <name><surname>McEachern</surname><given-names>D.</given-names></name>; <name><surname>Przybranowski</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>M.</given-names></name>; <name><surname>Stuckey</surname><given-names>J.</given-names></name>; <name><surname>Meagher</surname><given-names>J.</given-names></name>; <name><surname>Bai</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Lin</surname><given-names>M.</given-names></name>; <name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Ziazadeh</surname><given-names>D. N.</given-names></name>; <name><surname>Xu</surname><given-names>F.</given-names></name>; <name><surname>Hu</surname><given-names>J.</given-names></name>; <name><surname>Xiang</surname><given-names>W.</given-names></name>; <name><surname>Huang</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Wen</surname><given-names>B.</given-names></name>; <name><surname>Sun</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>\\n<article-title>Discovery of QCA570 as an Exceptionally Potent and\\nEfficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the\\nBromodomain and Extra-Terminal (BET) Proteins Capable of Inducing\\nComplete and Durable Tumor Regression</article-title>. <source>J. Med.\\nChem.</source>\\n<year>2018</year>, <volume>61</volume> (<issue>15</issue>), <fpage>6685</fpage>&#x2013;<lpage>6704</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.jmedchem.8b00506</pub-id>.<pub-id pub-id-type=\"pmid\">30019901</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref17\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit17\"><name><surname>Raina</surname><given-names>K.</given-names></name>; <name><surname>Lu</surname><given-names>J.</given-names></name>; <name><surname>Qian</surname><given-names>Y.</given-names></name>; <name><surname>Altieri</surname><given-names>M.</given-names></name>; <name><surname>Gordon</surname><given-names>D.</given-names></name>; <name><surname>Rossi</surname><given-names>A. M. K.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Dong</surname><given-names>H.</given-names></name>; <name><surname>Siu</surname><given-names>K.</given-names></name>; <name><surname>Winkler</surname><given-names>J. D.</given-names></name>; <name><surname>Crew</surname><given-names>A. P.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>; <name><surname>Coleman</surname><given-names>K. G.</given-names></name>\\n<article-title>PROTAC-Induced\\nBET Protein Degradation as a Therapy for Castration-Resistant Prostate\\nCancer</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>\\n<year>2016</year>, <volume>113</volume> (<issue>26</issue>), <fpage>7124</fpage>&#x2013;<lpage>7129</lpage>. <pub-id pub-id-type=\"doi\">10.1073/pnas.1521738113</pub-id>.<pub-id pub-id-type=\"pmid\">27274052</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref18\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit18\"><name><surname>Remillard</surname><given-names>D.</given-names></name>; <name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>Paulk</surname><given-names>J.</given-names></name>; <name><surname>Brien</surname><given-names>G. L.</given-names></name>; <name><surname>Sonnett</surname><given-names>M.</given-names></name>; <name><surname>Seo</surname><given-names>H.-S.</given-names></name>; <name><surname>Dastjerdi</surname><given-names>S.</given-names></name>; <name><surname>W&#xFC;hr</surname><given-names>M.</given-names></name>; <name><surname>Dhe-Paganon</surname><given-names>S.</given-names></name>; <name><surname>Armstrong</surname><given-names>S. A.</given-names></name>; <name><surname>Bradner</surname><given-names>J. E.</given-names></name>\\n<article-title>Degradation of the\\nBAF Complex Factor BRD9 by Heterobifunctional Ligands</article-title>. <source>Angew. Chem.</source>\\n<year>2017</year>, <volume>129</volume> (<issue>21</issue>), <fpage>5832</fpage>&#x2013;<lpage>5837</lpage>. <pub-id pub-id-type=\"doi\">10.1002/ange.201611281</pub-id>.</mixed-citation>\\n      </ref>\\n      <ref id=\"ref19\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit19\"><name><surname>Gechijian</surname><given-names>L. N.</given-names></name>; <name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>Lawlor</surname><given-names>M. A.</given-names></name>; <name><surname>Reyes</surname><given-names>J. M.</given-names></name>; <name><surname>Paulk</surname><given-names>J.</given-names></name>; <name><surname>Ott</surname><given-names>C. J.</given-names></name>; <name><surname>Winter</surname><given-names>G. E.</given-names></name>; <name><surname>Erb</surname><given-names>M. A.</given-names></name>; <name><surname>Scott</surname><given-names>T. G.</given-names></name>; <name><surname>Xu</surname><given-names>M.</given-names></name>; <name><surname>Seo</surname><given-names>H. S.</given-names></name>; <name><surname>Dhe-Paganon</surname><given-names>S.</given-names></name>; <name><surname>Kwiatkowski</surname><given-names>N. P.</given-names></name>; <name><surname>Perry</surname><given-names>J. A.</given-names></name>; <name><surname>Qi</surname><given-names>J.</given-names></name>; <name><surname>Gray</surname><given-names>N. S.</given-names></name>; <name><surname>Bradner</surname><given-names>J. E.</given-names></name>\\n<article-title>Functional\\nTRIM24 Degrader via Conjugation of Ineffectual Bromodomain and VHL\\nLigands</article-title>. <source>Nat. Chem. Biol.</source>\\n<year>2018</year>, <volume>14</volume> (<issue>4</issue>), <fpage>405</fpage>&#x2013;<lpage>412</lpage>. <pub-id pub-id-type=\"doi\">10.1038/s41589-018-0010-y</pub-id>.<pub-id pub-id-type=\"pmid\">29507391</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref20\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit20\"><name><surname>Schiedel</surname><given-names>M.</given-names></name>; <name><surname>Herp</surname><given-names>D.</given-names></name>; <name><surname>Hammelmann</surname><given-names>S.</given-names></name>; <name><surname>Swyter</surname><given-names>S.</given-names></name>; <name><surname>Lehotzky</surname><given-names>A.</given-names></name>; <name><surname>Robaa</surname><given-names>D.</given-names></name>; <name><surname>Ol&#xE1;h</surname><given-names>J.</given-names></name>; <name><surname>Ov&#xE1;di</surname><given-names>J.</given-names></name>; <name><surname>Sippl</surname><given-names>W.</given-names></name>; <name><surname>Jung</surname><given-names>M.</given-names></name>\\n<article-title>Chemically Induced\\nDegradation of\\nSirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based\\non Sirtuin Rearranging Ligands (SirReals)</article-title>. <source>J.\\nMed. Chem.</source>\\n<year>2018</year>, <volume>61</volume> (<issue>2</issue>), <fpage>482</fpage>&#x2013;<lpage>491</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.jmedchem.6b01872</pub-id>.<pub-id pub-id-type=\"pmid\">28379698</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref21\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit21\"><name><surname>Bassi</surname><given-names>Z. I.</given-names></name>; <name><surname>Fillmore</surname><given-names>M. C.</given-names></name>; <name><surname>Miah</surname><given-names>A. H.</given-names></name>; <name><surname>Chapman</surname><given-names>T. D.</given-names></name>; <name><surname>Maller</surname><given-names>C.</given-names></name>; <name><surname>Roberts</surname><given-names>E. J.</given-names></name>; <name><surname>Davis</surname><given-names>L. C.</given-names></name>; <name><surname>Lewis</surname><given-names>D. E.</given-names></name>; <name><surname>Galwey</surname><given-names>N. W.</given-names></name>; <name><surname>Waddington</surname><given-names>K. E.</given-names></name>; <name><surname>Parravicini</surname><given-names>V.</given-names></name>; <name><surname>Macmillan-Jones</surname><given-names>A. L.</given-names></name>; <name><surname>Gongora</surname><given-names>C.</given-names></name>; <name><surname>Humphreys</surname><given-names>P. G.</given-names></name>; <name><surname>Churcher</surname><given-names>I.</given-names></name>; <name><surname>Prinjha</surname><given-names>R. K.</given-names></name>; <name><surname>Tough</surname><given-names>D. F.</given-names></name>\\n<article-title>Modulating PCAF/GCN5\\nImmune Cell Function Through a\\nPROTAC Approach</article-title>. <source>ACS Chem. Biol.</source>\\n<year>2018</year>, <volume>13</volume> (<issue>10</issue>), <fpage>2862</fpage>&#x2013;<lpage>2867</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acschembio.8b00705</pub-id>.<pub-id pub-id-type=\"pmid\">30200762</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref22\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit22\"><name><surname>Lai</surname><given-names>A. C.</given-names></name>; <name><surname>Toure</surname><given-names>M.</given-names></name>; <name><surname>Hellerschmied</surname><given-names>D.</given-names></name>; <name><surname>Salami</surname><given-names>J.</given-names></name>; <name><surname>Jaime-Figueroa</surname><given-names>S.</given-names></name>; <name><surname>Ko</surname><given-names>E.</given-names></name>; <name><surname>Hines</surname><given-names>J.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>\\n<article-title>Modular PROTAC Design for the Degradation\\nof Oncogenic BCR-ABL</article-title>. <source>Angew. Chem., Int. Ed.</source>\\n<year>2016</year>, <volume>55</volume> (<issue>2</issue>), <fpage>807</fpage>&#x2013;<lpage>810</lpage>. <pub-id pub-id-type=\"doi\">10.1002/anie.201507634</pub-id>.</mixed-citation>\\n      </ref>\\n      <ref id=\"ref23\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit23\"><name><surname>Huang</surname><given-names>H.-T.</given-names></name>; <name><surname>Dobrovolsky</surname><given-names>D.</given-names></name>; <name><surname>Paulk</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>G.</given-names></name>; <name><surname>Weisberg</surname><given-names>E. L.</given-names></name>; <name><surname>Doctor</surname><given-names>Z. M.</given-names></name>; <name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>Cho</surname><given-names>J.-H.</given-names></name>; <name><surname>Ko</surname><given-names>E.</given-names></name>; <name><surname>Jang</surname><given-names>J.</given-names></name>; <name><surname>Shi</surname><given-names>K.</given-names></name>; <name><surname>Choi</surname><given-names>H. G.</given-names></name>; <name><surname>Griffin</surname><given-names>J. D.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Treon</surname><given-names>S. P.</given-names></name>; <name><surname>Fischer</surname><given-names>E. S.</given-names></name>; <name><surname>Bradner</surname><given-names>J. E.</given-names></name>; <name><surname>Tan</surname><given-names>L.</given-names></name>; <name><surname>Gray</surname><given-names>N. S.</given-names></name>\\n<article-title>A Chemoproteomic Approach to Query the Degradable Kinome\\nUsing a Multi-Kinase Degrader</article-title>. <source>Cell Chem. Biol.</source>\\n<year>2018</year>, <volume>25</volume> (<issue>1</issue>), <fpage>88</fpage>&#x2013;<lpage>99</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.chembiol.2017.10.005</pub-id>.<pub-id pub-id-type=\"pmid\">29129717</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref24\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit24\"><name><surname>Crew</surname><given-names>A. P.</given-names></name>; <name><surname>Raina</surname><given-names>K.</given-names></name>; <name><surname>Dong</surname><given-names>H.</given-names></name>; <name><surname>Qian</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Vigil</surname><given-names>D.</given-names></name>; <name><surname>Serebrenik</surname><given-names>Y. V.</given-names></name>; <name><surname>Hamman</surname><given-names>B. D.</given-names></name>; <name><surname>Morgan</surname><given-names>A.</given-names></name>; <name><surname>Ferraro</surname><given-names>C.</given-names></name>; <name><surname>Siu</surname><given-names>K.</given-names></name>; <name><surname>Neklesa</surname><given-names>T. K.</given-names></name>; <name><surname>Winkler</surname><given-names>J. D.</given-names></name>; <name><surname>Coleman</surname><given-names>K. G.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>\\n<article-title>Identification and Characterization\\nof Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs)\\nof TANK-Binding Kinase 1</article-title>. <source>J. Med. Chem.</source>\\n<year>2018</year>, <volume>61</volume> (<issue>2</issue>), <fpage>583</fpage>&#x2013;<lpage>598</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.jmedchem.7b00635</pub-id>.<pub-id pub-id-type=\"pmid\">28692295</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref25\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit25\"><name><surname>Olson</surname><given-names>C. M.</given-names></name>; <name><surname>Jiang</surname><given-names>B.</given-names></name>; <name><surname>Erb</surname><given-names>M. A.</given-names></name>; <name><surname>Liang</surname><given-names>Y.</given-names></name>; <name><surname>Doctor</surname><given-names>Z. M.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>T.</given-names></name>; <name><surname>Kwiatkowski</surname><given-names>N.</given-names></name>; <name><surname>Boukhali</surname><given-names>M.</given-names></name>; <name><surname>Green</surname><given-names>J. L.</given-names></name>; <name><surname>Haas</surname><given-names>W.</given-names></name>; <name><surname>Nomanbhoy</surname><given-names>T.</given-names></name>; <name><surname>Fischer</surname><given-names>E. S.</given-names></name>; <name><surname>Young</surname><given-names>R. A.</given-names></name>; <name><surname>Bradner</surname><given-names>J. E.</given-names></name>; <name><surname>Winter</surname><given-names>G. E.</given-names></name>; <name><surname>Gray</surname><given-names>N. S.</given-names></name>\\n<article-title>Pharmacological Perturbation of CDK9 Using Selective\\nCDK9 Inhibition or Degradation</article-title>. <source>Nat. Chem. Biol.</source>\\n<year>2017</year>, <volume>14</volume> (<issue>2</issue>), <fpage>163</fpage>&#x2013;<lpage>170</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nchembio.2538</pub-id>.<pub-id pub-id-type=\"pmid\">29251720</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref26\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit26\"><name><surname>Robb</surname><given-names>C. M.</given-names></name>; <name><surname>Contreras</surname><given-names>J. I.</given-names></name>; <name><surname>Kour</surname><given-names>S.</given-names></name>; <name><surname>Taylor</surname><given-names>M. A.</given-names></name>; <name><surname>Abid</surname><given-names>M.</given-names></name>; <name><surname>Sonawane</surname><given-names>Y. A.</given-names></name>; <name><surname>Zahid</surname><given-names>M.</given-names></name>; <name><surname>Murry</surname><given-names>D. J.</given-names></name>; <name><surname>Natarajan</surname><given-names>A.</given-names></name>; <name><surname>Rana</surname><given-names>S.</given-names></name>\\n<article-title>Chemically Induced Degradation of CDK9 by a Proteolysis Targeting\\nChimera (PROTAC)</article-title>. <source>Chem. Commun.</source>\\n<year>2017</year>, <volume>53</volume> (<issue>54</issue>), <fpage>7577</fpage>&#x2013;<lpage>7580</lpage>. <pub-id pub-id-type=\"doi\">10.1039/C7CC03879H</pub-id>.</mixed-citation>\\n      </ref>\\n      <ref id=\"ref27\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit27\"><name><surname>Shibata</surname><given-names>N.</given-names></name>; <name><surname>Nagai</surname><given-names>K.</given-names></name>; <name><surname>Morita</surname><given-names>Y.</given-names></name>; <name><surname>Ujikawa</surname><given-names>O.</given-names></name>; <name><surname>Ohoka</surname><given-names>N.</given-names></name>; <name><surname>Hattori</surname><given-names>T.</given-names></name>; <name><surname>Koyama</surname><given-names>R.</given-names></name>; <name><surname>Sano</surname><given-names>O.</given-names></name>; <name><surname>Imaeda</surname><given-names>Y.</given-names></name>; <name><surname>Nara</surname><given-names>H.</given-names></name>; <name><surname>Cho</surname><given-names>N.</given-names></name>; <name><surname>Naito</surname><given-names>M.</given-names></name>\\n<article-title>Development of Protein\\nDegradation Inducers of Androgen Receptor by Conjugation of Androgen\\nReceptor Ligands and Inhibitor of Apoptosis Protein Ligands</article-title>. <source>J. Med. Chem.</source>\\n<year>2018</year>, <volume>61</volume> (<issue>2</issue>), <fpage>543</fpage>&#x2013;<lpage>575</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.jmedchem.7b00168</pub-id>.<pub-id pub-id-type=\"pmid\">28594553</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref28\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit28\"><name><surname>Salami</surname><given-names>J.</given-names></name>; <name><surname>Alabi</surname><given-names>S.</given-names></name>; <name><surname>Willard</surname><given-names>R. R.</given-names></name>; <name><surname>Vitale</surname><given-names>N. J.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Dong</surname><given-names>H.</given-names></name>; <name><surname>Jin</surname><given-names>M.</given-names></name>; <name><surname>McDonnell</surname><given-names>D. P.</given-names></name>; <name><surname>Crew</surname><given-names>A. P.</given-names></name>; <name><surname>Neklesa</surname><given-names>T. K.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>\\n<article-title>Androgen\\nReceptor\\nDegradation by the Proteolysis-Targeting Chimera ARCC-4 Outperforms\\nEnzalutamide in Cellular Models of Prostate Cancer Drug Resistance</article-title>. <source>Commun. Biol.</source>\\n<year>2018</year>, <volume>1</volume>, <fpage>100</fpage><pub-id pub-id-type=\"doi\">10.1038/s42003-018-0105-8</pub-id>.<pub-id pub-id-type=\"pmid\">30271980</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref29\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit29\"><name><surname>Maniaci</surname><given-names>C.</given-names></name>; <name><surname>Hughes</surname><given-names>S. J.</given-names></name>; <name><surname>Testa</surname><given-names>A.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name>; <name><surname>Lamont</surname><given-names>D. J.</given-names></name>; <name><surname>Rocha</surname><given-names>S.</given-names></name>; <name><surname>Alessi</surname><given-names>D. R.</given-names></name>; <name><surname>Romeo</surname><given-names>R.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Homo-PROTACs:\\nBivalent Small-Molecule Dimerizers of the VHL E3 Ubiquitin Ligase\\nto Induce Self-Degradation</article-title>. <source>Nat. Commun.</source>\\n<year>2017</year>, <volume>8</volume> (<issue>1</issue>), <fpage>830</fpage><pub-id pub-id-type=\"doi\">10.1038/s41467-017-00954-1</pub-id>.<pub-id pub-id-type=\"pmid\">29018234</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref30\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit30\"><name><surname>Steinebach</surname><given-names>C.</given-names></name>; <name><surname>Lindner</surname><given-names>S.</given-names></name>; <name><surname>Udeshi</surname><given-names>N. D.</given-names></name>; <name><surname>Mani</surname><given-names>D. C.</given-names></name>; <name><surname>Kehm</surname><given-names>H.</given-names></name>; <name><surname>K&#xF6;pff</surname><given-names>S.</given-names></name>; <name><surname>Carr</surname><given-names>S. A.</given-names></name>; <name><surname>G&#xFC;tschow</surname><given-names>M.</given-names></name>; <name><surname>Kronke</surname><given-names>J.</given-names></name>\\n<article-title>Homo-PROTACs for the\\nChemical Knockdown of Cereblon</article-title>. <source>ACS Chem. Biol.</source>\\n<year>2018</year>, <volume>13</volume> (<issue>9</issue>), <fpage>2771</fpage>&#x2013;<lpage>2782</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acschembio.8b00693</pub-id>.<pub-id pub-id-type=\"pmid\">30118587</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref31\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit31\"><name><surname>Cyrus</surname><given-names>K.</given-names></name>; <name><surname>Wehenkel</surname><given-names>M.</given-names></name>; <name><surname>Choi</surname><given-names>E.-Y.</given-names></name>; <name><surname>Lee</surname><given-names>H.</given-names></name>; <name><surname>Swanson</surname><given-names>H.</given-names></name>; <name><surname>Kim</surname><given-names>K.-B.</given-names></name>\\n<article-title>Jostling for Position: Optimizing Linker Location in\\nthe Design of Estrogen Receptor-Targeting PROTACs</article-title>. <source>ChemMedChem</source>\\n<year>2010</year>, <volume>5</volume> (<issue>7</issue>), <fpage>979</fpage>&#x2013;<lpage>985</lpage>. <pub-id pub-id-type=\"doi\">10.1002/cmdc.201000146</pub-id>.<pub-id pub-id-type=\"pmid\">20512796</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref32\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit32\"><name><surname>Zorba</surname><given-names>A.</given-names></name>; <name><surname>Nguyen</surname><given-names>C.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Starr</surname><given-names>J.</given-names></name>; <name><surname>Borzilleri</surname><given-names>K.</given-names></name>; <name><surname>Smith</surname><given-names>J.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>; <name><surname>Farley</surname><given-names>K. A.</given-names></name>; <name><surname>Ding</surname><given-names>W.</given-names></name>; <name><surname>Schiemer</surname><given-names>J.</given-names></name>; <name><surname>Feng</surname><given-names>X.</given-names></name>; <name><surname>Chang</surname><given-names>J. S.</given-names></name>; <name><surname>Uccello</surname><given-names>D. P.</given-names></name>; <name><surname>Young</surname><given-names>J. A.</given-names></name>; <name><surname>Garcia-Irrizary</surname><given-names>C. N.</given-names></name>; <name><surname>Czabaniuk</surname><given-names>L.</given-names></name>; <name><surname>Schuff</surname><given-names>B.</given-names></name>; <name><surname>Oliver</surname><given-names>R.</given-names></name>; <name><surname>Montgomery</surname><given-names>J.</given-names></name>; <name><surname>Hayward</surname><given-names>M. M.</given-names></name>; <name><surname>Coe</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Niosi</surname><given-names>M.</given-names></name>; <name><surname>Luthra</surname><given-names>S.</given-names></name>; <name><surname>Shah</surname><given-names>J. C.</given-names></name>; <name><surname>El-Kattan</surname><given-names>A.</given-names></name>; <name><surname>Qiu</surname><given-names>X.</given-names></name>; <name><surname>West</surname><given-names>G. M.</given-names></name>; <name><surname>Noe</surname><given-names>M. C.</given-names></name>; <name><surname>Shanmugasundaram</surname><given-names>V.</given-names></name>; <name><surname>Gilbert</surname><given-names>A. M.</given-names></name>; <name><surname>Brown</surname><given-names>M. F.</given-names></name>; <name><surname>Calabrese</surname><given-names>M. F.</given-names></name>\\n<article-title>Delineating\\nthe Role of Cooperativity in the Design of Potent PROTACs for BTK</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>\\n<year>2018</year>, <volume>115</volume> (<issue>31</issue>), <fpage>E7285</fpage>&#x2013;<lpage>E7292</lpage>. <pub-id pub-id-type=\"doi\">10.1073/pnas.1803662115</pub-id>.<pub-id pub-id-type=\"pmid\">30012605</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref33\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit33\"><name><surname>Bulatov</surname><given-names>E.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Targeting Cullin&#x2013;RING\\nE3 Ubiquitin Ligases for\\nDrug Discovery: Structure, Assembly and Small-Molecule Modulation</article-title>. <source>Biochem. J.</source>\\n<year>2015</year>, <volume>467</volume> (<issue>3</issue>), <fpage>365</fpage>&#x2013;<lpage>386</lpage>. <pub-id pub-id-type=\"doi\">10.1042/BJ20141450</pub-id>.<pub-id pub-id-type=\"pmid\">25886174</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref34\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit34\"><name><surname>Lucas</surname><given-names>X.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Recognition of Substrate Degrons by E3 Ubiquitin Ligases\\nand Modulation by Small-Molecule Mimicry Strategies</article-title>. <source>Curr. Opin. Struct. Biol.</source>\\n<year>2017</year>, <volume>44</volume>, <fpage>101</fpage>&#x2013;<lpage>110</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.sbi.2016.12.015</pub-id>.<pub-id pub-id-type=\"pmid\">28130986</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref35\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit35\"><name><surname>Fischer</surname><given-names>E. S.</given-names></name>; <name><surname>Scrima</surname><given-names>A.</given-names></name>; <name><surname>B&#xF6;hm</surname><given-names>K.</given-names></name>; <name><surname>Matsumoto</surname><given-names>S.</given-names></name>; <name><surname>Lingaraju</surname><given-names>G. M.</given-names></name>; <name><surname>Faty</surname><given-names>M.</given-names></name>; <name><surname>Yasuda</surname><given-names>T.</given-names></name>; <name><surname>Cavadini</surname><given-names>S.</given-names></name>; <name><surname>Wakasugi</surname><given-names>M.</given-names></name>; <name><surname>Hanaoka</surname><given-names>F.</given-names></name>; <name><surname>Iwai</surname><given-names>S.</given-names></name>; <name><surname>Gut</surname><given-names>H.</given-names></name>; <name><surname>Sugasawa</surname><given-names>K.</given-names></name>; <name><surname>Thom&#xE4;</surname><given-names>N. H.</given-names></name>\\n<article-title>The Molecular Basis of CRL4DDB2/CSA\\nUbiquitin Ligase Architecture, Targeting, and Activation</article-title>. <source>Cell</source>\\n<year>2011</year>, <volume>147</volume> (<issue>5</issue>), <fpage>1024</fpage>&#x2013;<lpage>1039</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.cell.2011.10.035</pub-id>.<pub-id pub-id-type=\"pmid\">22118460</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref36\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit36\"><name><surname>Petroski</surname><given-names>M. D.</given-names></name>; <name><surname>Deshaies</surname><given-names>R. J.</given-names></name>\\n<article-title>Function and Regulation of Cullin&#x2013;RING\\nUbiquitin\\nLigases</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>\\n<year>2005</year>, <volume>6</volume> (<issue>1</issue>), <fpage>9</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nrm1547</pub-id>.<pub-id pub-id-type=\"pmid\">15688063</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref37\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit37\"><name><surname>Zhu</surname><given-names>Y. X.</given-names></name>; <name><surname>Braggio</surname><given-names>E.</given-names></name>; <name><surname>Shi</surname><given-names>C.-X.</given-names></name>; <name><surname>Bruins</surname><given-names>L. A.</given-names></name>; <name><surname>Schmidt</surname><given-names>J. E.</given-names></name>; <name><surname>Van Wier</surname><given-names>S.</given-names></name>; <name><surname>Chang</surname><given-names>X.-B.</given-names></name>; <name><surname>Bjorklund</surname><given-names>C. C.</given-names></name>; <name><surname>Fonseca</surname><given-names>R.</given-names></name>; <name><surname>Bergsagel</surname><given-names>P. L.</given-names></name>; <name><surname>Orlowski</surname><given-names>R. Z.</given-names></name>; <name><surname>Stewart</surname><given-names>A. K.</given-names></name>\\n<article-title>Cereblon\\nExpression is Required for the Antimyeloma Activity of Lenalidomide\\nand Pomalidomide</article-title>. <source>Blood</source>\\n<year>2011</year>, <volume>118</volume> (<issue>18</issue>), <fpage>4771</fpage>&#x2013;<lpage>4779</lpage>. <pub-id pub-id-type=\"doi\">10.1182/blood-2011-05-356063</pub-id>.<pub-id pub-id-type=\"pmid\">21860026</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref38\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit38\"><name><surname>Theodoulou</surname><given-names>N. H.</given-names></name>; <name><surname>Bamborough</surname><given-names>P.</given-names></name>; <name><surname>Bannister</surname><given-names>A. J.</given-names></name>; <name><surname>Becher</surname><given-names>I.</given-names></name>; <name><surname>Bit</surname><given-names>R. A.</given-names></name>; <name><surname>Che</surname><given-names>K. H.</given-names></name>; <name><surname>Chung</surname><given-names>C.</given-names></name>; <name><surname>Dittmann</surname><given-names>A.</given-names></name>; <name><surname>Drewes</surname><given-names>G.</given-names></name>; <name><surname>Drewry</surname><given-names>D. H.</given-names></name>; <name><surname>Gordon</surname><given-names>L.</given-names></name>; <name><surname>Grandi</surname><given-names>P.</given-names></name>; <name><surname>Leveridge</surname><given-names>M.</given-names></name>; <name><surname>Lindon</surname><given-names>M.</given-names></name>; <name><surname>Michon</surname><given-names>A. M.</given-names></name>; <name><surname>Molnar</surname><given-names>J.</given-names></name>; <name><surname>Robson</surname><given-names>S. C.</given-names></name>; <name><surname>Tomkinson</surname><given-names>N. C.</given-names></name>; <name><surname>Kouzarides</surname><given-names>T.</given-names></name>; <name><surname>Prinjha</surname><given-names>R. K.</given-names></name>; <name><surname>Humphreys</surname><given-names>P. G.</given-names></name>\\n<article-title>Discovery\\nof I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain\\nContaining Protein 9 Inhibition</article-title>. <source>J. Med. Chem.</source>\\n<year>2016</year>, <volume>59</volume> (<issue>4</issue>), <fpage>1425</fpage>&#x2013;<lpage>1439</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.jmedchem.5b00256</pub-id>.<pub-id pub-id-type=\"pmid\">25856009</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref39\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit39\"><name><surname>Kadoch</surname><given-names>C.</given-names></name>; <name><surname>Hargreaves</surname><given-names>D. C.</given-names></name>; <name><surname>Hodges</surname><given-names>C.</given-names></name>; <name><surname>Elias</surname><given-names>L.</given-names></name>; <name><surname>Ho</surname><given-names>L.</given-names></name>; <name><surname>Ranish</surname><given-names>J.</given-names></name>; <name><surname>Crabtree</surname><given-names>G. R.</given-names></name>\\n<article-title>Proteomic and Bioinformatic Analysis\\nof Mammalian SWI/SNF Complexes Identifies Extensive Roles in Human\\nMalignancy</article-title>. <source>Nat. Genet.</source>\\n<year>2013</year>, <volume>45</volume> (<issue>6</issue>), <fpage>592</fpage>&#x2013;<lpage>601</lpage>. <pub-id pub-id-type=\"doi\">10.1038/ng.2628</pub-id>.<pub-id pub-id-type=\"pmid\">23644491</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref40\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit40\"><name><surname>Kaeser</surname><given-names>M. D.</given-names></name>; <name><surname>Aslanian</surname><given-names>A.</given-names></name>; <name><surname>Dong</surname><given-names>M.-Q.</given-names></name>; <name><surname>Yates</surname><given-names>J. R.</given-names></name>; <name><surname>Emerson</surname><given-names>B. M.</given-names></name>\\n<article-title>BRD7, a\\nNovel PBAF-Specific SWI/SNF Subunit, is Required for Target Gene Activation\\nand Repression in Embryonic Stem Cells</article-title>. <source>J. Biol.\\nChem.</source>\\n<year>2008</year>, <volume>283</volume> (<issue>47</issue>), <fpage>32254</fpage>&#x2013;<lpage>32263</lpage>. <pub-id pub-id-type=\"doi\">10.1074/jbc.M806061200</pub-id>.<pub-id pub-id-type=\"pmid\">18809673</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref41\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit41\"><name><surname>Narlikar</surname><given-names>G. J.</given-names></name>; <name><surname>Sundaramoorthy</surname><given-names>R.</given-names></name>; <name><surname>Owen-Hughes</surname><given-names>T.</given-names></name>\\n<article-title>Mechanisms and Functions of ATP-Dependent\\nChromatin-Remodeling Enzymes</article-title>. <source>Cell</source>\\n<year>2013</year>, <volume>154</volume> (<issue>3</issue>), <fpage>490</fpage>&#x2013;<lpage>503</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.cell.2013.07.011</pub-id>.<pub-id pub-id-type=\"pmid\">23911317</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref42\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit42\"><name><surname>Hohmann</surname><given-names>A. F.</given-names></name>; <name><surname>Vakoc</surname><given-names>C. R.</given-names></name>\\n<article-title>A Rationale to Target the SWI/SNF Complex for Cancer\\nTherapy</article-title>. <source>Trends Genet.</source>\\n<year>2014</year>, <volume>30</volume> (<issue>8</issue>), <fpage>356</fpage>&#x2013;<lpage>363</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.tig.2014.05.001</pub-id>.<pub-id pub-id-type=\"pmid\">24932742</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref43\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit43\"><name><surname>Martens</surname><given-names>J. A.</given-names></name>\\n<article-title>Evidence\\nThat Swi/Snf Directly Represses Transcription in S. Cerevisiae</article-title>. <source>Genes Dev.</source>\\n<year>2002</year>, <volume>16</volume> (<issue>17</issue>), <fpage>2231</fpage>&#x2013;<lpage>2236</lpage>. <pub-id pub-id-type=\"doi\">10.1101/gad.1009902</pub-id>.<pub-id pub-id-type=\"pmid\">12208846</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref44\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit44\"><name><surname>Kang</surname><given-names>J. U.</given-names></name>; <name><surname>Koo</surname><given-names>S. H.</given-names></name>; <name><surname>Kwon</surname><given-names>K. C.</given-names></name>; <name><surname>Park</surname><given-names>J. W.</given-names></name>; <name><surname>Kim</surname><given-names>J. M.</given-names></name>\\n<article-title>Gain at\\nChromosomal Region 5p15.33, Containing TERT, is the Most Frequent\\nGenetic Event in Early Stages of Non-Small Cell Lung Cancer</article-title>. <source>Cancer Genet. Cytogenet.</source>\\n<year>2008</year>, <volume>182</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.cancergencyto.2007.12.004</pub-id>.<pub-id pub-id-type=\"pmid\">18328944</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref45\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit45\"><name><surname>Scotto</surname><given-names>L.</given-names></name>; <name><surname>Narayan</surname><given-names>G.</given-names></name>; <name><surname>Nandula</surname><given-names>S. V.</given-names></name>; <name><surname>Subramaniyam</surname><given-names>S.</given-names></name>; <name><surname>Kaufmann</surname><given-names>A. M.</given-names></name>; <name><surname>Wright</surname><given-names>J. D.</given-names></name>; <name><surname>Pothuri</surname><given-names>B.</given-names></name>; <name><surname>Mansukhani</surname><given-names>M.</given-names></name>; <name><surname>Schneider</surname><given-names>A.</given-names></name>; <name><surname>Arias-Pulido</surname><given-names>H.</given-names></name>; <name><surname>Murty</surname><given-names>V. V.</given-names></name>\\n<article-title>Integrative Genomics\\nAnalysis of Chromosome 5p Gain in Cervical Cancer Reveals Target Over-Expressed\\nGenes, Including Drosha</article-title>. <source>Mol. Cancer</source>\\n<year>2008</year>, <volume>7</volume>, <fpage>58</fpage><pub-id pub-id-type=\"doi\">10.1186/1476-4598-7-58</pub-id>.<pub-id pub-id-type=\"pmid\">18559093</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref46\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit46\"><name><surname>Yu</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Shen</surname><given-names>J.</given-names></name>\\n<article-title>BRD7: A Novel\\nTumor Suppressor Gene in Different Cancers</article-title>. <source>Am. J. Transl. Res.</source>\\n<year>2016</year>, <volume>8</volume> (<issue>2</issue>), <fpage>742</fpage>&#x2013;<lpage>748</lpage>.<pub-id pub-id-type=\"pmid\">27158366</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref47\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit47\"><name><surname>Drost</surname><given-names>J.</given-names></name>; <name><surname>Mantovani</surname><given-names>F.</given-names></name>; <name><surname>Tocco</surname><given-names>F.</given-names></name>; <name><surname>Elkon</surname><given-names>R.</given-names></name>; <name><surname>Comel</surname><given-names>A.</given-names></name>; <name><surname>Holstege</surname><given-names>H.</given-names></name>; <name><surname>Kerkhoven</surname><given-names>R.</given-names></name>; <name><surname>Jonkers</surname><given-names>J.</given-names></name>; <name><surname>Voorhoeve</surname><given-names>P. M.</given-names></name>; <name><surname>Agami</surname><given-names>R.</given-names></name>; <name><surname>Del Sal</surname><given-names>G.</given-names></name>\\n<article-title>BRD7 Is a Candidate Tumour Suppressor\\nGene Required for P53 Function</article-title>. <source>Nat. Cell Biol.</source>\\n<year>2010</year>, <volume>12</volume> (<issue>4</issue>), <fpage>380</fpage>&#x2013;<lpage>389</lpage>. <pub-id pub-id-type=\"doi\">10.1038/ncb2038</pub-id>.<pub-id pub-id-type=\"pmid\">20228809</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref48\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit48\"><name><surname>Chiu</surname><given-names>Y.-H.</given-names></name>; <name><surname>Lee</surname><given-names>J. Y.</given-names></name>; <name><surname>Cantley</surname><given-names>L. C.</given-names></name>\\n<article-title>BRD7, a\\nTumor Suppressor, Interacts\\nwith P85&#x3B1; and Regulates PI3K Activity</article-title>. <source>Mol. Cell</source>\\n<year>2014</year>, <volume>54</volume> (<issue>1</issue>), <fpage>193</fpage>&#x2013;<lpage>202</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.molcel.2014.02.016</pub-id>.<pub-id pub-id-type=\"pmid\">24657164</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref49\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit49\"><name><surname>Harte</surname><given-names>M. T.</given-names></name>; <name><surname>O&#x2019;Brien</surname><given-names>G. J.</given-names></name>; <name><surname>Ryan</surname><given-names>N. M.</given-names></name>; <name><surname>Gorski</surname><given-names>J. J.</given-names></name>; <name><surname>Savage</surname><given-names>K. I.</given-names></name>; <name><surname>Crawford</surname><given-names>N. T.</given-names></name>; <name><surname>Mullan</surname><given-names>P. B.</given-names></name>; <name><surname>Harkin</surname><given-names>D. P.</given-names></name>\\n<article-title>BRD7, a\\nSubunit\\nof SWI/SNF Complexes, Binds Directly to BRCA1 and Regulates BRCA1-Dependent\\nTranscription</article-title>. <source>Cancer Res.</source>\\n<year>2010</year>, <volume>70</volume> (<issue>6</issue>), <fpage>2538</fpage>&#x2013;<lpage>2547</lpage>. <pub-id pub-id-type=\"doi\">10.1158/0008-5472.CAN-09-2089</pub-id>.<pub-id pub-id-type=\"pmid\">20215511</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref50\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit50\"><name><surname>Niu</surname><given-names>W.</given-names></name>; <name><surname>Luo</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Fu</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Yin</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Fan</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Xiong</surname><given-names>W.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>G.</given-names></name>; <name><surname>Ren</surname><given-names>C.</given-names></name>; <name><surname>Tan</surname><given-names>M.</given-names></name>; <name><surname>Zhou</surname><given-names>M.</given-names></name>\\n<article-title>BRD7 Inhibits the Warburg\\nEffect and Tumor Progression Through Inactivation of HIF1&#x3B1;/LDHA\\nAxis in Breast Cancer</article-title>. <source>Cell Death Dis.</source>\\n<year>2018</year>, <volume>9</volume> (<issue>5</issue>), <fpage>519</fpage><pub-id pub-id-type=\"doi\">10.1038/s41419-018-0536-7</pub-id>.<pub-id pub-id-type=\"pmid\">29725006</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref51\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit51\"><name><surname>Gatenby</surname><given-names>R. A.</given-names></name>; <name><surname>Gillies</surname><given-names>R. J.</given-names></name>\\n<article-title>Why Do Cancers Have\\nHigh Aerobic Glycolysis?</article-title>. <source>Nat. Rev. Cancer</source>\\n<year>2004</year>, <volume>4</volume> (<issue>11</issue>), <fpage>891</fpage>&#x2013;<lpage>899</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nrc1478</pub-id>.<pub-id pub-id-type=\"pmid\">15516961</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref52\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit52\"><name><surname>Park</surname><given-names>S. W.</given-names></name>; <name><surname>Herrema</surname><given-names>H.</given-names></name>; <name><surname>Salazar</surname><given-names>M.</given-names></name>; <name><surname>Cakir</surname><given-names>I.</given-names></name>; <name><surname>Cabi</surname><given-names>S.</given-names></name>; <name><surname>Basibuyuk Sahin</surname><given-names>F.</given-names></name>; <name><surname>Chiu</surname><given-names>Y.-H.</given-names></name>; <name><surname>Cantley</surname><given-names>L. C.</given-names></name>; <name><surname>Ozcan</surname><given-names>U.</given-names></name>\\n<article-title>BRD7 Regulates\\nXBP1s&#x2019; Activity and Glucose Homeostasis Through its Interaction\\nwith the Regulatory Subunits of PI3K</article-title>. <source>Cell Metab.</source>\\n<year>2014</year>, <volume>20</volume> (<issue>1</issue>), <fpage>73</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.cmet.2014.04.006</pub-id>.<pub-id pub-id-type=\"pmid\">24836559</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref53\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit53\"><name><surname>Pan</surname><given-names>D.</given-names></name>; <name><surname>Kobayashi</surname><given-names>A.</given-names></name>; <name><surname>Jiang</surname><given-names>P.</given-names></name>; <name><surname>Ferrari de Andrade</surname><given-names>L.</given-names></name>; <name><surname>Tay</surname><given-names>R. E.</given-names></name>; <name><surname>Luoma</surname><given-names>A. M.</given-names></name>; <name><surname>Tsoucas</surname><given-names>D.</given-names></name>; <name><surname>Qiu</surname><given-names>X.</given-names></name>; <name><surname>Lim</surname><given-names>K.</given-names></name>; <name><surname>Rao</surname><given-names>P.</given-names></name>; <name><surname>Long</surname><given-names>H. W.</given-names></name>; <name><surname>Yuan</surname><given-names>G. C.</given-names></name>; <name><surname>Doench</surname><given-names>J.</given-names></name>; <name><surname>Brown</surname><given-names>M.</given-names></name>; <name><surname>Liu</surname><given-names>X. S.</given-names></name>; <name><surname>Wucherpfennig</surname><given-names>K. W.</given-names></name>\\n<article-title>A Major\\nChromatin Regulator Determines Resistance of Tumor Cells to T Cell-Mediated\\nKilling</article-title>. <source>Science</source>\\n<year>2018</year>, <volume>359</volume> (<issue>6377</issue>), <fpage>770</fpage>&#x2013;<lpage>775</lpage>. <pub-id pub-id-type=\"doi\">10.1126/science.aao1710</pub-id>.<pub-id pub-id-type=\"pmid\">29301958</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref54\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit54\"><name><surname>Clark</surname><given-names>P. G. K.</given-names></name>; <name><surname>Vieira</surname><given-names>L. C. C.</given-names></name>; <name><surname>Tallant</surname><given-names>C.</given-names></name>; <name><surname>Fedorov</surname><given-names>O.</given-names></name>; <name><surname>Singleton</surname><given-names>D. C.</given-names></name>; <name><surname>Rogers</surname><given-names>C. M.</given-names></name>; <name><surname>Monteiro</surname><given-names>O. P.</given-names></name>; <name><surname>Bennett</surname><given-names>J. M.</given-names></name>; <name><surname>Baronio</surname><given-names>R.</given-names></name>; <name><surname>M&#xFC;ller</surname><given-names>S.</given-names></name>; <name><surname>Daniels</surname><given-names>D. L.</given-names></name>; <name><surname>M&#xE9;ndez</surname><given-names>J.</given-names></name>; <name><surname>Knapp</surname><given-names>S.</given-names></name>; <name><surname>Brennan</surname><given-names>P. E.</given-names></name>; <name><surname>Dixon</surname><given-names>D. J.</given-names></name>\\n<article-title>LP99: Discovery\\nand Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor</article-title>. <source>Angew. Chem., Int. Ed.</source>\\n<year>2015</year>, <volume>54</volume> (<issue>21</issue>), <fpage>6217</fpage>&#x2013;<lpage>6221</lpage>. <pub-id pub-id-type=\"doi\">10.1002/anie.201501394</pub-id>.</mixed-citation>\\n      </ref>\\n      <ref id=\"ref55\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit55\"><name><surname>Hay</surname><given-names>D. A.</given-names></name>; <name><surname>Rogers</surname><given-names>C. M.</given-names></name>; <name><surname>Fedorov</surname><given-names>O.</given-names></name>; <name><surname>Tallant</surname><given-names>C.</given-names></name>; <name><surname>Martin</surname><given-names>S.</given-names></name>; <name><surname>Monteiro</surname><given-names>O. P.</given-names></name>; <name><surname>M&#xFC;ller</surname><given-names>S.</given-names></name>; <name><surname>Knapp</surname><given-names>S.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name>; <name><surname>Brennan</surname><given-names>P. E.</given-names></name>\\n<article-title>Design and Synthesis\\nof Potent and Selective Inhibitors\\nof BRD7 and BRD9 Bromodomains</article-title>. <source>MedChemComm</source>\\n<year>2015</year>, <volume>6</volume> (<issue>7</issue>), <fpage>1381</fpage>&#x2013;<lpage>1386</lpage>. <pub-id pub-id-type=\"doi\">10.1039/C5MD00152H</pub-id>.</mixed-citation>\\n      </ref>\\n      <ref id=\"ref56\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit56\"><name><surname>Martin</surname><given-names>L.\\nJ.</given-names></name>; <name><surname>Koegl</surname><given-names>M.</given-names></name>; <name><surname>Bader</surname><given-names>G.</given-names></name>; <name><surname>Cockcroft</surname><given-names>X.-L.</given-names></name>; <name><surname>Fedorov</surname><given-names>O.</given-names></name>; <name><surname>Fiegen</surname><given-names>D.</given-names></name>; <name><surname>Gerstberger</surname><given-names>T.</given-names></name>; <name><surname>Hofmann</surname><given-names>M. H.</given-names></name>; <name><surname>Hohmann</surname><given-names>A. F.</given-names></name>; <name><surname>Kessler</surname><given-names>D.</given-names></name>; <name><surname>Knapp</surname><given-names>S.</given-names></name>; <name><surname>Knesl</surname><given-names>P.</given-names></name>; <name><surname>Kornigg</surname><given-names>S.</given-names></name>; <name><surname>M&#xFC;ller</surname><given-names>S.</given-names></name>; <name><surname>Nar</surname><given-names>H.</given-names></name>; <name><surname>Rogers</surname><given-names>C.</given-names></name>; <name><surname>Rumpel</surname><given-names>K.</given-names></name>; <name><surname>Schaaf</surname><given-names>O.</given-names></name>; <name><surname>Steurer</surname><given-names>S.</given-names></name>; <name><surname>Tallant</surname><given-names>C.</given-names></name>; <name><surname>Vakoc</surname><given-names>C. R.</given-names></name>; <name><surname>Zeeb</surname><given-names>M.</given-names></name>; <name><surname>Zoephel</surname><given-names>A.</given-names></name>; <name><surname>Pearson</surname><given-names>M.</given-names></name>; <name><surname>Boehmelt</surname><given-names>G.</given-names></name>; <name><surname>McConnell</surname><given-names>D.</given-names></name>\\n<article-title>Structure-Based\\nDesign of an in Vivo Active Selective BRD9 Inhibitor</article-title>. <source>J. Med. Chem.</source>\\n<year>2016</year>, <volume>59</volume> (<issue>10</issue>), <fpage>4462</fpage>&#x2013;<lpage>4475</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.jmedchem.5b01865</pub-id>.<pub-id pub-id-type=\"pmid\">26914985</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref57\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit57\"><name><surname>Crawford</surname><given-names>T. D.</given-names></name>; <name><surname>Vartanian</surname><given-names>S.</given-names></name>; <name><surname>C&#xF4;t&#xE9;</surname><given-names>A.</given-names></name>; <name><surname>Bellon</surname><given-names>S.</given-names></name>; <name><surname>Duplessis</surname><given-names>M.</given-names></name>; <name><surname>Flynn</surname><given-names>E. M.</given-names></name>; <name><surname>Hewitt</surname><given-names>M.</given-names></name>; <name><surname>Huang</surname><given-names>H.-R.</given-names></name>; <name><surname>Kiefer</surname><given-names>J. R.</given-names></name>; <name><surname>Murray</surname><given-names>J.</given-names></name>; <name><surname>Nasveschuk</surname><given-names>C. G.</given-names></name>; <name><surname>Pardo</surname><given-names>E.</given-names></name>; <name><surname>Romero</surname><given-names>F. A.</given-names></name>; <name><surname>Sandy</surname><given-names>P.</given-names></name>; <name><surname>Tang</surname><given-names>Y.</given-names></name>; <name><surname>Taylor</surname><given-names>A. M.</given-names></name>; <name><surname>Tsui</surname><given-names>V.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Zawadzke</surname><given-names>L.</given-names></name>; <name><surname>Albrecht</surname><given-names>B. K.</given-names></name>; <name><surname>Magnuson</surname><given-names>S. R.</given-names></name>; <name><surname>Cochran</surname><given-names>A. G.</given-names></name>; <name><surname>Stokoe</surname><given-names>D.</given-names></name>\\n<article-title>Inhibition of Bromodomain-Containing\\nProtein 9 for the Prevention of Epigenetically-Defined Drug Resistance</article-title>. <source>Bioorg. Med. Chem. Lett.</source>\\n<year>2017</year>, <volume>27</volume> (<issue>15</issue>), <fpage>3534</fpage>&#x2013;<lpage>3541</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.bmcl.2017.05.063</pub-id>.<pub-id pub-id-type=\"pmid\">28606761</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref58\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit58\"><name><surname>Hohmann</surname><given-names>A. F.</given-names></name>; <name><surname>Martin</surname><given-names>L. J.</given-names></name>; <name><surname>Minder</surname><given-names>J. L.</given-names></name>; <name><surname>Roe</surname><given-names>J.-S.</given-names></name>; <name><surname>Shi</surname><given-names>J.</given-names></name>; <name><surname>Steurer</surname><given-names>S.</given-names></name>; <name><surname>Bader</surname><given-names>G.</given-names></name>; <name><surname>McConnell</surname><given-names>D.</given-names></name>; <name><surname>Pearson</surname><given-names>M.</given-names></name>; <name><surname>Gerstberger</surname><given-names>T.</given-names></name>; <name><surname>Gottschamel</surname><given-names>T.</given-names></name>; <name><surname>Thompson</surname><given-names>D.</given-names></name>; <name><surname>Suzuki</surname><given-names>Y.</given-names></name>; <name><surname>Koegl</surname><given-names>M.</given-names></name>; <name><surname>Vakoc</surname><given-names>C. R.</given-names></name>\\n<article-title>Sensitivity\\nand Engineered Resistance of Myeloid Leukemia Cells to BRD9 Inhibition</article-title>. <source>Nat. Chem. Biol.</source>\\n<year>2016</year>, <volume>12</volume> (<issue>9</issue>), <fpage>672</fpage>&#x2013;<lpage>679</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nchembio.2115</pub-id>.<pub-id pub-id-type=\"pmid\">27376689</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref59\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit59\"><name><surname>Han</surname><given-names>T.</given-names></name>; <name><surname>Goralski</surname><given-names>M.</given-names></name>; <name><surname>Gaskill</surname><given-names>N.</given-names></name>; <name><surname>Capota</surname><given-names>E.</given-names></name>; <name><surname>Kim</surname><given-names>J.</given-names></name>; <name><surname>Ting</surname><given-names>T. C.</given-names></name>; <name><surname>Xie</surname><given-names>Y.</given-names></name>; <name><surname>Williams</surname><given-names>N. S.</given-names></name>; <name><surname>Nijhawan</surname><given-names>D.</given-names></name>\\n<article-title>Anticancer\\nSulfonamides Target Splicing by Inducing RBM39 Degradation via Recruitment\\nto DCAF15</article-title>. <source>Science</source>\\n<year>2017</year>, <volume>356</volume> (<issue>6336</issue>), <elocation-id>eaal3755</elocation-id><pub-id pub-id-type=\"doi\">10.1126/science.aal3755</pub-id>.<pub-id pub-id-type=\"pmid\">28302793</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref60\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit60\"><name><surname>Uehara</surname><given-names>T.</given-names></name>; <name><surname>Minoshima</surname><given-names>Y.</given-names></name>; <name><surname>Sagane</surname><given-names>K.</given-names></name>; <name><surname>Sugi</surname><given-names>N. H.</given-names></name>; <name><surname>Mitsuhashi</surname><given-names>K. O.</given-names></name>; <name><surname>Yamamoto</surname><given-names>N.</given-names></name>; <name><surname>Kamiyama</surname><given-names>H.</given-names></name>; <name><surname>Takahashi</surname><given-names>K.</given-names></name>; <name><surname>Kotake</surname><given-names>Y.</given-names></name>; <name><surname>Uesugi</surname><given-names>M.</given-names></name>; <name><surname>Yokoi</surname><given-names>A.</given-names></name>; <name><surname>Inoue</surname><given-names>A.</given-names></name>; <name><surname>Yoshida</surname><given-names>T.</given-names></name>; <name><surname>Mabuchi</surname><given-names>M.</given-names></name>; <name><surname>Tanaka</surname><given-names>A.</given-names></name>; <name><surname>Owa</surname><given-names>T.</given-names></name>\\n<article-title>Selective\\nDegradation of Splicing Factor CAPER&#x3B1; by Anticancer Sulfonamides</article-title>. <source>Nat. Chem. Biol.</source>\\n<year>2017</year>, <volume>13</volume> (<issue>6</issue>), <fpage>675</fpage>&#x2013;<lpage>680</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nchembio.2363</pub-id>.<pub-id pub-id-type=\"pmid\">28437394</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref61\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit61\"><name><surname>Galdeano</surname><given-names>C.</given-names></name>; <name><surname>Gadd</surname><given-names>M. S.</given-names></name>; <name><surname>Soares</surname><given-names>P.</given-names></name>; <name><surname>Scaffidi</surname><given-names>S.</given-names></name>; <name><surname>Van Molle</surname><given-names>I.</given-names></name>; <name><surname>Birced</surname><given-names>I.</given-names></name>; <name><surname>Hewitt</surname><given-names>S.</given-names></name>; <name><surname>Dias</surname><given-names>D. M.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Structure-Guided\\nDesign and Optimization of Small Molecules Targeting the Protein&#x2013;Protein\\nInteraction Between the Von Hippel&#x2013;Lindau (VHL) E3 Ubiquitin\\nLigase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in\\nVitro Nanomolar Affinities</article-title>. <source>J. Med. Chem.</source>\\n<year>2014</year>, <volume>57</volume> (<issue>20</issue>), <fpage>8657</fpage>&#x2013;<lpage>8663</lpage>. <pub-id pub-id-type=\"doi\">10.1021/jm5011258</pub-id>.<pub-id pub-id-type=\"pmid\">25166285</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref62\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit62\"><name><surname>Frost</surname><given-names>J.</given-names></name>; <name><surname>Galdeano</surname><given-names>C.</given-names></name>; <name><surname>Soares</surname><given-names>P.</given-names></name>; <name><surname>Gadd</surname><given-names>M. S.</given-names></name>; <name><surname>Grzes</surname><given-names>K. M.</given-names></name>; <name><surname>Ellis</surname><given-names>L.</given-names></name>; <name><surname>Epemolu</surname><given-names>O.</given-names></name>; <name><surname>Shimamura</surname><given-names>S.</given-names></name>; <name><surname>Bantscheff</surname><given-names>M.</given-names></name>; <name><surname>Grandi</surname><given-names>P.</given-names></name>; <name><surname>Read</surname><given-names>K. D.</given-names></name>; <name><surname>Cantrell</surname><given-names>D. A.</given-names></name>; <name><surname>Rocha</surname><given-names>S.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Potent and Selective\\nChemical Probe\\nof Hypoxic Signalling Downstream of HIF-&#x3B1; Hydroxylation via\\nVHL Inhibition</article-title>. <source>Nat. Commun.</source>\\n<year>2016</year>, <volume>7</volume>, <fpage>13312</fpage><pub-id pub-id-type=\"doi\">10.1038/ncomms13312</pub-id>.<pub-id pub-id-type=\"pmid\">27811928</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref63\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit63\"><name><surname>Soares</surname><given-names>P.</given-names></name>; <name><surname>Gadd</surname><given-names>M. S.</given-names></name>; <name><surname>Frost</surname><given-names>J.</given-names></name>; <name><surname>Galdeano</surname><given-names>C.</given-names></name>; <name><surname>Ellis</surname><given-names>L.</given-names></name>; <name><surname>Epemolu</surname><given-names>O.</given-names></name>; <name><surname>Rocha</surname><given-names>S.</given-names></name>; <name><surname>Read</surname><given-names>K. D.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Group-Based\\nOptimization of Potent and Cell-Active Inhibitors of the von Hippel&#x2013;Lindau\\n(VHL) E3 Ubiquitin Ligase: Structure&#x2013;Activity Relationships\\nLeading to the Chemical Probe (2<italic>S</italic>,4<italic>R</italic>)-1-((<italic>S</italic>)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-<italic>N</italic>-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\\n(VH298)</article-title>. <source>J. Med. Chem.</source>\\n<year>2018</year>, <volume>61</volume> (<issue>2</issue>), <fpage>599</fpage>&#x2013;<lpage>618</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.jmedchem.7b00675</pub-id>.<pub-id pub-id-type=\"pmid\">28853884</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref64\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit64\"><name><surname>Fischer</surname><given-names>E. S.</given-names></name>; <name><surname>B&#xF6;hm</surname><given-names>K.</given-names></name>; <name><surname>Lydeard</surname><given-names>J. R.</given-names></name>; <name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Stadler</surname><given-names>M. B.</given-names></name>; <name><surname>Cavadini</surname><given-names>S.</given-names></name>; <name><surname>Nagel</surname><given-names>J.</given-names></name>; <name><surname>Serluca</surname><given-names>F.</given-names></name>; <name><surname>Acker</surname><given-names>V.</given-names></name>; <name><surname>Lingaraju</surname><given-names>G. M.</given-names></name>; <name><surname>Tichkule</surname><given-names>R. B.</given-names></name>; <name><surname>Schebesta</surname><given-names>M.</given-names></name>; <name><surname>Forrester</surname><given-names>W. C.</given-names></name>; <name><surname>Schirle</surname><given-names>M.</given-names></name>; <name><surname>Hassiepen</surname><given-names>U.</given-names></name>; <name><surname>Ottl</surname><given-names>J.</given-names></name>; <name><surname>Hild</surname><given-names>M.</given-names></name>; <name><surname>Beckwith</surname><given-names>R. E.</given-names></name>; <name><surname>Harper</surname><given-names>J. W.</given-names></name>; <name><surname>Jenkins</surname><given-names>J. L.</given-names></name>; <name><surname>Thom&#xE4;</surname><given-names>N. H.</given-names></name>\\n<article-title>Structure\\nof the DDB1&#x2013;CRBN\\nE3 Ubiquitin Ligase in Complex with Thalidomide</article-title>. <source>Nature</source>\\n<year>2014</year>, <volume>512</volume> (<issue>7512</issue>), <fpage>49</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nature13527</pub-id>.<pub-id pub-id-type=\"pmid\">25043012</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref65\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit65\"><name><surname>Zhou</surname><given-names>B.</given-names></name>; <name><surname>Hu</surname><given-names>J.</given-names></name>; <name><surname>Xu</surname><given-names>F.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Bai</surname><given-names>L.</given-names></name>; <name><surname>Fernandez-Salas</surname><given-names>E.</given-names></name>; <name><surname>Lin</surname><given-names>M.</given-names></name>; <name><surname>Liu</surname><given-names>L.</given-names></name>; <name><surname>Yang</surname><given-names>C.-Y.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>McEachern</surname><given-names>D.</given-names></name>; <name><surname>Przybranowski</surname><given-names>S.</given-names></name>; <name><surname>Wen</surname><given-names>B.</given-names></name>; <name><surname>Sun</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>\\n<article-title>Discovery\\nof a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET)\\nProteins with Picomolar Cellular Potencies and Capable of Achieving\\nTumor Regression</article-title>. <source>J. Med. Chem.</source>\\n<year>2018</year>, <volume>61</volume> (<issue>2</issue>), <fpage>462</fpage>&#x2013;<lpage>481</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.jmedchem.6b01816</pub-id>.<pub-id pub-id-type=\"pmid\">28339196</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref66\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit66\"><name><surname>Ishoey</surname><given-names>M.</given-names></name>; <name><surname>Chorn</surname><given-names>S.</given-names></name>; <name><surname>Singh</surname><given-names>N.</given-names></name>; <name><surname>Jaeger</surname><given-names>M. G.</given-names></name>; <name><surname>Brand</surname><given-names>M.</given-names></name>; <name><surname>Paulk</surname><given-names>J.</given-names></name>; <name><surname>Bauer</surname><given-names>S.</given-names></name>; <name><surname>Erb</surname><given-names>M. A.</given-names></name>; <name><surname>Parapatics</surname><given-names>K.</given-names></name>; <name><surname>M&#xFC;ller</surname><given-names>A. C.</given-names></name>; <name><surname>Bennett</surname><given-names>K. L.</given-names></name>; <name><surname>Ecker</surname><given-names>G. F.</given-names></name>; <name><surname>Bradner</surname><given-names>J. E.</given-names></name>; <name><surname>Winter</surname><given-names>G. E.</given-names></name>\\n<article-title>Translation\\nTermination Factor GSPT1 Is a Phenotypically\\nRelevant Off-Target of Heterobifunctional Phthalimide Degraders</article-title>. <source>ACS Chem. Biol.</source>\\n<year>2018</year>, <volume>13</volume> (<issue>3</issue>), <fpage>553</fpage>&#x2013;<lpage>560</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acschembio.7b00969</pub-id>.<pub-id pub-id-type=\"pmid\">29356495</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref67\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit67\"><name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>Raina</surname><given-names>K.</given-names></name>; <name><surname>Darricarrere</surname><given-names>N.</given-names></name>; <name><surname>Hines</surname><given-names>J.</given-names></name>; <name><surname>Gustafson</surname><given-names>J. L.</given-names></name>; <name><surname>Smith</surname><given-names>I. E.</given-names></name>; <name><surname>Miah</surname><given-names>A. H.</given-names></name>; <name><surname>Harling</surname><given-names>J. D.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>\\n<article-title>HaloPROTACS:\\nUse of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion\\nProteins</article-title>. <source>ACS Chem. Biol.</source>\\n<year>2015</year>, <volume>10</volume> (<issue>8</issue>), <fpage>1831</fpage>&#x2013;<lpage>1837</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acschembio.5b00442</pub-id>.<pub-id pub-id-type=\"pmid\">26070106</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref68\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit68\"><name><surname>Van\\nMolle</surname><given-names>I.</given-names></name>; <name><surname>Thomann</surname><given-names>A.</given-names></name>; <name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>So</surname><given-names>E. C.</given-names></name>; <name><surname>Lang</surname><given-names>S.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name>\\n<article-title>Dissecting Fragment-Based\\nLead Discovery at the Von Hippel-Lindau Protein:Hypoxia Inducible\\nFactor 1&#x3B1; Protein-Protein Interface</article-title>. <source>Chem.\\nBiol.</source>\\n<year>2012</year>, <volume>19</volume> (<issue>10</issue>), <fpage>1300</fpage>&#x2013;<lpage>1312</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.chembiol.2012.08.015</pub-id>.<pub-id pub-id-type=\"pmid\">23102223</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref69\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit69\"><name><surname>Riching</surname><given-names>K. M.</given-names></name>; <name><surname>Mahan</surname><given-names>S.</given-names></name>; <name><surname>Corona</surname><given-names>C. R.</given-names></name>; <name><surname>McDougall</surname><given-names>M.</given-names></name>; <name><surname>Vasta</surname><given-names>J. D.</given-names></name>; <name><surname>Robers</surname><given-names>M. B.</given-names></name>; <name><surname>Urh</surname><given-names>M.</given-names></name>; <name><surname>Daniels</surname><given-names>D. L.</given-names></name>\\n<article-title>Quantitative\\nLive-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC\\nMode of Action</article-title>. <source>ACS Chem. Biol.</source>\\n<year>2018</year>, <volume>13</volume> (<issue>9</issue>), <fpage>2758</fpage>&#x2013;<lpage>2770</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acschembio.8b00692</pub-id>.<pub-id pub-id-type=\"pmid\">30137962</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref70\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit70\"><name><surname>Soucy</surname><given-names>T. A.</given-names></name>; <name><surname>Smith</surname><given-names>P. G.</given-names></name>; <name><surname>Milhollen</surname><given-names>M. A.</given-names></name>; <name><surname>Berger</surname><given-names>A. J.</given-names></name>; <name><surname>Gavin</surname><given-names>J. M.</given-names></name>; <name><surname>Adhikari</surname><given-names>S.</given-names></name>; <name><surname>Brownell</surname><given-names>J. E.</given-names></name>; <name><surname>Burke</surname><given-names>K. E.</given-names></name>; <name><surname>Cardin</surname><given-names>D. P.</given-names></name>; <name><surname>Critchley</surname><given-names>S.</given-names></name>; <name><surname>Cullis</surname><given-names>C. A.</given-names></name>; <name><surname>Doucette</surname><given-names>A.</given-names></name>; <name><surname>Garnsey</surname><given-names>J. J.</given-names></name>; <name><surname>Gaulin</surname><given-names>J. L.</given-names></name>; <name><surname>Gershman</surname><given-names>R. E.</given-names></name>; <name><surname>Lublinsky</surname><given-names>A. R.</given-names></name>; <name><surname>McDonald</surname><given-names>A.</given-names></name>; <name><surname>Mizutani</surname><given-names>H.</given-names></name>; <name><surname>Narayanan</surname><given-names>U.</given-names></name>; <name><surname>Olhava</surname><given-names>E. J.</given-names></name>; <name><surname>Peluso</surname><given-names>S.</given-names></name>; <name><surname>Rezaei</surname><given-names>M.</given-names></name>; <name><surname>Sintchak</surname><given-names>M. D.</given-names></name>; <name><surname>Talreja</surname><given-names>T.</given-names></name>; <name><surname>Thomas</surname><given-names>M. P.</given-names></name>; <name><surname>Traore</surname><given-names>T.</given-names></name>; <name><surname>Vyskocil</surname><given-names>S.</given-names></name>; <name><surname>Weatherhead</surname><given-names>G. S.</given-names></name>; <name><surname>Yu</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Dick</surname><given-names>L. R.</given-names></name>; <name><surname>Claiborne</surname><given-names>C. F.</given-names></name>; <name><surname>Rolfe</surname><given-names>M.</given-names></name>; <name><surname>Bolen</surname><given-names>J. B.</given-names></name>; <name><surname>Langston</surname><given-names>S. P.</given-names></name>\\n<article-title>An Inhibitor\\nof NEDD8-Activating Enzyme as a New Approach to Treat Cancer</article-title>. <source>Nature</source>\\n<year>2009</year>, <volume>458</volume> (<issue>7239</issue>), <fpage>732</fpage>&#x2013;<lpage>736</lpage>. <pub-id pub-id-type=\"doi\">10.1038/nature07884</pub-id>.<pub-id pub-id-type=\"pmid\">19360080</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref71\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit71\"><name><surname>Loenarz</surname><given-names>C.</given-names></name>; <name><surname>Mecinovi&#x107;</surname><given-names>J.</given-names></name>; <name><surname>Chowdhury</surname><given-names>R.</given-names></name>; <name><surname>McNeill</surname><given-names>L. A.</given-names></name>; <name><surname>Flashman</surname><given-names>E.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name>\\n<article-title>Evidence\\nfor a Stereoelectronic Effect in Human Oxygen\\nSensing</article-title>. <source>Angew. Chem., Int. Ed.</source>\\n<year>2009</year>, <volume>48</volume> (<issue>10</issue>), <fpage>1784</fpage>&#x2013;<lpage>1787</lpage>. <pub-id pub-id-type=\"doi\">10.1002/anie.200805427</pub-id>.</mixed-citation>\\n      </ref>\\n      <ref id=\"ref72\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit72\"><name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Sansam</surname><given-names>C. G.</given-names></name>; <name><surname>Thom</surname><given-names>C. S.</given-names></name>; <name><surname>Metzger</surname><given-names>D.</given-names></name>; <name><surname>Evans</surname><given-names>J. A.</given-names></name>; <name><surname>Nguyen</surname><given-names>P. T. L.</given-names></name>; <name><surname>Roberts</surname><given-names>C. W. M.</given-names></name>\\n<article-title>Oncogenesis Caused by Loss of the\\nSNF5 Tumor Suppressor is Dependent on Activity of BRG1, the ATPase\\nof the SWI/SNF Chromatin Remodeling Complex</article-title>. <source>Cancer Res.</source>\\n<year>2009</year>, <volume>69</volume> (<issue>20</issue>), <fpage>8094</fpage>&#x2013;<lpage>8101</lpage>. <pub-id pub-id-type=\"doi\">10.1158/0008-5472.CAN-09-0733</pub-id>.<pub-id pub-id-type=\"pmid\">19789351</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref73\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit73\"><name><surname>Zhang</surname><given-names>C.</given-names></name>; <name><surname>Han</surname><given-names>X.-R.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Jiang</surname><given-names>B.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Xiong</surname><given-names>Y.</given-names></name>; <name><surname>Jin</surname><given-names>J.</given-names></name>\\n<article-title>Proteolysis Targeting Chimeras (PROTACs)\\nof Anaplastic Lymphoma Kinase (ALK)</article-title>. <source>Eur. J.\\nMed. Chem.</source>\\n<year>2018</year>, <volume>151</volume>, <fpage>304</fpage>&#x2013;<lpage>314</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.ejmech.2018.03.071</pub-id>.<pub-id pub-id-type=\"pmid\">29627725</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref74\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit74\"><name><surname>Greiner</surname><given-names>R.</given-names></name>; <name><surname>Ziegler</surname><given-names>D. S.</given-names></name>; <name><surname>Cibu</surname><given-names>D.</given-names></name>; <name><surname>Jakowetz</surname><given-names>A. C.</given-names></name>; <name><surname>Auras</surname><given-names>F.</given-names></name>; <name><surname>Bein</surname><given-names>T.</given-names></name>; <name><surname>Knochel</surname><given-names>P.</given-names></name>\\n<article-title>Preparation of Polyfunctional Naphthyridines\\nby Cobalt-Catalyzed Cross-Couplings of Halogenated Naphthyridines\\nwith Magnesium and Zinc Organometallics</article-title>. <source>Org.\\nLett.</source>\\n<year>2017</year>, <volume>19</volume> (<issue>23</issue>), <fpage>6384</fpage>&#x2013;<lpage>6387</lpage>. <pub-id pub-id-type=\"doi\">10.1021/acs.orglett.7b03242</pub-id>.<pub-id pub-id-type=\"pmid\">29152984</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref75\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit75\"><name><surname>Lin</surname><given-names>Y. A.</given-names></name>; <name><surname>Chalker</surname><given-names>J. M.</given-names></name>; <name><surname>Davis</surname><given-names>B. G.</given-names></name>\\n<article-title>Olefin Cross-Metathesis\\non Proteins:\\nInvestigation of Allylic Chalcogen Effects and Guiding Principles\\nin Metathesis Partner Selection</article-title>. <source>J. Am. Chem.\\nSoc.</source>\\n<year>2010</year>, <volume>132</volume> (<issue>47</issue>), <fpage>16805</fpage>&#x2013;<lpage>16811</lpage>. <pub-id pub-id-type=\"doi\">10.1021/ja104994d</pub-id>.<pub-id pub-id-type=\"pmid\">21050005</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref76\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit76\"><name><surname>Zhang</surname><given-names>Q.</given-names></name>; <name><surname>Ren</surname><given-names>H.</given-names></name>; <name><surname>Baker</surname><given-names>G. L.</given-names></name>\\n<article-title>Synthesis of a Library of Propargylated and PEGylated\\n&#x3B1;-Hydroxy Acids Toward &#x201C;Clickable&#x201D; Polylactides\\nvia Hydrolysis of Cyanohydrin Derivatives</article-title>. <source>J.\\nOrg. Chem.</source>\\n<year>2014</year>, <volume>79</volume> (<issue>20</issue>), <fpage>9546</fpage>&#x2013;<lpage>9555</lpage>. <pub-id pub-id-type=\"doi\">10.1021/jo5016135</pub-id>.<pub-id pub-id-type=\"pmid\">25255205</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref77\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit77\"><name><surname>Ihara</surname><given-names>M.</given-names></name>; <name><surname>Suzuki</surname><given-names>S.</given-names></name>; <name><surname>Taniguchi</surname><given-names>N.</given-names></name>; <name><surname>Fukumoto</surname><given-names>K.</given-names></name>\\n<article-title>Deconjugation of &#x3B1;,&#x3B2;-Unsaturated\\nEsters and an Intramolecular Michael Reaction of Bis-&#x3B1;,&#x3B2;-Unsaturated\\nEsters with Trialkylsilyl Trifluoromethanesulfonate in the Presence\\nof Tertiary Amine: Synthesis of (&#xB1;)-Ricciocarpin A</article-title>. <source>J. Chem. Soc., Perkin Trans. 1</source>\\n<year>1993</year>, (<issue>19</issue>), <fpage>2251</fpage>&#x2013;<lpage>2258</lpage>. <pub-id pub-id-type=\"doi\">10.1039/P19930002251</pub-id>.</mixed-citation>\\n      </ref>\\n      <ref id=\"ref78\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit78\"><name><surname>Kabsch</surname><given-names>W.</given-names></name>\\n<article-title>XDS</article-title>. <source>Acta Crystallogr.,\\nSect. D: Biol. Crystallogr.</source>\\n<year>2010</year>, <volume>66</volume> (<issue>2</issue>), <fpage>125</fpage>&#x2013;<lpage>132</lpage>. <pub-id pub-id-type=\"doi\">10.1107/S0907444909047337</pub-id>.<pub-id pub-id-type=\"pmid\">20124692</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref79\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit79\"><name><surname>Evans</surname><given-names>P.</given-names></name>\\n<article-title>Scaling and\\nAssessment of Data Quality</article-title>. <source>Acta Crystallogr.,\\nSect. D: Biol. Crystallogr.</source>\\n<year>2006</year>, <volume>62</volume> (<issue>1</issue>), <fpage>72</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type=\"doi\">10.1107/S0907444905036693</pub-id>.<pub-id pub-id-type=\"pmid\">16369096</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref80\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit80\"><name><surname>Winn</surname><given-names>M. D.</given-names></name>; <name><surname>Ballard</surname><given-names>C. C.</given-names></name>; <name><surname>Cowtan</surname><given-names>K. D.</given-names></name>; <name><surname>Dodson</surname><given-names>E. J.</given-names></name>; <name><surname>Emsley</surname><given-names>P.</given-names></name>; <name><surname>Evans</surname><given-names>P. R.</given-names></name>; <name><surname>Keegan</surname><given-names>R. M.</given-names></name>; <name><surname>Krissinel</surname><given-names>E. B.</given-names></name>; <name><surname>Leslie</surname><given-names>A. G. W.</given-names></name>; <name><surname>McCoy</surname><given-names>A.</given-names></name>; <name><surname>McNicholas</surname><given-names>S. J.</given-names></name>; <name><surname>Murshudov</surname><given-names>G. N.</given-names></name>; <name><surname>Pannu</surname><given-names>N. S.</given-names></name>; <name><surname>Potterton</surname><given-names>E. A.</given-names></name>; <name><surname>Powell</surname><given-names>H. R.</given-names></name>; <name><surname>Read</surname><given-names>R. J.</given-names></name>; <name><surname>Vagin</surname><given-names>A.</given-names></name>; <name><surname>Wilson</surname><given-names>K. S.</given-names></name>\\n<article-title>Overview\\nof the CCP4 Suite and Current Developments</article-title>. <source>Acta Crystallogr., Sect. D: Biol. Crystallogr.</source>\\n<year>2011</year>, <volume>67</volume> (<issue>4</issue>), <fpage>235</fpage>&#x2013;<lpage>242</lpage>. <pub-id pub-id-type=\"doi\">10.1107/S0907444910045749</pub-id>.<pub-id pub-id-type=\"pmid\">21460441</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref81\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit81\"><name><surname>Vagin</surname><given-names>A.</given-names></name>; <name><surname>Teplyakov</surname><given-names>A.</given-names></name>\\n<article-title>MOLREP: An\\nAutomated Program for Molecular Replacement</article-title>. <source>J. Appl. Crystallogr.</source>\\n<year>1997</year>, <volume>30</volume> (<issue>6</issue>), <fpage>1022</fpage>&#x2013;<lpage>1025</lpage>. <pub-id pub-id-type=\"doi\">10.1107/S0021889897006766</pub-id>.</mixed-citation>\\n      </ref>\\n      <ref id=\"ref82\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit82\"><name><surname>Emsley</surname><given-names>P.</given-names></name>; <name><surname>Cowtan</surname><given-names>K.</given-names></name>\\n<article-title>Coot: Model-Building\\nTools for Molecular Graphics</article-title>. <source>Acta Crystallogr.,\\nSect. D: Biol. Crystallogr.</source>\\n<year>2004</year>, <volume>60</volume> (<issue>12</issue>), <fpage>2126</fpage>&#x2013;<lpage>2132</lpage>. <pub-id pub-id-type=\"doi\">10.1107/S0907444904019158</pub-id>.<pub-id pub-id-type=\"pmid\">15572765</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref83\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit83\"><name><surname>Murshudov</surname><given-names>G. N.</given-names></name>; <name><surname>Vagin</surname><given-names>A. A.</given-names></name>; <name><surname>Dodson</surname><given-names>E. J.</given-names></name>\\n<article-title>Refinement\\nof Macromolecular Structures\\nby the Maximum-Likelihood Method</article-title>. <source>Acta Crystallogr.,\\nSect. D: Biol. Crystallogr.</source>\\n<year>1997</year>, <volume>53</volume> (<issue>3</issue>), <fpage>240</fpage>&#x2013;<lpage>255</lpage>. <pub-id pub-id-type=\"doi\">10.1107/S0907444996012255</pub-id>.<pub-id pub-id-type=\"pmid\">15299926</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref84\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit84\"><name><surname>Sch&#xFC;ttelkopf</surname><given-names>A.\\nW.</given-names></name>; <name><surname>van Aalten</surname><given-names>D. M. F.</given-names></name>\\n<article-title>PRODRG:\\nA Tool for High-Throughput Crystallography\\nof Protein&#x2013;Ligand Complexes</article-title>. <source>Acta Crystallogr.,\\nSect. D: Biol. Crystallogr.</source>\\n<year>2004</year>, <volume>60</volume> (<issue>8</issue>), <fpage>1355</fpage>&#x2013;<lpage>1363</lpage>. <pub-id pub-id-type=\"doi\">10.1107/S0907444904011679</pub-id>.<pub-id pub-id-type=\"pmid\">15272157</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref85\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit85\"><name><surname>Chen</surname><given-names>V. B.</given-names></name>; <name><surname>Arendall</surname><given-names>W. B.</given-names></name>; <name><surname>Headd</surname><given-names>J. J.</given-names></name>; <name><surname>Keedy</surname><given-names>D. A.</given-names></name>; <name><surname>Immormino</surname><given-names>R. M.</given-names></name>; <name><surname>Kapral</surname><given-names>G. J.</given-names></name>; <name><surname>Murray</surname><given-names>L. W.</given-names></name>; <name><surname>Richardson</surname><given-names>J. S.</given-names></name>; <name><surname>Richardson</surname><given-names>D. C.</given-names></name>\\n<article-title>MolProbity: All-Atom Structure Validation\\nfor Macromolecular\\nCrystallography</article-title>. <source>Acta Crystallogr., Sect. D:\\nBiol. Crystallogr.</source>\\n<year>2010</year>, <volume>66</volume> (<issue>1</issue>), <fpage>12</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type=\"doi\">10.1107/S0907444909042073</pub-id>.<pub-id pub-id-type=\"pmid\">20057044</pub-id></mixed-citation>\\n      </ref>\\n      <ref id=\"ref86\">\\n        <mixed-citation publication-type=\"journal\" id=\"cit86\"><name><surname>Kim</surname><given-names>K. H.</given-names></name>; <name><surname>Roberts</surname><given-names>C. W.</given-names></name>\\n<article-title>Mechanisms by Which SMARCB1 Loss\\nDrives Rhabdoid Tumor\\nGrowth</article-title>. <source>Cancer Genet.</source>\\n<year>2014</year>, <volume>207</volume> (<issue>9</issue>), <fpage>365</fpage>&#x2013;<lpage>372</lpage>. <pub-id pub-id-type=\"doi\">10.1016/j.cancergen.2014.04.004</pub-id>.<pub-id pub-id-type=\"pmid\">24853101</pub-id></mixed-citation>\\n      </ref>\\n    </ref-list>\\n  </back>\\n</article>\\n</pmc-articleset>'"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from Bio import Entrez\n",
    "\n",
    "def fetch_article(pmc_id):\n",
    "    Entrez.email = \"your.email@example.com\"  # Provide your email here\n",
    "    handle = Entrez.efetch(db=\"pmc\", id=pmc_id, retmode=\"xml\")\n",
    "    article_xml = handle.read()  # Read raw XML content\n",
    "    handle.close()\n",
    "    return article_xml\n",
    "\n",
    "# Example usage\n",
    "pmc_id = f\"PMC{pmc_ids[0]}\"  # Replace with an actual PMC ID\n",
    "article_xml = fetch_article(pmc_id)\n",
    "article_xml"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Parse article XML data into a Python dictionary:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "number of sections: 4\n",
      "section title: Introduction\n",
      "--------------------------------------------------------------------------------\n",
      "section text: Targeted\n",
      "protein degradation is an emerging strategy to use small\n",
      "molecules to knock down a protein by hijacking the ubiquitin–proteasome\n",
      "system.1,2 PROTACs (proteolysis targeting chimeras)\n",
      "are bifunctional degrader molecules composed of a ligand for the target\n",
      "protein and a ligand for E3 ligase recruitment, connected by a linker.3,4 Upon formation of a ternary complex target:degrader:E3,5−7 the protein of interest is ubiquitinated and degraded by the proteasome.\n",
      "Compared to target blockade, pos\n",
      "--------------------------------------------------------------------------------\n",
      "number of subsections: 0\n",
      "====================================================================================================\n",
      "\n",
      "section title: Results and DiscussionFirst Generation of BRD7 and BRD9 DegradersSynthesis\n",
      "of the BRD7/9 Ligand Synthesis of the\n",
      "First Generation of DegradersThermodynamic Parameters of Formation\n",
      "of Binary and Ternary Complexes between VCB, BRD9 Bromodomain, and\n",
      "Compound  Measured by Isothermal Titration Calorimetry\n",
      "(ITC)Second Generation of BRD7 and BRD9 DegradersSAR of Second Generation of PROTACsSynthesis of Compound Synthesis of Compounds –Third Generation\n",
      "of BRD7 and BRD9 DegradersSAR of Third Generation\n",
      "of PROTACsGeneral Synthetic Routes for Third-Generation\n",
      "CompoundsBiophysical Comparison between BRD9\n",
      "Degraders from Three Generations\n",
      "--------------------------------------------------------------------------------\n",
      "section text: We began\n",
      "our investigation by designing a small set of PROTACs aimed to induce\n",
      "BRD7/9 degradation by recruiting three different E3 ubiquitin ligases:\n",
      "VHL, CRBN, and DCAF15.59,60 We aimed to leverage available\n",
      "E3 ligase ligands and to maximize the opportunity for complementary\n",
      "surfaces between the bromodomain and the ligase within the ternary\n",
      "complex. As BRD7/9 bromodomain ligands, we selected compounds 1a,b (Figure 1),56 on the basis of their\n",
      "high binding affinity56 and of their superiority\n",
      "as B\n",
      "--------------------------------------------------------------------------------\n",
      "number of subsections: 3\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: First Generation of BRD7 and BRD9 Degraders\n",
      "\tsubsection text: We began\n",
      "our investigation by designing a small set of PROTACs aimed to induce\n",
      "BRD7/9 degradation by recruiting three different E3 ubiquitin ligases:\n",
      "VHL, CRBN, and DCAF15.59,60 We aimed to leverage available\n",
      "E3 ligase ligands and to maximize the opportunity for complementary\n",
      "surfaces between the bromodomain and the ligase within the ternary\n",
      "complex. As BRD7/9 bromodomain ligands, we selected compounds 1a,b (Figure 1),56 on the basis of their\n",
      "high binding affinity56 and of their superiority\n",
      "as B\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Second Generation of BRD7 and BRD9 Degraders\n",
      "\tsubsection text: To improve\n",
      "ternary complex formation and degradation activity of PROTACs 5 and 6, we explored the impact of varying their\n",
      "derivatization point, linker length, and composition (compounds 22–31, Table 2). First, to expand the conjugation pattern\n",
      "between VHL1 and BrdL1 (Figure 1), the number of PEG units was modified (3 units for 24; 5 units for 22), a more lipophilic 11-atoms\n",
      "chain was inserted (compound 23), and a different attachment\n",
      "to BrdL1 moiety via amide conjugation was explored (compound 2\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Third Generation\n",
      "of BRD7 and BRD9 Degraders\n",
      "\tsubsection text: The pronounced\n",
      "degradation of BRD9 observed with 26 motivated us to\n",
      "design a third generation of PROTACs with the goal to further optimize\n",
      "our degrader. On the basis of the SAR previously acquired, the design\n",
      "strategy was to keep VHL4 moiety fixed and to focus on systematically\n",
      "varying the linker length and composition, as well as the substitution\n",
      "and conjugation chemistry at the BRD7/9 warhead. The focus on the\n",
      "linker concentrated on exploring varying ratios between hydrophilic\n",
      "and lipophilic p\n",
      "====================================================================================================\n",
      "\n",
      "section title: Conclusion\n",
      "--------------------------------------------------------------------------------\n",
      "section text: We describe the development of a new series\n",
      "of PROTACs against\n",
      "BRD9, a target thought as not degradable through recruitment of the\n",
      "E3 ligase VHL. In spite of starting from unimpressive degradation\n",
      "profiles of initial compounds, VHL-based degraders could be optimized\n",
      "by systematically varying the conjugation patterns and monitoring\n",
      "cellular degradation activities and formation of ternary complexes.\n",
      "Throughout the campaign, we revealed important structure–activity\n",
      "relationships that proved invalua\n",
      "--------------------------------------------------------------------------------\n",
      "number of subsections: 0\n",
      "====================================================================================================\n",
      "\n",
      "section title: Experimental SectionChemistry. SynthesisGeneral Method AGeneral Method BGeneral Method CGeneral\n",
      "Method DGeneral Method EGeneral Method FGeneral method G4-(3,5-Dimethoxy-4-(piperazin-1-ylmethyl)phenyl)-2-methyl-2,7-naphthyridin-1(2)-one ()(2,4)-1-((S)-2-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\n",
      "()(2,4)-1-(()-2-(-Butyl)-17-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\n",
      "()2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)--(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)acetamide\n",
      "()14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)--(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-3,6,9,12-tetraoxatetradecanamide\n",
      "()-(4-(-(3-Chloro-1-indol-7-yl)sulfamoyl)benzyl)-2-(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetamide\n",
      "()-(4-(-(3-Chloro-1-indol-7-yl)sulfamoyl)benzyl)-14-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecanamide\n",
      "()-Butyl 4-(4-Bromo-2,6-dimethoxybenzyl)piperazine-1-carboxylate\n",
      "()4-Iodo-2-methyl-2,7-naphthyridin-1(2)-one\n",
      "()-Butyl\n",
      "2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetate\n",
      "()-Butyl\n",
      "14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecanoate\n",
      "()2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetic\n",
      "Acid ()17-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecanoic\n",
      "Acid ()(2,4)-1-(()-2-(2-(2-((5-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)-1-(()-2-(1-Cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)--(2-(2-(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)-1-((S)-2-Acetamido-3,3-dimethylbutanoyl)--(2-(2-(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-((14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)-1-(()-2-(1-Cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)--(2-((14-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)--(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-3,6,9,12-tetraoxatetradecanamide\n",
      "()2-(2-(Hex-5-en-1-yloxy)ethoxy)ethan-1-ol\n",
      "()2-(2-(Hex-5-en-1-yloxy)ethoxy)acetic\n",
      "Acid ()(2,4)-1-(()-2-(2-(2-(Hex-5-en-1-yloxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\n",
      "()2-(2-(Allyloxy)ethoxy)ethan-1-ol\n",
      "()3,6,9,12-Tetraoxapentadec-14-en-1-ol\n",
      "()(2,4)--(2-(2-(2-(Allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-(2-(2-(Allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)-1-(()-2-Acetamido-3,3-dimethylbutanoyl)--(2-(2-(2-(allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-acetamido-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-(2-(2-(4-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-((5-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "(, VZ185)(2,4)--(2-((5-(4-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-(2-(2-((1-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-2-oxoethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-(2-(2-((1-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-2-oxoethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-((5-((1-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-5-oxopentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-((5-((1-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-5-oxopentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-(2-(2,2-Diethoxyethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)--(2-((5,5-Dimethoxypentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()(2,4)-1-(()-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)-2-(2-(2-oxoethoxy)ethoxy)benzyl)pyrrolidine-2-carboxamide\n",
      "()(2,4)-1-(()-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)-2-((5-oxopentyl)oxy)benzyl)pyrrolidine-2-carboxamide\n",
      "()2-(2-(2-(((2,4)-1-(()-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethoxy)acetic\n",
      "Acid ()5-(2-(((2,4)-1-(()-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)pentanoic\n",
      "Acid ()Biology. Cell CultureTesting Compounds in CellsSmall Interfering RNAMechanistic EvaluationImmunoblottingProliferation\n",
      "AssaysMS ProteomicsSample\n",
      "PreparationnLC–MS/MS AnalysisPeptide\n",
      "and Protein Identification and QuantificationProtein Expression and PurificationCrystallization and Structure Solution of BRD9 Bromodomain Binary\n",
      "ComplexAlphaLISA Proximity AssayFluorescence PolarizationIsothermal\n",
      "Titration CalorimetryLive Cell Kinetic Analysis of BRD7 and BRD9\n",
      "DegradationNanoBRET Ubiquitination of BRD7 and BRD9\n",
      "--------------------------------------------------------------------------------\n",
      "section text: Chemicals,\n",
      "commercially available,\n",
      "were purchased from Apollo Scientific, Sigma-Aldrich, Fluorochem,\n",
      "or Manchester Organics and used without any further purification.\n",
      "All reactions were carried out using anhydrous solvents. Analytical\n",
      "thin-layer chromatography (TLC) was performed on precoated TLC plates\n",
      "(layer 0.20 mm silica gel 60 with fluorescent indicator (UV 254: Merck)).\n",
      "The TLC plates were air-dried and revealed under UV lamp (254/365\n",
      "nm). Flash column chromatography was performed using pr\n",
      "--------------------------------------------------------------------------------\n",
      "number of subsections: 69\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Chemistry. Synthesis\n",
      "\tsubsection text: Chemicals,\n",
      "commercially available,\n",
      "were purchased from Apollo Scientific, Sigma-Aldrich, Fluorochem,\n",
      "or Manchester Organics and used without any further purification.\n",
      "All reactions were carried out using anhydrous solvents. Analytical\n",
      "thin-layer chromatography (TLC) was performed on precoated TLC plates\n",
      "(layer 0.20 mm silica gel 60 with fluorescent indicator (UV 254: Merck)).\n",
      "The TLC plates were air-dried and revealed under UV lamp (254/365\n",
      "nm). Flash column chromatography was performed using pr\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: General Method A\n",
      "\tsubsection text: To a mixture of aryl bromide (1 equiv)\n",
      "in dioxane (0.2 M), Pd(dppf)Cl2 (0.1 equiv), bis(pinacolato)diboron\n",
      "(1.2 equiv), and KOAc (3 equiv) were added. The mixture was heated\n",
      "under microwave conditions at 140 °C for 40 min. Then aryl iodide 14 (1 equiv) and a degassed solution of K2CO3 2 M (2 equiv) were added. The reaction mixture was heated\n",
      "in microwave at 120 °C for 30 min. The resulting mixture was\n",
      "filtered through Celite and washed several times with DCM. The organic\n",
      "phase was washed with H2\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: General Method B\n",
      "\tsubsection text: To a solution of acid (1 equiv) in\n",
      "DMF (0.2 M), HATU (1 equiv), HOAt (1 equiv), amine (1 equiv), and\n",
      "DIPEA (5 equiv) were added. The reaction mixture was stirred at rt\n",
      "for 2 h. The solvent was evaporated under reduced pressure to give\n",
      "the corresponding crude, which was chromatographically purified to\n",
      "yield the final compound.\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: General Method C\n",
      "\tsubsection text: A mixture of aldehyde (1 equiv), amine\n",
      "(HCl salt, 1.1 equiv), and TEA (1.1 equiv) in DMF (0.2 M) was stirred\n",
      "at rt. After 15 min, NaBH(OAc)3 (1.5 equiv) was added,\n",
      "and the reaction was stirred overnight at rt under nitrogen. The solvent\n",
      "was evaporated under reduced pressure to give the corresponding crude,\n",
      "which was purified accordingly to yield the desired compound.\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: General\n",
      "Method D\n",
      "\tsubsection text: To a stirred solution of oxalyl chloride\n",
      "(1.5 equiv) in DCM (0.3 M), DMSO (2 equiv) was added dropwise at −78\n",
      "°C. After 10 min at −78 °C, the alcohol starting\n",
      "material (1 equiv) in DCM (0.3 M) was added. The reaction was stirred\n",
      "at −78 °C for 1 h, TEA (10 equiv) was added dropwise,\n",
      "and temperature was increased to rt. After 1 h, the reaction mixture\n",
      "was diluted with DCM, washed with a saturated solution of ammonium\n",
      "chloride. The organic phases were combined, washed with brine, dried\n",
      "over MgSO4, \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: General Method E\n",
      "\tsubsection text: To a solution of\n",
      "the alcohol starting\n",
      "material (1 equiv) and trimethylamine (1.5 equiv) in DCM (0.2 M),\n",
      "methansulfonyl chloride (1.2 equiv) was added at 0 °C. The reaction\n",
      "mixture was stirred at 0 °C for 3 h. The reaction was quenched\n",
      "with a saturated solution of ammonium chloride and extracted with\n",
      "DCM. The organic phases were combined, dried over MgSO4, filtered, and evaporated to dryness. The crude (1.5 equiv) was\n",
      "suspended in DMF (0.2 M), and 2b–d inhibitor derivative (1 equiv) and K2CO3 (3\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: General Method F\n",
      "\tsubsection text: A 1 M aqueous solution\n",
      "of HCl (1 mL)\n",
      "was added to the VHL-acetal linker (0.06 mmol) in THF (1 mL). The\n",
      "reaction mixture was heated at 50 °C for 2 h. The solvent was\n",
      "evaporated under reduced pressure, and the product was extracted with\n",
      "DCM/MeOH (9:1). The organic phases were combined, dried over MgSO4, filtered, and evaporated to dryness. The crude was used\n",
      "directly without any further purification.\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: General method G\n",
      "\tsubsection text: Aldehyde (1 equiv) was taken up in t-BuOH and water\n",
      "(4:1) (0.3 M). Then 2-methyl-2-butene 2\n",
      "M in THF (4 equiv) was added, followed by sodium phosphate dibasic\n",
      "(1 equiv) and sodium chlorite (2 equiv). The reaction mixture was\n",
      "stirred at rt for 4 h. A 1 M aqueous solution of HCl was added. The\n",
      "product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "The crude was used directly without any further purification.\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 4-(3,5-Dimethoxy-4-(piperazin-1-ylmethyl)phenyl)-2-methyl-2,7-naphthyridin-1(2)-one ()\n",
      "\tsubsection text: Following general method\n",
      "A, compound 1c was obtained from compound 12 and 14 as brown powder. Yield: 50 mg, 55%. 1H NMR (400 MHz, MeOD) δ: 9.67 (s, 1H), 8.76 (d, J = 6.9 Hz, 1H), 8.27 (s, 1H), 8.21 (d, J = 6.9 Hz,\n",
      "1H), 6.95 (s, 2H), 4.62 (s, 2H), 4.03 (s, 6H), 3.81 (s, 3H), 3.73\n",
      "(s, 8H). 13C NMR (101 MHz, CDCl3) δ: 161.5,\n",
      "161.4, 148.6, 146.3, 145.5, 141.9, 139.7, 122.9, 117.9, 107.1, 105.8,\n",
      "57.2, 50.8, 49.7, 41.9, 37.9. MS m/z calcd for C22H26N4O3 394.2, found 395.3 [M + H+].\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-((S)-2-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method B, compound 5 was obtained from 19 and 2a (synthesized\n",
      "accordingly to literature61). The crude\n",
      "was purified by HPLC using a gradient of 5% to 95% v/v acetonitrile\n",
      "in 0.1% aqueous solution of formic acid to obtain 5 as\n",
      "white powder. Yield: 6.3 mg, 44%. 1H NMR (400 MHz, MeOD)\n",
      "δ: 9.44 (s, 1H), 8.80 (s, 1H), 8.59 (d, J =\n",
      "5.5 Hz, 1H), 7.66 (s, 1H), 7.54 (d, J = 5.9 Hz, 1H),\n",
      "7.37 (q, J = 7.8 Hz, 4H), 6.73 (s, 2H), 4.66 (s,\n",
      "1H), 4.52–4.26 (m, 4H), 4.05–3.95 (m, 4H), 3.86–3.72\n",
      "(\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-(()-2-(-Butyl)-17-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method B, compound 6 was obtained from 20 and 2a (synthesized\n",
      "accordingly to literature61). The crude\n",
      "was purified by HPLC using a gradient of 5% to 95% v/v acetonitrile\n",
      "in 0.1% aqueous solution of formic acid to obtain 6 as\n",
      "white powder. Yield: 4.9 mg, 30%. 1H NMR (400 MHz, MeOD)\n",
      "δ: 9.44 (s, 1H), 8.81 (s, 1H), 8.60 (d, J =\n",
      "5.6 Hz, 1H), 7.67 (s, 1H), 7.54 (d, J = 5.6 Hz, 1H),\n",
      "7.37 (q, J = 9.0 Hz, 4H), 6.73 (s, 2H), 4.63 (s,\n",
      "1H), 4.53–4.26 (m, 4H), 4.02–3.94 (m, 4H), 3.84–3.72\n",
      "(\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)--(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)acetamide\n",
      "()\n",
      "\tsubsection text: Following general method B, compound 7 was obtained from compound 19 and 3a (synthesized accordingly to literature73). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid to obtain compound 7 as yellow powder. Yield: 5.6 mg, 33%. 1H NMR\n",
      "(400 MHz, MeOD) δ: 9.54 (d, J = 0.8 Hz, 1H),\n",
      "8.70 (d, J = 6.0 Hz, 1H), 8.11 (s, 1NH), 7.84 (s,\n",
      "1H), 7.73 (dd, J = 0.6, 6.0 Hz, 1H), 7.55–7.49\n",
      "(m, 1H), 7.10–7.03 (m, 2H), 6.87 (s, 2H), 5.08 (dd, J =\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)--(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-3,6,9,12-tetraoxatetradecanamide\n",
      "()\n",
      "\tsubsection text: A mixture of 45 (1 equiv),\n",
      "osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate\n",
      "(4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was\n",
      "stirred at rt for 48 h. Then H2O was added to the reaction\n",
      "and the product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "Then, following general method A, from the aldehyde derivative and 1c compound 31 was obtained after purification\n",
      "by HPLC using a gradient of 5% to 95% v/v acetonitrile in 0\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: -(4-(-(3-Chloro-1-indol-7-yl)sulfamoyl)benzyl)-2-(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetamide\n",
      "()\n",
      "\tsubsection text: Following general method B, compound 9 was obtained from compound 19 and 4a (synthesis detailed in the Supporting Information). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid to obtain compound 9 as white powder. Yield: 10.8 mg, 34%. 1H NMR\n",
      "(400 MHz, MeOD) δ: 9.54 (s, 1H), 8.69 (d, J = 5.8 Hz, 1H), 8.27 (s, 1NH), 7.75 (s, 1H), 7.68–7.62 (m,\n",
      "3H), 7.39 (d, J = 8.3 Hz, 2H), 7.33 (dd, J = 0.9, 8.1 Hz, 1H), 7.26 (s, 1H), 6.91 (t, \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: -(4-(-(3-Chloro-1-indol-7-yl)sulfamoyl)benzyl)-14-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecanamide\n",
      "()\n",
      "\tsubsection text: Following general method B, compound 10 was obtained from compound 20 and 4a (synthesis detailed in the Supporting Information). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid to obtain compound 10 as white powder. Yield: 11.1 mg, 37%. 1H NMR\n",
      "(400 MHz, MeOD) δ: 9.54 (d, J = 0.6 Hz, 1H),\n",
      "8.69 (d, J = 5.7 Hz, 1H), 8.30 (s, 1NH), 7.75 (s,\n",
      "1H), 7.68–7.62 (m, 3H), 7.41 (d, J = 8.2 Hz,\n",
      "2H), 7.34 (dd, J = 0.8, 8.1 Hz, 1H), 7.27 (s, \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: -Butyl 4-(4-Bromo-2,6-dimethoxybenzyl)piperazine-1-carboxylate\n",
      "()\n",
      "\tsubsection text: Following general method C, compound 12 was obtained from 4-bromo-2,6-dimethoxybenzaldehyde\n",
      "(11) and boc-piperazine (both commercially available).\n",
      "The reaction was quenched with saturated solution of NaHCO3, extracted with DCM, washed with water and brine. The organic phases\n",
      "were combined, dried over MgSO4, filtered, and evaporated\n",
      "to dryness to give the desired compound without any further purification\n",
      "as sticky oil. Yield: 495 mg, 97%. 1H NMR (500 MHz, CDCl3) δ: 6.69 (s, 2H), 3.78 (s, 6H), 3.6\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 4-Iodo-2-methyl-2,7-naphthyridin-1(2)-one\n",
      "()\n",
      "\tsubsection text: A mixture of 4-iodo-2,7-naphthyridin-1(2H)-one 13 (synthesized accordingly to literature74) (1 equiv) and NaH (2 equiv) was stirred 30\n",
      "min at 0 °C in DMF (0.2 M). Then CH3I (1.6 equiv)\n",
      "was added and the reaction mixture was stirred at 0 °C for 5\n",
      "h. Water was added, and the precipitate formed was filtered and dried\n",
      "in vacuum. Yield: 300 mg, 95%. 1H NMR (400 MHz, DMSO) δ:\n",
      "9.27 (s, 1H), 8.82 (d, J = 5.6 Hz, 1H), 8.26 (s,\n",
      "1H), 7.47 (d, J = 5.5 Hz, 1H), 3.52 (s,3H). 13C NMR (101 MHz, DMSO) δ: 160.3, \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: -Butyl\n",
      "2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetate\n",
      "()\n",
      "\tsubsection text: Following general method D, compound 17 was obtained from tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)acetate 15 and 1c after purification by HPLC using a\n",
      "gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of\n",
      "ammonia as white powder. Yield: 8.8 mg, 32%. 1H NMR (500\n",
      "MHz, CDCl3) δ: 9.69 (d, J = 0.8\n",
      "Hz, 1H), 8.70 (d, J = 5.7 Hz, 1H), 7.43 (dd, J = 0.8, 5.6 Hz, 1H), 7.26 (s, 1H), 6.52 (s, 2H), 4.00 (s,\n",
      "2H), 3.81 (s, 6H), 3.70–3.60 (m, 11H), 2.65–2.56 (m,\n",
      "10H), 1.46 (s, 9H). 13C NMR (125 MHz\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: -Butyl\n",
      "14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecanoate\n",
      "()\n",
      "\tsubsection text: Following general method D, compound 18 was obtained from tert-butyl 14-hydroxy-3,6,9,12-tetraoxatetradecanoate 16 and 1c after purification by HPLC using a\n",
      "gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of\n",
      "ammonia as white powder. Yield: 10.7 mg, 34%. 1H NMR (500\n",
      "MHz, CDCl3) δ: 9.69 (d, J = 0.8\n",
      "Hz, 1H), 8.70 (d, J = 5.6 Hz, 1H), 7.43 (d, J = 5.6 Hz, 1H), 7.26 (s, 1H), 6.52 (s, 2H), 4.00 (s, 2H),\n",
      "3.81 (s, 6H), 3.73–3.57 (m, 19H), 2.67–2.55 (m, 10H),\n",
      "1.46 (s, 9H). 13C NMR (125 MH\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetic\n",
      "Acid ()\n",
      "\tsubsection text: A mixture of compound 17 (0.015 mmol), TFA (0.5 mL), and DCM (0.5 mL) was stirred at rt for\n",
      "3 h. Then the solvent was evaporated; the crude was dried under high\n",
      "pressure overnight and used directly in the next step without any\n",
      "further purification. Quantitative yield. MS m/z calcd for C28H36N4O7 540.26, found 541.4 [M + H+].\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 17-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecanoic\n",
      "Acid ()\n",
      "\tsubsection text: A mixture of compound 18 (0.034 mmol), TFA (0.5 mL), and DCM (0.5 mL) was stirred at rt for\n",
      "3 h. Then the solvent was evaporated; the crude was dried under high\n",
      "pressure overnight and used directly without any further purification.\n",
      "Quantitative yield. MS m/z calcd\n",
      "for C34H48N4O10 672.34,\n",
      "found 673.36 [M + H+].\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-(()-2-(2-(2-((5-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: A mixture of 35 (1 equiv),\n",
      "osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate\n",
      "(4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was\n",
      "stirred at rt for 48 h. Then H2O was added to the reaction\n",
      "and the product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "The crude was dissolved in DCE, and a mixture of 1c (1\n",
      "equiv) and TEA (1.1 equiv) in DCE (0.02 M) was added. After 15 min,\n",
      "NaBH(OAc)3 was added and the reaction mixture was \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: A mixture of 40 (1 equiv),\n",
      "osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate\n",
      "(4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was\n",
      "stirred at rt for 48 h. Then H2O was added to the reaction\n",
      "and the product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "Then, following general method A, compound 26 was synthesized\n",
      "from the aldehyde derivative and 1c. The solvent was\n",
      "removed in vacuum to give the corresponding crude, which w\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-(()-2-(1-Cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)--(2-(2-(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: A mixture of 42 (1 equiv),\n",
      "osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate\n",
      "(4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was\n",
      "stirred at rt for 48 h. Then H2O was added to the reaction\n",
      "and the product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "Then, following general method A, from the aldehyde derivative and 1c compound 27 was obtained after purification\n",
      "by HPLC using a gradient of 5% to 95% v/v acetonitrile in 0\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-((S)-2-Acetamido-3,3-dimethylbutanoyl)--(2-(2-(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: A mixture of 44 (1 equiv),\n",
      "osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate\n",
      "(4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was\n",
      "stirred at rt for 48 h. Then H2O was added to the reaction\n",
      "and the product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "Then, following general method A, from the aldehyde derivative and 1c compound 28 was obtained after purification\n",
      "by HPLC using a gradient of 5% to 95% v/v acetonitrile in 0\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-((14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: A mixture of 41 (1 equiv),\n",
      "osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate\n",
      "(4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was\n",
      "stirred at rt for 48 h. Then H2O was added to the reaction\n",
      "and the product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "Then, following general method A, from the aldehyde derivative and 1c compound 29 was obtained after purification\n",
      "by HPLC using a gradient of 5% to 95% v/v acetonitrile in 0\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-(()-2-(1-Cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)--(2-((14-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: A mixture of 43 (1 equiv),\n",
      "osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate\n",
      "(4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was\n",
      "stirred at rt for 48 h. Then H2O was added to the reaction\n",
      "and the product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "Then, following general method A, from the aldehyde derivative and 1c compound 30 was obtained after purification\n",
      "by HPLC using a gradient of 5% to 95% v/v acetonitrile in 0\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 2-(2-(Hex-5-en-1-yloxy)ethoxy)ethan-1-ol\n",
      "()\n",
      "\tsubsection text: To a suspension of NaH (2.5 equiv) in DMF\n",
      "(1 M) and THF (1 M),\n",
      "diethylene glycol (5 equiv) was added at 0 °C under nitrogen.\n",
      "After 45 min 6-bromo-1-hexene (1 equiv) was added dropwise at 0 °C.\n",
      "Then the ice bath was removed, and the reaction mixture was stirred\n",
      "overnight at rt under nitrogen. Distillate water was added, and the\n",
      "reaction mixture was acidified with HCl 1 M up to pH 2. The product\n",
      "was extracted with CHCl3. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 2-(2-(Hex-5-en-1-yloxy)ethoxy)acetic\n",
      "Acid ()\n",
      "\tsubsection text: A mixture of 30 (1 equiv), BAIB (2.2\n",
      "equiv), TEMPO (0.22 equiv)\n",
      "in ACN/H2O (1:1) (0.5 M) was stirred overnight at rt. The\n",
      "day after the solvent was evaporated, the crude was resuspended in\n",
      "DCM and washed with H2O. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "The resulting product was purified by flash column chromatography\n",
      "using a gradient from 0% to 20% of MeOH in DCM to obtain compound 34 as an oil. Yield: 472 mg, 81%. 1H NMR (400 MHz,\n",
      "CDCl3) δ: 5.84\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-(()-2-(2-(2-(Hex-5-en-1-yloxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method B, compound 35 was obtained from compounds 34 and 2a (synthesized accordingly to literature61). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid to obtain 35 as white powder. Yield: 14.7 mg, 30%. 1H NMR\n",
      "(400 MHz, CDCl3) δ: 8.64 (s, 1H), 7.28–7.23\n",
      "(m, 4H), 5.74–5.63 (m, 1H), 4.93–4.82 (m, 2H), 4.65\n",
      "(t, J = 7.9 Hz, 1H), 4.49–4.21 (m, 4H), 4.03–3.85\n",
      "(m, 3H), 3.59–3.47 (m, 5H), 3.40–3.34 (m, 2H), 2.47–2.39\n",
      "\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 2-(2-(Allyloxy)ethoxy)ethan-1-ol\n",
      "()\n",
      "\tsubsection text: To a mixture of NaOH (1 equiv) in dioxane\n",
      "(0.3 M), diethylene glycol\n",
      "(2 equiv) and allyl bromide (1 equiv) were added dropwise. The mixture\n",
      "was heated overnight at 55 °C. Then the reaction mixture was\n",
      "dried over MgSO4, filtered, and evaporated in vacuum. The\n",
      "crude was purified by flash column chromatography using a gradient\n",
      "from 50% to 100% of ethyl acetate in heptane to obtain compound 38 as an oil. Yield: 329 mg, 54%. 1H NMR (400 MHz,\n",
      "CDCl3) δ: 5.90–5.80 (m, 1H), 5.21 (qd, J = 1.6, 17.2 Hz, 1H\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 3,6,9,12-Tetraoxapentadec-14-en-1-ol\n",
      "()\n",
      "\tsubsection text: Following the same procedure applied for\n",
      "compound 38, from tetraethylene glycol and allyl bromide\n",
      "compound 39 was obtained as oil. Yield: 3.29 g, 68%.\n",
      "Analytical data matched\n",
      "those previously reported.75\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-(2-(2-(Allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method E, compound 40 was obtained from compounds 38 and 2d (synthesis detailed in the Supporting Information). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid. Yield: 21.7\n",
      "mg, 42%. 1H NMR (500 MHz, MeOD) δ: 8.91 (s, 1H),\n",
      "8.52 (t, J = 5.9 Hz, 1H), 7.55 (dd, J = 3.4, 9.4 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.10\n",
      "(d, J = 1.6 Hz, 1H), 7.06 (dd, J = 1.6, 7.8 Hz, 1H), 5.98–5.90 (m, 1H), 5.30 (ddt, J = 1.7, 6.9, 8.6 \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method E, compound 41 was obtained from compounds 39 and 2d (synthesis detailed in the Supporting Information). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid. Yield: 26.9\n",
      "mg, 46%. 1H NMR (500 MHz, MeOD) δ: 8.91 (s, 1H),\n",
      "8.51 (t, J = 6.1 Hz, 1H), 7.56 (dd, J = 3.2, 9.6 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.10\n",
      "(d, J = 1.6 Hz, 1H), 7.06 (dd, J = 1.7, 7.7 Hz, 1H), 5.97–5.89 (m, 1H), 5.30 (ddt, J = 1.7, 6.9, 8.7 \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-(2-(2-(Allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method E, compound 42 was obtained from compounds 38 and 2c (synthesized as previously reported29). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid. Yield: 15.8\n",
      "mg, 61%. 1H NMR (500 MHz, MeOD) δ: 8.91 (s, 1H),\n",
      "8.50 (t, J = 5.9 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.10 (d, J = 1.8 Hz, 1H), 7.06 (dd, J = 1.7, 8.0 Hz, 1H), 5.98–5.90 (m, 1H), 5.30 (ddt, J = 1.8, 6.9, 8.6 Hz, 1H), 5.20–5.16 (m, 1H), 4.71–4.64\n",
      "(m, 2H\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method E, compound 43 was obtained from compounds 39 and 2c (synthesized as previously reported29). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid. Yield: 15.3\n",
      "mg, 52%. 1H NMR (500 MHz, MeOD) δ: 8.91 (s, 1H),\n",
      "8.49 (t, J = 6.1 Hz, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.10 (d, J = 1.6 Hz, 1H), 7.06 (dd, J = 1.6, 7.7 Hz, 1H), 5.97–5.89 (m, 1H), 5.30 (ddt, J = 1.6, 6.9, 8.6 Hz, 1H), 5.19–5.16 (m, 1H), 4.71–4.64\n",
      "(m, 2H\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-(()-2-Acetamido-3,3-dimethylbutanoyl)--(2-(2-(2-(allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method E, compound 44 was obtained from compounds 38 and 2b (synthesized accordingly to literature29). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid. Yield: 12.7\n",
      "mg, 53%. 1H NMR (400 MHz, MeOD) δ: 8.91 (s, 1H),\n",
      "7.52 (d, J = 7.8 Hz, 1H), 7.08 (s, 1H), 7.04 (dd, J = 1.4, 7.8 Hz, 1H), 5.99–5.88 (m, 1H), 5.30 (dq, J = 1.7, 6.9 Hz, 1H), 5.18 (dq, J = 1.3,\n",
      "4.5 Hz, 1H), 4.67–4.60 (m, 2H), 4.55–4.42 (m, 3H), 4.30–4\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-acetamido-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method E, compound 45 was obtained from compounds 39 and 2b (synthesized accordingly to literature29). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid. Yield: 13.8\n",
      "mg, 53%. 1H NMR (400 MHz, MeOD) δ: 8.92 (s, 1H),\n",
      "7.52 (d, J = 7.9 Hz, 1H), 7.08 (s, 1H), 7.04 (dd, J = 1.5, 7.8 Hz, 1H), 6.01–5.88 (m, 1H), 5.29 (dq, J = 1.7, 6.9 Hz, 1H), 5.17 (dq, J = 1.3,\n",
      "4.5 Hz, 1H), 4.67–4.60 (m, 2H), 4.56–4.39 (m, 2H), 4.29–4\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method C, from 69 (0.033 mmol) and 1c (0.033 mmol) compound 46 was obtained after purification by HPLC using a gradient\n",
      "of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\n",
      "as white powder. Yield: 5.3 mg, 16%. 1H NMR (400 MHz, MeOD)\n",
      "δ: 9.61 (s, 1H), 8.95 (s, 1H), 8.71 (d, J =\n",
      "6.2 Hz, 1H), 7.97 (s, 1H), 7.85 (d, J = 6.0 Hz, 1H),\n",
      "7.53 (d, J = 8.2 Hz, 1H), 7.10–7.07 (m, 2H),\n",
      "6.90 (s, 2H), 4.78 (s, 1H), 4.66 (t, J = 8.5 Hz,\n",
      "1H), 4.54–4.44 (m, 3H), 4.32–4.29 (m, 2H)\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-(2-(2-(4-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method C, from 69 (0.033 mmol) and 1d (synthesis detailed in\n",
      "the Supporting Information) (0.033 mmol)\n",
      "compound 47 was obtained after purification by HPLC using\n",
      "a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution\n",
      "of formic acid as white powder. Yield: 5.3 mg, 5%. 1H NMR\n",
      "(400 MHz, MeOD) δ: 9.52 (s, 1H), 8.91 (s, 1H), 8.62 (d, J = 5.7 Hz, 1H), 7.65 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 7.23–7.19 (m, 2H), 7.10 (d, J = 1.2 Hz, 1H), 7.06 (dd, J = 1.6, 7.7 Hz, 1H),\n",
      "6.98 (s,\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-((5-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "(, VZ185)\n",
      "\tsubsection text: Following general method C, from 70 (0.02 mmol) and 1c (0.02 mmol) compound 51 was obtained after purification by HPLC using a gradient\n",
      "of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\n",
      "as white powder. Yield: 4.8 mg, 24%. 1H NMR (400 MHz, MeOD)\n",
      "δ: 9.56 (d, J = 0.8 Hz, 1H), 8.92 (s, 1H),\n",
      "8.71 (d, J = 5.8 Hz, 1H), 7.78 (s, 1H), 7.65 (dd, J = 0.7, 5.8 Hz, 1H), 7.52 (d, J = 7.7\n",
      "Hz, 1H), 7.07–7.03 (m, 2H), 6.86 (s, 2H), 4.79 (s, 1H), 4.67\n",
      "(t, J = 12.4 Hz, 1H), 4.55–4.47 (m, 3H), \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-((5-(4-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method C, from 70 (0.02 mmol) and 1d (0.02 mmol) compound 52 was obtained after purification by HPLC using a gradient\n",
      "of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\n",
      "as white powder. Yield: 4 mg, 20%. 1H NMR (400 MHz, MeOD)\n",
      "δ: 9.53 (s, 1H), 8.92 (s, 1H), 8.62 (d, J =\n",
      "5.7 Hz, 1H), 7.65 (s, 1H), 7.53 (d, J = 7.4 Hz, 1H),\n",
      "7.23–7.19 (m, 2H), 7.05 (s, 2H), 7.02 (s, 1H), 4.79 (s, 1H),\n",
      "4.68 (t, J = 8.4 Hz, 1H), 4.55–4.47 (m, 3H),\n",
      "4.15 (t, J = 5.9 Hz, 2H), 3.92–3.\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-(2-(2-((1-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-2-oxoethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method B, from the 71 (0.02 mmol) and 1e (0.02 mmol) compound 55 was obtained after purification by HPLC using a gradient\n",
      "of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of ammonia\n",
      "as white powder. Yield: 2.4 mg, 12%. 1H NMR (400 MHz, MeOD)\n",
      "δ: 9.56 (d, J = 0.6 Hz, 1H), 8.93 (s, 1H),\n",
      "8.71 (d, J = 6.0 Hz, 1H), 7.80 (s, 1H), 7.63 (dd, J = 0.6, 5.8 Hz, 1H), 7.55 (d, J = 8.1\n",
      "Hz, 1H), 7.12–7.08 (m, 2H), 6.89 (s, 2H), 4.80–4.64\n",
      "(m, 3H), 4.60–4.31 (m, 11H), 4.23 (s, 2H), 4.06 (t\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-(2-(2-((1-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-2-oxoethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method B, from 71 (0.02 mmol) and 1f (synthesis detailed in\n",
      "the Supporting Information) (0.02 mmol)\n",
      "compound 56 was obtained after purification by HPLC using\n",
      "a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution\n",
      "of ammonia as white powder. Yield: 3.3 mg, 17%. 1H NMR\n",
      "(400 MHz, MeOD) δ: 9.39 (s, 1H), 8.80 (s, 1H), 8.49 (d, J = 5.7 Hz, 1H), 7.54 (s, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.10 (s, 1H), 7.04 (d, J = 5.6 Hz,\n",
      "1H), 6.99 (s, 1H), 6.98–6.94 (m, 2H), 4.66 (s, 1H), 4.6\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-((5-((1-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-5-oxopentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method B, from 72 (0.025 mmol) and 1e (0.025 mmol) compound 61 was obtained after purification by HPLC using a gradient\n",
      "of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\n",
      "as white powder. Yield: 4.5 mg, 18%. 1H NMR (400 MHz, MeOD)\n",
      "δ: 9.45 (d, J = 0.5 Hz, 1H), 8.81 (s, 1H),\n",
      "8.61 (d, J = 5.7 Hz, 1H), 7.68 (s, 1H), 7.54 (d, J = 5.5 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H),\n",
      "6.96–6.91 (m, 2H), 6.74 (s, 2H), 4.69 (s, 1H), 4.58 (t, J = 8.5 Hz, 1H), 4.54–4.32 (m, 5H), 4.24 \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-((5-((1-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-5-oxopentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method B, from 72 (0.025 mmol) and 1f (0.025 mmol) compound 62 was obtained after purification by HPLC using a gradient\n",
      "of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid\n",
      "as white powder. Yield: 5.8 mg, 23%. 1H NMR (400 MHz, MeOD)\n",
      "δ: 9.51 (d, J = 0.7 Hz, 1H), 8.91 (s, 1H),\n",
      "8.62 (d, J = 6.0 Hz, 1H), 7.64 (s, 1H), 7.52 (d, J = 7.5 Hz, 1H), 7.19 (dd, J = 0.8, 5.8\n",
      "Hz, 1H), 7.14 (s, 1H), 7.06–7.02 (m, 2H), 7.01 (s, 1H), 4.79\n",
      "(s, 1H), 4.69 (t, J = 8.5 Hz, 1H), 4.58\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-(2-(2,2-Diethoxyethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method E, compound 67 was obtained after reaction between 2-(2,2-diethoxyethoxy)ethan-1-ol\n",
      "(synthesized accordingly to literature76) and 2d as white powder. Yield: 92 mg, 87%. 1H NMR (400 MHz, CDCl3) δ: 8.66 (s, 1H), 7.31 (d, J = 7.7 Hz, 1H), 6.95 (dd, J = 1.2, 7.7\n",
      "Hz, 1H), 6.88 (s, 1H), 4.66 (t, J = 7.6 Hz, 2H),\n",
      "4.55–4.40 (m, 4H), 4.23–4.13 (m, 2H), 3.97–3.87\n",
      "(m, 3H), 3.71–3.49 (m, 7H), 2.50 (s, 3H), 2.44–2.34\n",
      "(m, 1H), 2.13–2.05 (m, 1H), 1.35–1.26 (m, 4H), 1.18\n",
      "(t, J = 7.1 Hz,\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)--(2-((5,5-Dimethoxypentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-(()-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: A mixture of 2d (0.075 mmol,\n",
      "1 equiv), 5-bromo-1,1-dimethoxypentane 66 (synthesized\n",
      "accordingly to literature77) (0.112 mmol,\n",
      "1.8 equiv), and K2CO3 (0.225 mmol, 3 equiv)\n",
      "in DMF (0.5 mL) was stirred at 70 °C overnight. The reaction\n",
      "mixture was diluted with water and extracted with DCM, dried over\n",
      "MgSO4, filtered and evaporated to dryness. The crude was\n",
      "purified by flash column chromatography using a gradient from 0% to\n",
      "20% of methanol in DCM to obtain the desired compound as white powder.\n",
      "Yield: \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-(()-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)-2-(2-(2-oxoethoxy)ethoxy)benzyl)pyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method F, compound 69 was obtained from 67 (0.066 mmol) and directly\n",
      "used in the next step without any further purification. MS m/z calcd for C30H39FN4O7S 618.15, found 619.3 [M + H+].\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: (2,4)-1-(()-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxy--(4-(4-methylthiazol-5-yl)-2-((5-oxopentyl)oxy)benzyl)pyrrolidine-2-carboxamide\n",
      "()\n",
      "\tsubsection text: Following general method F, compound 70 was obtained from 68 (0.04 mmol) and directly\n",
      "used in the next step without any further purification. MS m/z calcd for C31H41FN4O6S 616.27, found 617.3 [M + H+].\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 2-(2-(2-(((2,4)-1-(()-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethoxy)acetic\n",
      "Acid ()\n",
      "\tsubsection text: Following general method G, compound 71 was obtained from compound 69 (0.04 mmol)\n",
      "and was used in the next step without any further purification. Quantitative\n",
      "yield. MS m/z calcd for C30H39FN4O8S 634.25, found 635.3 [M\n",
      "+ H+].\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: 5-(2-(((2,4)-1-(()-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)pentanoic\n",
      "Acid ()\n",
      "\tsubsection text: Following general method G, compound 72 was obtained from compound 70 (0.05 mmol)\n",
      "and was used in the next step without any further purification. Quantitative\n",
      "yield. MS m/z calcd for C31H41FN4O7S 632.27, found 633.3 [M\n",
      "+ H+].\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Biology. Cell Culture\n",
      "\tsubsection text: Human cell\n",
      "lines HeLa and Hek293\n",
      "were purchased from ATCC and propagated in DMEM medium (Gibco), supplemented\n",
      "with 10% fetal bovine serum (FBS) (Gibco), l-glutamine (Gibco),\n",
      "100 μg mL–1 of penicillin/streptomycin. RI-1\n",
      "cells, purchased from DSMZ, were propagated in RPMI medium (Gibco),\n",
      "supplemented with 10% fetal bovine serum (FBS) (Gibco), l-glutamine, 100 μg mL–1 of penicillin/streptomycin.\n",
      "Cells were kept at 37 °C and 5% of CO2. EOL-1 and\n",
      "A-204 cell lines were purchased from ATCC and DSMZ. EO\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Testing Compounds in Cells\n",
      "\tsubsection text: HeLa and Hek293 cells were\n",
      "seeded at either 0.3 × 106 or 0.5 × 106 cells per well in 6-well plate in 2 mL of medium. At 80% confluency,\n",
      "cells were treated with compounds at the desired concentration, with\n",
      "final DMSO concentration of 0.1% v/v. Cells were incubated at 37 °C\n",
      "and 5% of CO2 for the desired time before harvesting. For\n",
      "protein extraction from adherent cells, cells were washed twice with\n",
      "DPBS (Gibco) and lysed with RIPA buffer (Sigma-Aldrich), supplemented\n",
      "with cOmplete Mini EDTA-free p\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Small Interfering RNA\n",
      "\tsubsection text: HeLa cells were seeded at 0.3\n",
      "× 106 cells per well in 6-well plates in 2 mL of medium,\n",
      "with a goal to achieve 70% of confluence on the day of transfection.\n",
      "BRD7, BRD9, and CRBN targeting siRNA (L-020297-00-0005 ON-TARGETplus\n",
      "human BRD7, L-014250-02-0005 ON-TARGETplus human BRD9, and L-021086-00-0005\n",
      "ON-TARGETplus human CRBN SMARTpool, 5 nmol, Dharmacon) were prepared\n",
      "as a 20 μM solution in RNase-free 1× siRNA buffer (Dharmacon).\n",
      "Nontargeting siRNA (On-TARGETplus control pool, nontargeting pool\n",
      "D\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Mechanistic Evaluation\n",
      "\tsubsection text: Cells were\n",
      "seeded in 6-well\n",
      "plates with 5 × 105 cells per well in 2 mL of complete\n",
      "medium to aim for 80% confluence on the day of treatment. At time\n",
      "zero, ML4924 was added at final concentration of 3 μM with 0.1%\n",
      "v/v of DMSO. DMSO was added to the remaining wells in order to match\n",
      "concentration of vehicle in all wells. After 3 h, MG132 (50 μM)\n",
      "or VH298 (100 μM) was added to the designated wells at a final\n",
      "concentration of 0.1% v/v of DMSO. Again, DMSO was added to the remaining\n",
      "wells to match ve\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Immunoblotting\n",
      "\tsubsection text: Proteins were resolved by SDS–PAGE\n",
      "on NuPage 4–12% Bis-Tris Midi Gel (Invitrogen) and transferred\n",
      "to Amersham Protran 0.45 NC nitrocellulose membrane (GE Healthcare)\n",
      "using wet transfer. The membrane was blocked with 5% w/v milk in Tris-buffered\n",
      "saline (TBS) with 0.1% w/v Tween-20. The following primary antibodies\n",
      "at the given concentration were used: anti β-actin (Cell Signaling\n",
      "Technology, 4970S, 13E5) 1:2000, anti-Brd9 (Bethyl A303-781A) 1:1000,\n",
      "anti-Brd7 (Bethyl A302-304A) 1:1000, VHL rabbit \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Proliferation\n",
      "Assays\n",
      "\tsubsection text: A-204 cells (1 × 103) were seeded\n",
      "per well of 384-well plates. After overnight incubation,\n",
      "compounds were added to the cells at logarithmic dose series using\n",
      "the HP digital dispenser D300 (Tecan), normalizing for added DMSO.\n",
      "1 day and 8 days after seeding cellular ATP content was measured using\n",
      "CellTiterGlo (Promega). Measurements after 8 days were divided by\n",
      "the measurement after 1 day (i.e., the T0 plate) to derive fold proliferation. Data were analyzed with GraphPad\n",
      "Prism software to obtain E\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: MS Proteomics\n",
      "\tsubsection text: RI-1 cells were seeded at 2 ×\n",
      "106 cells/mL in a 10 cm plate 12 h before treatment. Cells\n",
      "were treated with 0.1% DMSO as vehicle control and with 100 nM VZ185\n",
      "and 100 nM cisVZ185 as negative control. Cells were\n",
      "incubated at 37 °C and 5% CO2 for 4 h before harvesting.\n",
      "Cells were washed twice with DPBS (Gibco) and lysed with 0.5 mL of\n",
      "100 mM Tris, pH 8.0, 4% (w/v) SDS, supplemented with cOmplete Mini\n",
      "EDTA-free protease inhibitor cocktail (Roche). Lysates were sonicated\n",
      "(2 × 10 s) and centrifuged at\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Sample\n",
      "Preparation\n",
      "\tsubsection text: RI-1 cells were seeded at 2 ×\n",
      "106 cells/mL in a 10 cm plate 12 h before treatment. Cells\n",
      "were treated with 0.1% DMSO as vehicle control and with 100 nM VZ185\n",
      "and 100 nM cisVZ185 as negative control. Cells were\n",
      "incubated at 37 °C and 5% CO2 for 4 h before harvesting.\n",
      "Cells were washed twice with DPBS (Gibco) and lysed with 0.5 mL of\n",
      "100 mM Tris, pH 8.0, 4% (w/v) SDS, supplemented with cOmplete Mini\n",
      "EDTA-free protease inhibitor cocktail (Roche). Lysates were sonicated\n",
      "(2 × 10 s) and centrifuged at\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: nLC–MS/MS Analysis\n",
      "\tsubsection text: The fractions\n",
      "were analyzed\n",
      "sequentially on a Q Exactive HF hybrid quadrupole-Orbitrap mass spectrometer\n",
      "(Thermo Scientific) coupled to an UltiMate 3000 RSLCnano UHPLC system\n",
      "(Thermo Scientific) and EasySpray column (75 μm × 50 cm,\n",
      "PepMap RSLC C18 column, 2 μm, 100 Å, Thermo Scientific).\n",
      "A mix of buffer A (0.1% formic acid in H2O) and B (0.08%\n",
      "formic acid in 80% CH3CN) was used over a linear gradient\n",
      "from 5% to 35% buffer B over 125 min using a flow rate of 300 nL/min.\n",
      "Column temperature was set\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Peptide\n",
      "and Protein Identification and Quantification\n",
      "\tsubsection text: The raw MS\n",
      "data files for all 20 fractions were merged and searched\n",
      "against the Uniprot-sprot-Human-Canonical database by Maxquant software\n",
      "1.6.0.16 for protein identification and TMT reporter ion quantitation.\n",
      "The identifications were based on the following criteria: enzyme used\n",
      "trypsin/P; maximum number of missed cleavages equal to 2; precursor\n",
      "mass tolerance equal to 10 ppm; fragment mass tolerance equal\n",
      "to 20 ppm. Variable modifications: oxidation (M), acetyl (N-term),\n",
      "deamidation (NQ), Gln \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Protein Expression and Purification\n",
      "\tsubsection text: Human proteins\n",
      "VHL (UniProt accession number P40337), ElonginC (Q15369), and ElonginB\n",
      "(Q15370) and the bromodomain (residues 134–239) for BRD9 (Q9H8M2)\n",
      "were used for all protein expression. His6-tagged constructs\n",
      "were transformed into Escherichia coli BL21(DE3),\n",
      "and expression was induced by the addition of isopropyl β-d-1-thiogalactopyranoside (IPTG). E. coli cells\n",
      "were lysed using a pressure cell homogenizer (Stansted Fluid Power);\n",
      "lysates were clarified by centrifuge and loaded onto a HisTrap\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Crystallization and Structure Solution of BRD9 Bromodomain Binary\n",
      "Complex\n",
      "\tsubsection text: The binary complex of Brd9-BD:5 was\n",
      "generated by incubating 500 μM Brd9 bromodomain with 750 μM\n",
      "compound 5 (from a 100 mM stock in DMSO). Crystals were\n",
      "grown using the hanging-drop vapor diffusion method by mixing equal\n",
      "volumes of binary complex solution and a crystallization solution\n",
      "containing 24% PEG 3350 and 0.2 M NH4F. Small needle crystals\n",
      "appeared within 48 h but took approximately 2 weeks to reach a suitable\n",
      "size for harvesting. Crystals were flash-frozen in liquid nitrogen\n",
      "using 20% eth\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: AlphaLISA Proximity Assay\n",
      "\tsubsection text: All assays were performed\n",
      "at room temperature in 384-well plates with a final assay volume of\n",
      "25 μL per well, as described previously.5 All reagents were prepared as 5× stocks diluted in\n",
      "50 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% (w/v) bovine\n",
      "serum albumin, and 0.02% (w/v) 3-[(cholamidopropyl)dimethylammonio]-1-propanesulfonate\n",
      "(CHAPS). Plates were sealed by transparent film and briefly centrifuged\n",
      "at 100g between additions of reagents. Biotinylated\n",
      "VCB (100 nM final) and His6-BRD9-bromodomain (100 \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Fluorescence Polarization\n",
      "\tsubsection text: All measurements were taken\n",
      "using a PHERAstar FS (BMG LABTECH) with fluorescence excitation and\n",
      "emission wavelengths (λ) of 485 and 520 nm, respectively. FP\n",
      "competitive binding assays were run in triplicate in 384-well plates\n",
      "(Corning 3575) using a total well volume of 15 μL (ref (63)). Each well solution contained\n",
      "15 nM VCB protein, 10 nM FAM-labeled HIF-1α peptide (FAM-DEALAHypYIPMDDDFQLRSF, Kd = 3 nM as measured by a direct FP titration),\n",
      "and decreasing concentrations of PROTAC (14-point seri\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Isothermal\n",
      "Titration Calorimetry\n",
      "\tsubsection text: ITC experiments were\n",
      "performed in an ITC200 microcalorimeter (GE Healthcare) as described\n",
      "previously.5 Titrations were carried out\n",
      "at 25 °C while stirring at 750 rpm and were performed as reverse\n",
      "mode (protein in the syringe and the ligand in the cell). Compounds\n",
      "were diluted in ITC buffer (20 mM Bis-Tris propane, 100 mM NaCl, 1\n",
      "mM tris(2-carboxyethyl)phosphine (TCEP), pH 7.5) from 10 mM\n",
      "DMSO stock solutions to a final concentration of 20 μM (0.2%\n",
      "DMSO). Each run consisted of 19 injections of 2 \n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: Live Cell Kinetic Analysis of BRD7 and BRD9\n",
      "Degradation\n",
      "\tsubsection text: HEK293 cells stably expressing LgBiT protein\n",
      "cultured in DMEM (Gibco)\n",
      "supplemented with 10% fetal bovine serum (Seradigm) and maintained\n",
      "at 37 °C and 5% CO2 were genome-edited using CRISPR/Cas9\n",
      "to generate endogenous HiBiT-BRD7 or HiBiT-BRD9 fusions. Clonal populations\n",
      "were isolated, and cells were plated in 96-well tissue culture plates\n",
      "at a density of 2 × 104 cells per well in 100 μL\n",
      "of growth medium. Following overnight incubation at 37 °C and\n",
      "5% CO2 medium was replaced with CO2-independent\n",
      "m\n",
      "--------------------------------------------------------------------------------\n",
      "\tsubsection title: NanoBRET Ubiquitination of BRD7 and BRD9\n",
      "\tsubsection text: Clonal populations\n",
      "of edited HEK293 cells expressing HiBiT-BRD7 or HiBiT-BRD9 were plated\n",
      "in tissue 96-well tissue culture plates at a density of 2 × 104 cells per well in 100 μL of growth medium and incubated\n",
      "overnight at 37 °C, 5% CO2. Following treatment with\n",
      "1 μM VZ185 for the indicated time frames, medium was replaced\n",
      "with Opti-MEM (Gibco) containing 200 μg/mL digitonin, 1:200\n",
      "dilution of primary anti-Ub antibody (Enzo Life Sciences, BML-PW8810),\n",
      "1:500 dilution of secondary anti-mouse Alexa\n",
      "====================================================================================================\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from lxml import etree\n",
    "\n",
    "def format_references(sup_element):\n",
    "    \"\"\"Format reference citations found within <sup> tags.\"\"\"\n",
    "    references = sup_element.xpath('.//xref[@ref-type=\"bibr\"]/text()')\n",
    "    # Join multiple references with commas and enclose in brackets\n",
    "    return '[' + ', '.join(references) + ']'\n",
    "\n",
    "def parse_paragraph(paragraph):\n",
    "    \"\"\"Parse a paragraph element, combining text nodes and references.\"\"\"\n",
    "    text_segments = []\n",
    "    for node in paragraph.iterchildren():\n",
    "        if node.tag == 'sup':\n",
    "            text_segments.append(format_references(node))\n",
    "        else:\n",
    "            # Directly append text from other tags if needed\n",
    "            text_segments.append(node.xpath('string()'))\n",
    "    # Prepend any leading text in the paragraph before the first child element\n",
    "    leading_text = paragraph.xpath('text()')[0] if paragraph.xpath('text()') else ''\n",
    "    full_text = leading_text + ''.join(text_segments)\n",
    "    return full_text\n",
    "\n",
    "def parse_section(section):\n",
    "    \"\"\"Recursively parse a section to extract its title, text, and any subsections.\"\"\"\n",
    "    section_data = {\n",
    "        'title': \"\".join(section.xpath('.//title/text()')),\n",
    "        'text': \"\".join(section.xpath('.//p//text()')),\n",
    "        # 'text': ' '.join([parse_paragraph(p) for p in section.xpath('.//p')]),\n",
    "    }\n",
    "    \n",
    "    # Process any subsections recursively\n",
    "    subsections = section.xpath('.//sec')\n",
    "    for subsection in subsections:\n",
    "        subsection_title = \"\".join(subsection.xpath('./title/text()')).strip()\n",
    "        section_data[subsection_title] = parse_section(subsection)\n",
    "    \n",
    "    return section_data\n",
    "\n",
    "def parse_article_data(article_xml):\n",
    "    root = etree.fromstring(article_xml)\n",
    "    # Use correct XPaths based on the XML namespace if applicable\n",
    "    title = root.xpath('//article-meta//article-title/text()')\n",
    "    abstract = \" \".join(root.xpath('//abstract//p/text()'))\n",
    "    keywords = root.xpath('//kwd-group/kwd/text()')\n",
    "    year = root.xpath('//article-meta//pub-date/year/text()')\n",
    "    \n",
    "    # Adjust XPath expressions based on actual XML structure\n",
    "    # sections = [\"\".join(sec.xpath('.//text()')) for sec in root.xpath('//body//sec')]\n",
    "    sections = [parse_section(sec) for sec in root.xpath('//body/sec')]\n",
    "\n",
    "    tables = [{\"caption\": \"\".join(table.xpath('.//caption//title//text()')), \"content\": etree.tostring(table)} for table in root.xpath('//body//table-wrap')]\n",
    "    figures = [{\"caption\": \"\".join(fig.xpath('.//caption//p//text()')), \"content\": etree.tostring(fig)} for fig in root.xpath('//body//fig')]\n",
    "    \n",
    "    return {\n",
    "        \"title\": title,\n",
    "        \"abstract\": abstract,\n",
    "        \"keywords\": keywords,\n",
    "        \"year\": year,\n",
    "        \"sections\": sections,\n",
    "        \"tables\": tables,\n",
    "        \"figures\": figures\n",
    "    }\n",
    "\n",
    "\n",
    "# Use the parse_article_data function on the fetched data\n",
    "article_info = parse_article_data(article_xml)\n",
    "# for k, v in article_info.items():\n",
    "#     print(f\"{k}: {v}\\n\")\n",
    "#     # if k == 'sections':\n",
    "#     #     print(''.join(v))\n",
    "#     print('='*100 + '\\n')\n",
    "\n",
    "print(f'number of sections: {len(article_info[\"sections\"])}')\n",
    "for sec in article_info[\"sections\"]:\n",
    "    print(f'section title: {sec[\"title\"]}')\n",
    "    print('-'*80)\n",
    "    print(f'section text: {sec[\"text\"][:500]}')\n",
    "    print('-'*80)\n",
    "    print(f'number of subsections: {len(sec) - 2}')\n",
    "    for subsec in sec:\n",
    "        if subsec not in ['title', 'text']:\n",
    "            print('-'*80)\n",
    "            print(f'\\tsubsection title: {subsec}')\n",
    "            print(f'\\tsubsection text: {sec[subsec][\"text\"][:500]}')\n",
    "    print('='*100 + '\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tables: 4\n",
      "Thermodynamic Parameters of Formation\n",
      "of Binary and Ternary Complexes between VCB, BRD9 Bromodomain, and\n",
      "Compound 5 Measured by Isothermal Titration Calorimetry\n",
      "(ITC)a \n",
      "\n",
      "b'<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"tbl1\" position=\"float\">\\n          <label>Table 1</label>\\n          <caption>\\n            <title>Thermodynamic Parameters of Formation\\nof Binary and Ternary Complexes between VCB, BRD9 Bromodomain, and\\nCompound <bold>5</bold> Measured by Isothermal Titration Calorimetry\\n(ITC)<xref rid=\"t1fn1\" ref-type=\"table-fn\">a</xref></title>\\n          </caption>\\n          <table frame=\"hsides\" rules=\"groups\" border=\"0\">\\n            <colgroup>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n            </colgroup>\\n            <thead>\\n              <tr>\\n                <th style=\"border:none;\" align=\"center\">syringe</th>\\n                <th style=\"border:none;\" align=\"center\">cell</th>\\n                <th style=\"border:none;\" align=\"center\"><italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">&#916;<italic>H</italic> (kcal/mol)</th>\\n                <th style=\"border:none;\" align=\"center\">&#916;<italic>G</italic> (kcal/mol)</th>\\n                <th style=\"border:none;\" align=\"center\">&#8211;<italic>T</italic>&#916;<italic>S</italic> (kcal/mol)</th>\\n                <th style=\"border:none;\" align=\"center\">\\n                  <italic>N</italic>\\n                </th>\\n                <th style=\"border:none;\" align=\"center\">&#945;</th>\\n              </tr>\\n            </thead>\\n            <tbody>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">BRD9-BD</td>\\n                <td style=\"border:none;\" align=\"left\">\\n                  <bold>5</bold>\\n                </td>\\n                <td style=\"border:none;\" align=\"left\">15&#160;&#177;&#160;3</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;12.5&#160;&#177;&#160;0.4</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;10.7&#160;&#177;&#160;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">1.8&#160;&#177;&#160;0.5</td>\\n                <td style=\"border:none;\" align=\"left\">0.753&#160;&#177;&#160;0.004</td>\\n                <td style=\"border:none;\" align=\"left\">&#160;</td>\\n              </tr>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">VCB</td>\\n                <td style=\"border:none;\" align=\"left\">\\n                  <bold>5</bold>\\n                </td>\\n                <td style=\"border:none;\" align=\"left\">33&#160;&#177;&#160;2</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;15.2&#160;&#177;&#160;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;10.2&#160;&#177;&#160;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">4.9&#160;&#177;&#160;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">0.60&#160;&#177;&#160;0.01</td>\\n                <td style=\"border:none;\" align=\"left\">&#160;</td>\\n              </tr>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">&#160;</td>\\n                <td style=\"border:none;\" align=\"left\">BRD9-BD:<bold>5</bold></td>\\n                <td style=\"border:none;\" align=\"left\">73&#160;&#177;&#160;2</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;6.4&#160;&#177;&#160;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;9.7&#160;&#177;&#160;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;3.3&#160;&#177;&#160;0.1</td>\\n                <td style=\"border:none;\" align=\"left\">0.75&#160;&#177;&#160;0.05</td>\\n                <td style=\"border:none;\" align=\"left\">0.45</td>\\n              </tr>\\n            </tbody>\\n          </table>\\n          <table-wrap-foot>\\n            <fn id=\"t1fn1\">\\n              <label>a</label>\\n              <p>All ITC titrations were performed\\nat 25 &#176;C. Values reported are the mean &#177; SEM from at least\\nthree independent measurements (<italic>n</italic> &#8805; 3).</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n      '\n",
      "====================================================================================================\n",
      "\n",
      "SAR of Second Generation of PROTACsa \n",
      "\n",
      "b'<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"tbl2\" position=\"float\">\\n          <label>Table 2</label>\\n          <caption>\\n            <title>SAR of Second Generation of PROTACs<xref rid=\"t2fn1\" ref-type=\"table-fn\">a</xref></title>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0018\" id=\"GRAPHIC-d7e1465-autogenerated\" position=\"float\"/>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0019\" id=\"gr18\" position=\"float\"/>\\n          <table-wrap-foot>\\n            <fn id=\"t2fn1\">\\n              <label>a</label>\\n              <p>Footnote: *Degradation\\nactivity\\nreported as % of total protein remaining after 1 &#956;M compound\\ntreatment relative to 0.1% DMSO vehicle as quantified by Western blotting\\nof HeLa cell lysates.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "SAR of Third Generation\n",
      "of PROTACsa \n",
      "\n",
      "b'<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"tbl3\" position=\"float\">\\n          <label>Table 3</label>\\n          <caption>\\n            <title>SAR of Third Generation\\nof PROTACs<xref rid=\"t3fn1\" ref-type=\"table-fn\">a</xref></title>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0020\" id=\"GRAPHIC-d7e1999-autogenerated\" position=\"float\"/>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0021\" id=\"gr19\" position=\"float\"/>\\n          <table-wrap-foot>\\n            <fn id=\"t3fn1\">\\n              <label>a</label>\\n              <p>Footnote: *Degradation activity\\nreported as % of total protein remaining after 1 &#956;M compound\\ntreatment relative to 0.1% DMSO vehicle as quantified by Western blotting\\nof HeLa and RI-1 cell lysates.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Biophysical Comparison between BRD9\n",
      "Degraders from Three Generations \n",
      "\n",
      "b'<table-wrap xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"tbl4\" position=\"float\">\\n          <label>Table 4</label>\\n          <caption>\\n            <title>Biophysical Comparison between BRD9\\nDegraders from Three Generations</title>\\n          </caption>\\n          <table frame=\"hsides\" rules=\"groups\" border=\"0\">\\n            <colgroup>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n              <col align=\"left\"/>\\n            </colgroup>\\n            <thead>\\n              <tr>\\n                <th style=\"border:none;\" align=\"center\">&#160;</th>\\n                <th colspan=\"4\" align=\"center\">ITC<xref rid=\"t4fn1\" ref-type=\"table-fn\">a</xref><hr/></th>\\n                <th colspan=\"3\" align=\"center\">FP<xref rid=\"t4fn2\" ref-type=\"table-fn\">b</xref><hr/></th>\\n                <th style=\"border:none;\" align=\"center\">AlphaLISA</th>\\n              </tr>\\n              <tr>\\n                <th style=\"border:none;\" align=\"center\">compd</th>\\n                <th style=\"border:none;\" align=\"center\">binary <italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">ternary <italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">&#945;</th>\\n                <th style=\"border:none;\" align=\"center\">total &#916;<italic>G</italic> (kcal/mol)</th>\\n                <th style=\"border:none;\" align=\"center\">binary <italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">ternary <italic>K</italic><sub>d</sub> (nM)</th>\\n                <th style=\"border:none;\" align=\"center\">&#945;</th>\\n                <th style=\"border:none;\" align=\"center\">max intensity</th>\\n              </tr>\\n            </thead>\\n            <tbody>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">\\n                  <bold>5</bold>\\n                </td>\\n                <td style=\"border:none;\" align=\"left\">33&#160;&#177;&#160;2</td>\\n                <td style=\"border:none;\" align=\"left\">73&#160;&#177;&#160;2</td>\\n                <td style=\"border:none;\" align=\"left\">0.45</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;20.4</td>\\n                <td style=\"border:none;\" align=\"left\">24&#160;&#177;&#160;6</td>\\n                <td style=\"border:none;\" align=\"left\">98&#160;&#177;&#160;2</td>\\n                <td style=\"border:none;\" align=\"left\">0.24</td>\\n                <td style=\"border:none;\" align=\"left\">1.0&#160;&#215;&#160;10<sup>6</sup></td>\\n              </tr>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">\\n                  <bold>26</bold>\\n                </td>\\n                <td style=\"border:none;\" align=\"left\">87&#160;&#177;&#160;5</td>\\n                <td style=\"border:none;\" align=\"left\">83&#160;&#177;&#160;2</td>\\n                <td style=\"border:none;\" align=\"left\">1.05</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;20.7</td>\\n                <td style=\"border:none;\" align=\"left\">70&#160;&#177;&#160;14</td>\\n                <td style=\"border:none;\" align=\"left\">60&#160;&#177;&#160;5</td>\\n                <td style=\"border:none;\" align=\"left\">1.17</td>\\n                <td style=\"border:none;\" align=\"left\">1.56&#160;&#215;&#160;10<sup>6</sup></td>\\n              </tr>\\n              <tr>\\n                <td style=\"border:none;\" align=\"left\">VZ185</td>\\n                <td style=\"border:none;\" align=\"left\">26&#160;&#177;&#160;9</td>\\n                <td style=\"border:none;\" align=\"left\">27&#160;&#177;&#160;3</td>\\n                <td style=\"border:none;\" align=\"left\">0.96</td>\\n                <td style=\"border:none;\" align=\"left\">&#8211;21.7</td>\\n                <td style=\"border:none;\" align=\"left\">35&#160;&#177;&#160;5</td>\\n                <td style=\"border:none;\" align=\"left\">35&#160;&#177;&#160;6</td>\\n                <td style=\"border:none;\" align=\"left\">1.00</td>\\n                <td style=\"border:none;\" align=\"left\">1.47&#160;&#215;&#160;10<sup>6</sup></td>\\n              </tr>\\n            </tbody>\\n          </table>\\n          <table-wrap-foot>\\n            <fn id=\"t4fn1\">\\n              <label>a</label>\\n              <p>All ITC titrations\\nwere performed\\nat 25 &#176;C. Values reported are the mean &#177; SEM from at least\\ntwo independent measurements (<italic>n</italic> &#8805; 2).</p>\\n            </fn>\\n            <fn id=\"t4fn2\">\\n              <label>b</label>\\n              <p><italic>K</italic><sub>d</sub> values\\nare reported as the mean &#177; SEM of at least two individual experiments\\nperformed in triplicate.</p>\\n            </fn>\\n          </table-wrap-foot>\\n        </table-wrap>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Figures: 17\n",
      "Chemical structures of parent (1a, 1b, 2–4) and modified\n",
      "(1c, 2a–4a) BRD7/9 and\n",
      "E3 ligase ligands.\n",
      "Functional groups selected for conjugation are shown in blue on parent\n",
      "ligands and in red on modified ligands. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig1\" position=\"float\">\\n        <label>Figure 1</label>\\n        <caption>\\n          <p>Chemical structures of parent (<bold>1a</bold>, <bold>1b</bold>, <bold>2</bold>&#8211;<bold>4</bold>) and modified\\n(<bold>1c</bold>, <bold>2a</bold>&#8211;<bold>4a</bold>) BRD7/9 and\\nE3 ligase ligands.\\nFunctional groups selected for conjugation are shown in blue on parent\\nligands and in red on modified ligands.</p>\\n        </caption>\\n        <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0001\" id=\"gr1\" position=\"float\"/>\\n      </fig>\\n    '\n",
      "====================================================================================================\n",
      "\n",
      "Reagents\n",
      "and conditions: (a)\n",
      "1-Boc-piperazine, NaBH(OAc)3, THF, rt, overnight, yield\n",
      "97%; (b) NaH, CH3I, DMF, 0 °C, 5 h, yield 95%. (c)\n",
      "Step 1: 12, B2pin2, KOAc, Pd(dppf)Cl2, 1,4 dioxane, microwave, 140 °C, 40 min. Step 2: 14 and K2CO3 (aq) are added to step\n",
      "1; microwave, 120 °C, 30 min, yield 55%. (d) HCl 4 M in dioxane,\n",
      "DCM, rt, 1 h, quantitative yield. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"sch1\" position=\"float\">\\n          <label>Scheme 1</label>\\n          <caption>\\n            <title>Synthesis\\nof the BRD7/9 Ligand <bold>1c</bold></title>\\n            <p id=\"s1fn1\">Reagents\\nand conditions: (a)\\n1-Boc-piperazine, NaBH(OAc)<sub>3</sub>, THF, rt, overnight, yield\\n97%; (b) NaH, CH<sub>3</sub>I, DMF, 0 &#176;C, 5 h, yield 95%. (c)\\nStep 1: <bold>12</bold>, B<sub>2</sub>pin<sub>2</sub>, KOAc, Pd(dppf)Cl<sub>2</sub>, 1,4 dioxane, microwave, 140 &#176;C, 40 min. Step 2: <bold>14</bold> and K<sub>2</sub>CO<sub>3</sub> (aq) are added to step\\n1; microwave, 120 &#176;C, 30 min, yield 55%. (d) HCl 4 M in dioxane,\\nDCM, rt, 1 h, quantitative yield.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0013\" id=\"gr13\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Reagents and conditions:\n",
      "(a)\n",
      "oxalyl chloride, DMSO, DCM, then TEA, −78 °C to rt, 2\n",
      "h; (b) 1c, NaBH(OAc)3, TEA, DMF, rt, overnight;\n",
      "(c) TFA, DCM, rt, 2 h; (d) E3 ligand (2a, 3a, or 4a), HATU, HOAt, DIPEA, DMF, rt, 2 h. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"sch2\" position=\"float\">\\n          <label>Scheme 2</label>\\n          <caption>\\n            <title>Synthesis of the\\nFirst Generation of Degraders</title>\\n            <p id=\"s2fn1\">Reagents and conditions:\\n(a)\\noxalyl chloride, DMSO, DCM, then TEA, &#8722;78 &#176;C to rt, 2\\nh; (b) <bold>1c</bold>, NaBH(OAc)<sub>3</sub>, TEA, DMF, rt, overnight;\\n(c) TFA, DCM, rt, 2 h; (d) E3 ligand (<bold>2a</bold>, <bold>3a</bold>, or <bold>4a</bold>), HATU, HOAt, DIPEA, DMF, rt, 2 h.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0014\" id=\"gr14\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Screening of first generation\n",
      "of degraders. (A) Western blot analysis\n",
      "of BRD9 and BRD7 levels after treatment of HeLa cells with 1 μM\n",
      "compounds for 4 and 16 h before harvesting. Degradation activity is\n",
      "reported below each lane as % of protein abundance relative to 0.1%\n",
      "DMSO vehicle. (B) Western blot analysis of BRD9 and BRD7 levels after\n",
      "48 h transfection with 1.25 nM siRNA targeting respectively BRD7,\n",
      "BRD9, or negative control (N.C.) siRNA. Intensity values are quantified\n",
      "as described in the Experimental Section. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig2\" position=\"float\">\\n          <label>Figure 2</label>\\n          <caption>\\n            <p>Screening of first generation\\nof degraders. (A) Western blot analysis\\nof BRD9 and BRD7 levels after treatment of HeLa cells with 1 &#956;M\\ncompounds for 4 and 16 h before harvesting. Degradation activity is\\nreported below each lane as % of protein abundance relative to 0.1%\\nDMSO vehicle. (B) Western blot analysis of BRD9 and BRD7 levels after\\n48 h transfection with 1.25 nM siRNA targeting respectively BRD7,\\nBRD9, or negative control (N.C.) siRNA. Intensity values are quantified\\nas described in the <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0002\" id=\"gr2\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Structures of compounds 7 and 21.18 \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig3\" position=\"float\">\\n          <label>Figure 3</label>\\n          <caption>\\n            <p>Structures of compounds <bold>7</bold> and <bold>21</bold>.<sup><xref ref-type=\"bibr\" rid=\"ref18\">18</xref></sup></p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0003\" id=\"gr3\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Ternary complex formation and analysis\n",
      "of binding mode for compound 5. (A) Cocrystal structure\n",
      "of BRD9-BD and compound 5. The warhead component of the\n",
      "degrader (purple and cyan; one from\n",
      "each protomer in the ASU) recapitulates the binding of inhibitor 1a (magenta, PDB code 5EUI),56 whereas\n",
      "the alkylated piperazine used to attach the linker is solvent-exposed\n",
      "and does not form any unfavorable interactions with the protein. (B) Fo – Fc omit\n",
      "map of compound 5 (contoured at 2.5σ) showing electron\n",
      "density for the alkylated piperazine ring. (C) BRD9-BD titrated into 5 alone. (D) VCB titrated into 5 alone. (E) VCB\n",
      "titrated into BRD9-BD:5 binary complex. VCB binds more\n",
      "weakly to the binary complex BRD9-BD:5 (Kd = 73 nM) compared to compound 5 alone (Kd = 33 nM), indicating negative cooperativity. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig4\" position=\"float\">\\n          <label>Figure 4</label>\\n          <caption>\\n            <p>Ternary complex formation and analysis\\nof binding mode for compound <bold>5</bold>. (A) Cocrystal structure\\nof BRD9-BD and compound <bold>5</bold>. The warhead component of the\\ndegrader (purple and cyan; one from\\neach protomer in the ASU) recapitulates the binding of inhibitor <bold>1a</bold> (magenta, PDB code 5EUI),<sup><xref ref-type=\"bibr\" rid=\"ref56\">56</xref></sup> whereas\\nthe alkylated piperazine used to attach the linker is solvent-exposed\\nand does not form any unfavorable interactions with the protein. (B) <italic>F</italic><sub>o</sub> &#8211; <italic>F</italic><sub>c</sub> omit\\nmap of compound <bold>5</bold> (contoured at 2.5&#963;) showing electron\\ndensity for the alkylated piperazine ring. (C) BRD9-BD titrated into <bold>5</bold> alone. (D) VCB titrated into <bold>5</bold> alone. (E) VCB\\ntitrated into BRD9-BD:<bold>5</bold> binary complex. VCB binds more\\nweakly to the binary complex BRD9-BD:<bold>5</bold> (<italic>K</italic><sub>d</sub> = 73 nM) compared to compound <bold>5</bold> alone (<italic>K</italic><sub>d</sub> = 33 nM), indicating negative cooperativity.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0004\" id=\"gr4\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Reagents and conditions: (a)\n",
      "NaH, 6-bromo-1-hexene, DMF/THF, rt, overnight; (b) BAIB, TEMPO, ACN/H2O, rt, overnight; (c) 2a, HATU, HOAt, DIPEA,\n",
      "DMF, rt, 2 h; (d) OsO4 4 wt % in H2O, NaIO4, pyridine, dioxane/H2O, rt; (e) 1c, NaBH(OAc)3, TEA, DMF, rt, overnight. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"sch3\" position=\"float\">\\n          <label>Scheme 3</label>\\n          <caption>\\n            <title>Synthesis of Compound <bold>23</bold></title>\\n            <p id=\"s3fn1\">Reagents and conditions: (a)\\nNaH, 6-bromo-1-hexene, DMF/THF, rt, overnight; (b) BAIB, TEMPO, ACN/H<sub>2</sub>O, rt, overnight; (c) <bold>2a</bold>, HATU, HOAt, DIPEA,\\nDMF, rt, 2 h; (d) OsO<sub>4</sub> 4 wt % in H<sub>2</sub>O, NaIO<sub>4</sub>, pyridine, dioxane/H<sub>2</sub>O, rt; (e) <bold>1c</bold>, NaBH(OAc)<sub>3</sub>, TEA, DMF, rt, overnight.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0015\" id=\"gr15\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Reagents and conditions: (a)\n",
      "NaOH, allyl bromide, dioxane, rt, overnight; (b) MsCl, TEA, DCM, rt,\n",
      "3 h; (c) VHL ligands 2b–d, K2CO3, DMF, 70 °C, overnight; (d) OsO4, NaIO4, pyridine, dioxane/H2O, rt; (e) 1c, NaBH(OAc)3, TEA, DMF, rt, overnight. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"sch4\" position=\"float\">\\n          <label>Scheme 4</label>\\n          <caption>\\n            <title>Synthesis of Compounds <bold>26</bold>&#8211;<bold>31</bold></title>\\n            <p id=\"s4fn1\">Reagents and conditions: (a)\\nNaOH, allyl bromide, dioxane, rt, overnight; (b) MsCl, TEA, DCM, rt,\\n3 h; (c) VHL ligands <bold>2b</bold>&#8211;<bold>d</bold>, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 &#176;C, overnight; (d) OsO<sub>4</sub>, NaIO<sub>4</sub>, pyridine, dioxane/H<sub>2</sub>O, rt; (e) <bold>1c</bold>, NaBH(OAc)<sub>3</sub>, TEA, DMF, rt, overnight.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0016\" id=\"gr16\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Compound 26 induces rapid and profound depletion of\n",
      "BRD9 in cells. (A) Western blot analysis of BRD9, BRD7, and β-actin\n",
      "after treatment of HeLa cells with 1 μM compounds for 4 h before\n",
      "harvesting (data reported in Table 2). (B) Chemical structure of 26. (C) Quantification\n",
      "of BRD9 protein levels after treatment of HeLa with six different\n",
      "concentrations of 26 at 30 min and 4 h before harvesting.\n",
      "(D) Quantification of BRD9 protein levels after treatment with 1 μM 26 in HeLa at the desired time points. Intensity values, DC50, and half-lives were quantified as described in the Experimental Section. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig5\" position=\"float\">\\n          <label>Figure 5</label>\\n          <caption>\\n            <p>Compound <bold>26</bold> induces rapid and profound depletion of\\nBRD9 in cells. (A) Western blot analysis of BRD9, BRD7, and &#946;-actin\\nafter treatment of HeLa cells with 1 &#956;M compounds for 4 h before\\nharvesting (data reported in <xref rid=\"tbl2\" ref-type=\"other\">Table <xref rid=\"tbl2\" ref-type=\"other\">2</xref></xref>). (B) Chemical structure of <bold>26</bold>. (C) Quantification\\nof BRD9 protein levels after treatment of HeLa with six different\\nconcentrations of <bold>26</bold> at 30 min and 4 h before harvesting.\\n(D) Quantification of BRD9 protein levels after treatment with 1 &#956;M <bold>26</bold> in HeLa at the desired time points. Intensity values, DC<sub>50</sub>, and half-lives were quantified as described in the <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0005\" id=\"gr5\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Improved ternary complex formation by series-2 degraders. (A) Overlay\n",
      "of compound 26 titrations shows no difference between\n",
      "binary (VCB into 26 alone; black) and ternary (VCB into\n",
      "BRD9-BD:26 binary complex; green) titrations. (B) Fluorescence\n",
      "polarization measurements for compound 5 in the presence\n",
      "(red) and absence (black) of BRD9-BD. The rightward shift in the presence\n",
      "of BRD9-BD indicates negative cooperativity. Each point is the mean\n",
      "± SEM of at least two individual experiments performed in triplicate.\n",
      "(C) Fluorescence polarization measurements for compound 26 in the presence (green) and absence (black) of BRD9-BD. Each point\n",
      "is the mean ± SEM of at least two individual experiments performed\n",
      "in triplicate. (D) AlphaLISA assay showing increased ternary complex\n",
      "formation for 26 (green) compared to 5 (red).\n",
      "Each point is the mean ± SEM of at least one experiment performed\n",
      "in quadruplicate. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig6\" position=\"float\">\\n          <label>Figure 6</label>\\n          <caption>\\n            <p>Improved ternary complex formation by series-2 degraders. (A) Overlay\\nof compound <bold>26</bold> titrations shows no difference between\\nbinary (VCB into <bold>26</bold> alone; black) and ternary (VCB into\\nBRD9-BD:<bold>26</bold> binary complex; green) titrations. (B) Fluorescence\\npolarization measurements for compound <bold>5</bold> in the presence\\n(red) and absence (black) of BRD9-BD. The rightward shift in the presence\\nof BRD9-BD indicates negative cooperativity. Each point is the mean\\n&#177; SEM of at least two individual experiments performed in triplicate.\\n(C) Fluorescence polarization measurements for compound <bold>26</bold> in the presence (green) and absence (black) of BRD9-BD. Each point\\nis the mean &#177; SEM of at least two individual experiments performed\\nin triplicate. (D) AlphaLISA assay showing increased ternary complex\\nformation for <bold>26</bold> (green) compared to <bold>5</bold> (red).\\nEach point is the mean &#177; SEM of at least one experiment performed\\nin quadruplicate.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0006\" id=\"gr6\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Reagents and conditions: (a)\n",
      "MsCl, TEA, DCM, rt, 3 h; (b) 2d, K2CO3, DMF, 70 °C, overnight; (c) K2CO3, DMF, 70 °C, overnight; (d) HCl 1 N, THF (1:1), 50 °C,\n",
      "2 h; (e) 1c,d, NaBH(OAc)3, TEA,\n",
      "DMF, rt, overnight; (f) Na2HPO4, NaClO2, 2-methyl-2-butene, t-BuOH, H2O, rt,\n",
      "4 h ; (g) 1e,f, HATU, HOAt, DIPEA, DMF,\n",
      "rt, 2 h. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"sch5\" position=\"float\">\\n          <label>Scheme 5</label>\\n          <caption>\\n            <title>General Synthetic Routes for Third-Generation\\nCompounds</title>\\n            <p id=\"s5fn1\">Reagents and conditions: (a)\\nMsCl, TEA, DCM, rt, 3 h; (b) <bold>2d</bold>, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 &#176;C, overnight; (c) K<sub>2</sub>CO<sub>3</sub>, DMF, 70 &#176;C, overnight; (d) HCl 1 N, THF (1:1), 50 &#176;C,\\n2 h; (e) <bold>1c</bold>,<bold>d</bold>, NaBH(OAc)<sub>3</sub>, TEA,\\nDMF, rt, overnight; (f) Na<sub>2</sub>HPO<sub>4</sub>, NaClO<sub>2</sub>, 2-methyl-2-butene, <italic>t</italic>-BuOH, H<sub>2</sub>O, rt,\\n4 h ; (g) <bold>1e</bold>,<bold>f</bold>, HATU, HOAt, DIPEA, DMF,\\nrt, 2 h.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0017\" id=\"gr17\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Screening\n",
      "of third generation of degraders. (A) Western-blot analysis\n",
      "of BRD9 and BRD7 levels after treatment of HeLa cells with 1 μM\n",
      "compounds for 4 h before harvesting. (B) Western blot analysis of\n",
      "BRD9 and BRD7 levels after treatment of RI-1 cells with 1 μM\n",
      "compounds for 2 h before harvesting. (C) Western blot analysis of\n",
      "BRD9 and BRD7 levels after treatment of RI-1 cells with 1 μM 7, 26, 46, and 51 for\n",
      "2 and 8 h before harvesting. Intensity values were quantified as described\n",
      "in the Experimental Section. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig7\" position=\"float\">\\n          <label>Figure 7</label>\\n          <caption>\\n            <p>Screening\\nof third generation of degraders. (A) Western-blot analysis\\nof BRD9 and BRD7 levels after treatment of HeLa cells with 1 &#956;M\\ncompounds for 4 h before harvesting. (B) Western blot analysis of\\nBRD9 and BRD7 levels after treatment of RI-1 cells with 1 &#956;M\\ncompounds for 2 h before harvesting. (C) Western blot analysis of\\nBRD9 and BRD7 levels after treatment of RI-1 cells with 1 &#956;M <bold>7</bold>, <bold>26</bold>, <bold>46</bold>, and <bold>51</bold> for\\n2 and 8 h before harvesting. Intensity values were quantified as described\\nin the <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0007\" id=\"gr7\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "VZ185 induces strong and rapid degradation in a time-\n",
      "and dose-dependent\n",
      "manner. (A) Western blot analysis of BRD9, BRD7, and β-actin\n",
      "after treatment of RI-1 cells with six different concentrations of\n",
      "compounds 46 and 51 for 2 and 8 h before\n",
      "harvesting. (B) Chemical structures of 51 (VZ185) and 46. (C) Quantification of protein levels relative to DMSO\n",
      "control after treatment with different concentration of VZ185 and\n",
      "DC50 values. (D) Time-dependent experiment in RI-1 cells\n",
      "after treatment with 10 nM and 100 nM 51 at the desired\n",
      "time points. Intensity values and DC50 were quantified\n",
      "as described in the Experimental Section. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig8\" position=\"float\">\\n          <label>Figure 8</label>\\n          <caption>\\n            <p>VZ185 induces strong and rapid degradation in a time-\\nand dose-dependent\\nmanner. (A) Western blot analysis of BRD9, BRD7, and &#946;-actin\\nafter treatment of RI-1 cells with six different concentrations of\\ncompounds <bold>46</bold> and <bold>51</bold> for 2 and 8 h before\\nharvesting. (B) Chemical structures of <bold>51</bold> (VZ185) and <bold>46</bold>. (C) Quantification of protein levels relative to DMSO\\ncontrol after treatment with different concentration of VZ185 and\\nDC<sub>50</sub> values. (D) Time-dependent experiment in RI-1 cells\\nafter treatment with 10 nM and 100 nM <bold>51</bold> at the desired\\ntime points. Intensity values and DC<sub>50</sub> were quantified\\nas described in the <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0008\" id=\"gr8\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Quantitative live-cell kinetics of VZ185 induced degradation of\n",
      "BRD7 and BRD9. Degradation profile (A), calculation of DC50 values (B), and initial degradation rate (C) across concentration\n",
      "series indicated of VZ185 using continual luminescent reading of CRISPR/Cas9\n",
      "endogenously tagged HiBiT-BRD7 or HiBiT-BRD9 in HEK293 cells. Error\n",
      "bars are expressed as SEM taken from n = 3 experiments. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig9\" position=\"float\">\\n          <label>Figure 9</label>\\n          <caption>\\n            <p>Quantitative live-cell kinetics of VZ185 induced degradation of\\nBRD7 and BRD9. Degradation profile (A), calculation of DC<sub>50</sub> values (B), and initial degradation rate (C) across concentration\\nseries indicated of VZ185 using continual luminescent reading of CRISPR/Cas9\\nendogenously tagged HiBiT-BRD7 or HiBiT-BRD9 in HEK293 cells. Error\\nbars are expressed as SEM taken from <italic>n</italic> = 3 experiments.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0009\" id=\"gr9\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Mechanistic characterization of VZ185 mode of action.\n",
      "(A) VZ185\n",
      "activity is proteasome and CRL2VHL-dependent. RI-1 cells\n",
      "were treated in two replicates with MG132, MLN4924, VH298, and cisVZ185 in the presence of absence of VZ185 (100 nM) at\n",
      "desired time points before harvesting. (B) NanoBRET experiments in\n",
      "HEK293 cells to monitor ubiquitination of HiBiT endogenously tagged\n",
      "BRD9 (purple) or BRD7 (green) using monoclonal-Ub primary and Alexa594\n",
      "secondary antibodies at times indicated after treatment with 1 μM\n",
      "VZ185. Error bars expressed as SEM of n = 3 experiments. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig10\" position=\"float\">\\n          <label>Figure 10</label>\\n          <caption>\\n            <p>Mechanistic characterization of VZ185 mode of action.\\n(A) VZ185\\nactivity is proteasome and CRL2<sup>VHL</sup>-dependent. RI-1 cells\\nwere treated in two replicates with MG132, MLN4924, VH298, and <italic>cis</italic>VZ185 in the presence of absence of VZ185 (100 nM) at\\ndesired time points before harvesting. (B) NanoBRET experiments in\\nHEK293 cells to monitor ubiquitination of HiBiT endogenously tagged\\nBRD9 (purple) or BRD7 (green) using monoclonal-Ub primary and Alexa594\\nsecondary antibodies at times indicated after treatment with 1 &#956;M\\nVZ185. Error bars expressed as SEM of <italic>n</italic> = 3 experiments.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0010\" id=\"gr10\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Effect of BRD7/9 degradation\n",
      "on viability of BRD9-sensitive cancer\n",
      "cell lines. Cell proliferation activity assessed in EOL-1 (A) and\n",
      "A-204 (B) cell lines after treatment with 1a, 1b, VZ185, 7, 21 (dBRD9), and doxorubicin\n",
      "for 7 days. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig11\" position=\"float\">\\n          <label>Figure 11</label>\\n          <caption>\\n            <p>Effect of BRD7/9 degradation\\non viability of BRD9-sensitive cancer\\ncell lines. Cell proliferation activity assessed in EOL-1 (A) and\\nA-204 (B) cell lines after treatment with <bold>1a</bold>, <bold>1b</bold>, VZ185, <bold>7</bold>, <bold>21</bold> (dBRD9), and doxorubicin\\nfor 7 days.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0011\" id=\"gr11\" position=\"float\"/>\\n        </fig>\\n        '\n",
      "====================================================================================================\n",
      "\n",
      "Impact of VZ185 on the cellular proteome after treatment\n",
      "of RI-1\n",
      "cells with 100 nM compound for 4 h before harvesting. Data are plotted\n",
      "as fold change (%) versus −log10 of p-value (t test) for a total of 6273 proteins, expressed\n",
      "as the mean of the replicates. For quantification, see Experimental Section. \n",
      "\n",
      "b'<fig xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" id=\"fig12\" position=\"float\">\\n          <label>Figure 12</label>\\n          <caption>\\n            <p>Impact of VZ185 on the cellular proteome after treatment\\nof RI-1\\ncells with 100 nM compound for 4 h before harvesting. Data are plotted\\nas fold change (%) versus &#8722;log<sub>10</sub> of <italic>p</italic>-value (<italic>t</italic> test) for a total of 6273 proteins, expressed\\nas the mean of the replicates. For quantification, see <xref rid=\"sec4\" ref-type=\"other\">Experimental Section</xref>.</p>\\n          </caption>\\n          <graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"jm-2018-01413x_0012\" id=\"gr12\" position=\"float\"/>\\n        </fig>\\n      '\n",
      "====================================================================================================\n",
      "\n"
     ]
    }
   ],
   "source": [
    "from IPython.display import display_html\n",
    "\n",
    "print(f'Tables: {len(article_info[\"tables\"])}')\n",
    "for table in article_info['tables']:\n",
    "    print(table['caption'], '\\n')\n",
    "    print(table['content'])\n",
    "    print('='*100 + '\\n')\n",
    "\n",
    "print(f'Figures: {len(article_info[\"figures\"])}')\n",
    "for fig in article_info['figures']:\n",
    "    print(fig['caption'], '\\n')\n",
    "    print(fig['content'])\n",
    "    print('='*100 + '\\n')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Deprecated"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Section: Introduction\n",
      "\n",
      "Targeted\n",
      "protein degradation is an emerging strategy to use small\n",
      "molecules to knock down a protein by hijacking the ubiquitin–proteasome\n",
      "system [1,2]. PROTACs (proteolysis targeting chimeras)\n",
      "are bifunctional degrader molecules composed of a ligand for the target\n",
      "protein and a ligand for E3 ligase recruitment, connected by a linker [3,4]. Upon formation of a ternary complex target:degrader:E3 [5−7], the protein of interest is ubiquitinated and degraded by the proteasome.\n",
      "Compared to target bloc...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Results and Discussion\n",
      "\n",
      "We began\n",
      "our investigation by designing a small set of PROTACs aimed to induce\n",
      "BRD7/9 degradation by recruiting three different E3 ubiquitin ligases:\n",
      "VHL, CRBN, and DCAF15 [59,60]. We aimed to leverage available\n",
      "E3 ligase ligands and to maximize the opportunity for complementary\n",
      "surfaces between the bromodomain and the ligase within the ternary\n",
      "complex. As BRD7/9 bromodomain ligands, we selected compounds 1a,b (Figure 1) [56], on the basis of their\n",
      "high binding affinity[56] and of their superior...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: First Generation of BRD7 and BRD9 Degraders\n",
      "\n",
      "We began\n",
      "our investigation by designing a small set of PROTACs aimed to induce\n",
      "BRD7/9 degradation by recruiting three different E3 ubiquitin ligases:\n",
      "VHL, CRBN, and DCAF15 [59,60]. We aimed to leverage available\n",
      "E3 ligase ligands and to maximize the opportunity for complementary\n",
      "surfaces between the bromodomain and the ligase within the ternary\n",
      "complex. As BRD7/9 bromodomain ligands, we selected compounds 1a,b (Figure 1) [56], on the basis of their\n",
      "high binding affinity[56] and of their superior...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Second Generation of BRD7 and BRD9 Degraders\n",
      "\n",
      "To improve\n",
      "ternary complex formation and degradation activity of PROTACs 5 and 6, we explored the impact of varying their\n",
      "derivatization point, linker length, and composition (compounds 22–31, Table 2). First, to expand the conjugation pattern\n",
      "between VHL1 and BrdL1 (Figure 1), the number of PEG units was modified (3 units for 24; 5 units for 22), a more lipophilic 11-atoms\n",
      "chain was inserted (compound 23), and a different attachment\n",
      "to BrdL1 moiety via amide conjugation was explored (compound 2...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Third Generation\n",
      "of BRD7 and BRD9 Degraders\n",
      "\n",
      "The pronounced\n",
      "degradation of BRD9 observed with 26 motivated us to\n",
      "design a third generation of PROTACs with the goal to further optimize\n",
      "our degrader. On the basis of the SAR previously acquired, the design\n",
      "strategy was to keep VHL4 moiety fixed and to focus on systematically\n",
      "varying the linker length and composition, as well as the substitution\n",
      "and conjugation chemistry at the BRD7/9 warhead. The focus on the\n",
      "linker concentrated on exploring varying ratios between hydrophilic\n",
      "and lipophilic p...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Conclusion\n",
      "\n",
      "We describe the development of a new series\n",
      "of PROTACs against\n",
      "BRD9, a target thought as not degradable through recruitment of the\n",
      "E3 ligase VHL. In spite of starting from unimpressive degradation\n",
      "profiles of initial compounds, VHL-based degraders could be optimized\n",
      "by systematically varying the conjugation patterns and monitoring\n",
      "cellular degradation activities and formation of ternary complexes.\n",
      "Throughout the campaign, we revealed important structure–activity\n",
      "relationships that proved invalua...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Experimental Section\n",
      "\n",
      "Chemicals,\n",
      "commercially available,\n",
      "were purchased from Apollo Scientific, Sigma-Aldrich, Fluorochem,\n",
      "or Manchester Organics and used without any further purification.\n",
      "All reactions were carried out using anhydrous solvents. Analytical\n",
      "thin-layer chromatography (TLC) was performed on precoated TLC plates\n",
      "(layer 0.20 mm silica gel 60 with fluorescent indicator (UV 254: Merck)).\n",
      "The TLC plates were air-dried and revealed under UV lamp (254/365\n",
      "nm). Flash column chromatography was performed using pr...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Chemistry. Synthesis\n",
      "\n",
      "Chemicals,\n",
      "commercially available,\n",
      "were purchased from Apollo Scientific, Sigma-Aldrich, Fluorochem,\n",
      "or Manchester Organics and used without any further purification.\n",
      "All reactions were carried out using anhydrous solvents. Analytical\n",
      "thin-layer chromatography (TLC) was performed on precoated TLC plates\n",
      "(layer 0.20 mm silica gel 60 with fluorescent indicator (UV 254: Merck)).\n",
      "The TLC plates were air-dried and revealed under UV lamp (254/365\n",
      "nm). Flash column chromatography was performed using pr...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: General Method A\n",
      "\n",
      "To a mixture of aryl bromide (1 equiv)\n",
      "in dioxane (0.2 M), Pd(dppf)Cl2 (0.1 equiv), bis(pinacolato)diboron\n",
      "(1.2 equiv), and KOAc (3 equiv) were added. The mixture was heated\n",
      "under microwave conditions at 140 °C for 40 min. Then aryl iodide 14 (1 equiv) and a degassed solution of K2CO3 2 M (2 equiv) were added. The reaction mixture was heated\n",
      "in microwave at 120 °C for 30 min. The resulting mixture was\n",
      "filtered through Celite and washed several times with DCM. The organic\n",
      "phase was washed with H2...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: General Method B\n",
      "\n",
      "To a solution of acid (1 equiv) in\n",
      "DMF (0.2 M), HATU (1 equiv), HOAt (1 equiv), amine (1 equiv), and\n",
      "DIPEA (5 equiv) were added. The reaction mixture was stirred at rt\n",
      "for 2 h. The solvent was evaporated under reduced pressure to give\n",
      "the corresponding crude, which was chromatographically purified to\n",
      "yield the final compound....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: General Method C\n",
      "\n",
      "A mixture of aldehyde (1 equiv), amine\n",
      "(HCl salt, 1.1 equiv), and TEA (1.1 equiv) in DMF (0.2 M) was stirred\n",
      "at rt. After 15 min, NaBH(OAc)3 (1.5 equiv) was added,\n",
      "and the reaction was stirred overnight at rt under nitrogen. The solvent\n",
      "was evaporated under reduced pressure to give the corresponding crude,\n",
      "which was purified accordingly to yield the desired compound....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: General\n",
      "Method D\n",
      "\n",
      "To a stirred solution of oxalyl chloride\n",
      "(1.5 equiv) in DCM (0.3 M), DMSO (2 equiv) was added dropwise at −78\n",
      "°C. After 10 min at −78 °C, the alcohol starting\n",
      "material (1 equiv) in DCM (0.3 M) was added. The reaction was stirred\n",
      "at −78 °C for 1 h, TEA (10 equiv) was added dropwise,\n",
      "and temperature was increased to rt. After 1 h, the reaction mixture\n",
      "was diluted with DCM, washed with a saturated solution of ammonium\n",
      "chloride. The organic phases were combined, washed with brine, dried\n",
      "over MgSO4, ...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: General Method E\n",
      "\n",
      "To a solution of\n",
      "the alcohol starting\n",
      "material (1 equiv) and trimethylamine (1.5 equiv) in DCM (0.2 M),\n",
      "methansulfonyl chloride (1.2 equiv) was added at 0 °C. The reaction\n",
      "mixture was stirred at 0 °C for 3 h. The reaction was quenched\n",
      "with a saturated solution of ammonium chloride and extracted with\n",
      "DCM. The organic phases were combined, dried over MgSO4, filtered, and evaporated to dryness. The crude (1.5 equiv) was\n",
      "suspended in DMF (0.2 M), and 2b–d inhibitor derivative (1 equiv) and K2CO3 (3\n",
      "...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: General Method F\n",
      "\n",
      "A 1 M aqueous solution\n",
      "of HCl (1 mL)\n",
      "was added to the VHL-acetal linker (0.06 mmol) in THF (1 mL). The\n",
      "reaction mixture was heated at 50 °C for 2 h. The solvent was\n",
      "evaporated under reduced pressure, and the product was extracted with\n",
      "DCM/MeOH (9:1). The organic phases were combined, dried over MgSO4, filtered, and evaporated to dryness. The crude was used\n",
      "directly without any further purification....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: General method G\n",
      "\n",
      "Aldehyde (1 equiv) was taken up in t-BuOH and water\n",
      "(4:1) (0.3 M). Then 2-methyl-2-butene 2\n",
      "M in THF (4 equiv) was added, followed by sodium phosphate dibasic\n",
      "(1 equiv) and sodium chlorite (2 equiv). The reaction mixture was\n",
      "stirred at rt for 4 h. A 1 M aqueous solution of HCl was added. The\n",
      "product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "The crude was used directly without any further purification....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 4-(3,5-Dimethoxy-4-(piperazin-1-ylmethyl)phenyl)-2-methyl-2,7-naphthyridin-1(2\n",
      "\n",
      "Following general method\n",
      "A, compound 1c was obtained from compound 12 and 14 as brown powder. Yield: 50 mg, 55%. [1]H NMR (400 MHz, MeOD) δ: 9.67 (s, 1H), 8.76 (d, J = 6.9 Hz, 1H), 8.27 (s, 1H), 8.21 (d, J = 6.9 Hz,\n",
      "1H), 6.95 (s, 2H), 4.62 (s, 2H), 4.03 (s, 6H), 3.81 (s, 3H), 3.73\n",
      "(s, 8H). [13]C NMR (101 MHz, CDCl3) δ: 161.5,\n",
      "161.4, 148.6, 146.3, 145.5, 141.9, 139.7, 122.9, 117.9, 107.1, 105.8,\n",
      "57.2, 50.8, 49.7, 41.9, 37.9. MS m/z calcd for C22H26N4O3 394.2, found 395.3 [M + H[+]]....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: (2\n",
      "\n",
      "Following general method F, compound 70 was obtained from 68 (0.04 mmol) and directly\n",
      "used in the next step without any further purification. MS m/z calcd for C31H41FN4O6S 616.27, found 617.3 [M + H[+]]....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-\n",
      "\n",
      "Following general method B, compound 7 was obtained from compound 19 and 3a (synthesized accordingly to literature[73]). The crude was purified by HPLC using a gradient of 5% to 95% v/v\n",
      "acetonitrile in 0.1% aqueous solution of formic acid to obtain compound 7 as yellow powder. Yield: 5.6 mg, 33%. [1]H NMR\n",
      "(400 MHz, MeOD) δ: 9.54 (d, J = 0.8 Hz, 1H),\n",
      "8.70 (d, J = 6.0 Hz, 1H), 8.11 (s, 1NH), 7.84 (s,\n",
      "1H), 7.73 (dd, J = 0.6, 6.0 Hz, 1H), 7.55–7.49\n",
      "(m, 1H), 7.10–7.03 (m, 2H), 6.87 (s, 2H), 5.08 (dd,...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-\n",
      "\n",
      "A mixture of 45 (1 equiv),\n",
      "osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate\n",
      "(4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was\n",
      "stirred at rt for 48 h. Then H2O was added to the reaction\n",
      "and the product was extracted with DCM. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "Then, following general method A, from the aldehyde derivative and 1c compound 31 was obtained after purification\n",
      "by HPLC using a gradient of 5% to 95% v/v acetonitrile in 0...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: None\n",
      "\n",
      "Following general method D, compound 18 was obtained from tert-butyl 14-hydroxy-3,6,9,12-tetraoxatetradecanoate 16 and 1c after purification by HPLC using a\n",
      "gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of\n",
      "ammonia as white powder. Yield: 10.7 mg, 34%. [1]H NMR (500\n",
      "MHz, CDCl3) δ: 9.69 (d, J = 0.8\n",
      "Hz, 1H), 8.70 (d, J = 5.6 Hz, 1H), 7.43 (d, J = 5.6 Hz, 1H), 7.26 (s, 1H), 6.52 (s, 2H), 4.00 (s, 2H),\n",
      "3.81 (s, 6H), 3.73–3.57 (m, 19H), 2.67–2.55 (m, 10H),\n",
      "1.46 (s, 9H). [13]C NMR (12...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 4-Iodo-2-methyl-2,7-naphthyridin-1(2\n",
      "\n",
      "A mixture of 4-iodo-2,7-naphthyridin-1(2H)-one 13 (synthesized accordingly to literature[74]) (1 equiv) and NaH (2 equiv) was stirred 30\n",
      "min at 0 °C in DMF (0.2 M). Then CH3I (1.6 equiv)\n",
      "was added and the reaction mixture was stirred at 0 °C for 5\n",
      "h. Water was added, and the precipitate formed was filtered and dried\n",
      "in vacuum. Yield: 300 mg, 95%. [1]H NMR (400 MHz, DMSO) δ:\n",
      "9.27 (s, 1H), 8.82 (d, J = 5.6 Hz, 1H), 8.26 (s,\n",
      "1H), 7.47 (d, J = 5.5 Hz, 1H), 3.52 (s,3H). [13]C NMR (101 MHz, DMSO) δ: 1...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetic\n",
      "Acid (\n",
      "\n",
      "A mixture of compound 17 (0.015 mmol), TFA (0.5 mL), and DCM (0.5 mL) was stirred at rt for\n",
      "3 h. Then the solvent was evaporated; the crude was dried under high\n",
      "pressure overnight and used directly in the next step without any\n",
      "further purification. Quantitative yield. MS m/z calcd for C28H36N4O7 540.26, found 541.4 [M + H[+]]....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 17-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecanoic\n",
      "Acid (\n",
      "\n",
      "A mixture of compound 18 (0.034 mmol), TFA (0.5 mL), and DCM (0.5 mL) was stirred at rt for\n",
      "3 h. Then the solvent was evaporated; the crude was dried under high\n",
      "pressure overnight and used directly without any further purification.\n",
      "Quantitative yield. MS m/z calcd\n",
      "for C34H48N4O10 672.34,\n",
      "found 673.36 [M + H[+]]....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 2-(2-(Hex-5-en-1-yloxy)ethoxy)ethan-1-ol\n",
      "(\n",
      "\n",
      "To a suspension of NaH (2.5 equiv) in DMF\n",
      "(1 M) and THF (1 M),\n",
      "diethylene glycol (5 equiv) was added at 0 °C under nitrogen.\n",
      "After 45 min 6-bromo-1-hexene (1 equiv) was added dropwise at 0 °C.\n",
      "Then the ice bath was removed, and the reaction mixture was stirred\n",
      "overnight at rt under nitrogen. Distillate water was added, and the\n",
      "reaction mixture was acidified with HCl 1 M up to pH 2. The product\n",
      "was extracted with CHCl3. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated ...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 2-(2-(Hex-5-en-1-yloxy)ethoxy)acetic\n",
      "Acid (\n",
      "\n",
      "A mixture of 30 (1 equiv), BAIB (2.2\n",
      "equiv), TEMPO (0.22 equiv)\n",
      "in ACN/H2O (1:1) (0.5 M) was stirred overnight at rt. The\n",
      "day after the solvent was evaporated, the crude was resuspended in\n",
      "DCM and washed with H2O. The organic phases were combined,\n",
      "dried over MgSO4, filtered, and evaporated to dryness.\n",
      "The resulting product was purified by flash column chromatography\n",
      "using a gradient from 0% to 20% of MeOH in DCM to obtain compound 34 as an oil. Yield: 472 mg, 81%. [1]H NMR (400 MHz,\n",
      "CDCl3) δ: 5....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 2-(2-(Allyloxy)ethoxy)ethan-1-ol\n",
      "(\n",
      "\n",
      "To a mixture of NaOH (1 equiv) in dioxane\n",
      "(0.3 M), diethylene glycol\n",
      "(2 equiv) and allyl bromide (1 equiv) were added dropwise. The mixture\n",
      "was heated overnight at 55 °C. Then the reaction mixture was\n",
      "dried over MgSO4, filtered, and evaporated in vacuum. The\n",
      "crude was purified by flash column chromatography using a gradient\n",
      "from 50% to 100% of ethyl acetate in heptane to obtain compound 38 as an oil. Yield: 329 mg, 54%. [1]H NMR (400 MHz,\n",
      "CDCl3) δ: 5.90–5.80 (m, 1H), 5.21 (qd, J = 1.6, 17.2 Hz, ...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 3,6,9,12-Tetraoxapentadec-14-en-1-ol\n",
      "(\n",
      "\n",
      "Following the same procedure applied for\n",
      "compound 38, from tetraethylene glycol and allyl bromide\n",
      "compound 39 was obtained as oil. Yield: 3.29 g, 68%.\n",
      "Analytical data matched\n",
      "those previously reported [75]....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 2-(2-(2-(((2\n",
      "\n",
      "Following general method G, compound 71 was obtained from compound 69 (0.04 mmol)\n",
      "and was used in the next step without any further purification. Quantitative\n",
      "yield. MS m/z calcd for C30H39FN4O8S 634.25, found 635.3 [M\n",
      "+ H[+]]....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: 5-(2-(((2\n",
      "\n",
      "Following general method G, compound 72 was obtained from compound 70 (0.05 mmol)\n",
      "and was used in the next step without any further purification. Quantitative\n",
      "yield. MS m/z calcd for C31H41FN4O7S 632.27, found 633.3 [M\n",
      "+ H[+]]....\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Biology. Cell Culture\n",
      "\n",
      "Human cell\n",
      "lines HeLa and Hek293\n",
      "were purchased from ATCC and propagated in DMEM medium (Gibco), supplemented\n",
      "with 10% fetal bovine serum (FBS) (Gibco), l-glutamine (Gibco),\n",
      "100 μg mL[–1] of penicillin/streptomycin. RI-1\n",
      "cells, purchased from DSMZ, were propagated in RPMI medium (Gibco),\n",
      "supplemented with 10% fetal bovine serum (FBS) (Gibco), l-glutamine, 100 μg mL[–1] of penicillin/streptomycin.\n",
      "Cells were kept at 37 °C and 5% of CO2. EOL-1 and\n",
      "A-204 cell lines were purchased from ATCC and DSMZ...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Testing Compounds in Cells\n",
      "\n",
      "HeLa and Hek293 cells were\n",
      "seeded at either 0.3 × 10[6] or 0.5 × 10[6] cells per well in 6-well plate in 2 mL of medium. At 80% confluency,\n",
      "cells were treated with compounds at the desired concentration, with\n",
      "final DMSO concentration of 0.1% v/v. Cells were incubated at 37 °C\n",
      "and 5% of CO2 for the desired time before harvesting. For\n",
      "protein extraction from adherent cells, cells were washed twice with\n",
      "DPBS (Gibco) and lysed with RIPA buffer (Sigma-Aldrich), supplemented\n",
      "with cOmplete Mini EDTA-fr...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Small Interfering RNA\n",
      "\n",
      "HeLa cells were seeded at 0.3\n",
      "× 10[6] cells per well in 6-well plates in 2 mL of medium,\n",
      "with a goal to achieve 70% of confluence on the day of transfection.\n",
      "BRD7, BRD9, and CRBN targeting siRNA (L-020297-00-0005 ON-TARGETplus\n",
      "human BRD7, L-014250-02-0005 ON-TARGETplus human BRD9, and L-021086-00-0005\n",
      "ON-TARGETplus human CRBN SMARTpool, 5 nmol, Dharmacon) were prepared\n",
      "as a 20 μM solution in RNase-free 1× siRNA buffer (Dharmacon).\n",
      "Nontargeting siRNA (On-TARGETplus control pool, nontargeting pool...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Mechanistic Evaluation\n",
      "\n",
      "Cells were\n",
      "seeded in 6-well\n",
      "plates with 5 × 10[5] cells per well in 2 mL of complete\n",
      "medium to aim for 80% confluence on the day of treatment. At time\n",
      "zero, ML4924 was added at final concentration of 3 μM with 0.1%\n",
      "v/v of DMSO. DMSO was added to the remaining wells in order to match\n",
      "concentration of vehicle in all wells. After 3 h, MG132 (50 μM)\n",
      "or VH298 (100 μM) was added to the designated wells at a final\n",
      "concentration of 0.1% v/v of DMSO. Again, DMSO was added to the remaining\n",
      "wells to match ...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Immunoblotting\n",
      "\n",
      "Proteins were resolved by SDS–PAGE\n",
      "on NuPage 4–12% Bis-Tris Midi Gel (Invitrogen) and transferred\n",
      "to Amersham Protran 0.45 NC nitrocellulose membrane (GE Healthcare)\n",
      "using wet transfer. The membrane was blocked with 5% w/v milk in Tris-buffered\n",
      "saline (TBS) with 0.1% w/v Tween-20. The following primary antibodies\n",
      "at the given concentration were used: anti β-actin (Cell Signaling\n",
      "Technology, 4970S, 13E5) 1:2000, anti-Brd9 (Bethyl A303-781A) 1:1000,\n",
      "anti-Brd7 (Bethyl A302-304A) 1:1000, VHL rabbit ...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Proliferation\n",
      "Assays\n",
      "\n",
      "A-204 cells (1 × 10[3]) were seeded\n",
      "per well of 384-well plates. After overnight incubation,\n",
      "compounds were added to the cells at logarithmic dose series using\n",
      "the HP digital dispenser D300 (Tecan), normalizing for added DMSO.\n",
      "1 day and 8 days after seeding cellular ATP content was measured using\n",
      "CellTiterGlo (Promega). Measurements after 8 days were divided by\n",
      "the measurement after 1 day (i.e., the T0 plate) to derive fold proliferation. Data were analyzed with GraphPad\n",
      "Prism software to obtain...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: MS Proteomics\n",
      "\n",
      "RI-1 cells were seeded at 2 ×\n",
      "10[6] cells/mL in a 10 cm plate 12 h before treatment. Cells\n",
      "were treated with 0.1% DMSO as vehicle control and with 100 nM VZ185\n",
      "and 100 nM cisVZ185 as negative control. Cells were\n",
      "incubated at 37 °C and 5% CO2 for 4 h before harvesting.\n",
      "Cells were washed twice with DPBS (Gibco) and lysed with 0.5 mL of\n",
      "100 mM Tris, pH 8.0, 4% (w/v) SDS, supplemented with cOmplete Mini\n",
      "EDTA-free protease inhibitor cocktail (Roche). Lysates were sonicated\n",
      "(2 × 10 s) and centrifuged ...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Sample\n",
      "Preparation\n",
      "\n",
      "RI-1 cells were seeded at 2 ×\n",
      "10[6] cells/mL in a 10 cm plate 12 h before treatment. Cells\n",
      "were treated with 0.1% DMSO as vehicle control and with 100 nM VZ185\n",
      "and 100 nM cisVZ185 as negative control. Cells were\n",
      "incubated at 37 °C and 5% CO2 for 4 h before harvesting.\n",
      "Cells were washed twice with DPBS (Gibco) and lysed with 0.5 mL of\n",
      "100 mM Tris, pH 8.0, 4% (w/v) SDS, supplemented with cOmplete Mini\n",
      "EDTA-free protease inhibitor cocktail (Roche). Lysates were sonicated\n",
      "(2 × 10 s) and centrifuged ...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: nLC–MS/MS Analysis\n",
      "\n",
      "The fractions\n",
      "were analyzed\n",
      "sequentially on a Q Exactive HF hybrid quadrupole-Orbitrap mass spectrometer\n",
      "(Thermo Scientific) coupled to an UltiMate 3000 RSLCnano UHPLC system\n",
      "(Thermo Scientific) and EasySpray column (75 μm × 50 cm,\n",
      "PepMap RSLC C18 column, 2 μm, 100 Å, Thermo Scientific).\n",
      "A mix of buffer A (0.1% formic acid in H2O) and B (0.08%\n",
      "formic acid in 80% CH3CN) was used over a linear gradient\n",
      "from 5% to 35% buffer B over 125 min using a flow rate of 300 nL/min.\n",
      "Column temperature was set...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Peptide\n",
      "and Protein Identification and Quantification\n",
      "\n",
      "The raw MS\n",
      "data files for all 20 fractions were merged and searched\n",
      "against the Uniprot-sprot-Human-Canonical database by Maxquant software\n",
      "1.6.0.16 for protein identification and TMT reporter ion quantitation.\n",
      "The identifications were based on the following criteria: enzyme used\n",
      "trypsin/P; maximum number of missed cleavages equal to 2; precursor\n",
      "mass tolerance equal to 10 ppm; fragment mass tolerance equal\n",
      "to 20 ppm. Variable modifications: oxidation (M), acetyl (N-term),\n",
      "deamidation (NQ), Gln ...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Protein Expression and Purification\n",
      "\n",
      "Human proteins\n",
      "VHL (UniProt accession number P40337), ElonginC (Q15369), and ElonginB\n",
      "(Q15370) and the bromodomain (residues 134–239) for BRD9 (Q9H8M2)\n",
      "were used for all protein expression. His6-tagged constructs\n",
      "were transformed into Escherichia coli BL21(DE3),\n",
      "and expression was induced by the addition of isopropyl β-d-1-thiogalactopyranoside (IPTG). E. coli cells\n",
      "were lysed using a pressure cell homogenizer (Stansted Fluid Power);\n",
      "lysates were clarified by centrifuge and loaded onto a HisTrap...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Crystallization and Structure Solution of BRD9 Bromodomain Binary\n",
      "Complex\n",
      "\n",
      "The binary complex of Brd9-BD:5 was\n",
      "generated by incubating 500 μM Brd9 bromodomain with 750 μM\n",
      "compound 5 (from a 100 mM stock in DMSO). Crystals were\n",
      "grown using the hanging-drop vapor diffusion method by mixing equal\n",
      "volumes of binary complex solution and a crystallization solution\n",
      "containing 24% PEG 3350 and 0.2 M NH4F. Small needle crystals\n",
      "appeared within 48 h but took approximately 2 weeks to reach a suitable\n",
      "size for harvesting. Crystals were flash-frozen in liquid nitrogen\n",
      "using 20% eth...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: AlphaLISA Proximity Assay\n",
      "\n",
      "All assays were performed\n",
      "at room temperature in 384-well plates with a final assay volume of\n",
      "25 μL per well, as described previously [5]. All reagents were prepared as 5× stocks diluted in\n",
      "50 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% (w/v) bovine\n",
      "serum albumin, and 0.02% (w/v) 3-[(cholamidopropyl)dimethylammonio]-1-propanesulfonate\n",
      "(CHAPS). Plates were sealed by transparent film and briefly centrifuged\n",
      "at 100g between additions of reagents. Biotinylated\n",
      "VCB (100 nM final) and His6-BRD9-bromodomain (1...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Fluorescence Polarization\n",
      "\n",
      "All measurements were taken\n",
      "using a PHERAstar FS (BMG LABTECH) with fluorescence excitation and\n",
      "emission wavelengths (λ) of 485 and 520 nm, respectively. FP\n",
      "competitive binding assays were run in triplicate in 384-well plates\n",
      "(Corning 3575) using a total well volume of 15 μL (ref (63)). Each well solution contained\n",
      "15 nM VCB protein, 10 nM FAM-labeled HIF-1α peptide (FAM-DEALAHypYIPMDDDFQLRSF, Kd = 3 nM as measured by a direct FP titration),\n",
      "and decreasing concentrations of PROTAC (14-point seri...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Isothermal\n",
      "Titration Calorimetry\n",
      "\n",
      "ITC experiments were\n",
      "performed in an ITC200 microcalorimeter (GE Healthcare) as described\n",
      "previously [5]. Titrations were carried out\n",
      "at 25 °C while stirring at 750 rpm and were performed as reverse\n",
      "mode (protein in the syringe and the ligand in the cell). Compounds\n",
      "were diluted in ITC buffer (20 mM Bis-Tris propane, 100 mM NaCl, 1\n",
      "mM tris(2-carboxyethyl)phosphine (TCEP), pH 7.5) from 10 mM\n",
      "DMSO stock solutions to a final concentration of 20 μM (0.2%\n",
      "DMSO). Each run consisted of 19 injections of...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: Live Cell Kinetic Analysis of BRD7 and BRD9\n",
      "Degradation\n",
      "\n",
      "HEK293 cells stably expressing LgBiT protein\n",
      "cultured in DMEM (Gibco)\n",
      "supplemented with 10% fetal bovine serum (Seradigm) and maintained\n",
      "at 37 °C and 5% CO2 were genome-edited using CRISPR/Cas9\n",
      "to generate endogenous HiBiT-BRD7 or HiBiT-BRD9 fusions. Clonal populations\n",
      "were isolated, and cells were plated in 96-well tissue culture plates\n",
      "at a density of 2 × 10[4] cells per well in 100 μL\n",
      "of growth medium. Following overnight incubation at 37 °C and\n",
      "5% CO2 medium was replaced with CO2-independent...\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "Section: NanoBRET Ubiquitination of BRD7 and BRD9\n",
      "\n",
      "Clonal populations\n",
      "of edited HEK293 cells expressing HiBiT-BRD7 or HiBiT-BRD9 were plated\n",
      "in tissue 96-well tissue culture plates at a density of 2 × 10[4] cells per well in 100 μL of growth medium and incubated\n",
      "overnight at 37 °C, 5% CO2. Following treatment with\n",
      "1 μM VZ185 for the indicated time frames, medium was replaced\n",
      "with Opti-MEM (Gibco) containing 200 μg/mL digitonin, 1:200\n",
      "dilution of primary anti-Ub antibody (Enzo Life Sciences, BML-PW8810),\n",
      "1:500 dilution of secondary anti-mouse Ale...\n",
      "\n",
      "====================================================================================================\n",
      "\n"
     ]
    }
   ],
   "source": [
    "def get_all_text(elem, namespaces):\n",
    "    \"\"\"\n",
    "    Recursively retrieve all text within an element, including nested tags.\n",
    "    Text within <sup> tags is included in brackets.\n",
    "    :param elem: The current element to process\n",
    "    :param namespaces: Dictionary of XML namespaces\n",
    "    \"\"\"\n",
    "    text = elem.text if elem.text is not None else \"\"\n",
    "    for child in elem:\n",
    "        # Extract local tag name ignoring namespace\n",
    "        tag = child.tag.split('}')[-1]  # Splits on '}' and takes the last part, which is the local tag name\n",
    "        if tag == 'sup':\n",
    "            text += \"[\" + get_all_text(child, namespaces) + \"]\"  # Process <sup> content with brackets\n",
    "        else:\n",
    "            text += get_all_text(child, namespaces)\n",
    "        if child.tail is not None:\n",
    "            text += child.tail\n",
    "    # Replace \".[<some text>]\" with \" [<some text>].\" in one go. Both brachets and dot are preserved.\n",
    "    text = re.sub(r'\\.\\[([^\\]]+)\\]', r' [\\1].', text)\n",
    "    text = re.sub(r',\\[([^\\]]+)\\]', r' [\\1],', text)\n",
    "    return text\n",
    "\n",
    "def parse_article_xml(article_xml):\n",
    "    # Define the namespaces used in the XML document\n",
    "    namespaces = {\n",
    "        'oai': 'http://www.openarchives.org/OAI/2.0/',\n",
    "        'jats': 'https://jats.nlm.nih.gov/ns/archiving/1.3/'\n",
    "    }\n",
    "\n",
    "    # Find the body element\n",
    "    # Note: Adjust the XPath expression based on the actual structure and namespaces\n",
    "    body = article_xml.find('.//jats:body', namespaces)\n",
    "\n",
    "    if not body:\n",
    "        print(\"No body found in the XML.\")\n",
    "        return None\n",
    "\n",
    "    # Initialize a dictionary to hold section titles and their corresponding text\n",
    "    sections = {'body': {}, 'back': {}, 'front': {}}\n",
    "    # Iterate over each section in the XML\n",
    "    for sec in body.findall('.//jats:sec', namespaces):\n",
    "        # Extract the section title\n",
    "        title = sec.find('.//jats:title', namespaces).text if sec.find('.//jats:title', namespaces) is not None else \"No Title\"\n",
    "        # Extract and concatenate all paragraph texts within this section\n",
    "        paragraphs = sec.findall('.//jats:p', namespaces)\n",
    "        section_text = \"\\n\\n\".join([get_all_text(p, namespaces) for p in paragraphs if p.text])\n",
    "        \n",
    "        # Add this section's text to the dictionary\n",
    "        sections['body'][title] = section_text\n",
    "    \n",
    "    back = article_xml.find('.//jats:back', namespaces)\n",
    "    if back:\n",
    "        for sec in back.findall('.//jats:sec', namespaces):\n",
    "            title = sec.find('.//jats:title', namespaces).text if sec.find('.//jats:title', namespaces) is not None else \"No Title\"\n",
    "            paragraphs = sec.findall('.//jats:p', namespaces)\n",
    "            section_text = \"\\n\\n\".join([get_all_text(p, namespaces) for p in paragraphs if p.text])\n",
    "            sections['back'][title] = section_text\n",
    "    return sections\n",
    "\n",
    "\n",
    "article_text = parse_article_xml(article_xml)\n",
    "for sec, text in article_text['body'].items():\n",
    "    print(f\"Section: {sec}\\n\\n{text[:500]}...\\n\")\n",
    "    print(\"=\"*100 + \"\\n\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
